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Benzene Related Hematological Disorders: Evidence for a Threshold in Animals and 
Humans 
 
James McCluskey 
 
Abstract 
 
 Significant benzene exposure has historically been associated with the 
development of a host of hematological disorders in humans and animals.   In particular, 
benzene is known to cause disturbances of the peripheral blood, aplastic anemia and 
cancer of the lymphohematopoietic system.  In 1928, the first modern report of an 
association between cancer and benzene exposure was published.  This case report was 
followed by additional reports from around the world.  In most instances, ailments 
resulted from long term, high level exposure to benzene found in glues, and through 
accidental industrial spills.  Throughout the 1960’s and 1970’s, case reports accumulated 
linking benzene exposure to hematological cancers, particularly among leather workers in 
Turkey and Italy.  At the time, only qualitative measures of benzene exposure were often 
available and most exposure information was based upon short term grab samples and 
subjective symptoms.  However, this situation changed drastically in the mid-1970s, 
when the first report was published on a little known industry that manufactured rubber 
hydrochloride, also known as Pliofilm.  This clear film product was made from natural 
rubber latex and processing utilized benzene in multiple stages.  It appeared from the 
outset that there were an unusually large number of acute leukemia cases in this cohort of 
workers.  Since that time, multiple follow-up evaluations of the same cohort have 
attempted to refine the benzene exposure of these workers. Benzene has subsequently 
been classified as a human carcinogen by several regulatory bodies and the allowable 8 
hour time-weighted average has been lowered to 1 ppm.  In pursuing the goal of 
protecting workers, regulatory bodies utilize a linear extrapolation, or no threshold dose, 
approach to cancer causation.  This methodology assumes that every exposure brings an 
incremental rise in risk.  In this work, the linear extrapolation methodology is tested 
utilizing the criteria proposed by Sir Bradford Hill.  The Hill Criteria are used to critically 
evaluate the weight of evidence for a threshold dose that can cause hematological cancer 
in humans following benzene exposure.   This evaluation revealed that there is sufficient 
evidence for a threshold dose and that linear extrapolation is designed to protect, not 
predict disease.   
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Chapter One: Introduction 
 
Most governmental organizations and regulatory bodies worldwide, including the 
U.S. Occupational Safety and Health Administration (OSHA), the U.S. Environmental 
Protection Agency (EPA) and the International Agency on Cancer Research (IARC), use a 
one-hit, linear model of cancer causation.  Although this model is unproven, and in many 
cases is clearly incorrect, these bodies continue to assume that no threshold for 
carcinogenicity exists and each increase in exposure is accompanied by an incremental 
increase in risk of cancer.  Further, the one-hit model assumes that a single, unique and 
irreversible event occurs in the genetic material of an organism and there is no repair of that 
injury.  Yet, multiple DNA repair mechanisms are at work within all human cells and we 
repair and /or destroy damaged cells every minute of our respective lives.   
  Benzene is a very commonly used feedstock and industrial chemical throughout the 
world.  In addition, low levels are found in ambient air throughout the world and in every 
human body.  Common sources of benzene exposure include tobacco smoke, automobile 
emissions, products of combustion and drinking water.  Historically, there has been a strong 
association between high benzene exposures, adverse health outcomes and cancer(s) of the 
blood-forming units.  Although a no-threshold, linear extrapolation model is assumed by 
regulatory agencies, this is done with the express mission of protecting the health of the 
public.  Inherent to this goal is the incorporation of multiple safety factors and the level 
propounded by a governmental body is not an absolute “red line” for disease.  For instance, 
someone who is exposed to a substance at 1.01 part per million (ppm) for a working lifetime, 
versus the regulatory limit of 1.0 ppm, would not realistically have any excess risk above that 
of someone exposed to the regulatory level (Reference).  And in fact, they may have no 
measurable risk at the regulatory limit.  With that in mind, the stated purpose of this work is 
to thoroughly analyze both the human and animal data for evidence consistent with a 
threshold dose of benzene exposure at which no individual would be expected to develop a 
cancer of the hematopoietic system beyond the background rate of disease.  It must be 
understood that “risk” is not “disease” – risk is a statistical measure that suggests a 
theoretical increase in probability of an adverse event, and is not an actual adverse event.  Far 
too often, it is assumed that statistically significant “risk” is an absolute, and disease is 
simply a forgone conclusion.     
In 1965, Sir Bradford Hill, an English statistician, elucidated a number of “criteria” 
that he felt should be considered when determining the validity of any causal association 
(Hill 1965).  These criteria were in many ways a restatement of the scientific method – 
observe, hypothesize, empirically test, re-evaluate, consider all new knowledge and 
continuously eliminate or explain potential confounders as well as alternative explanations.  
The method is not necessarily a static process and solutions may change with acquisition of 
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new knowledge, or the dismissal of disproven hypotheses.  Hill formulated the following 
criteria, and each is explained in terms of evaluating a threshold dose for benzene: 
1. Strength – Does a certain dose cause a clearly elevated rate of cancer above that 
expected due to chance?  Measurement of statistical significance is used to evaluate 
the likelihood of chance causation; however, it is not a measure of how large the 
effect is, or the “significance” of the finding.  For instance, what does 0.1 deaths per 
million persons mean?  Can this be assumed to mean that 1 person in 10,000,000 will 
die from this cause?   
2. Consistency – Is there a dose at which no measurable increase in mortality occurs, no 
matter the investigator? 
3. Specificity – Is there a dose at which the exposed person is at the same risk level as 
someone without any known exposure above the generally accepted background.  Are 
there other causes of the disease that could explain the occurrence independent of the 
dose proposed? 
4. Temporality – The disease must follow the exposure in a logical and explainable 
format.  Is there an appropriate latency period?   
5. Biological Gradient – Is there consistent dose response relationship? 
6. Plausibility – This clearly depends upon the status of the knowledge base.  Is there a 
dose at which the requisite sub-chronic effects are evident that will invariably lead to 
cancer?  
7. Coherence – Is there suggestive animal evidence, or cell-based model evidence? 
8. Experiment - If doses are reduced over time, is there a point at which the rate of 
cancer falls to an imperceptible rate above background? 
9. Analogy – Are there other chemicals with similar mechanisms of action where a 
threshold is clearly evident? 
 
Although not all of these criteria are relevant to this investigation, they serve as a 
guide for evaluating the existing literature on benzene-related hematopoietic cancer.  This 
investigation was undertaken knowing that the majority of the medical literature searches for 
“statistical significance”, yet this construct is frequently misinterpreted by medical and lay 
individuals.  Over-analysis and dependence upon statistical measures of significance were 
addressed by Hill (Hill 1965), as follows: 
 
“…. there are innumerable situations in which they are totally unnecessary – because 
the difference is grotesquely obvious, because it is negligible, or because, whether it 
be formally significant or not, it is too small to be of any practical importance.  What 
is worse the glitter of the t table diverts attention from the inadequacies of the fare.”      
 
 If a “significant” finding is based upon an inadequate methodology, erroneous 
findings result.  For instance, in order to ascertain whether there is a threshold dose for 
cancer causation by benzene from occupational exposure, a number of steps must logically 
follow:  The dose must be accurately measured (exposure assessment), the disease of interest 
must be accurately and specifically identified in the exposed and unexposed populations, a 
 3
matched comparison group must be evaluated and bias/confounding/modifying factors must 
be eliminated or controlled.  In lieu of this methodology, laboratory investigations can be 
undertaken in a controlled environment in order to test the hypotheses.  However, laboratory 
investigations can only offer so much information, particularly when attempting to 
extrapolate animal data to human beings.  When using animal data to evaluate a scientific 
question the underlying question is always – What differences exist between an animal 
species and human being that may invalidate/modify the findings? 
 The vast majority of cases and cohorts detailing benzene and hematological cancer 
causation do not have quantitative measures of benzene exposure.  Almost all of the early 
reports of an association had only qualitative metrics such as benzene content in products 
used by workers or subjective symptom reports.  Although these reports are informative and 
important regarding uncontrolled exposure and the risk for adverse outcomes from benzene 
exposure, they are of minimal value for answering the question asked in this investigation.  
Since the recognition of the various disease processes related to excess benzene exposure, 
retrospective and prospective cohort investigations had been undertaken in several industries, 
particularly rubber hydrochloride (Pliofilm), various branches of petroleum companies, 
rubber products manufacturing, chemical synthesis, several manufacturing entities and 
rotogravure (printing).  With that said, most do not have any way of estimating exposure 
beyond broad categories such as low, medium and high and therefore can offer little help 
determining whether a threshold dose exists, beyond qualitative information  For practical 
purposes, the retrospective cohort and case-control study have been the most common 
methods used to study benzene exposure and health outcomes.  Unfortunately, any 
retrospective occupational investigation examining exposures is subject to the limitations 
imposed by inadequate documentation, absent and inaccurate exposure measurements, as 
well as potential biases from multiple sources.  Regarding benzene exposure, particularly 
related to the Pliofilm cohort, these limitations have provided ample fodder for publication, 
estimation and re-interpretation by a host of investigators.  In addition to the Pliofilm cohort, 
several groups of exposed workers and cases have been studied in other industries where 
quantitative measures are available and the actual numbers and likelihood of disease can be 
compared to an estimated dose.   
One of the primary challenges of studying benzene exposure and cancer causation in 
the current workforce is the welcome absence of cancer in presently exposed workers.  In 
1987, OSHA lowered the permissible exposure limit of benzene to 1 ppm over an 8 hour 
time weighted average.  Some may argue that the lack of statistical significance between 
benzene exposure and cancer causation in current workers is prima facie evidence that a 
threshold exists and the current regulatory level is above that level; however, apparently self-
evident hypotheses still need to be tested and proven, thus this investigation. 
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Question  
  
Is there a threshold dose for benzene exposure where there is no theoretical risk for 
hematologic cancer? 
 
Hypothesis of this Investigation 
 
There is evidence to support a threshold dose for benzene where no theoretical risk for 
hematologic cancer would be expected.   
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Chapter Two: Methods 
 
This investigation is a systematic, critical evaluation of the published literature 
detailing the relationship between benzene exposure and lymphohematopoietic cancer.  
Published literature is noted because some early investigations were undertaken by 
companies (particularly in the petroleum industry) and/or articles were only available in a 
foreign language.  However, in the case of early internal company documents and studies, 
most have been written about in the publicly available literature by subsequent company 
investigators.  For instance, every major petroleum company with operations in the United 
States (Exxon, Mobil, Shell, Texaco, Chevron and Union) has published mortality studies of 
their workforce(s) at various operations.  Invariably, details of early company documents and 
studies have been included in the discussion section of the subsequent reports and 
information has been gleaned from these sources.  Regarding the foreign literature, (French, 
Italian, Turkish, etc.) although many articles were obtained during the literature search 
portion of this investigation, only the abstract was typically available in English.  With that 
said, most were case reports or case series and there were no instances found where benzene 
measurements were systematically compared with health outcomes.  In the course of 
conducting this research, over 450 scientific articles and studies on benzene exposure, health 
effects, biomarkers and physiology were critically evaluated.  Of these 450, approximately 
50 articles were critical to understanding the issue of a possible threshold dose associated 
with benzene exposure.            
 As mentioned previously, most human studies to date have only looked at mortality 
and have not been capable of correlating a cumulative, peak or average benzene exposure in 
particular workers, with a health outcome.  They have simply compared the rate of an 
outcome of interest with a population rate to ascertain if there is an increased risk of disease 
with the exposure.  Alternatively, a large number of animal studies have been performed that 
look at not only outcomes, but also the associated dose.  Yet, the exact metabolism of 
benzene is unknown in both humans and rodents, thus the question of human applicability 
always remains.  From a purely practical standpoint, the lifespan of any rodent is years, 
versus the decade(s) of potential benzene exposure that are typically associated with human 
hematological cancers.  In many cases, rodent data are only valuable for testing mechanisms 
versus health outcomes.   
 In addition to human cohort studies with no quantitative exposure estimates, there is a 
growing body of literature regarding human exposure that examines the sub-chronic effects 
of benzene exposure.  This database includes studies on chromosomal aberrations, peripheral 
blood counts, metabolite production and biomarkers of exposure.  Similar to the animal data, 
there are questions regarding the direct applicability of abnormalities in these measures and 
any relationship to eventual cancer causation.  For instance, is benzene the only cause of 
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peripheral lymphocyte chromosomal aberrations, or is there a background rate of these in 
unexposed individuals that leads to no increased risk of developing a hematological cancer?  
In this investigation, the literature on the sub-chronic effects of benzene exposure was 
carefully and critically evaluated, particularly regarding any relationship to future cancer 
causation.   
 The primary information available that correlates exposure information with human 
cancer cases is limited to a relatively small number of studies.  The most heavily studied 
group of workers in this cadre is the Pliofilm cohort, and in fact it is the only cohort judged to 
be adequate for risk assessment purposes by the U.S. Environmental Protection Agency 
(Infante, Rinsky et al. 1977; Infante 1978; Rinsky, Young et al. 1981; Rinsky, Smith et al. 
1987; Paustenbach, Price et al. 1992; Crump 1994; Paxton, Chinchilli et al. 1994; Paxton, 
Chinchilli et al. 1994; Crump 1996; Schnatter, Nicolich et al. 1996; Rinsky, Hornung et al. 
2002; Williams and Paustenbach 2003).  This is primarily due to the limited exposures, 
except for benzene, that these workers could have possibly encountered while working at one 
of three rubber hydrochloride plants.  In addition, there are two nested case-control mortality 
studies in the U.K. and Canadian petroleum industries, as well as, a nested case-control 
mortality and incidence study in the Australian petroleum industry (Schnatter, Armstrong et 
al. 1996; Rushton and Romaniuk 1997; Glass, Gray et al. 2003).  Three series of studies in 
the American chemical industry also have estimates of exposure associated with disease 
outcomes (Ott, Townsend et al. 1978; Bond, McLaren et al. 1986; Wong 1987; Wong 1987; 
Ireland, Collins et al. 1997; Collins, Ireland et al. 2003; Bloemen, Youk et al. 2004).  A 
cooperative study was started in the 1980s between the United States National Cancer 
Institute and the Chinese government agency responsible for worker health (Yin, Hayes et al. 
1996; Yin, Hayes et al. 1996).  This expansive study group attempted to incorporate all of the 
workers in industries with benzene and correlate their health outcomes with benzene 
exposure.  In addition to the aforementioned studies, there are also three small studies that 
have examined hematopoietic cancer mortality and benzene exposure in caprolactam 
workers, shoe factory workers and gas/electricity utility workers.  These studies are the total 
of human evidence available that directly links quantitatively measured benzene exposure 
with hematological cancer.  For that reason, each study was critically evaluated, within the 
context of its underlying cohort studies (when applicable), and this evaluation is the primary 
work of this investigation.  Although other studies can offer pieces of the puzzle, only these 
studies are “real-life” evaluations that measure actual cancer cases versus the calculated 
“risk” of cancer.  As mentioned in the introduction section, the “risk” of disease is a 
mathematical consideration subject to re-interpretation, but only a case is an undeniable fact.   
 Critical evaluation of the literature has been mentioned throughout this section, yet, 
this deserves further explanation.  Although the results of any study are potentially important, 
the results always depend upon the underlying question(s) asked, study design, methods of 
data collection, analysis method, comparison group(s), missing information and estimation 
procedures, study assumptions, biases, misclassification and confounders.  In addition to 
surveying the literature results, each study has been carefully examined for any factor which 
detracts or limits the potential validity and implications of the findings.  In many cases, the 
studies suffer from a lack of statistical power which could potentially be remedied by 
combining various cohorts.  However, because of the divergent nature of the studies, it is 
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literally impossible to perform a meta-analysis of all studies.  Only within industries utilizing 
similar methods can this hope to be accomplished. For this reason, a weight of evidence 
methodology based upon the criteria suggested by Hill has been used to draw conclusions in 
this investigation.            
 Interestingly, some of the most important reading that can be undertaken prior to 
examining the results of any study is found in the methods section and the last few 
paragraphs of the article.  The methods section should tell you quite clearly if it is even 
possible to answer the questions posed in the investigation, as well as what is known about 
the factors that might impact upon the outcomes (confounder and modifying factors).  
Conversely, the last few paragraphs of most papers contain the limitations of the study, per 
the author(s).  These are the two areas that this investigation primarily focused upon, in 
addition to the results.   
 In the following write-up of this investigation, the results section first details the 
seven groups of studies that have examined a correlation between quantitative benzene 
exposure and health outcomes, particularly hematologic cancer.  In this portion of the results, 
a synopsis of the study description and study findings is presented.  When multiple articles 
have been written by the author(s) about the same data, the articles have been presented 
together under the same heading.  These grouped articles have only one description of the 
method and results.  In most cases, each study, or group of related studies, is followed by the 
limitations of the respective study or studies, as determined by this investigator.  However, in 
other instances there were no clear cut limitations that could be discerned from the 
information presented.  With that said, there is no “perfect” study and an apparent lack of 
limitations may be the result of unstated limitations throughout the study series.  For 
example, every study that draws conclusions about the Pliofilm Cohort includes the 
underlying uncertainty associated with the incomplete documentation of plant working 
conditions, equipment, personal protection use, as well as the inadequate industrial hygiene 
data available from the early years of Pliofilm production at both the St. Marys and Akron 
facilities.  In addition, some primary research articles in the seven quantitative groups have 
been commented upon in editorials, as well as standalone articles have been written about the 
suspected deficiencies.  These editorials and articles have been detailed immediately 
following the primary research article.  In addition, any reply from the author(s) of the 
primary research study has been included, so as to capture their perspective on the editorial 
limitations. 
The write-up detailing the quantitative study groups is followed by qualitative studies 
and finally the animal data for a threshold dose of benzene-related leukemogenesis.  The 
qualitative studies are presented in table format, as this best lends itself to describing the vast 
number of studies and their associated findings.  Alternatively, the animal data is broken into 
sub-chronic toxicity and carcinogenicity studies.  The results are followed by a discussion 
section that consolidates and explains the data presented, as well as the limitations of the 
studies.  The Hill criteria are then used to determine if adequate evidence exists to support a 
threshold dose for leukemogenesis following benzene exposure.  Finally, the conclusions are 
stated, the limitations of this investigation are described and suggestions for future research 
are presented.    
 
 8
 
 
 
 
 
 
Chapter Three: Results 
 
 
A. Evaluation of the Human Studies with Quantitative Exposure Measurements 
 
1.  The Pliofilm Cohort 
 
Infante, P. F., R. A. Rinsky, et al. (1977). "Leukaemia in benzene workers." Lancet 2(8028): 
76-8. (Infante, Rinsky et al. 1977) 
-----AND----- 
Infante, P. F. (1978). "Leukemia among workers exposed to benzene." Tex Rep Biol Med 37: 
153-61. (Infante 1978) 
 
Historical description, Cohort Description and Study Methods: 
 
Natural rubber was masticated and then mixed with benzene in an agitating mixer.  
The solution was pumped to a blending tank and transferred in a reactor vessel where it was 
treated with hydrochloric acid to form rubber hydrochloride.  Benzene was added to adjust 
the proportion of solids.  This was then transferred to a neutralizing tank where scraps, soda 
ash, steam, plasticizers and more benzene were added.  After filtration, the rubber 
hydrochloride was sent to a casting unit, benzene was evaporated and recovered, and finished 
film was taken onto a roll.  The manufacturing process was essentially identical at both Ohio 
plants.  In 1942, a management member recommended periodic air monitoring, complete 
blood counts for new employees and ventilation additions.  Shortly thereafter, extensive 
ventilation equipment was installed in the Pliofilm department in one locality.  In 1946, tests 
conducted by the Industrial Commission of Ohio in that department revealed that in most 
instances benzol concentrations ranged from zero to 10 or 15 parts per million.  Between 
1963-1974 benzene point source concentrations were measured by company personnel in 112 
surveys.  These indicated that benzene exposures were generally below the recommended 
limit in effect at the time of each survey.  The allowable concentrations by time were as 
follows – 1941: 100 MAC, 1947: 50TWA, 1948: 35 TWA, 1957: 25 TWA, 1963: 25 Ceiling 
and 1969: 10 TWA. 
Historical environmental data was missing for the second locality.  Through the 
author’s observations, discussions with company personnel, and meager environmental data 
it is suggested that the benzene exposure was generally well within the recommended limits.      
Workers occupationally exposed to benzene in 1940-49 were followed for vital status 
up to 1975.  Person-years of observation and causes of death were determined for the period 
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Jan 1, 1950 to June 30, 1975.  The cohort consisted of 748 workers, of which the vital status 
was confirmed for 75%.  The missing workers were assumed to be alive for the purposes of 
the study.  The data before 1950 was excluded because vital statistics on lymphatic and 
hematopoietic malignancies were not published before that date.  Comparison was made 
between two control populations, the U.S. white male population standardized for age and 
time period, as well as, 1447 white men who had been employed in Ohio at a fibrous glass 
construction products factory during the same period.   
 
Results: 
There were a total of 140 deaths from all causes in the benzene-exposed workers 
which was below the expected number of 140.  Compared to the two populations, there was a 
significant (p<0.002) excess of leukemia observed in the cohort.  Seven deaths (four acute 
Myelogenous, 2 monocytic and 1 chronic Myelogenous) were recorded compared with an 
expected the number of 1.38 (p<0.002) for US white males and 1.48 (p<0.002) for the 
fibrous glass workers.  The latency period from initial exposure to death was 2-21 years.  
There was a significant excess of hematopoietic deaths, with an SMR=506 (p<0.002) for all 
leukemias (ICD 204) and SMR=260 for malignancy of the lymphatic and hematopoietic 
systems (ICD 200-205) when compared to the US male population.  The corresponding 
numbers for the fibrous glass workers was 474 and 176, respectively.  When compared to the 
expected incidence for myeloid and monocytic and total leukemia form the Connecticut 
Tumor registry – 50.37% should be of this type.  The expected deaths should be 0.6967 
versus the 7 observed, resulting in an SMR of 1004.  The authors concluded that there was a 
10 fold risk of dying from myelogenous and/or monocytic leukemia in this cohort.    
 
Limitations: 
1. The vital information for the cohort was only 75% complete, thus cases may have 
been missed.  This was rectified in a later analysis. 
2. The exposures were considered to be same at each plant, although this was primarily 
due to a lack of measurements at the Akron facility. 
3. The exposure assessment was a generalization indicating that exposures were mostly 
within the accepted regulatory limit at the time of exposure.   
4. The authors studied only the “wet side” workers and assumed that the “dry side” 
workers had no benzene exposure.   
 
 
Tabershaw, I. R. and S. H. Lamm (1977). "Benzene and leukaemia." Lancet 2(8043): 867-9. 
(Tabershaw and Lamm 1977) 
 
Comments about the Infante et al. (1977) Study: 
In response to the above Infante article, two partial cohorts for plants 200 miles away 
where data was collected, analyzed separately and combined.  They excluded workers from 
the “dry side” were benzene levels were still as high as 20 ppm up to 1974.  This was based 
upon an environmental survey conducted by the Occupational Health Study Group at the 
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University of North Carolina, School of Public Health (1974).  They also excluded 
pipefitters, mechanics and maintenance workers and an unknown number of workers who 
left plant A prior to 1944.  Workers at plant B worked only on Pliofilm, while those at plant 
A also worked in tire, hose, foams, rubber chemicals and metal products manufacture.  They 
called into question the sensitivity and reliability of measurements in the range noted by 
Infante (10-15 ppm) at that time.  A report by the Ohio Health Department at location A in 
the 1940’s indicated a concentration up to 500 ppm. (Fluker, J.R. Division of Safety and 
Hygiene Report, Ohio State Department of Health, May 4, 1948.)  In addition, measurements 
in the 1970s by the Occupational Health Study Group revealed levels as high as 355 ppm and 
means of 30 ppm (Environmental Survey, Occupational Health Study Group, University of 
North Carolina, School of Public Health, 1974.).   
Case 1-5 came from location A (310 workers) and Cases 6-7 were from location B 
(436 workers), case 8 was at location B but was not part of the study cohort.    Plant A 
manufactured many products and workers moved from process to process, while workers at 
plant B tended to stay within the Pliofilm process. 
 
The application of relative incidence of leukemia types to mortality is questionable 
because chronic leukemia lasts much longer.  More appropriate calculations of age-specific 
mortality rate for specific types of leukemia by 5 year age groups for the USA from 1962-
1967  can be calculated.  The relative probability of specific leukemia type for a person dying 
of leukemia at a specific age can be calculated.  Table II gives the expected distribution of 
leukemia by specific type for a group of 7 white males dying of leukemia at the same ages as 
in the reported cohort. “The differences between the observed and expected lies well within 
the realm of chance.” 
The vital status of 95% of the cohort has now been determined without any additional 
cases being identified.  
 
 
Infante, P.F., Rinsky, R.A., Wagoner, J.K. and Young, R.J. Letter to the editor.  Lancet ii: 
868-869 (1977).  
 
Response from the authors: 
Men employed in Pliofilm operations but not on production jobs were never intended 
to be included.  No details of the Environmental survey done by the University of North 
Carolina (sampling location, duration, analytical procedure or definition of department) was 
given to interpret the only data points (0.11,8 and 20 ppm) in that report.  At least one 
pipefitter (not included in the study) had responsibilities in Pliofilm production and died of 
AML.  An unknown number of workers in locality A left employment before 1944 and could 
not be included.   
Job mobility, as judged by personnel records did not seem to be different at the two 
locations.  The only common denominator of exposure at each locality was Pliofilm 
production.    The 500ppm noted by Tabershaw and Lamm was at the top of a tank.  
However, in some areas, high benzene concentrations existed where workers were present 
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intermittently.  “There are conflicting reports of respirator use for workers entering those 
areas and it is impossible to determine exact exposure levels at which the cases of leukemia 
may have been induced.” 
In studies of long latency, calculations should be based upon age-specific person-
years at risk.  When reanalyzed the Lamm and Tabershaw age-specific leukemia mortality 
rates with age-specific person-years of observation, the results indicate 6 cases of AML and 1 
monocytic leukemia observed versus 0.70 expected (SMR =857).  This is a conservative 
estimate because acute leukemia rates include lymphatic leukemia and none where found in 
this cohort.  With the new data up to July 22, 1977 the SMR is 560 (7 vs. 1.25).  Thus the 
SMR increased.   
 
 
Rinsky, R. A., R. J. Young, et al. (1981). "Leukemia in benzene workers." Am J Ind Med 
2(3): 217-45. (Rinsky, Young et al. 1981) 
 
 Cohort Description and Methods: 
  The cases were broken up into 2 groups: Group 1 consisted of 748 individuals who 
worked for at least 1 day between 01/01/41 and 12/31/1949.  Group 2 consisted of 258 
individuals who worked between 01/01/1950 and 12/31/1959.  Vital status was ascertained 
for 98% of the entire cohort and the remaining 2% were considered to be alive as of the study 
end date 06/30/1975.  Age and calendar year specific US white male death rates were used as 
referent rates to calculate the expected number of deaths for each temporal group.  Mean 
duration of exposure to benzene was brief, and 437 (58%) of the cohort were exposed for less 
than 1 year. Location 1 (formerly location B in Infante study) operated from 1939 and 
completely ceased in April 1976.  Location 2 (formerly location A in Infante study) had two 
plants that operated form 1937 – 1949 and 1949 to 1965, respectively.  Almost all industrial 
hygiene data was generated from Location 1 (St. Mary’s).  At location 1, benzene 
concentrations prior to the installation of an exhaust system in 1946 are unavailable.  The 
authors believe that benzene exposures at location 2 were similar to those at location 1.   
 
Case Descriptions with abnormal notations 
Case 2 – According to company records, it is alleged that on at least one occasion he entered 
a “quencher” in an attempt to break up some solidified soda ash.  It is possible that exposure 
levels during this encounter were in excess of 1,000ppm.   
Case 3 – Starting in 1944, he had other jobs in the plant but it is not known whether any of 
the other jobs involved exposure to benzene. 
Case 4 – Starting in 1934 (up to 1959), he had other jobs in the plant but it is not known 
whether any of the other jobs involved exposure to benzene. 
Case 5 – No environmental data exist prior to 1946, although concentrations of 100ppm were 
considered safe at the time.  It is estimated that he had 40ppm 8-hour TWA from 1948-1959.  
At various times in his career at the plant he was involved in the manufacture of tires, where 
he probably had some exposure to solvents, although it is unknown if that included benzene.   
Case 6 – He had worked at several jobs in the plant prior to starting in the rubber 
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hydrochloride department which may have involved some contact with solvents.  These 
solvents could not be determined.   
Case 7 - He had worked at several jobs in the plant prior to starting in the rubber 
hydrochloride department which may have involved some contact with solvents.  These 
solvents could not be determined.   
Case 8 – Starting in 1952, he worked at several other jobs at the plant and it is not known if 
this involved potential benzene exposure.  The benzene concentrations at the stripper rolls 
ranged from 66-680 ppm.  These measurements represent peak exposure conditions, and the 
8-hour time-weighted average exposures would have been considerably less. 
 
Results: 
A sharp increase in the SMR is seen among the group of workers exposed for longer 
than 5 years.  Five leukemia deaths were seen whereas only 0.23 was expected (SMR 
=2100).  When examined separately, location one had 2 cases of leukemia with only 0.58 
expected (SMR =345).  Location 2 had 5 cases with 0.67 expected, yielding an SMR of 746.   
The case with the longest latency interval among the additional cases noted (did not 
fit in cohort) was in a worker whose mean benzene exposure was estimated to have been 16 
ppm.  There is no evidence to suggest that exposures between the two locations differed 
widely, either in type or in severity.  Reliability of the instrumentation and methods used to 
measure these exposures were adequate for the levels being evaluated.  The highest values 
observed were in areas not entered by workers or where they would have only occasional 
brief exposures. A tabular description of the cases is presented in the following pages.  
 
Limitations: 
1. The case descriptions are very informative and start to outline a persistent group of 
missing information that will never be accounted for, including:  Lack of information 
regarding worker exposures prior to starting work at the Pliofilm plants, job mobility 
within the cohort (particularly to areas with exposures besides benzene) and inability 
to accurately estimate incident exposures such as peaks that are inherent to the worker 
and his practices versus the process related exposures.  Although there are many 
estimations and assumptions regarding worker practices, personal protective 
equipment and potential for peak exposure the information is literally unverifiable. 
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Table 1 – Results for Group 1 Workers 
At least 1 day of Work in a Department with the Potential for Benzene Exposure between 1/1/40 and 12/31/49 – 748 individuals. 
Case 
# 
Age 
at 
Death 
Year 
of 
Death 
Cause of 
Death 
Work 
Site 
Work Type Exposure Period Benzene  
Exposure  
(years) 
Latenc
y 
(years) 
Estimated 
Exposure 
(mean) 
1 36 1958 Monocytic 
Leukemia 
(ICD 204) 
Loc. 
1 
Casting Operator 12/30/40-03/20/42 
04/13/42-07/14/42 
1.5 17 Unknown 
prior to 1946 
2 29 1950 Chronic 
Myelogenous 
Leukemia 
(ICD 204) 
Loc. 
1 
Utility Operator* 08/23/48-09/30/48 1 month 2 35ppm* 
3 60 1958 Acute 
Myelocytic 
Leukemia 
(ICD 204) 
Loc. 
2 
Solution 
Neutralizer “ “ 
08/21/45-10/03/45 
07/18/45-08/21/45 
03/10/47-06/13/49 
09/23/49-06/24/53 
08/11/53-11/26/58 
11.5 13.5 35ppm 
4 65 1960 Acute 
Myelocytic 
Leukemia 
(ICD 204) 
Loc. 
2 
Casting Operator 
 
Cutting/Packing 
Film 
01/19/49-09/19/49 
05/17/50-02/26/58 
09/19/49-05/17/50 
02/26/58-03/31/58 
8.5 10.5 40ppm 
5 62 1961 Acute 
Myelocytic 
L:eukemia 
(ICD 204) 
Loc. 
2 
Casting Operator 
 
Order preparation 
Rolling/inspecting 
film 
05/11/39-11/13/40 
03/30/48-12/08/59 
12/08/59-12/21/59 
12/21/59-04/10/61 
13 22 Unknown 
prior to 1946 
1948-1959 
40ppm 
6 57 1961 Acute 
Granulocytic 
Leukemia 
(ICD 204) 
Loc. 
2 
Cement Mixer 
Casting Op 
Helper 
Casting Operator 
 
Supervisor 
09/25/41-10/07/41 
10/07/41-05/11/48 
05/11/48-08/25/50 
05/07/52-08/25/61 
08/25/50-05/07/52 
~20 ~20 1947-1957 
40ppm 
1957-1961 
25ppm 
7 57 1957 Acute 
Monocytic 
Leukemia 
(204) 
Loc. 
2 
Neutralizer 
Cameron machine 
operator 
Reactor operator 
Solution operator 
06/15/42-08/27/47 ~5 ~15.5 <10ppm 
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Table 2 – Results for Group 2 Workers 
At least 2 day of Work in a Department with the Potential for Benzene Exposure between 1/1/50 and 12/31/49 – 258 Individuals 
Case 
# 
Age at 
Death 
Year of 
Death 
Cause of 
Death 
Work 
Site 
Work Type Exposure Period ~Benzene 
Exposure 
(years) 
Latency 
(years) 
Estimated 
Exposure 
(mean) 
8 28 1954 Myleogenous 
Leukemia 
(ICD 204) 
Loc. 1 Utility Man 
Breakdown 
Mill 
Operator 
Casting 
Operator 
5/31/50-7/20/05 
7/20/50-9/27/50 
3/10/51-1/23/52 
9/27/50-3/10/51 
1/31/52-2/17/52 
1.5 3.5 Stripper 
rolls ranged 
from 66-
680 ppm 
average 
less. 
 
. 
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Table 3-Additional Cases of Leukemia Deaths 
These workers were not included in either Groups 1 or 2 – Reason for Exclusion in Bold 
Case 
# 
Age at 
Death 
Year of 
Death 
Cause of 
Death 
Work 
Site 
Work Type Exposure Period ~Benzene 
Exposure 
(years) 
Latency 
(years) 
Estimated 
Exposure 
(mean) 
9 67 1979** Acute 
Myeloblastic 
Leukemia 
(ICD 204) 
Loc. 2 Neutralizer 
operator 
9/18/42-3/4/60 14 35 16ppm 
(Range 0-
50ppm) 
10 38 1955 Acute 
Myeloblastic 
Leukemia 
Loc. 2 Supervisor 
(salaried) 
1/16/48-6/30/49 ~1.5 7.5 Unknown 
11 58 1950 Accidental 
Poisoning 
(ICD 961) 
Leukemia 
Lymphocytic 
Aleukemia 
Phase 
Loc. 2 Neutralizer 
Operator 
10/07/37-4/28/41 3.5 ~13 Unknown 
1267 48 1958 Benzol 
Poisoning 
(ICD 882) 
Acute 
Myelocytic 
Leukemia 
Loc. 2 Ass. Reactor 
Operator 
7/10/50-1/09-52 
8/13/52-5/21/54 
~3 years ~6 Unknown 
Infante, P.F. and M.C. White (1983).  “Benzene: epidemiologic observations of leukemia by 
cell type and adverse health effects associated with low-level exposure.” Environ Health 
Perspt 52: 75-82. 
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Historical Context and Review:  
Raised the fact that the previous evaluation by Rinsky et al. (Letter to the editor) that 
applied age specific death rates for acute and monocytic leukemia from the National Cancer 
Institute to the person-year distribution of the benzene exposed cohort was conservative.  The 
expected number of deaths from acute and monocytic leukemia was calculated to be 0.70 
with an SMR of 857.  This SMR would be conservative because the rates included other 
types of cancer not seen such Acute lymphatic leukemia.  A 29 year old with Chronic 
Myelogenous leukemia was not included because he died within 2 years of initial exposure to 
benzene.  It is possible that he died of AML.   
Commented about the Thorpe et al. paper and the methodological deficiencies:  1) 
The age breakdown of the entire population was unobtainable and had to be estimated from 
the age distribution of one company’s work force.  2)  The mortality rates used to generate 
the expected number of leukemia deaths reflect an average mortality experience of only some 
of the eight countries included.  3) Many companies had no mechanism which assured that 
the death of the worker or the cause of death would be reported to the company, and 
therefore an unknown number of deaths were missing from the analysis. 4)  No verification 
of cause of death or of diagnosis of leukemia was available. 5)  Infrequent monitoring and 
incomplete occupational histories made it difficult to distinguish persons exposed to benzene 
from those not exposed.   
Brief et al. estimated that in petroleum refineries, the probability of benzene levels 
exceeding 1 ppm TWA is less than 5%, and in petrochemical plants, the probability of 
benzene levels exceeding 5 ppm TWA is less than 8%.   
Scottenfeld reported an excess of total leukemia but was not statistically significant 
(11 observed vs. 7.56 expected), but the excess in the incidence of specifically lymphocytic 
leukemia was significant (7 observed vs. 2.56 expected, p=0.03).   
In 1965, Browning reviewed the literature and found 61 reported cases of leukemia 
among persons exposed to benzene:  6 acute myeloid, 1 subacute myeloid, 21 chronic 
myeloid, 7 lymphatic, 14 aleukemic and 12 erythroleukemic.   
Vigliani and Forni remarked on 44 persons with chronic benzene exposure in Paris 
form 1950 to 1965, including 23 cases of acute leukemia, 13 chronic myeloid leukemia and 8 
chronic lymphocytic leukemia.   
Aksoy reported on 42 workers with chronic benzene exposure in Turkey, including 
16 acute myeloblastic, 8 acute erythroleukemia, 7 preleukemia, 4 acute lymphoblastic 
leukemia, 3 acute monocytic leukemia, 2 chronic myeloid leukemia and 1 acute 
Promyelocytic and acute undifferentiated leukemia.   
The epidemiological studies by Infante and Ott were of insufficient sample size and 
sensitivity to detect excesses in types of leukemia that may not demonstrate a risk as high as 
that for myelomonocytic leukemia.    For example the statistical power of the Infante et al. 
study to detect a two-fold excess risk in types of leukemia other than acute or monocytic 
leukemia (at the 0.05 α level) was only 0.10.   
 
The author commented upon threshold.  Two studies conducted by Dow Chemical suggest 
that adverse health effects can be caused by exposure to benzene at average concentrations of 
less than 10 ppm.  Ott suggested that all three workers had been exposed to benzene at TWA 
 17
concentrations less than 10 ppm.  A second study by Dow researchers demonstrated a 
significant increase in structural chromosome aberrations in workers whose average benzene 
exposures were below 10 ppm.  Shown at OSHA docket.  Data from cytogenetic studies 
shows that the percentage of workers who had cells with chromosome breaks was 
significantly greater for the benzene exposed group.  Moreover, the percentage of workers 
who had both chromosome breaks and marker chromosomes was ten times higher among the 
benzene exposed workers.  A later analysis showed chromosomal damage at exposures 
averaging below 2.5 ppm, as well as a dose-response relationship between chromosomal 
damage and benzene exposure level.  Although there was a discrepancy between controls, 
who were much younger, and the exposed, large population studies have shown that 
cytogenetic breakage is not associated with age.  An analysis of the distribution of benzene 
workers in this study with both chromosome breaks and markers showed no difference 
related to age.  (Picianao, 1979) 
For the Infante et al. (1977) study, the calculation of the risk assessment was based on 
the experience of cohort members with 5 years of work experience or more (5 observed 
versus 0.23 expected SMR =2100) They made two assumptions, 1) They were exposed for 5 
years to estimates of average benzene exposure between 1937-53 and 30 years to average 
benzene exposure between 1937-75.  Since dose response data were not available, the one-hit 
model was used to estimate the excess leukemia risk which could have result from a working 
lifetime exposure (assumed to be 45 years) at the current (10ppm) and proposed (1 ppm) 
PEL.  The number of excess leukemia deaths at 10ppm for 45 years was 44-152 per 1000 
exposed workers.  The number of excess leukemia deaths at 1 ppm for 45 years was 5-16 per 
1000 exposed workers.    In the Ott et al. study exposure to 10ppm for 45 years would result 
in an excess number of myelogenous leukemia deaths was estimated to be 48-136.3 per 1000 
and 5 - 15 deaths at 1 ppm.  “Because any risk assessment is attended by a great deal of 
uncertainty, these figures should be interpreted with caution.” 
The author concluded that epidemiological studies of workers exposed specifically to 
benzene have been too insensitive to determine the risk of death from cell types of leukemia 
that may have risk ratios of less than 5.0.  Case series have indicated associations with 
chronic leukemia and lymphatic leukemia.  Cytogenetic studies have indicated damage at 
levels below 10ppm.   
 
 
Rinsky, R. A., A. B. Smith, et al. (1987). "Benzene and leukemia. An epidemiologic risk 
assessment." N Engl J Med 316(17): 1044-50. (Rinsky, Smith et al. 1987) 
 
 Historical Context and Methods: 
The three analyses completed by White et al, the EPA and IARC indicated that the 
amount of benzene exposure has been found to correlate positively with the risk of death 
from leukemia.  All three, however, were based on estimates of group exposure rather than 
on estimates of the exposure of individual workers.  The resultant risk estimates were 
therefore subject to wide variances.   
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This is an update of the original Pliofilm cohort with 6.5 more years of observation 
which updated the analysis to 1982.  In addition the life-table analysis system of NIOSH 
were modified to allow incorporation of data on individual exposures, whereas previous 
analysis only the duration of employment could be used as a surrogate for exposure.  The 
authors reiterated that “benzene was the only chemical in the rubber hydrochloride plants that 
could reasonably be associated with hematologic toxicity”.  The rubber hydrochloride plants 
were located within larger industrial facilities.  Employees were likely during their working 
careers to have worked in areas of these facilities where materials other than rubber 
hydrochloride were produced.” 
Each unique rubber hydrochloride job title (described in a short narrative on the 
personnel record) was assigned a numerical code.  Job codes and employment dates were 
then abstracted for each employee who had worked in a rubber hydrochloride department.  
Because of the large number of job codes, all workers were fitted to broader categories, 
referred to as “exposure classes,” which could be associated with specific manufacturing 
areas.  In general, exposure classes represented areas in which industrial hygiene 
measurements had been collected.  In some instances, job titles did not readily fit into a 
single area; in such situations, hybrid exposure classes were developed.   
A job-exposure matrix, which tabulated exposure-class codes by year, was 
constructed for each of the two locations.  Cells for which no data where available were 
completed by interpolation between available previous and subsequent values.  When 
interpolation could not be performed because no measured value existed for an exposure 
class in the first or last year of the study, the nearest measured value for that exposure class 
was projected forward or backward.  “Processes and job assignments were essentially 
identical at both locations, so benzene exposure levels measured at Location 1 were assumed 
to be naturally occurring simulations of exposure levels in corresponding areas at Location 2, 
when actual exposure measurements did not exist.” 
A total of 1165 workers with at least 1 ppm-day of cumulative exposure through 
December 31, 1965 were included in the cohort.  Vital status was ascertained for the cohort 
through December 31, 1981.  Sixteen were lost to follow-up (1.4%).   
 
Results: 
There was a statistically significant increase in deaths from all lymphatic and 
hematopoietic neoplasms (15 observed vs. 6.6 expected, SMR 227 95% CI: 127 - 376.  This 
was primarily due to the excess numbers of deaths from leukemia.  With stratification 
according to levels of cumulative exposure, the SMR for leukemia increased from 109 to 322 
(<40 ppm-years), 1186 (40-199 ppm-years) and 6637 (>400ppm-years). Even with halving 
and doubling of the respective cumulative benzene exposure categories (0 to 19, 20 to 99, 
100 to 199 and >200 ppm-years, as well as, 0 to 79, 80 to 399 and >400 ppm –years) in both 
instances the SMR continued to show a strong trend of increasing risk with increasing 
exposure (x½ = 134, 277, 0 and 2338 and x2=141, 609 and 6833). 
From the case-control analysis 10 controls were matched with each case (cases had a 
mean cumulative exposure of 254 vs. 50 ppm-years).  Average duration of exposure was 8.7 
years for the exposed and 2.6 years for the controls.  The controls were chosen from among 
the cohort members still alive at the time of death of the corresponding case.  They were 
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matched by year of birth and the year first employed The case control study was intended to: 
1) Evaluate the exposure terms that govern the relation between the risk of death from 
leukemia and exposure to benzene, 2) evaluate the effect of potential confounders and effect 
modifiers on this relation, and 3) identify the functional form of the exposure-response 
relation.  .   
After examining several models, the first examination looks at cumulative exposure, 
duration of exposure and average exposure rate.  In the three separate models, cumulative 
exposure (ppm-years) was found to be the strongest single predictor of death from leukemia 
(ß=0.0126; 95% CI: 0.0028 to 0.0224; chi-square =6.4, P=0.011).  “In this model, only 
cumulative exposure was found to contribute materially to the risk of death from leukemia, 
although it is not possible with only nine cases to establish cumulative exposure as the 
unqualified best expression.” 
To examine the shape of the exposure-response relation, a conditional logistic-
regression analysis was performed, in which 10 controls were matched to each cohort 
member with leukemia.  The exposure-response function was evaluated by logarithmic 
transformation (chi square=4.86; p=0.027) of cumulative exposures vs. untransformed 
cumulative exposures (chi-square=6.4) the untransformed fit the model best.  A quadratic 
was added to form the odds ratio for leukemia in relation to cumulative exposure to benzene.    
OR = exp(0.0126 x ppm-years)    From this equation, the average cumulative exposure of the 
cases and controls (69 ppm-years) was found to produce an odds ratio relative to the 
unexposed workers of 2.4 (95% CI 1.2 to 4.7).  Upon re-examining the effect of cumulative 
exposure, the odds ratio increased slightly (ß = 0.0169), as did the statistical significance of 
the observation (chi-square=6.7; P=0.010). 
The authors concluded that an average exposure level of 10 ppm for 40 years would 
have an increased risk of death from leukemia of 154.5 (95% CI: 3.1 – 77.85). At 1 ppm, the 
increase would be 1.7 (95% CI: 1.1 to 2.5) and at 0.1 ppm the increase would be virtually 
equivalent to the background risk (OR, 1.05 with CI: 1.01 to 1.09).  
A tabular description of the Pliofilm cohort is detailed in the following pages.    
 
Comments on Rinsky 1987 article: 
Max Bader – No employee first exposed after 1954 had leukemia or myeloma, even 
though hiring continued for 11 years and even though 7 of the 13 cases had the onset of 
disease within 20 years of first exposure.  Cases were followed through 1981, so there should 
have been some cases).  In the study, two subjects died within 3.5 years of exposure.  
Looking at the year of initial exposure of the 13 cases, one can see that 9 had first exposures 
before the end of World War II.  One wonders about the measuring instruments in that 
situation.   
The authors responded that the most likely explanation for this finding is a reduction 
of cumulative exposure; relatively few workers were hired after 1954 and among those 
workers, total lifetime exposure was kept low by decreases in production and progressive 
diminution in exposure standards.   
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Table 4- A Comparison of Case Details Between the 1981 and 1987 Rinsky et al. Analyses 
Case # Age at 
Death 
Work Site Benzene 
Exposure 
Rinsky 
1981 (years) 
Benzene 
Exposure 
Rinsky 
1987 (years) 
Latency 
Rinsky 
1981 (years) 
Latency 
Rinsky 
1987 (years) 
Estimated 
Exposure 
Rinsky 
1981 
(mean) 
Estimated 
Exposure 
Rinsky 
1987 (ppm-
years) 
1 36 Loc. 1 1.5 1.5 17 17 Unknown 
prior to 
1946 
49.99 
2 29 Loc. 1 1 month 1 month 2 2 35ppm* 0.010 
3 60 Loc. 2 11.5 11.5 13.5 13.5 35ppm 259.50 
4 65 Loc. 2 8.5 14 10.5 15.5 40ppm 498.23 
5 62 Loc. 2 13  22 22 Unknown 
prior to 
1946 
1948-1959 
40ppm 
478.45 
6 57 Loc. 2 ~20 20 ~20 20 1947-1957 
40ppm 
1957-1961 
25ppm 
639.84 
7 57 Loc. 2 ~5 5 ~15.5 15 <100 ppm 98.55 
8 28 Loc. 1 1.5 1.5 3.5 3.5 Peak 66-680 
average less 
10.16 
9 67 Loc. 2 14 14 35 37 16 ppm 
(Range 0-
50) 
252.66 
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Table 5 - Descriptions of Deaths from Leukemia and Multiple Myeloma in 13 Workers Exposed to Benzene 
Case No. Age at 
Death 
Year of 
Death 
Latency* 
(yr) 
Cause of Death† Corroborating 
Medical 
Reports 
Plant 
Location: 
Duration of 
Employment 
Cumulative 
Benzene 
Exposure 
(ppm-yr) 
1 36 1958 17 Monocytic 
Leukemia (204) 
None available Location 1:  
1 ½ yr. 
49.99 
2 29 1950 2 Chronic 
Myelogenous 
Leukemia (204) 
Hospital, 
autopsy, tissue 
slides 
Location 1:  
1 mo. 
0.10 
3 60 1958 13 ½  Acute Myelocytic 
Leukemia(204) 
Hospital, 
hematologist 
Location 2:  
11 ½ yr. 
259.50 
4 65 1960 15 ½ Acute 
Myelogenous 
Leukemia (204) 
Hematologist, 
hospital, tissue 
slides 
Location 2:  
14 yr. 
498.23 
5 62 1961 22 Di Guglielmo’s 
Acute Myelocytic 
Leukemia (204) 
Hospital, 
physician 
Location 2:  
13 yr. 
478.45 
6 57 1961 20 Acute 
Granulocytic 
Leukemia (204) 
Hospital, tissue 
slides, autopsy 
Location 2:  
20 yr. 
639.84 
7 57 1957 15 Acute Monocytic 
Leukemia (204) 
Tissue slides Location 2:  
5 yr. 
98.55 
8 28 1954 3 ½ Myelogenous 
Leukemia (204) 
None available Location 1:  
1 ½ yr. 
10.16 
9 67 1979 37 Acute 
Myeloblastic 
Leukemia (204) 
None available Location 2:  
14 yr. 
252.66 
10 69 1980 25 ½ Multiple 
Myeloma (203) 
None available Location 1:  
1 ½ yr. 
19.50 
11 52 1963 22 ½ Multiple 
Myeloma (203) 
Hospital Location 1:  
4 days 
0.11 
12 62 1968 24 ½  Plasma-cell 
Sarcoma (203) 
Hospital  Location 1:  
23 yr. 
652.66 
13 68 1981 26 ½  Multiple 
Myeloma (203) 
None available Location 1:  
9 mo. 
7.75 
*Latency was defined as the length of time (in years) from the date of first exposure until death. 
†In parentheses is the International Classification of Diseases code as determined by a nosologist from 
information on the death certificate. 
 
R.A. Rinsky, A.B. Smith, R. Hornung, T.G. Filloon, R.J. Young, A.H. Okun and P.J. Landrigan. 1987. Benzene 
and Leukemia: An Epidemiologic Risk Assessment.  The New England Journal of Medicine 14(2): 1044-1050.
22 
Rinsky, R. A. (1989). "Benzene and leukemia: an epidemiologic risk assessment."  
Environ Health Perspect 82: 189-91. (Rinsky 1989) 
 
This was very similar to the 1987 article by the same author.  Subsequent to the 
previous analysis (Rinsky 1987) they learned of another leukemia death among the cohort.  
Ten additional controls were chosen and the case-control analysis was repeated.  This 
resulted in slightly lower odds ratio but increased the statistical significance of the 
relationship.  The data from this additional case serves as additional corroborating evidence.   
 
(From Rinsky 1987 article) “It is of interest that the deaths from multiple myeloma 
occurred among the group with the lowest cumulative exposure to benzene (<40 ppm) and 
that all four required exceptionally long latency periods for hematologic malignancies (>20 
years).  This raises the possibility that low cumulative exposure to benzene may produce 
relatively well differentiated malignancy such as multiple myeloma, whereas higher 
exposures lead to leukemia.”   (From this article) “It is conceivable that the progressive 
reduction in benzene levels which has been achieved over the last several decades, may lead 
to a situation in which multiple myeloma will in the future become manifest in a large 
population of workers with relatively low cumulative exposures to benzene. The present 
observations must, however, be interpreted cautiously in absence of further corroborations.”  
 
 
Lamm, S. H., A. S. Walters, et al. (1989). "Consistencies and inconsistencies underlying the 
quantitative assessment of leukemia risk from benzene exposure." Environ Health Perspect 
82: 289-97. (Lamm, Walters et al. 1989) 
 
Review of Methods and Comments:  
This paper deals with the concept of consistency among the studies that generally 
support the concept of an association between benzene exposure and excess risk of leukemia 
within the studies critical to the quantitative assessment of that risk. In particular, the NIOSH 
study by Rinsky et al. is closely examined the consequences of the findings upon the possible 
dose response are determined.   
 The 2 primary classes of leukemia emanate from distinctly different cell lines, lymph 
tissue and marrow.  These classes are further divided into acute and chronic subtypes.  The 
particular type of leukemia most closely associated with benzene exposure, acute 
myelogenous leukemia, includes a number of further subtypes such as  
myeloblastic, promyelocytic, myelomonocytic, monoblastic, erythroleukemic and 
megakaryoblastic.  It contradicts our present understanding of cancer for a particular 
carcinogen to produce one type of leukemia in some people and another type in other 
individuals.  Although it is possible, such a finding would suggest a different metabolic 
pathway and in the case of benzene there is no evidence to suggest that is the case.   
Regarding the Ohio Pliofilm cohort, Plant 1 was established in 1939 and continued 
manufacturing Pliofilm until 1976.  Plant 2A at Location 2 in Akron, Ohio commercially 
produced Pliofilm from 1936-1949 and Plant 2B produced Pliofilm from 1949-1965. The 
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authors of the NIOSH study asserted that the benzene exposure for Pliofilm processed at each 
of these 3 plants was identical, although all of the benzene measurements came from plant 1.   
This has to be taken as a matter of faith.   All of the AML cases came from one location – 
Plant 2A – where no benzene-exposure data was available, while no cases of AML were 
diagnosed among workers at Plant 1 and 2B where some benzene exposure data are 
available.  All the cases of AML occurred in workers hired at Plant 2A prior to 1945. None 
of the workers hired at Plant 2A from 1945 to 49 or at Plant 2B from 1949 to 65 has been 
reported to have any type of leukemia. None of the workers hired at the Plant 1 from 1939 to 
1965 has been reported to have AML although the follow-up periods range from 16 to 42 
years. The cohort of people from Plant 2A has incomplete personal records from that 
location. Records prior to 1945 were missing, except for records of people who continued to 
be employed after 1945, yet were hired prior to that point.  Among the cohorts for whom 
employee rosters are complete, there is no known case of AML. This would suggest that 
exposures prior to 1945 were critical.  See table 6 below for a breakdown of cases by 
location, diagnosis, year of hire, latency, year of death and cumulative benzene exposure.     
 
 
Table 6 - Case List of Leukemias and Multiple Myelomas Ordered by Location and 
Year of Hire (11) 
Location Diagnosisa Year of 
Hire 
Latency 
Years 
Year of 
Death 
Cumulative 
benzene 
Exposure, 
ppm-year 
2 AML 1939 22 1961 478.5 
2 AML 1941 20 1961 639.84 
2 AMoL 1942 15 1957 98.55 
2 AML 1942 37 1979 252.66 
2 AML 1944 13.5 1958 259.5 
2 AML 1944 15.5 1960 498.23 
1 MM 1940 22.5 1963 0.11 
1 MoL 1941 17 1958 49.99 
1 PCS 1943 24.5 1968 652.66 
1 CML 1948 2 1950 0.1 
1 ML 1950 3.5 1954 10.16 
1 MM 1954 25.5 1980 19.5 
1 MM 1954 26.5 1981 7.75 
aAML, Acute Myeloid Leukemia; AMoL, Acute Monoblastic Leukemia; MM, Multiple 
Myeloma; MoL, Monocytic Leukemia; PCS, Plasma Cell Sarcoma; CML, Chronic Myeloid 
Leukemia; ML, Myeloid Leukemia.  
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S.H. Lamm, A.S. Walters, R. Wilson, D. Byrd and H. Grunwald.  1989. Consistencies and 
Inconsistencies Underlying the Quantitative Assessment of Leukemia Risk from Benzene 
Exposure.  Environmental Health Perspectives 82: 289-297. 
 
 
The AML cases in the study had latency periods ranging from 13.5 to 37 years, with a 
mean of 20.5 years. Typically, AML secondary to chemotherapeutic agents have a latency 
ranging from 0.5 to 10 years and a mean range of 2-5 years.   In addition, the latencies 
reported by Rinsky are long when compared to other benzene exposed groups.  Analysis of 
literature in the 1980’s showed that 80% of benzene-associated leukemia deaths occurred no 
more than two years after the last benzene exposure.  
Rinsky estimated that the AML cases at Location 2A have a cumulative benzene 
dosage 250 - 650 part per million years, yet all of the data that forms those measurements 
come from Location 1.  In addition the workforces at the two plants differed in their potential 
for exposure to benzene and other chemicals in the non-Pliofilm job sites. Plants 2A and 2B 
were part of a large industrial tire building complex, while Location 1 a stand alone plant.  In 
addition, exposure levels were considered to be the same when exposure data existed at one 
plant and this was also extrapolated when no exposure data existed.   For instance, one job 
had measurement data for 1976 only, so it was assumed that this was the same level in 1945.  
Alternatively, Crump and Allen developed an exposure assumption in 1984 in which they 
estimated cumulative benzene exposure, as well as peak intensity exposure.  To calculate or 
estimate exposure levels for jobs during time periods for which data existed, they calculated 
all exposure data for a particular job as a percentage of the allowable level at that time and 
then applied that percentage or proportion to each time period. Given the earlier example, 
with the extrapolation from 1976 to 1945, the Crump and Allen data would find a value of 
150 ppm versus the 15 ppm determined by Rinsky.   
Due to the different methods of extrapolating exposures, the Crump and Allen 
exposures are generally much higher than the Rinsky estimations.  In addition, Rinsky 
limited the analysis to the “wet side”, while Crump included these workers.  It was reported 
that the odor of benzene was “perceptible” on the dry side of the process in the 1940s. The 
estimations of Crump and Allen are corroborated by the study performed by Kipen et al. 
which analyzed the available hematology data on the Pliofilm cohort.  This analysis revealed 
a correlation coefficient for the white blood cell counts of 0.72 with the Crump and Allen 
data versus 0.03 for the Rinsky data when looking at the years 1940-1948.   Unfortunately, 
by eliminating the dry side workers, Rinsky limited the inclusion and analysis of lower level 
exposures.   
 The authors noted that they found it “difficult to accept that the benzene exposure 
levels at Location 2, where all the AML cases occur, could have been the same as exposure 
levels at Location 1 where no AML cases occurred.”  They further noted that they would 
have reported the risk analyses separately for the two facilities.   When comparing the two 
exposure estimates, there is a statistically significant excess of leukemia with the Rinsky 
measures at >40 ppm, while the Crump and Allen only achieves statistical significance with 
>250 ppm.   
The Rinsky assumptions conclude that a statistically significant leukemia risk exists 
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with peak benzene exposure over 20 ppm and a work/life average exposure over 6 ppm. 
Alternatively, the Crump assumption, using the same model, included a statistically 
significant leukemia risk with peak exposure over 250 ppm and a work/life average exposure 
over 11 ppm. That would be 450 ppm-years divided by 40 years equals 11.25 ppm. The 
determination of risk is clearly dependent upon the methodological assumptions made in 
analyzing in the data.  This data suggests a nonlinear dose-response relationship and 
threshold toxicity.    
 
 
Byrd, D. M. and E. T. Barfield (1989). "Uncertainty in the estimation of benzene risks: 
application of an uncertainty taxonomy to risk assessments based on an epidemiology study 
of rubber hydrochloride workers." Environ Health Perspect 82: 283-7. (Byrd and Barfield 
1989) 
 
The impact of uncertainty about the structure of a risk model will vary with exposure 
level.  For example, simple substitution of a quadratic term for cumulative exposure in the 
retrospective case-control formula results in a difference of two orders of magnitude in risk at 
5 ppm-year instead of 500 ppm-year (0.0004 instead of (0.03), using the 1981 data.  The 
1987 data of Rinsky et al.  improves the measurement uncertainty by about an order of 
magnitude, whereas the effect of a quadratic term on risk magnitude remains the same.  
Further, extrapolation to environmental levels of benzene (5-0.5 ppb) results in a five to six 
orders of magnitude difference in risk if a quadratic term is used.   Use of a quadratic term 
instead of a linear term constitutes a minimal change in methodological assumptions.   
Confounding factors such as sources of benzene exposure other than inhalation, 
systematic errors in exposure measurement, joint effects of other substances with benzene, 
indirect effects of benzene exposure through other effects on hematologic status, correlated 
exposure of benzene with other substances, skew in population age or chance occurrence 
could hypothetically explain the association seen among the cohort.  
“Disagreements about appropriate values for parameters derived from a study for a 
risk model (for example, the number of observed cases, population at risk, exposure levels, 
duration of exposure, latency of effect and/or appropriate control group for comparison)  
usually do not obtain much attention.  This paper suggests that for benzene the preoccupation 
is justified.  Methodological uncertainty constitutes the major source of uncertainty in 
benzene risk estimates.” 
 In animal studies, intermittent exposure to high concentrations of benzene also creates 
greater risk than continuous exposure.  And current understanding of the effect of benzene on 
synchronization of hematopoietic cells does not suggest a linear dose-response relationship 
(Irons 1979). 
 
Paustenbach, D. J., P. S. Price, et al. (1992). "Reevaluation of benzene exposure for the 
Pliofilm (rubber worker) cohort (1936-1976)." J Toxicol Environ Health 36(3): 177-231. 
(Paustenbach, Price et al. 1992)  
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Results:   
The results of this re-evaluation agreed far more with the estimates of Crump and 
Allen versus the Rinsky estimates.   The estimates presented in this paper and Crump’s were 
both ~5x greater with every job title when compared with the Rinsky data.  However,  there 
were two differences from the Crump data noted by the authors:  1) the average 
concentration of the two active facilities were higher than the estimate and 2) the wet side 
exposures, particularly the neutralizer,  were higher than those for the dry side workers 
represented by the operator.  The Paustenbach analysis incorporated new information into 
their model, including data about the accuracy of the measuring devices used to gather the 
existing industrial hygiene data, particularly from the early years of operation; evidence of 
extended work weeks beyond the 40 hours per week assumed by Rinsky et al.; the fact that 
the St. Marys facility was shut down during WWII; medical evidence of elevated exposure 
(Kipen, 1988) in the early years of operation; evidence of improved engineering controls 
over time (thus assumptions of the same exposure over time are incorrect); incorporation of 
dermal exposure into the model; changes in some exposure categories for certain jobs (based 
on new interview information)    
The sensitivity analysis showed that no single factor produced a major change in the 
overall estimate exposure.  For example, the assumption of higher workplace concentrations 
during the early years of production raised the estimates of exposure by 20%.  The 
assumptions of an increased work week and use of personal protection devices changed the 
average estimate by less than 15%.  During the 1940-1949 period, the assumption of 
increasing workplace concentration during the early years of production raised estimates of 
exposure by 30%.  The role of erroneous analytical measure had only a minor impact on the 
estimates of exposure in either location.   
 The conclusion that Pliofilm manufacture was a relatively high exposure job was 
based on four factors.   
1. Medical and clinical items of toxicity in Akron St. Mary’s workers.    
2. Evidence of significant engineering changes in St. Mary’s in 1946 and at Akron 
3. Industrial hygiene experience in other industries.  
4. The higher TLVs that were in place in the 1940s and 50s 
 
The lack of Pliofilm manufacture at St. Mary’s from 1942-1945 raised a potential 
contradiction with the findings of Kipen et al, regarding the effects on blood.  In the Kipen et 
al study, the workers blood count showed some indication of improving blood count in 1943; 
however, in 1946 when production resumed the blood counts did not fall.  It is possible that 
this is related to how the records were kept.   
For a number of reasons, some caution should be used in interpreting the data from 
the Pliofilm cohort.  There may an effect that selected for tolerance, as there can be 
significant differences in inter-individual susceptibility to the effects of benzene.  For 
instance, a susceptible person may have left the workforce due to forced removal following a 
decreased blood count.  Second, some workers may have had additional, unaccounted for 
benzene exposure due to other workplace exposures.     
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Crump, K. S. (1994). "Risk of benzene-induced leukemia: a sensitivity analysis of the 
Pliofilm cohort with additional follow-up and new exposure estimates." J Toxicol Environ 
Health 42(2): 219-42. (Crump 1994) 
 
Historical Description and Methods: 
Three sets of exposure estimates have been proposed for the Pliofilm cohort, 
including Rinsky 1987, Crump and Allen 1984 and Paustenbach 1992.  The primary 
differences between the evaluations have centered on the different methods used to estimate 
the exposures in the early years of production for very limited air monitoring data.  The 
Paustenbach estimates are more consistent with the Crump and Allen versus the Rinsky data.   
This paper updated the risk assessment of Crump and Allen up to 1987 and 
incorporated the exposure matrix of Paustenbach.  A sensitivity analysis was performed to 
evaluate the effect of model assumptions on the risk estimates.  Several dose response 
models were examined, including models that allow nonlinear dose response relationships.  
In addition, the fidelity of various models in describing the underlying data was studied.  
Dose response modeling was conducted for AMML and total leukemia. Two of the 
leukemia cases were of an unidentified type. The background rates used in the life table 
analyses and dose response modeling were as follows: AMML - 1973 - 1977 US mortality 
date, U.S. white males, ICD code 205 acute granulocytic leukemia and 206, acute monocytic 
leukemia, all leukemia -  1975 U.S. white males,  ICD codes 204 to 207, all lymphatic and 
hematologic cancer - 1975 U.S. white males.  These periods were considered reasonable 
because the leukemia rates were stable over time during the follow-up period.  For all 
leukemia, all lymphatic and hematopoietic cancer, the total mortality and the background 
mortality rates used were 1988 U.S. rates for all races and sexes.  
 
Results: 
Presented below in Table 7 is the life table analysis of the association of various 
categories of hematopoietic cancer with cumulative exposure based upon the Paustenbach 
exposure matrix.  Three categories are considered – AMLL, all leukemia and total 
lymphatic/hematopoietic cancer.  AMML had the strongest dose response and the other two 
are not significant if AMML is removed.  None of the non-AMML leukemias were 
associated with exposures of <400 ppm, while five of the AMM cases were associated with 
exposures greater than 1,000 ppm-years. Thus, AMML was the only response clearly related 
to benzene exposure.  
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Table 7 - Summary of Information on 21 Cases of Lymphatic and Hematopoietic 
Cancer Deaths in Males 
  Year of: Cumulative Exposure 
(ppm-yr) 
  
Locationa Caseb 
number 
Death Crump 
and 
Allen 
Paustenbach Leukemia AMMLc 
S 1 1958 381 127 X Y 
S 2 1950 3 3 X  
A 3 1958 251 1054 X X 
A 4 1960 1497 1242 X X 
A 5 1961 939 1122 X X 
A 6 1961 2155 1771 X X 
A 7 1957 307 670 X Y 
S 8 1954 23 54 X  
A 9 1979 325 1129 X X 
S 10 1980 31 51   
S 11 1963 0 0   
S 12 1968 1148 3075   
S 13 1981 16 12   
S 14 1973 54 651   
S 15 1978 175 138   
A 16 1984 65 338 X  
A 17 1985 18 598 X X 
S 18 1985 145 293 X  
S 19 1986 50 12 X ? 
S 20 1987 6 8 X ? 
A 22 1987 0 19   
aS, St. Marys; A, Akron. 
bCase number 1-13 provided by Rinsky et al. (1987) and 14-22 by Paxton et al. (1994a).  
Case number 21 was a female and was excluded from the present analysis. 
cIncludes acute myelocytic (X) and acute monocytic leukemia (Y). 
 
K.S. Crump. 1994. Risk of Benzene-Induced Leukemia: A Sensitivity Analysis of the 
Pliofilm Cohort with Additional Follow-up and New Exposure Estimates.  Journal of 
Toxicology and Environmental Health  42: 219-242. 
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Table 8 - Observed and Expected Numbers of Cancer Deaths by Cumulative Exposure 
(Paustenbach et. al. Exposure Matrix) for Different Categories of Lymphatic and 
Hematopoietic Cancers 
  AMML Leukemia Total Lymphatic and 
Hematopoietic 
Cumulative 
exposure, 
ppm-yr 
range 
(mean) 
Person-
years 
OBS EXP RR OBS EXP RR OBS EXP RR 
0-45 (11) 30,482 0-2a 0.82 0.0-
2.4 
3 2.41 1.2 6 6.16 1.0 
45-400 (151) 16,320 1 0.51 2.0 4 1.50 2.7 6 3.83 1.6 
400-1000 
(602) 
4867 2 0.22 9.1 2 0.65 3.1 3 1.65 1.8 
>1000 
(1341) 
915 5 0.06 82.8 5 0.18 28.1 6 0.44 13.5 
Total (132) 52,584 8-10 1.61 5.0-
6.2 
14 4.75 2.9 21 12.09 1.7 
Note. AMML, combined acute myelogenous (AML) and acute monocytic leukemia (ICD 
codes 205.0 and 206.0). Leukemia, ICD codes 204-207.  Total lymphatic and hematopoietic, 
ICD codes 200-209.  OBS, number of observed cancer deaths.  EXP, number of expected 
cancer deaths based on U.S. sex- and age-specific rates.  RR, OBS/EXP. 
aTwo leukemias could not be identified as to type. 
 
K.S. Crump. 1994. Risk of Benzene-Induced Leukemia: A Sensitivity Analysis of the 
Pliofilm Cohort with Additional Follow-up and New Exposure Estimates.  Journal of 
Toxicology and Environmental Health  42: 219-242. 
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The two exposure matrixes (Paustenbach and Crump) lead to different conclusions 
concerning the shape of the dose response. With the Crump and Allen matrix the dose 
response is essentially linear and there was little evidence of intensity dependent 
nonlinearity.  The dose responses derived using the Paustenbach exposure matrixes found 
that each of the three best fitting models were quadratic and departures from linearity with 
borderline significant in each case. The Paustenbach analysis was much more in-depth than 
the Crump and Allen analysis of exposure and likely provides a better representation of 
exposures in the cohort. Nevertheless, uncertainty still remains with regard to exposures 
during the earliest period of the plant.  The Paxton study (1994) revealed that the average 
exposure predicted from the Paustenbach matrix was ~2x greater than the Crump and Allen 
exposure matrix and ~4x greater than the Rinsky exposure matrix.   
Existence of nonlinearity in the dose responses derived from the Paustenbach 
exposure matrix provide some limited support for the Paustenbach matrix over the Crump 
and Allen matrix. “Random errors in classification of exposure will tend to obscure any 
nonlinearity that may be present in the dose response. Thus, if the true dose response is 
nonlinear, then a more accurate exposure characterization will tend to exhibit more 
nonlinearity. On the other hand, if a dose response is truly linear, then random errors in 
exposure characterization will tend to reduce the magnitude of the effect of exposure, but 
will not tend to make the dose response appear to be nonlinear.” 
The Rinsky exposure matrix did not conform to blood count data for this cohort as 
well as the Crump and Allen exposure matrix. Based on a study of over 17,000 peripheral 
blood counts collected from 459 workers at St. Mary’s between 1940 and 1975, Kipen found 
that higher benzene exposure during the 1940s were consistent with the blood count data.  An 
alternative hypothesis proposed by Hornung (1989) suggested that the temporal increase in 
blood counts was likely due to changing laboratory practices.  However, this was not consist 
with a follow-up study which showed a decrease in white blood cell counts of approximately 
1,000 cells/mm3 during the first four months of employment in workers. This was not 
consistent with the Rinsky, but was best explained by the Crump and Allen exposure matrix.   
Crump concluded that it was not possible to accurately determine the amount of 
nonlinearity present in the dose response curve based on the information now available from 
the cohort. Additional follow-up with the cohort should help to clarify the best response. It is 
possible that other measures of intensity dependent nonlinearity may be more appropriate, 
and if so, they might indicate nonlinearity more clearly.  
 
 
Paxton, M. B., V. M. Chinchilli, et al. (1994). "Leukemia risk associated with benzene 
exposure in the Pliofilm cohort. II. Risk estimates." Risk Anal 14(2): 155-61. (Paxton, 
Chinchilli et al. 1994) 
-----AND----- 
Paxton, M. B. (1996). "Leukemia risk associated with benzene exposure in the Pliofilm 
cohort." Environ Health Perspect 104 Suppl 6: 1431-6.(Paxton 1996)___________________ 
 
Study Description and Methods: 
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An absolute or at least a functional threshold seems possible for benzene induced by 
benzene; however, the conservative assumptions of regulatory agencies mandate the use of a 
linear dose mathematical model.   
In this study a proportional hazards analysis was used to examine more than 4x as 
much information (35% v. 8%) as the conditional logistic regression previously used.  Most 
importantly, it allows the incorporation of quantitative estimates of individual worker 
benzene exposure accumulated during the course of their employment.  In contrast, the much 
more crude SMR technique considers only broad exposure categories.    Proportional hazards 
analysis also reduces the possibility of arbitrary allocation of control by grouping controls 
with the cases in uniform strata.  In the table below the additional number of leukemia deaths 
based upon the Rinsky and Crump & Allen exposure estimates are presented. 
 
 
Table 9 - Previous Estimates(4) of Additional Leukemia Deathsa Derived Using the 
Conditional Logistic Model on the Pliofilm Cohort Updated 
  Cumulative Occupational Benzene 
Exposurec (ppm-years) 
Exposure Estimates Control Set 45 450 
Rinsky(2) Selected by Rinsky(3) 5.1 
(0.8-12) 
640 
(16-990) 
 Matched on plant, 
date of birth, start of 
Pliofilm job 
4.2 
(1.0-8.7) 
450 
(21-950) 
Crump(6) Selected by Rinsky(3) 0.5 
(0.1-1.0) 
8.3 
(1.4-20) 
 Matched on plant, 
date of birth, start of 
Pliofilm job 
0.5 
(0.1-1.0) 
7.9 
(1.1-20) 
aEstimated mean number of leukemia deaths over the lifetime of 1000 exposed individuals in 
excess of an assumed background rate of 7.07(13) (95% confidence interval). 
bAll estimates based upon 10 controls matched to each of the original nine leukemia cases. 
cStated occupational exposure assumed to result from exposure to a concentration of 1 or 10 
ppm for 8hr/day, 5 day/week, 50 week/year. 
 
M.B. Paxton, V.M. Chinchilli, S.M. Brett and J.V. Rodricks. 1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort.  II. Risk Estimates.  Risk Analysis 
14(2): 155-161. 
 
 
Paxton, M. B., V. M. Chinchilli, et al. (1994). "Leukemia risk associated with benzene 
exposure in the Pliofilm cohort: I. Mortality update and exposure distribution." Risk Anal 
14(2): 147-54. (Paxton, Chinchilli et al. 1994) 
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Study Description and Methods: 
 In the recent update of the Pliofilm cohort by NIOSH, only the wetside worker vital 
status data was updated, thus they are the only workers included in the SMR analysis.  An 
additional 123 deaths were identified.  In the update period 4,759 person years were accrued 
in addition to the 35,586 person years that had been recorded by the end of 1981. Loss to 
follow-up was minimal―2.6% through 1981 for the dryside workers and 0.9% for the 
wetside workers.  All workers were retained and this resulted in a total cohort of 1,212 
wetside workers.  Estimates of cumulative exposure were derived from the three exposure 
matrices (Rinsky, Paustenbach and Crump). The table below revises the SMR calculations 
with the updated (1981 and 1987) information.     
 
 
Table 10 - Summary of Changes in SMRs with Updatea 
 Update of Status Through: 
 1981 1987 
 Observed Expected SMR 95%CI Observed Expected SMR 95% 
CI 
Death 358 352.22 1.02 0.91-
1.13 
481 468.22 1.03 0.94-
1.12 
     
Nonmalignant 
diseases of    
     blood and 
blood-forming  
     organs 
4 0.86 4.65* 1.27-
11.90 
4 1.21 3.31 0.90-
8.47 
Cancer    72 70.88 1.02 0.79-
1.28 
111 102.57 1.08 0.89-
1.30 
     Lymphatic 
and  
     
hematopoietic 
cancers 
15 (9 
leukemias, 
4 multiple 
myelomas, 
2 others) 
6.93 2.16* 1.21-
3.57 
21 (14 
leukemias, 
4 multiple 
myelomas, 
3 others) 
9.51 2.21* 1.37-
3.38 
aN=1212 white male wetside workers; person-years start accumulating on 1/4/40. 
*p Value <0.05 by two-sided Poisson test. 
 
M.B. Paxton, V.M. Chinchilli, S.M. Brett, and J.V. Rodricks.  1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort: I. Mortality Update and Exposure 
Distribution.  Risk Analysis 14(2): 147-154. 
 
No new cases were reported in the update and the original statistically significant 
SMR of 4.65 decreased to a non-significant value of 3.31 for the nonmalignant diseases of 
the blood.  For all types of cancer, the SMR remained non-significant. There were no new 
deaths from multiple myeloma in the 1987 update with the addition of 5 new deaths from 
leukemia and 1 from lymphoma left the SMR for all lymphatic and hematopoietic cancers 
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literally the same.  However, the SMR=2.21 and was still significant.  The table below 
describes the SMRs for leukemia by update and location. 
 
 
Table 11 - SMRs for Leukemia in Pliofilm Workersa by Update and Location 
Location Update 
Through 
Person-
Yearsb 
Observed Expected SMRc 95% 
Confidence 
Interval 
All 1981 35,587 9 2.86 3.15** 1.44-5.98 
 1987 40,345 14 3.89 3.60** 1.97-6.04 
St. Marys 1981 19,945 3 1.26 2.38 0.49-6.95 
 1987 22,807 6 1.79 3.36* 1.23-7.31 
Akron 1981 15,642 6 1.60 3.76* 1.37-8.18 
 1987 17,358 8 2.10 3.81** 1.64-7.51 
aWhite male wetside workers. 
bAccumulation of person-years started on 1/1/40 or at the start of the first Pliofilm job, 
whichever was later. 
cp Values by two-sided Poisson test. 
*p <0.05 
**p<0.01. 
M.B. Paxton, V.M. Chinchilli, S.M. Brett, and J.V. Rodricks.  1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort: I. Mortality Update and Exposure 
Distribution.  Risk Analysis 14(2): 147-154. 
 
With the 1987 update and 5 new leukemia cases the SMR increased form 3.15 to 3.60 
with a narrower confidence interval.  In addition, the addition of 3 cases at St. Mary’s made 
the relationship statistically significant.   
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Table 12 - Distribution of Cumulative Exposuresa 
 Exposure Estimates for Job Categories 
(% in cumulative exposure category) 
 Rinsky(2) Crump(5) Paustenbach(6) 
Cumulative 
Exposure 
(ppm-years) 
St. 
Marys 
Akron St. 
Marys 
Akron St. 
Marys 
Akron 
0 10.9 19.0 0.2 4.9 0.6 4.4 
>0-5 52.6 32.0 44.3 34.4 31.0 15.5 
>5-50 23.3 27.2 31.9 33.3 35.6 31.6 
>50-500 12.3 20.6 20.9 22.4 25.2 34.3 
>500 0.9 1.2 2.7 5.0 7.6 14.2 
 100.0 100.0 100.0 100.0 100.0 100.0 
 Estimates for this cohorta 
(ppm-years) 
 Rinsky(2) Crump(5) Paustenbach(6) 
Descriptive 
Statistics 
St. 
Marys 
Akron St. 
Marys 
St. 
Marys 
Akron St. 
Marys 
Median  1.0 4.7 7.2 10.9 14.8 46.0 
Arithmetic 
mean 
33.1 44.7 63.6 100.3 112.4 199.0 
Maximum 728.0 815.2 1724.9 3185.5 3066.2 2321.6 
aFor white male wetside and dryside workers, N=958 at St. Marys and N=759 at Akron.   
 
M.B. Paxton, V.M. Chinchilli, S.M. Brett, and J.V. Rodricks.  1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort: I. Mortality Update and Exposure 
Distribution.  Risk Analysis 14(2): 147-154. 
 
Interestingly, the exposure estimates for the two facilities is divergent:  St. Mary’s has 
an even spread and Akron has almost all of the leukemia cases clustered in the higher portion 
of the exposure distribution.   
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Table 13 - Estimated Cumulative Exposures of Male Leukemia Casesa 
  Cumulative Exposure (ppm-years) 
Location Case no.b Rinsky(2) Crump(5) Paustenbach(6) 
St. Marys 1 49.8 379.4 126.2 
 2 0.1 2.8 2.6 
 8 10.1 22.6 54.3 
 18 61.7 144.4 286.1 
 19 6.5 49.6 11.4 
 20 0.7 6.5 8.5 
 Average of male 
cases  
21.5 100.9 81.5 
 Average of male 
controlsc 
33.2 63.3 112.6 
Akron 3 258.9 250.5 1051.2 
 4 496.8 1492.6 1238.5 
 5 474.3 937.2 1119.6 
 6 638.8 2148.6 1765.8 
 7 98.3 305.6 668.2 
 9 252.1 323.9 1125.9 
 16 90.3 64.6 337.4 
 17 0.9 14.7 596.2 
 Average of male 
cases  
288.8 692.2 987.8 
 Average of male 
controlsc 
43.1 94.0 190.6 
aThe female case (#21) had cumulative values by the three estimates of exposure of 0.0, 8.5 
and 161.3 ppm-years, respectively.   
bAs in Table IV. 
cFor white male wetside and dryside controls, N=952 at St. Marys and N=751 at Akron. 
 
M.B. Paxton, V.M. Chinchilli, S.M. Brett, and J.V. Rodricks.  1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort: I. Mortality Update and Exposure 
Distribution.  Risk Analysis 14(2): 147-154. 
 
For 5 of the 14 male leukemia cases of Crump is higher than the Paustenbach 
estimate.  Overall, the Crump exposure estimates give a lower mean value for the controls 
versus the Paustenbach exposure estimates. At St. Mary’s, however, the mean cumulative 
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exposure for the cases using the Crump exposure estimates is greater than that derived using 
the Paustenbach estimates, and the Paustenbach estimates actually give lower estimated 
average exposure for the cases than for the controls. 
 
 
 
 
Table 14 - SMRs for Leukemia in Pliofilm Workersa by Cumulative Exposure at All 
Locations 
Exposure 
Estimates 
Cumulative 
Exposure 
(ppm-
years) 
Person-
years 
Observed Expected SMRb 95% 
Confidence 
Interval 
Rinsky(2) 0-5 18,178 3 1.52 1.97 0.41-5.76 
 >5-50 13,456 3 1.31 2.29 0.47-6.69 
 >50-500 8,383 7 1.01 6.93** 2.78-14.28 
 >500 328 1 0.05 20.00 0.51-111.4 
Crump(5) 0-5 12,974 1 1.14 0.88 0.02-4.89 
 >5-50 13,951 4 1.23 3.25 0.88-8.33 
 >50-500 11,448 6 1.23 4.87* 1.79-10.63 
 >500 1,972 3 0.29 10.34** 2.13-30.21 
Paustenbach(6) 0-5 9,645 1 0.75 1.33 0.03-7.43 
 >5-50 12,882 2 1.12 1.79 0.22-6.45 
 >50-500 14,095 4 1.43 2.80 0.76-7.16 
 >500 3,723 7 0.59 11.86** 4.76-24.44 
aWhite male wetside workers. 
bp Value for two-sided Poisson test. 
cp <0.05; **p<0.01 
 
M.B. Paxton, V.M. Chinchilli, S.M. Brett, and J.V. Rodricks.  1994. Leukemia Risk 
Associated with Benzene Exposure in the Pliofilm Cohort: I. Mortality Update and Exposure 
Distribution.  Risk Analysis 14(2): 147-154. 
 
 
When evaluating the three sets of exposure estimates, there is a strong dose-response 
relationship, no matter the estimate. However, none of the estimates have a statistically 
significant increase in the SMRs for cumulative exposure < 50 ppm-years. This is consistent 
with the hypothesis that exposure in excess of some threshold value is necessary for 
leukemogenesis. The absence of any additional cases of multiple myeloma and the updates 
for 1987 weakens to non-significance the previous statistical association of this endpoint with 
benzene exposure.  Tables12, 13 and 14 present the information related to the three exposure 
matrices.    
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The 1987 update continues to be consistent with a threshold model of benzene 
leukemogenesis.  All leukemia deaths in the cohort have occurred in individuals who began 
working prior to 1950, the period of time with the greatest likelihood of high exposures.  The 
simplest explanation would be that industrial hygiene improved in both locations over the 
years and achieved a critical level of reduced benzene exposure in the early 1950s so that 
workers entering the workplace after that time were no longer at risk for developing 
leukemia. Alternatively, this phenomenon may be due to a lack of statistical power.   
 
 
Utterback, D. F. and R. A. Rinsky (1995). "Benzene exposure assessment in rubber 
hydrochloride workers: a critical evaluation of previous estimates." Am J Ind Med 27(5): 
661-76. (Utterback and Rinsky 1995) 
 
Methods: 
This report critically examines the analysis of Paustenbach in 1992. Paustenbach 
based his upward adjustments on the following data: 
 
1. Inaccuracy of benzene analytical methods employed for historical measurements. 
2. Estimated length of the work week at two of the three plants. 
3. Installation and use of exhaust ventilation controls. 
4. Benzene absorption through the skin of workers in the cohort. 
5. Selection and use of respirators by the workers. 
6. Evidence of overexposure and available medical information for the plant. 
 
Results: 
 
Based upon the benzene predictions suggested by Paustenbach, there would likely 
have been an “epidemic” of deadly non-malignant blood disorders in these workers; 
however, this did not occur.  Recent information from the WHO, indicates that a prolonged 
level of >100 ppm exposure who cause ~10% aplastic anemia.  Yet, less than 2.3% of the 
Pliofilm workers developed this condition.   
 
Only five lines of reasoning that are problematic are currently reviewed in this paper, 
including: 
 
1. Review of the use of engineering controls rubber hydrochloride plants. 
2. A search in the terminal exposure to benzene substantially added to the total body 
burden so that the estimates of exposure should be adjusted upward. 
3. Series of arguments that actual measurement data reflect background 
“concentrations” instead of peak exposures. 
4. Contention that the methods used to estimate exposure concentrations in the earlier 
years were biased low. 
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5. The ramifications of the method developed by Crump and Allen made TLV based 
adjustments to more recent exposure estimates in order to estimate earlier exposure 
concentrations. 
 
The 1942 Department of labor conference proceedings outline a great deal of 
information about the local exhaust ventilation in the plant.  The plant physician stated, “At 
present, benzol is used in the manufacture of Pliofilm, but in an enclosed system.” Control of 
benzene emissions from the spreaders was provided by “hooded ventilation with suction 
above and forced general ventilation in the room.” Concentrations of benzene in the vicinity 
of the rubber hydrochloride spreader units was stated in the proceedings to be controlled to a 
level “in the neighborhood of 20 to 60 part per million”. These were not noted by 
Paustenbach in his analysis.   
 
In addition, the conference proceedings conflict with several statements about the 
general ventilation of the facilities.  In 1946, the first engineering control measure was 
installed in the Pliofilm facility. A report in 1946, indicated that, “extensive exhaust 
equipment had recently been installed for the elimination of benzol vapors generated by 
presses”, and that “tests were made with benzol detectors and the results indicate the 
concentrations have been reduced to a safe level, and in most instances range from 0 to 10 or 
15 part per million”.  This was not mentioned in the Paustenbach exposure matrix.  Samples 
collected several years later after engineering control showed levels of 19 to 50 ppm. The 
State of Ohio included that the filter press ventilation system was sufficient to maintain 
benzene concentrations below 100 part per million and typically below 35 part per million.  
In addition, the 1946 report stated that, “concentrations have been reduced to a safe level and 
in most instances range from 0 to 10 or 15 part per million”.   These values are consistent 
with the levels measured in 1974-1975 (6-10 ppm).    
Another area of concern was dermal absorption, which Paustenbach estimated to be 
far greater than the Rinsky measurements.  In addition, the rubber hydrochloride component 
would result in significant skin irritation if it was applied as often as indicated by 
Paustenbach.  For this reason, the frequency and duration of contact selected by Paustenbach 
also appeared overestimated.  
Regarding the representativeness of benzene samples, Paustenbach had questions 
regarding detector tube accuracy and believed that they underestimated the actual 
concentration of benzene in the air at the time of measurement. By his own admission, 
Hayes’ results are inconsistent and unreliable, and therefore, do not support the adjustments 
made by Paustenbach.   
Regarding a TLV ratio method related to Crump and Allen, their method of 
adjustment assumes that as the TLV becomes more restrictive benzene exposures in 
industries were lowered, presumably through work practice and engineering control 
measures. Therefore, Crump contends that exposure for historical periods may be reasonably 
estimated based on proportionate changes in the TLVs for benzene. Crump increased recent 
benzene exposure estimates for specific job titles by the ratio of the historical TLV to the 
TLV at the time of the measurements. This has been suggested elsewhere. When 
Paustenbach, et al applied this method to the rubber hydrochloride cohort, the Crump and 
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Allen estimates for many job titles exceeded 250 part per million annual average exposure 
concentration for many consecutive years. These estimates seem unrealistic high.   In 
addition, the Crump estimates for the entire facility include annual average benzene exposure 
concentrations greater than the TLV eight-hour time weighted average for workers in seven 
out of eight job titles for the period of 1958 to 1965, and for six out of eight job titles for the 
period of 1949 to 1957. It is illogical on one hand to argue that the industry was sensitive to 
TLVs and would lower their exposure concentrations accordingly, while on the other hand 
showing the same industry in gross violation of those limits for the majority of the workers.  
In addition, there are other contradictions in the Paustenbach results when he used the Crump 
and Allen method of adjusting the exposure measures.   
In conclusion, Paustenbach used select information to adjust the previously reported 
benzene exposure estimates for the rubber hydrochloride worker cohort. Multiple 
adjustments of early monitoring results by a number of factors were apparently based on 
worst case assumptions. Their factors are determined through extrapolation of the data 
collected under substantially different and frequently unknown conditions. In addition, some 
reconstructed measures have cohort members exposed to prolonged levels greater than 100-
200ppm, levels that would result in epidemic blood disorders.  There have been no reports of 
substantial engineering improvements after 1942 to limit benzene exposure to a large number 
of cohort members over the decades of operation at St. Mary’s and Akron.  
  
 
Wong, O. (1995). "Risk of acute myeloid leukaemia and multiple myeloma in workers 
exposed to benzene." Occup Environ Med 52(6): 380-4. (Wong 1995) 
 
 
Table 15 - Acute Myeloid Leukemia by Cumulative Exposure to Benzene 
 Deaths  
Cumulative Exposure 
(ppm-years) 
Obs Exp SMR (95% CI) 
<40 1 0.84 1.19             (0.03-6.63)       
40-200 0 0.25 0                  (0-14.75)       
200-400 2 0.07 27.21** (3.29-98.24) 
>400 3 0.03 98.37** (20.28-287.65) 
Total 6 1.19 5.03** (1.84-10.97) 
**P<0.01. 
 
O. Wong. 1995. Risk of Acute Myeloid Leukaemia and Multiple Myeloma in Workers 
Exposed to Benzene.  Occup Environ Med 52: 380-384. 
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Table 16 - Multiple Myeloma by Cumulative Exposure to Benzene 
 Deaths  
Cumulative Exposure 
(ppm-years) 
Obs Exp SMR (95% CI) 
<40 3 0.93 3.21 (0.66-9.39) 
40-200 0 0.30 0 (0-12.29) 
200-400 0 0.10 0 (0-36.89) 
>400 1 0.04 25.17 (0.63-139.83) 
Total 4 1.37 2.91 (0.79-7.45) 
 
O. Wong. 1995. Risk of Acute Myeloid Leukaemia and Multiple Myeloma in Workers 
Exposed to Benzene.  Occup Environ Med 52: 380-384. 
 
This was a reanalysis of the Paxton et al. evaluation with the 1987 updated mortality.  
When analyzed by specific cell type, acute myeloid leukemia risk was only significant above 
200ppm of cumulative exposure.  In addition, Multiple myeloma was highly significant 
consistently at level greater than 400 ppm.  This analysis reiterates the author’s contention 
that leukemia risk should be analyzed by cell type.  See the tables above for specific risk for 
AML and multiple myeloma related to cumulative exposure.      
 
 
Schnatter, A. R., M. J. Nicolich, et al. (1996). "Determination of leukemogenic benzene 
exposure concentrations: refined analyses of the Pliofilm cohort." Risk Anal 16(6): 833-
40_(Schnatter, Nicolich et al. 1996)______________________________________________ 
  
Historical Context and Methods:   
This study looked at exposure rates and the effect upon leukemogenesis.  Effects of 
specific benzene exposure concentrations rather than the estimated cumulative exposure of 
benzene were analyzed. The exposure concentrations investigated included the work by 
Rinsky, Crump and Allen and Paustenbach.   Analyses were performed on each set of 
exposure estimates, plus an estimate was derived by considering the median of the three sets 
of estimates. The median exposure estimate was calculated by simply selecting the rank 
middle estimate for each cell in the job/department/time exposure matrix.  One advantage of 
this estimate is that it disregards extreme exposure estimates, which have been at the subject 
of previous criticism. Each worker’s maximally exposed job/department combination and a 
long term average concentration with that job, was calculated for the median as well as each 
series of exposure estimates. This enabled enumeration of subgroups of workers and controls 
who were always exposed to specific concentrations of benzene. This method is useful for 
identifying empirical thresholds, i.e., critical concentrations which are not associated with 
any risk in the database.  
It is clear that the estimates developed by Rinsky were on average lower than Crump 
and Allen, which was slightly lower then the estimates developed by Paustenbach.  Total 
leukemia SMRs are not different among those workers always exposed to benzene 
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concentration < 20 ppm. However, for workers exposed to concentrations between 20 and 40 
ppm, there is a non-statistically significant elevation of total leukemia for all estimates except 
Paustenbach.  But, when analyzed for AMML the Crump estimates no increase in levels <20 
ppm.  Alternatively, the Rinsky estimates support the notion of a critical concentration below 
20 ppm with an SMR=0 (95% CI: 0-4.53).  The median exposure estimates in the Crump and 
Allen exposure estimates are also indicative of this critical concentration with exposures <50 
ppm – SMR 0.86 (95% CI: 0.01-4.80.  The Paustenbach exposure estimates do not show 
markedly excess risk until concentrations of 140 ppm are reached.  
When the median exposure estimate is used, this critical concentration appears to be 
50 to 60 part per million when AMML is the end point, and could be as low as 38 part per 
million for total leukemias.   Risks for AMML are driving the risk for total leukemia.   
Previous epidemiologic analyses have examined the importance of exposure 
concentration versus the more traditional cumulative exposure metric in the cohort. Rinsky 
reported that cumulative exposure was the strongest single predictor of death from leukemia. 
Crump investigated several metrics and reported that the risk of leukemias is explained better 
by concentration dependent upon linear exposure metrics for the Paustenbach but not the 
Crump and Allen exposure estimates. Both of these approaches inherently consider the full 
range of exposure concentrations represented in the data in one model. While these 
approaches are useful, they may miss the effects of exposure concentration if the exposure 
concentration has variable effects along the entire gradient. Thus the use of a continuous 
function could mask relevant versus irrelevant values.  
The approach used in this paper did not depend on a model which simultaneously 
evaluates the entire exposure range for non linearities or rate effects. Instead, the approach is 
based on life table methodology and categorical exposure classification. The approach also 
lends itself to categorizing exposure data to directly examine the risk in relevant exposure 
categories, although this advantage is not unique to the life table approach. These analyses 
suggest that a critical concentration of benzene exposure must be reached in order for the risk 
of leukemia, more specifically AMML, to be expressed. When the median exposure estimate 
is used, the concentration appears to be between 50 and 60 part per million for both AMML 
and leukemia. The Rinsky exposure estimates critical concentrations were lower for both 
AMML and total leukemias, ranging between 20 and 25 part per million. While the duration 
of exposure is not explicitly accounted for in these analyses, the effects of exposure duration 
can be investigated. These results should not be taken to imply that instantaneous or short 
duration of exposures of 20 part per million can be leukemogenic.  When AMML is 
considered no risk was evident for exposures below 200 ppm-years using the Rinsky 
estimates or 400 ppm-years using the Paustenbach.   
In conclusion, this analysis suggests the following: 
 
1. AMML risk is shown only above a critical concentration of benzene exposure 
measured as a long term average and experienced for years. 
2. The critical concentration is between 50 to 60 part per million when using a median 
exposure estimate to derive three previous exposure estimates, and is between 20 and 
25 part per million using the lowest exposure estimates. 
 42
3. Risks for total leukemia are driven by risks for AMML suggesting that AMML is the 
sole type related to benzene exposure.  
  
 
Rinsky, R. A., R. W. Hornung, et al. (2002). "Benzene exposure and hematopoietic 
mortality: A long-term epidemiologic risk assessment." Am J Ind Med 42(6): 474-
80._(Rinsky, Hornung et al. 2002)_______________________________________________ 
 
Methods: 
This study reported the updated mortality of the Pliofilm cohort through December 
31, 1996 and additional 15 years from the last update.  Every living cohort member has at 
least 20 years of follow-up.   All 1,291 persons with at least 1 ppm day of exposure between 
January 1, 1940 and April 31, 1976 were included in the SMR analysis with no restrictions 
on race or gender. In addition, we modeled the exposure/disease relationship for all 1,845 
non-salaried workers (1,291 exposed and 554 unexposed) who were alive as of January 1, 
1950. 
Person years were stratified by increasing levels of cumulative exposure. For 
historical consistency in the SMR analysis, we maintained the strata used in our previous 
report, 1 ppm day to 39.99 ppm-years, 40 to 199.99 ppm-years, 200 to 399.99 ppm-years, 
and 400 or more ppm-years. U.S. population death rates were used for comparison with death 
rates observed in the cohort. For leukemia, the non-actual cause of death rate file for 1940 to 
1999, based on actual rates for 1940 to 1994 with rates for 1995 through 1999 duplicated 
from 1990 to 1994.  For multiple myeloma and non-Hodgkin’s lymphoma, cause specific 
rates of death are available only for 1960 onwards because prior to 1960 these causes were 
included in the category “Other lymphatic and hematopoietic malignancies.” Therefore, for 
these outcomes we began observation in 1960 and used the natural cause of death file for 
1960 to 1999 to obtain expected deaths. 
To evaluate the effects of benzene on the risk of leukemia and multiple myelomas 
along potential confounders and effective modifiers, a generalized form of a proportional 
hazards regression model was used. All workers employed for at least 1 day in the rubber 
hydrochloride department after January 1, 1940 and alive as of January 1, 1950 were eligible 
for inclusion in the risk sets, regardless of exposure status. 
Total benzene exposure was estimated by duration of exposure and by accumulative 
ppm-years. Benzene exposure was examined with dichotomous variables where workers with 
cumulative exposure of at least 1 ppm day were compared with other unexposed 
counterparts. Various lag periods were applied to allow for an induction period between 
exposure and death. 
 
Results:  
Nine hundred seventy-six (976) members of the 1,845 member cohort died between 
January 1, 1950 and December 31, 1996. For the 1,291 exposed workers, person years at risk 
of dying totaled 45,753. Ninety-seven percent (97%) of these person years at risk were 
contributed by males. 
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Deaths from lymphatic and hematopoietic neoplasms were elevated with a combined 
SMR of 1.64 (95% CI: 1.06 to 2.44). The SMR for leukemia was 2.47 (95% CI: 1.38 - 4.07).  
For white male workers the SMR was 2.56 (95% CI:1.43 to 4.22). There were 17 leukemia 
deaths in the cohort; however, 2 deaths—1 male and 1 female—did not have a minimum 1 
ppm day of cumulative exposure required by the SMR analysis.  Therefore, the deaths were 
not counted among leukemia deaths nor did they contribute to any expectation of death. 
The latency period for leukemia deaths varied widely with 6 or 15 deaths occurring 
≥30 years after first exposure.   See the table below for complete updated information related 
to the Pliofilm cohort. 
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Table 17 - Deaths From Leukemia and Multiple Myeloma in the Rubber Hydrochloride Cohort 
Year of Death Age 
at 
Death 
Latency 
(years 
since first 
exposed) 
Cause of Death (ICD code for 
cause of death, using ICD 
revision in effect at time of 
death) 
Plant 
location 
Duration of 
Employment 
Cumulative 
Benzene 
Exposure (ppm-
yr) 
a.  Descriptions 
of Deaths from 
Leukemia 
      
1950 29 2 Chronic Myelogenous 
Leukemia (204.1) 
1 1 month 0.10 
1954 28 3.5 Myelogenous Leukemia 
(204.1) 
1 1.5 years 10.16 
1957 57 15 Acute Monocytic Leukemia 
(204.2) 
2 5 years 98.55 
1958 36 17 Monocytic Leukemia (204.2) 1 1.5 years 49.99 
1958 60 13.5 Acute Myelocytic Leukemia 
(204.3) 
2 11.5 years 259.50 
1960 65 15.5 Acute Myelogenous Leukemia 
(204.3) 
2 14 years 498.23 
1961 62 22 Di Guglielmo’s Acute 
Myelocytic Leukemia (204.3) 
2 13 years 478.45 
1961 57 20 Acute Granulocytic Leukemia 
(204.3) 
2 20 years 639.84 
1974 (female) 82 Unexposed Acute Myeloid Leukemia 
(205.0) 
2 1.5 years Unexposed 
1979 67 37 Acute Myeloblastic Leukemia 
(205.0) 
2 14 years 252.66 
1984 67 17 Chronic Myeloid Leukemia 
(205.1) 
2 7 years 10.27 
1985 67 45 Acute Lymphoid Leukemia 
(204.0) 
1 16 years 52.53 
1985 67 27 Acute Myeloid Leukemia 
(205.0) 
2 9.5 years 0.72 
1986 80 Unexposed Chronic Myeloid Leukemia 
(205.1) 
2 3 days Unexposed 
1986 71 40 Leukemia – Unspecified 
(208.9) 
1 3 months 259.98 
1987 81 38 Leukemia – Unspecified 
(208.9) 
1 4 months 0.79 
1991 79 51 Myeloid Leukemia – 
Unspecified (205.9) 
1 7 months 5.75 
b.  Descriptions 
of Deaths from 
Multiple 
Myeloma (ICD-
203) 
      
1963 52 22.5  1 4 days 0.11 
1968 62 24.5  1 23 years 652.66 
1980 69 25.5  1 1.5 years 19.50 
1981 68 26.5  1 9 months 7.75 
1989 68 38  1 1 month 0.10 
1991 66 Unexposed  1 0.5 months Unexposed 
1993 78 Unexposed  2 4.5 years Unexposed 
1996 79 Unexposed  1 30 years Unexposed 
 45
R.A. Rinsky, R.W. Hornung, S.R. Silver and C.Y. Tseng. 2002. Benzene Exposure and Hematopoietic 
Mortality: A Long-Term Epidemiologic Risk Assessment.  American Journal of Industrial Medicine 42: 474-
480. 
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Beginning observation in 1960 and using 1960 to 1999 rates for multiple myeloma 
yielded an SMR of 2.04 with a 95% confidence interval of 0.66 to 4.76 for men and women 
of all races, and an SMR of 2.12 with a 95% confidence interval of 0.69 to 4.96 for white 
males. Four cases of multiple myeloma have occurred in this cohort since the 1981 update, 
bringing the total to 8 cases. Three of the 4 new cases occurred in unexposed persons who are 
not included in the SMR calculations. With the 5 cases of multiple myeloma occurring in 
exposed workers in this cohort, 4 occurred in the lowest exposure category—1 ppm day to 
30.99 ppm-years of exposure—with the fifth case in the highest exposure category of > 400 
ppm-years. 
This update suggests the relative risk has declined over time.    
 
 
Williams, P. R. and D. J. Paustenbach (2003). "Reconstruction of benzene exposure for the 
Pliofilm cohort (1936-1976) using Monte Carlo techniques." J Toxicol Environ Health A 
66(8): 677-781_(Williams and Paustenbach 2003)__________________________________ 
 
Methods: 
Another evaluation of the Pliofilm cohort was undertaken in order to answer previous 
discrepancies and criticisms.  This analysis used more complete information along with 
Monte Carlo techniques.  This allowed the estimation of a distribution of benzene exposures 
for various job categories based on input parameters that take into consideration the likely 
range of plausible exposures.  The Monte Carlo technique utilizes probability distributions 
rather than a single estimate to characterize the input values in the exposure assessment 
calculation. This is optimal for ensuring data transparency and can help to elucidate the 
strengths and weaknesses of the underlying data. 
 
Results: 
This analysis indicated that few workers would have likely had exposures that were 
>100ppm on a chronic basis.   No job categories had estimated benzene exposure above this 
level at the 50th percentile and only a few job categories had estimated benzene exposures 
>100 ppm in the 95th percentile. But these levels were only observed for about 3 years with 
the exception of workers involved in the neutralization process of Akron plant 1 and 2. 
The current analysis appears to yield results that are consistent with what one might 
expect in an enclosed facility that handled large quantities of benzene more than 50 years ago 
and that underwent improved ventilation starting in the mid-1940s. That is, estimated 
benzene exposures were greater for those job categories that involved frequent and close 
contact with benzene (that is, neutralizer and quencher) than for jobs that involve very little 
contact with benzene.  
Airborne benzene concentrations were still predicted to be significantly higher during 
the early years (1930s to 1950s) versus those measured in the mid-1960s and 1970s.  These 
findings are consistent with historical blood count data in which there was a clinically 
significant depression of white blood counts.  
One of the purposes for conducting this reanalysis was to evaluate and qualitatively 
address, where appropriate, the comments offered by Utterback & Rinsky (1995).  It was 
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suggested that a chronic level of 100-200 would result in an epidemic of fatal non-malignant 
blood disease which did not occur.  However, the acceptable limit was 100 ppm in 1946 and 
it was generally thought that aplastic anemia was avoided at this concentration.  In addition, 
some production workers transferred out of the same areas in Akron facilities either 
voluntarily or involuntarily as a result of single or repeated test results, indicating a 
significant depression in white blood cell counts. These findings suggest that benzene 
exposures for some jobs could have been in excess of 100 ppm for months or a few years.  In 
addition, the workforce may have been composed of persons who were less susceptible to the 
adverse effects of benzene. 
Utterback & Rinsky also suggested that engineering controls were installed in the 
plants in the early 1940s and that these were effective at controlling vapors in the workplace. 
They also note that benzene air concentrations reported by Fluker (1946) were consistent 
with airborne benzene concentrations measured in 1976 by NIOSH. However, the available 
information does not detail when the equipment was installed, or its effectiveness. 
Regarding dermal contact, follow-up discussions with former employees indicate that 
some jobs, particularly on the dry side, probably had less skin surface area exposed than 
previously estimated. On the other hand, prior estimates of the rate of benzene exposure 
appear to be reasonable based on re-review of the literature. In addition, dermal contact, 
regardless of the level, was found to have only a modest effect on total dose.   
Although we agree with Utterback & Rinsky that there is some degree of judgment in 
the approach we used to estimate benzene air concentration, we believe that this approach is 
more sound than relying solely on the results of detector tube samples. 
Utterback & Rinsky state that the approach used by Paustenbach et al. (1992) for 
dealing with detector tube inaccuracies and the use of the combustible gas detectors was 
probably incorrect. That is, these researchers concluded that the additional correction factor 
of 1.5 to account for analytical limitations was probably too high. Given the lack of available 
documentation on these devices, it is not possible to better understand these issues today. 
However, as described in the method section an analytical adjustment factor was not applied 
to any of the air monitoring data in the current analysis. 
Regarding the overtime hours worked, these were not considered by Utterback and 
Rinsky.  This is a potentially important factor for characterizing benzene exposures and is a 
particular biological significant that may account for why some workers in this cohort 
developed leukemia while other employees exposed to similar benzene levels may not have 
developed this disease. There is growing evidence that peak blood levels or peak target tissue 
concentrations have a greater influence on the cancer risk for benzene than that from 8-hour 
time-weighted samples. 
The re-evaluation of the data did not have a dramatic impact on estimated benzene 
exposure levels for many jobs or time periods. Specifically, estimates of benzene exposure 
were found to be too high in the 1992 analysis for some job categories and years. However, 
most predictions of benzene exposure were within the current 50th and 95th percentile 
estimates.  The conclusions of this study remain the same as the previous study.   
 There are some limitations to the current analysis, including:  the lack of information 
on how or why detector tube samples were collected makes it difficult to assess whether the 
benzene air sampling data represent background or peak exposure levels and the use of a 
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uniform probability distributions to characterize the benzene air concentration data and most 
other exposure parameters which are not particularly useful when addressing skewed data 
sets. The substitution of log normal or triangular distributions for uniform distributions when 
evaluating benzene air concentration was found to have a modest to moderate impact on the 
estimated exposure levels for the same job categories and time periods suggesting that these 
results are somewhat sensitive to the choice of probability distribution.  
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2.  The Chinese (NCI-CAPM) Cohort 
 
 
Yin, S. N., G. L. Li, et al. (1987). "Leukaemia in benzene workers: a retrospective cohort 
study." Br J Ind Med 44(2): 124-8. (Yin, Li et al. 1987) 
 
Cohort Description and Study Methods: 
The cohort consisted of 28,460 benzene exposed workers (178,556 person-years in 
1972-81) and 28,257 control workers (199,201 person-years).  
A retrospective cohort study was conducted (1982-1983) in 233 benzene factories and 
83 control factories in 12 cities in China. This included workplaces involved in the painting, 
shoe-making, rubber synthesis, adhesive synthesis and organic synthesis industries.  The 
exposed group worked in a factory for at least .5 year between January 1, 1972 and 
December 31, 1981.  The control cohort consisted of workers from machine production, 
textile and cloth factories with no known exposures to benzene or other occupational 
carcinogens.  The drop out rate was 0.8% in the benzene cohort and 1.3% in the control 
cohort.   
Items investigated through the use of factory records included the occupational 
history of the individuals, a history of benzene poisoning and other specific diseases, 
working conditions, and atmospheric benzene concentrations in the workplace.   
Benzene concentrations were determined by means of grab samples with gas 
chromatographic analysis.   
Cases of leukemia, aplastic anemia and benzene poisoning were obtained from 
hospital records.  Benzene poisoning was diagnosed based upon occupational history, a 
peripheral leukocyte count of less than 4000 cells/mm3, and symptoms or signs in the central 
nervous system.   
 
Results: 
Thirty cases of leukemia (25 dead and 5 alive) were detected in the exposed group 
and four cases of leukemia (all dead) in the control group.  Of the 25 cases of leukemia in the 
exposed group, seven had a history of chronic benzene poisoning before the leukemia 
developed. In the benzene exposed cohort, 196 cases of benzene poisoning and aplastic 
anemia were found. The leukemia mortality among benzene poisoning cases was 
700.70/100,000 person years, which was 49 times higher than the benzene exposed workers.   
The acute leukemias (76.6%) included 13 myelogenous, four monocytic, two 
myelocytic/monocytic, one erythromyelocytic and three lymphocytic leukemia cases.  The 
chronic leukemias (23.3%) included five myelogenous, one lymphosarcomatous and one 
unidentified case.  The leukemia mortality rate was 14/100,000 person-years in the benzene 
cohort and 2/100,000 person-years in the control cohort.  The relative risk for leukemia in 
benzene workers was 6.97.  The SMR for all deceased cases (excludes five living leukemia 
cases) was 5.74 (p > 0.01) - 5.01 (men) and 8.30 (women). The average latency of benzene 
leukemia in the exposed cohort was 11.4 (0.8 - 49.5) years. The mortality due to benzene 
 50
leukemia was highest in organic synthesis plants followed by painting and rubber synthesis 
industries.  
The concentration of benzene to which exposed workers with leukemia ranged from 
10 - 1000 mg/m3 (3.1321 - 313.21 ppm).  However, the authors asserted that most 
measurements ranged from 50 - 500 mg/ m3 (15.661 - 156.61 ppm).  Three cases of leukemia 
in the exposed group were associated with concentrations (grab samples) of 10 mg/m3 
(3.1321 ppm). 
 
Limitations: 
1. No personal, time-weighted industrial hygiene measurements. 
2. Exposure history was based upon standard company records, not individualized data, 
including work practices, personal protective equipment use, etc. 
3. Exposed workers were potentially working with innumerable chemicals, including 
benzene. 
4. Control workers additional exposures except for “benzene and other occupational 
carcinogens” not detailed. 
5. No control for potential confounders and modifying factors, such as smoking. 
6. The ascertainment of cases from hospital records could potentially lead to under-
attainment and misclassification. 
 
Yin, S. N., Q. Li, et al. (1987). "Occupational exposure to benzene in China." Br J Ind Med 
44(3): 192-5. (Yin, Li et al. 1987) 
 
Cohort Description and Study Methods: 
508,818 Chinese workers exposed to benzene or benzene mixtures out of a total of 
528,729 workers (92.6%).  26,319 4.98%) exposed to benzene and 502,410 (95.02%) 
exposed to mixtures typically containing benzene, toluene and xylene in various 
concentrations. The primary source of benzene was petroleum. The percentages of workers 
were as follows:  painting (63.6), organic synthesis (10.9), insulation varnish (5.4), 
shoemaking (4.2), printing (<3.5), rubber (<3.5) and refinery (<3.5).   There were 27,808 
factories using benzene and data were obtained from 19,969.   
 In the 1950’s, 3,917 factory workers with benzene exposure were examined and 481 
cases of chronic benzene poisoning were discovered (10.1%).  In the 1970s, 33,312 benzene 
workers were examined and 366 cases of chronic benzene poisoning were found, a 
prevalence rate of 1.1%.  This study was conducted from 1979 – 1981.   
Atmospheric benzene concentrations were determined by gas chromatographic or 
colorimetric testing.  These were short term samples. 
 
Results: 
Nine cases of benzene leukemia (6 men and 3 women) were found and exposure time 
ranged from 2-25 years.  Jobs included painting (4), shoemaking (1), insecticide packing (1), 
cleaning (1) and analytical technician (2).  There were six case of acute myelocytic, one case 
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of acute erythroleukemia, one case of acute monocytic leukemia and one case of acute 
lymphocytic leukemia, respectively. Six had had a preceding leukopenia or pancytopenia.  
Twenty-four cases of aplastic anemia were identified and complete records were 
available in 17 (7 men, 10 women).  Exposure ranged from 3.5-19 months.   Most cases came 
from shoemaking and paint production.   Benzene measurements ranged from 93 - 1,156 
mg/m3 (29.129 - 362.08 ppm).  In one shoemaking factory using glue with a 1:3 mixture of 
chlorobutadiene and benzene, four workers with aplastic anemia worked an average of 118.5 
days at an estimated daily concentration of 1035.6 mg/m3 (324.37 ppm). 
2,676 cases of benzene poisoning were found, a prevalence of 0.15%. The prevalence 
rate of benzene poisoning was 0.94% in workers exposed to benzene and 0.44% in workers 
exposed to benzene mixtures. The difference was statistically significant.  There was a 
positive correlation (0.42, p<0.05) between the prevalence of benzene poisoning (white blood 
cell count <4000/mm3 blood) and the concentration in shoemaking factories. The prevalence 
of benzene poisoning in shoemakers was ~5.8 times that of the general population, or 1.25% 
of workers.  See the table below for additional information on leukopenia in various 
industries. 
 
 
Table 18 - Comparison of Prevalence of Leucopaenia in Different Industries Using 
Benzene 
Industries Workers Cases % 
Shoemaking 19213 240 1.25 
Paint Producing 12359 67 0.54 
Painting 101379 415 0.41 
Spray Painting 175313 682 0.39 
Benzene Refining 6452 11 0.17 
Chemical Synthesis 42766 190 0.44 
Pharmaceuticals 6576 41 0.62 
Rubber 13877 56 0.40 
Insulation Varnish 24378 101 0.41 
Printing 15453 46 0.30 
Loading Workers 870 7 0.80 
Others 35906 142 0.40 
Total 454542 1998  
 
S.N. Yin, Q. Li Q, Y. Liu, F. Tian, C. Du, C. Jin. 1987. Occupational Exposure to Benzene in 
China.  British Journal of Industrial Medicine 44: 192-195. 
 
  Benzene concentration was higher than 25 mg/m3 (7.8304 ppm) in 86% of the 
shoemaking factories and 10 mg/m3 (3.1321 ppm) in only a few factories. 
The geometric mean concentration of benzene in 50,255 workplaces was 18.1 mg/m3 
(5.7005 ppm) with a 95% range of 0.06 to 844.74 mg/m3 (0.018793 - 264.59 ppm).  Sixty 
four percent of workplaces had a benzene value of less than 40 mg/m3 (12.529 ppm). 1.3% of 
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workplaces had benzene concentrations in excess of 1,000 mg/m3 (313.21 ppm). 
 
Limitations: 
1. No personal, time-weighted industrial hygiene measurements. 
2. Exposure history was based upon standard company records, not individualized data, 
including work practices, personal protective equipment use, etc. 
3. Exposed workers were potentially working with innumerable chemicals, including 
benzene. 
4. No control for potential confounders and modifying factors, such as smoking. 
 
 
Yin, S. N., G. L. Li, et al. (1989). "A retrospective cohort study of leukemia and other 
cancers in benzene workers." Environ Health Perspect 82: 207-13. (Yin, Li et al. 1989) 
 
Cohort Description and Study Methods: 
A retrospective cohort study was carried out in 1982-1983 among 28,460 benzene-
exposed workers (15,643 males, 12,817 females) from 233 factories and 28,257 control 
workers (16,621 males, 12,366 females) from 83 factories in 12 large cities in China.  There 
were 178,556 person years of follow-up in the exposed group and 199,201 in the unexposed 
group. 
 Exposed and unexposed workers were followed from January 1, 1972 – December 
31, 1981.  Factory and hospital list were used to ascertain information about vital status, job 
status and history of benzene poisoning, aplastic anemia, leukemia and other malignancies.  
Additional history, such as smoking history, was obtained from subjects and next of kin 
(deceased).  Detailed information was ascertained for all subjects with leukemia, aplastic 
anemia and other hematopoietic and lymphatic neoplasms.  Information about products 
manufactured, raw materials used, production processes and occupational history of subjects 
came from factory records and supervisors.  Participation was 99.2% of factories with 
benzene exposure and 98.7% among non-exposed factories.   
 Benzene levels were determined from factory records of benzene air measurements, 
benzene concentration in materials and products, as well as, factory information about 
environmental measures (ventilation, etc.) and personal protective equipment. 
 
Results: 
Age-adjusted, all cause mortality was significantly higher among all workers with 
benzene exposure (265.46/100,000 person-years vs. 139.06/100,000 person-years in 
controls).  Mortality from all malignant neoplasms had a similar pattern, 123.21/100,000 
person years vs. 54.7/100,000 person years, respectively.  In benzene exposed males, the 
total mortality rate was 393.90/100,000 person years and 194.61/100,000 person years in the 
unexposed. Conversely in the female group, the mortality rate was 101.87 and 52.61 per 
100,000 person years, respectively.   
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The SMR for leukemia in exposed workers was 5.74.  Relative risk of leukemia 
increased with duration of benzene exposure up to 15 years and declined with additional 
years of exposure.  No effect was found for smoking on leukemia mortality.  
Exposures for the 30 benzene-exposed leukemia cases average accumulation of 
lifetime levels of exposure where estimated using all available measurements.  The average 
exposures ranged from 6.5 – 487.0 mg/m3 (2.0359 - 152.54 ppm), while the cumulative 
exposures ranged from 33.2 – 16359.0 mg/m3 years (10.399 - 5123.9 ppm-years).  See the 
table below for complete information on the 30 cases of leukemia.   
    
 
 
 
 
 54
Table 19 - Description of Leukemia Cases by Sex, Age, Duration of Exposure and Type of Leukemia Among Benzene-Exposed and 
Control Workers from 12 Cities in China, 1972-1981 
i i f k i b i fLeukemia Cases Identified Age Duration of Benzene Exposure, Years Type of Leukemia 
1 35 11 Acute Myelomonocytic 
2 25 4 Acute Monocytic 
3 37 6 Acute Monocytic 
4 61 20 Acute Monocytic 
5 62 49 Lymphosarcomatous 
6 32 18 Acute Promyelocytic 
7 46 20 Acute Myelocytic 
8 60 6 Acute Myelocytic 
9 30 1 Chronic Myelocytic 
10 61 48 Acute Myelocytic 
11 31 12 Acute Myelocytic 
12 25 7 Acute Lymphocytic 
13 47 17 Chronic Myelocytic 
14 23 5 Acute Myelocytic 
15 53 8 Chronic Myelocytic 
16 36 7 Acute Myelocytic 
17 37 14 Acute Myelocytic 
18 57 3 Acute Myelomonocytic 
19 36 13 Chronic Myelocytic 
20 41 19 Acute Myelocytic 
21 47 18 Acute Unspecified 
22 24 8 Acute Myelocytic 
23 45 16 Acute Erythromyelocytic 
24 57 19 Chronic Myelocytic 
25 41 16 Acute Myelocytic 
26 47 1 Acute Monomyelocytic 
27 40 4 Acute Myelocytic 
28 42 19 Acute Lymphocytic 
29 25 6 Acute Myelocytic 
30 41 18 Lymphocytoid 
Control Workers    
1 36 22 Chronic Myelocytic 
2 34 12.5 Acute Myeloblastic 
3 72 30 Chronic Myelocytic 
4 54 22 Leukemia Unspecified 
S.-N. Yin, G.-L. Li, F.-D. Tain, Z.-I. Fu, C. Jin, Y.-J. Chen, S.-J Luo, P.-Z. Ye, J.-Z. Zhang, G.-C. Wang, X.-C. 
Zhang, H.-N. Wu and Q.-C. Zhong.  1989.  A Retrospective Cohort Study of Leukemia and Other Cancers in 
Benzene Workers.  Environmental Health Perspectives 82:207-213.
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66.6% of the exposed cases had a variant of acute non-lymphocytic leukemia 
compared with 50.1% of leukemia cases from the general population. Only 10% of the cases 
among the exposed group had acute lymphocytic leukemia compared with 23.5 in the general 
population.  
 
Limitations: 
1. There was no detailed description of exposure measurements, including purpose 
(peak, spill, personal, area, etc.), time period of samples (grab, short term, TWA, 
etc.), testing methodology and instrumentation and/or analysis methodology.  
2. The authors noted that there findings of leukemia following relatively low cumulative 
exposures must be interpreted cautiously because the estimated average and 
cumulative lifetime benzene exposure levels were based on relatively few 
measurements.  
3. Information about living and deceased subjects was ascertained from a variety of 
potentially non-consistent sources, including subject interviews, next of kin, hospital 
death certificates and local police stations.   
4. Information about the factories, production, benzene use and personal protection was 
ascertained from a variety of potentially non-consistent sources, particularly factory 
records and supervisors.   
 
 
Yin, S. N., M. S. Linet, et al. (1994). "Cohort study among workers exposed to benzene in 
China: I. General methods and resources." Am J Ind Med 26(3): 383-400. (Yin, Linet et al. 
1994) 
 
Description of the Study and Study Methods:   
This was an expansion (more exposed and unexposed workers) of the retrospective 
cohort mortality study completed by Yin et al. in 1987.  However, this study (CAPM-NCI) 
was designed independently of the earlier CAPM study.  Six more years of follow-up were 
included.  In addition, a detailed exposure evaluation was undertaken for the years 1949 – 
1987.  There were two major components, including a cohort and nested case-control study.  
Major objectives, included: 
1. Compare incident rates for leukemia and its subtypes, other hematopoietic and 
lymphoproliferative neoplasms and related non-malignant hematologic disorders 
among benzene exposed and unexposed workers and among workers with benzene 
poisoning; 
2. To classify risk of leukemia, other HLP disorders and other cancers by industry, 
occupation, job title, age and year of first exposure, level and duration of exposure; 
3. To examine the role of other risk factors including cigarette use, lifetime job related 
and environmental exposures, medical and family history and the benzene/leukemia 
relationship; 
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4. To determine the rates of mortality for cancers other than leukemia and other HLP 
malignancies among benzene exposed and unexposed workers by job and exposure 
characteristics 
 
The cohort study included workers from 672 factories with benzene use and 40 
unexposed factories.  Workers were identified from work units, the key administrative entity 
found in Chinese industrial settings.  A work unit typically consists of one or more rooms 
with workers performing closely related production tasks.  All workers employed for any 
length of time in the 1472 exposed work units was eligible for study inclusion.  Eligible 
workers were identified from a systematic review of factory records and their entire job 
history was also abstracted from the factory records.    
The nested-case control component of the study was intended to evaluate dose-
response relationships.  For each case of leukemia and hematolymphoproliferative (HLP – 
includes both malignant and nonmalignant) disorders, four controls were randomly selected 
from the pool of exposed and unexposed workers.  They were matched by sex, city and time 
period of employment (pre-1962, 1962-1971, 1972-1981 and 1982-1987).  Each control must 
have entered the cohort at an age that was younger than the case’s age at diagnosis and must 
have remained in the cohort without developing a blood malignancy or related disorder up to 
an age that was older than the case’s age at diagnosis. 
 Cause of death was obtained from medical records, other factory records or death 
certificates.  Next of kin were contacted as a last resort.  Medical records and available 
samples (pathology – blood smears) were sought for validation of all leukemia and HLP 
diagnoses.   A diagnosis and a corresponding level of certainty were assigned to each case.  
In addition, all available records preceding the diagnosis of each case were sought.   
 Standardized mortality ratios were calculated; however, national and city-specific 
mortality rates were only available for 1973 - 1975. Accurate cancer incidence data have 
been routinely collected in only one city back to the 1970’s and this limited the utility of 
external comparisons.  Internal comparison using Poisson regression models were 
used to estimate risk. Each cohort member contributed to person-year tables with partitioning 
across levels of demographic and exposure variables, with consideration of time dependency.  
Exposure was treated as a time dependent variable in all analyses.  Analysis of the nested-
case control data was completed using standard statistical methods, including conditional 
logistic regression.   
 
Results: 
The cohort study population included the 74,828 (38,832 males and 35,996 females) 
exposed workers and a control population of 35,905 (20,795 males and 15,010 females) non-
exposed workers.  Workers came from 712 factories: 603 with exposed work units, 40 with 
unexposed only and 69 with both exposed and unexposed. Approximately 60% of the person 
years were from workers hired between 1959 – 1978, while <20% came from workers hired 
after 1980.  Salary lists were used to identify 84% of exposed and unexposed workers; 
however, slightly more exposed workers were identified by this method.  At the end of the 
study period, there were 1,967 (1,369 exposed/598 unexposed) deaths (1.8%) and 237 (147 
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exposed/90 unexposed) had an unknown vital status (0.2).  There were 712 (1%) cases of 
benzene poisoning in exposed workers and 680 (95.5%) were still alive. 
 Regarding verification of the 95 cases of leukemia and HLP included in the case-
control study, 85 (89.5%) were verified with medical records, 7 (7.4%) were verified with 
other written records and 3 (3.1%) were only verified with oral information. Of the leukemia 
cases (n=51), 11 (21.6%) were confirmed by histopathology, 36 (70.6%) by cytology, 2 
(3.9%) by clinical evidence only and 2 (3.9%) were unknown.  In addition to leukemia, there 
were 7 persons with myelodysplasia, 23 with non-Hodgkin’s lymphoma or other neoplasms 
of lymphoid and histiocytic tissue, 2 with multiple myeloma, 9 with aplastic anemia, 2 with 
granulocytosis and one with another HLP disorder.  
Among the cases, 83(87%) were deceased and the interviews were completed by next 
of kin or others.  Only 6.8% of controls were deceased.  Interviewers included a detailed 
lifetime job history, residential exposure to benzene, xylene, toluene or paint. Past medical 
history including cancer, benzene poisoning or aplastic anemia, use of specific medications, 
history of diagnostic x-rays and radiation therapy, cigarette smoking history, use of hair dyes 
and family cancer histories. 
Quality control checks on 600 workers found discrepancies in demographic factors 
and vital status ranged from 0.5-0.8%, for job title or work unit from 0.7 to 3%, for duration 
of employment differences of 2-10 years 0.8 to 1.5% and for differences of <2 years from 3.9 
to 5.5%.  There were no discrepancies in determination of cancer as a cause of death.   
Review of the medical record data shows the level of information was quite detailed 
and generally complete for cases diagnosed in the 1980’s and varied in completeness for 
cases diagnosed in the 1970s.  Medical record information was located for 62% of the 95 
cases, less detailed or sketchy records for 27% of the cases and 11% of cases had no medical 
records. Pathology slides and/or peripheral blood smears were obtained for 23 (24%) of 
cases. 
According to the authors, the study has five unique strengths:  
1. Detailed characterization of exposure on the job title level within a given work unit 
time period for the cohort component and on the individual worker level for the case 
control component. 
2. A large number of benzene-exposed and unexposed workers including the largest 
cohort of female benzene exposed workers ever evaluated. 
3. A comprehensive assessment of lifestyle exposure to benzene and other factors that 
may confound the benzene/leukemia relationship for persons in the nested case 
control study. 
4. A substantially larger number of leukemia and other HLP cases. 
5. Detailed clinicopathologic characterization of these cases. 
 
Limitations: 
1. The authors noted the difficulty in coordinating >400 staff members, assuring 
consistency in the results and dealing with the differing resources among the various 
study centers, however, they noted the numerous quality checks performed 
throughout. 
2. 87% of cases were deceased, thus limiting and potentially distorting the data 
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gathered, as it was secondhand data.  Conversely, only 6.8% of the unexposed were 
deceased.   
3. Thirty-eight percent of cases had only limited or no medical information, yet 89.5% 
of all diagnoses came from medical records, 7.4% from other written records and 
3.1% from oral information.   
4. Four of 51 leukemia cases (12.75%) were diagnosed by clinical evidence (2) and 
unknown (2). 
 
 
Dosemeci, M., G. L. Li, et al. (1994). "Cohort study among workers exposed to benzene in 
China: II. Exposure assessment." Am J Ind Med 26(3): 401-11. (Dosemeci, Li et al. 1994) 
 
Historical Context and Study Methods: 
Until the early 1970s, pure benzene was commonly used as a solvent in various 
paints, varnishes, glues, coatings and other products. Monitoring was first undertaken in 
factories during the 1960’s, with colorimetric measures.  In 1972, gas chromatographic 
techniques became available.  During this same period (1972-1975), ventilation was 
improved and alternative solvents (xylene and toluene) were substituted for benzene.  
Historical estimates of benzene exposures since 1949 were generated for 75,008 
workers employed for at least one day during 1972 -1987.  In total, estimates were made for 
18,435 factory/work unit/job titles/calendar year time period combinations. 
A standardized job title dictionary was developed that classified 60 benzene 
exposures into 70 job title categories and 11 major activity groups.  An exposure factory 
form was used to collect factory level exposure information including industrial 
classification, major production activities, the types of amounts of historical changes in 
benzene containing raw materials and final products, engineering controls and use of 
personal protective equipment. In addition, all historical benzene and organic solvent 
measurements were identified by factory, work unit and job title.  Information on air 
monitoring data also included the sampling date and sampling location, the associated work 
unit and job title and the type of analytical method used. There were a total of 8,477 benzene 
measurements available since the 1950s.  
Historical exposure information at each factory was abstracted for seven time periods 
at the job title level, including: 
1. Information on the monitoring data for benzene and other organic solvents,  
2. Amount of benzene-containing materials use, 
3. Percent benzene of raw materials (1-29%, 30-59% and 65-100%), 
4. Average daily frequency of benzene exposure,  
5. Historical changes in engineering controls 
6. Change in the process for new locations,  
7. Use of personal protective equipment, 
8. Occurrence or change in other control measures  
All estimates of benzene exposure were completed by local industrial hygienists and 
other occupational health personnel for each work unit job title.  They categorized exposures 
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in six ranges: <1 ppm, 1-5 ppm, 6-10 ppm, 11-25 ppm, 26-50 ppm and >50 ppm over seven 
different calendar periods: 1949-1959, 1960-1964, 1965-1969, 1970-1974, 1975-1979, 1980-
1984 and ≥1985.  If the information listed above was limited, field center staff used all 
available exposure information and their professional judgment to estimate exposures.    
Subject work histories were abstracted from written factory records, including the 
name of the site, factory work unit, and job titles held by the subject with starting and ending 
dates of each job. Job title codes were assigned for each individual job based upon the job 
title dictionaries.  Average exposure (by time period and job held) and cumulative exposure 
was developed for each study subject. 
There were a total of 18,435 benzene exposure estimates, 38% were based on 
monitoring data primarily collected after 1972. Over the 7 time periods the estimated 
benzene exposure level was 16.7 parts per million, ranging from 20.4 parts per million in the 
first period to 11.5 parts per million in the last period. Percentage of estimates made with 
high confidence increased over time from 2% to 42% for the first and last periods, 
respectively.  See table below for further information related to confidence level of 
measurements by period. 
The highest benzene exposure was observed among rubber workers, especially 
among rubber workers with an average exposure level estimate of 52.6 ppm. Painters, paint 
manufacture workers, shoe glue applicators and chemical manufacturing workers were also 
highly exposed, with an average level of >20 ppm. 
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Table 20 - Cohort Study of Benzene Workers in China 1972-1987: Distribution of Exposure Variables 
and Estimates Over Seven Calendar-Year Periods 
Exposure Parameters 1949-
1959 
1960-
1964 
1965-
1969 
1970-
1974 
1975-
1979 
1980-
1984 
85+ All 
Years 
No. of estimates made 1,522 2,041 2,581 2,914 3,095 3,159 3,123 18,435 
No. of measurements 
done 
44 256 386 457 1,766 2,551 2,950 8,477 
No. of estimates based 
on meas. 
52 217 326 591 1,643 1,956 2,111 6,896 
% estimates based on 
measurements 
3.4 10.6 12.6 20.3 53.1 61.9 67.6 37.4 
Mean of measurements 
(ppm) 
25 33 33 27 15 11 8 13 
% benzene in materials 40 41 40 36 32 30 28 34 
Duration of 
exposure/day (hours) 
4.3 4.3 3.8 4.1 4.3 4.3 4.3 4.2 
% jobs having general 
ventilation 
63 68 75 77 81 85 86 78 
% jobs having local 
ventilation 
39 44 52 58 64 77 81 62 
% jobs having closed 
system 
2 2 4 5 7 11 13 7 
% jobs having process 
change 
2 4 7 10 18 36 46 20 
% jobs having glove 87 92 93 94 96 98 98 95 
% jobs having cloth 
mask 
87 91 92 93 95 97 97 94 
% jobs having 
cartridge mask 
5 11 12 16 24 30 31 20 
% jobs having work 
clothing 
83 86 87 89 92 93 93 90 
% jobs having 
monitoring 
7 22 27 40 81 94 98 59 
% jobs having safety 
education 
37 47 52 61 77 91 93 69 
% jobs having physical 
exam 
15 25 27 44 83 98 99 62 
Mean of estimates 
(ppm) 
20.4 19.6 17.5 17.2 16.8 13.9 11.5 16.7 
% estimate with high 
confidence 
2 6 6 11 31 38 42 22 
 
M. Dosemeci, G.-L. Li, R.B. Hayes, S.-N. Yin, M. Linet, W.-H. Chow, Y.-Z. Wang, Z.-L. Jiang, 
T.-R. Dai, W.-U. Zhang, X.-J. Chao, P.-Z. Ye, Q.-R. Kou, Y.-H. Fan, X.-C. Zhang, X-F. Lin, J.-
F. Meng, J.-S. Zho, S. Wacholder, R. Kneller, and W.J. Blot. 1994. Cohort Study Among 
Workers Exposed to Benzene in China: II. Exposure Assessment.  American Journal of 
Industrial Medicine 26: 401-411. 
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Limitations: 
1. The authors noted that there was no central team of industrial hygienists to walk 
through all factories.  All estimates, whether based upon historical data or 
extrapolations with little information were done by local industrial hygienists.  
Because of these limitations and historical nature of the retrospective exposure 
assessment, the exposure ranges were used rather than quantitative point estimates. 
2. Virtually all of the benzene measurements were based on short term area samples 
which may, or may not be indicative of personal exposure.  The area measurements 
are most likely a significant underestimation of personal exposure as these industries 
are task based and require the active participation of workers in the application of 
glues, etc.  For area samples to be equivalent to personal sampling, one must assume 
complete mixing of the workplace air which is unlikely. 
3. The authors assigned confidence scores to their exposure estimates and during the 
earliest period, they had only 2% high confidence, i.e. – they did not have confidence 
in 98% of these measurements.  This continued for much of the study and only 
reached a level of 42% high confidence for the measurements after 1985.  Given that 
the researchers did not consider the measurements to be highly accurate, it is difficult 
to except their conclusions regarding the dose-response curve and the level at which 
the workers supposedly had an elevated leukemia risk.        
 
 
Travis, L. B., C. Y. Li, et al. (1994). "Hematopoietic malignancies and related disorders 
among benzene-exposed workers in China." Leuk Lymphoma 14(1-2): 91-102. (Travis, Li et 
al. 1994) 
 
Cohort and Nested-Case Control Description: 
The retrospective cohort study of incident cases was conducted among 74,828 
benzene-exposed workers employed between January 1, 1972 and December 31, 1987, in 
672 factories in twelve Chinese cities. A comparison group consisted of 35,805 unexposed 
workers employed during the same period in 109 factories in the same cities. 
 
Study Methods: 
See Yin et al. 1994 – General Methods and Resources  
 
Results: 
Eighty-two hematopoietic malignancies and HLP cases were identified in exposed 
workers and 13 in unexposed workers.  Diagnoses confirmed by pathology reports and 
medical records for 51 benzene-exposed subjects included acute leukemia - 17 patients, 
myelodsyplastic syndrome (MDS) - 2 patients, chronic granulocytic leukemia (CGL) - 5 
patients, malignant lymphoma-related malignancies (ML) -16 patients, aplastic anemia (AA) 
- 8 patients and 3 other disorders. For the remaining 31 exposed cases, diagnosis was based 
on evaluation of histopathological material, including 9 cases of acute non-lymphocytic 
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leukemia (ANLL), 5 acute leukemias which could not be classified further, 5 MDS, 4 CGL, 4 
ML, 1 acute lymphoblastic leukemia (ALL) and 1 AA. 
Analysis indicate that the age and sex adjusted relative risk for all confirmed 
lymphohematopoetic disorders in exposed versus unexposed workers was 3.4, 95% CI (1.9-
6.1). 
 Important findings of this study include the observation that the hematopathological 
features of ANLL associated with benzene exposure resemble those following chemotherapy 
and radiotherapy.  There was a far greater diversity of hematologic malignancies than has 
typically been ascribed to benzene exposure.   In previous investigations only AML and 
aplastic anemia appeared to be consistently increased.  
 
Limitations: 
1. There was no breakdown and calculation of relative risk by particular cell and disease 
types, particularly leukemia subtypes.   
 
 
Yin, S. N., R. B. Hayes, et al. (1996). "A cohort study of cancer among benzene-exposed 
workers in China: overall results." Am J Ind Med 29(3): 227-35. (Yin, Hayes et al. 1996) 
-----AND----- 
Hayes, R. B., S. N. Yin, et al. (1996). "Mortality among benzene-exposed workers in China." 
Environ Health Perspect 104 Suppl 6: 1349-52. (Hayes, Yin et al. 1996) 
-----AND----- 
Yin, S. N., R. B. Hayes, et al. (1996). "An expanded cohort study of cancer among benzene-
exposed workers in China. Benzene Study Group." Environ Health Perspect 104 Suppl 6: 
1339-41. (Yin, Hayes et al. 1996) 
-----AND----- 
Linet, M. S., S. N. Yin, et al. (1996). "Clinical features of hematopoietic malignancies and 
related disorders among benzene-exposed workers in China. Benzene Study Group." Environ 
Health Perspect 104 Suppl 6: 1353-64. (Linet, Yin et al. 1996) 
 
Cohort and Case-Control Description: 
See Yin et al. 1994 
 
Study Methods: 
See Yin et al. 1994 
 
Combined Results: 
Benzene-exposed subjects were followed for an average of 10.5 years, while 
unexposed subjects were followed for 11.7. Women contributed 47% of the person years in 
the benzene-exposed group and 40% in the unexposed group. In the initial external analysis, 
which compared the population mortality rate (1973-1975), the all cause SMR was 0.5 (95% 
CI:  0.4 -0.5) and 0.4 (95% CI: 0.4 - 0.5 for the benzene-exposed and unexposed study 
groups, respectively.  Analysis by specific cause of death revealed an excess of leukemia 
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deaths (38) versus the population rate – SMR 1.5 (95% CI: 1.1 – 2.1) – as well as lymphoma 
deaths (17) – SMR 1.2 (95% CI: 0.7 – 2.0).  Further analysis was limited to consideration of 
disease occurrence due to the large differences between the external population mortality 
rates and the study population.  Significant excesses of mortality were noted for leukemia 
(RR=2.3) and lymphoma (RR=4.5) in exposed workers, with similar excesses for men and 
women.  There were no deaths due to multiple myeloma.   
 There were 81 total cases of hematopoietic disorders among exposed workers, 
including 63 malignancies and 18 “other” disorders.  Thirteen lymphohematopoietic 
malignancies and no “other” hematological disorders were found in the unexposed group.  Of 
9 ANLL with sufficient information to classify by the FAB subtype, 3 cases were M2, 4 
cases were M3, 1 case was M2 or M4, one case was M4 or 5.  The relative risk of all 
lymphohematopoietic malignancies in the exposed group was 2.6 (95% CI: 1.5 -5.0).  For all 
leukemia, there was a relative risk of 2.6 (95% CI: 1.3 – 5.7), myeloid leukemia was 3.0 
(95% CI: 1.3 – 7.9) and acute myelogenous leukemia was 3.1 (95% CI: 1.2 – 10.7).  There 
were non-significant excesses of chronic myelogenous leukemia and lymphocytic leukemia.  
Since table below of incidence data of types of cancer.     
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Table 21 - Incidence of Lymphohematopoietic Malignancies and Other Hematologic 
Disorders Among Benzene-Exposed and Unexposed Workers, China, 1972-1987 
Diagnosis Exposed 
Workers 
Unexposed 
Workers 
RRa 95% CIb 
Lymphohematopoietic 
Malignancies 
63 13 2.6 1.5-5.0 
  Malignant Lymphoma 20 3 3.5 1.2-14.9 
    Non-Hodgkin’s 
Lymphoma 
17 3 3.0 1.0-13.0 
  Multiple Myeloma 1 1 0.4 0.0-10.7 
  All Leukemia 42 9 2.6 1.3-5.7 
    Myeloid Leukemia 32 6 3.0 1.3-7.9 
      Acute Myelogenous 
Leukemia 
23 4 3.1 1.2-10.7 
      Chronic Myelogenous 
Leukemia 
9 2 2.6 0.7-16.9 
    Lymphocytic Leukemia 5 1 2.8 0.5-54.5 
      Acute Lymphocytic 
Leukemia 
5 1 2.8 0.5-54.5 
    Other NOSc 5 2 1.3 0.3-9.2 
Other Hematologic 
Disorders 
18 0 ∞ 4.8-∞ 
  Agranulocytosis 2 0 ∞ 0.3-∞ 
  Aplastic Anemia 9 0 ∞ 2.2-∞ 
  Myelodysplastic 
Syndrome 
7 0 ∞ 1.7-∞ 
Total 81 13 3.4 1.9-6.3 
 
aRR: relative risk, compared with nonexposed workers, adjusted for age and sex. 
bCI: confidence interval. 
cNOS= not otherwise specified. 
 
S.-N. Yin, R.B. Hayes, M.S. Linet, G.-L. Li, M. Dosemeci, L.B. Travis, C.-Y. Li, Z.-N. Zhang, D.-G. Li, W.-H. Chow, S. Wacholder, Y.-Z. 
Wang, Z.-L. Jiang, T.-R. Dai, W.-Y. Zhang, X.-J. Chao, P.-Z. Ye, Q.-R. Kou, X.-C. Zhang, X.-F. Lin, J.-F. Meng, C.-Y. Ding, J.-S. Zho, 
and W. Blot. 1996. A Cohort Study of Cancer Among Benzene-Exposed Workers in China: Overall Results.  American Journal of 
Industrial Medicine 29:227-235.
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Significant excess risks were noted for all nonmalignant hematopoietic disorders, 
including agranulocytosis, aplastic anemia and myelodysplastic syndrome.  In addition to the 
findings related to the hematopoietic malignancies, there was a moderately significant excess 
of lung cancer primarily due to an increase in men.  It is noteworthy that tobacco use is 
frequent among Chinese men but not among women. However, tobacco information was not 
available for the lung cancer cases.   
 Tests for trend of increasing risk with increasing exposure were undertaken and all 
cause mortality was slightly increased among workers with greater cumulative exposure to 
benzene (p value for trend < 0.01); however, this excess was largely due to cancer deaths (p 
value for trend < 0.002). Deaths due to all hematopoietic malignancies (p value for trend = 
0.01), which includes leukemia, were increased with greater cumulative exposure.  The 
relative risks for cumulative exposure (ppm-years) were as follows:  <10ppm – 2.5, 10-
39ppm – 2.1, 40-99ppm – 2.9, 100-400ppm – 3.0 and 400 + ppm – 2.0.     
 
Limitations: 
1. The authors noted that their previous estimates utilizing limited, general Chinese 
population comparisons may be unreliable.  With that said, they noted that the all 
cause mortality and deaths due to major disease groups were similar between the 
exposed and unexposed cohorts, which suggests that internal comparisons may be 
appropriate. 
2. The authors also noted that “exposure assessment relied upon limited measurement 
data, particularly for the early years of the study”. 
 
 
Dosemeci, M., S. N. Yin, et al. (1996). "Indirect validation of benzene exposure assessment 
by association with benzene poisoning." Environ Health Perspect 104 Suppl 6: 1343-7. 
(Dosemeci, Yin et al. 1996) 
-----AND----- 
Dosemeci, M., N. Rothman, et al. (1997). "Validation of benzene exposure assessment." Ann 
N Y Acad Sci 837: 114-21. (Dosemeci, Rothman et al. 1997) 
 
Description of the Study and Study Methods:  
 This was a “validation” exercise of the exposure estimates generated for workers 
exposed to benzene in Chinese industry.  Typically, validation of an assessment method is 
accomplished by comparing estimated results to actual monitoring data.  However, in this 
study there was a lack of historical monitoring data.  Alternatively, estimation of current 
levels based upon the methodology utilized to estimate previous unknown levels can be 
compared with current measured levels to indirectly validate past exposures.  Another 
alternative is to use a well established association between an exposure and effect to validate 
the exposure assessment method used in the study.  
In this study, the association between a clinical diagnosis of chronic benzene 
poisoning and estimated historical benzene exposures was used to evaluate the accuracy of 
the estimates developed from the assessment method.  Duration of exposure, intensity of 
 66
exposure and cumulative exposure to benzene were the exposure variables and the diagnosis 
of benzene poisoning was the outcome variable. 
Cases of benzene poisoning were identified from factory records.  Benzene poisoning 
was defined by Chinese government standards, including: White blood cell (WBC) <4,000 
mm3 blood or WBC between 4,000 and 5,000 mm3 blood and platelet count < 80,000/mm3 
blood.  These values must be documented on multiple occasions over several months, there 
must be documented benzene exposure for >6 months and other causes must be ruled out.   
 Subjects from one of 12 cities were excluded from the analysis due to difficulties 
categorizing benzene poisoned workers. 
 
Results: 
There were 412 benzene poisoning cases among 62,234 exposed subjects with 
614,509 person years in 11 cities. When determining the relative risk of  benzene poisoning 
by intensity of exposure at 1.5 years prior to the diagnosis of benzene poisoning, compared to 
subjects who had <5 ppm exposure at that time, they obtained relative risks of 2.2, 4.7, and 
7.2 for intensities ranging from 5 to 19 ppm, 20 to 39 ppm, and > 40 ppm, respectively.  
Relative risk of benzene poisoning by cumulative exposure to benzene are 1.7, 2.0 and 2.4 
for cumulative exposures of 40 - 99 ppm-years,  100 - 399 ppm-years and >400 ppm-years, 
respectively.  This was compared to subjects with cumulative exposure of >40 ppm-years.  
Higher relative risks were seen with recent intensity, suggesting that recent exposure level 
has a greater effect on benzene poisoning than duration of exposure or cumulative exposure.   
See table below for information on benzene poisoning cases.   
 
 
Table 22 - Relative Risks of Benzene Poisoning by Duration of Exposure, Intensity of 
Exposure and Cumulative Exposure 
Duration of Exposure <5 years 5-9 years 10-19 years 20+ years 
Relative risk [n] 
   (95% CI) 
1.0 [92] 
- 
1.3 [91] 
(1.0-1.8) 
1.6 [148] 
(1.2-2.1) 
2.7 [80] 
(1.9-3.9) 
     
Intensity of Exposurea <5 ppm 5-18 ppm 20-39 ppm 40+ ppm 
Relative risk [n] 
   (95% CI) 
1.0 [109] 
- 
2.2 [140] 
(1.7-2.9) 
4.7 [58] 
(3.4-6.5) 
7.2 [64] 
(5.3-9.8) 
     
Cumulative Exposure <40  
ppm-years 
40-99 
ppm-years 
100-399 
ppm-years 
400+ 
ppm-years 
Relative risk [n] 
   (95% CI) 
1.0 [109] 1.7 [74] 
(1.3-2.3) 
2.0 [128] 
(1.5-2.6) 
2.4 [100] 
(1.8-3.2) 
aRecent intensity of exposure (ppm) at 1.5 years prior to the diagnosis.. 
 
M. Dosemeci, N. Rothman, S.-N. Yin, Li G-L, M. Linet, S. Wacholder, W.-H. Chow, and R. 
Hayes.  1997. Validation of Benzene Exposure Assessment.  Annals New York Academy of 
Sciences 837: 114-121. 
 67
The authors determined that there was a strong relationship between benzene and 
benzene poisoning utilizing the assessment method in the cohort mortality study.  They 
concluded that their results suggested that the estimated exposure values were valid enough 
to detect the association between benzene exposure and hematotoxicity and therefore, are 
reasonable measures to use in the evaluation of the relationship between benzene exposure 
and cancer risk.   
 
Limitations: 
1. There is no reason to associate the intensity of exposure 1.5 years prior to the 
diagnosis of benzene poisoning with relative risk for a person having <5 ppm total 
exposure or any level of cumulative exposure. As stated in the study, recent exposure 
level has the greatest effect on benzene poisoning.  The reason for this lag was not 
explained in the study and potentially invalidates the “findings” of this validation 
exercise.  It was most likely a carryover of the 1997 case-control results which 
associated hematopoietic malignancy with values 1.5 years prior due to the lack of 
association between recent exposure and malignancy, unlike that seen in benzene 
poisoning.     
2. The authors noted the previous limitations, including: Lack of a walk through survey 
by a single industrial hygiene coordinator, lack of personal sampling and dependence 
on short term area sampling data.   
 
 
Hayes, R. B., S. N. Yin, et al. (1997). "Benzene and the dose-related incidence of 
hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National 
Cancer Institute Benzene Study Group." J Natl Cancer Inst 89(14): 1065-71. (Hayes, Yin et 
al. 1997) 
 
Description of the Study and Study Methods: 
This study reported the case-control results from the previously described cohort 
study results (Yin et al. 1996a, Yin et al. 1996b and Hayes et al.  1996).   For general 
methods, see Yin et al. 1994.  Because myelodysplastic syndromes (MDS) may be a 
precursor of acute non-lymphatic leukemia (ANLL), these values were combined in several 
analyses.  Subjects employed <6months, or hired prior to the exposure assessment period 
(1949) were excluded from analysis. This eliminated 1.4% of potentially exposed individuals 
and 0.8% of unexposed individuals. In order to derive stable risk estimates, fairly broad 
groups were defined for duration of exposure (<5, 5-9, and ≤10 years), average exposure 
(<10 ppm, 10-24 ppm and ≥25 ppm), and cumulative exposure (<40 ppm-years, 40-100 ppm-
years and >100 ppm).  Person years and disease events were assigned to benzene exposure 
levels with a 1.5 year lag, according to the level 1.5 years previously. A lag period of 1.5 
years was used in making these calculations because more recent exposures are unlikely to be 
biologically linked to the development of cancers. 
Tests for linear trend (two sided) of increasing risk with increasing amounts of 
benzene exposure were based on the mean of years in duration exposure categories, the log 
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of the mean of ppm in average exposure categories and the log of the mean of ppm in 
cumulative exposure categories. 
 
Results: 
In workers higher before 1972, there was an increased risk – RR= 2.9 (95% CI: 1.5-
5.4) for all hematological neoplasms.  The cancer risk assessment period began in 1972.  
From that point forward the relative risk fell to 2.5 (95% CI: 1.1-5.4).  Fifteen of the 16 
exposed cases of non-Hodgkin’s lymphoma occurred among workers hired before 1972, 
which was a RR=4.1 (95% CI: 1.2-14.4).  For ANLL (including AML), significantly 
increased risk was found for workers hired after 1972 with a RR=5.1 ((95% CI: 1.5-17.2).   
For ANLL/MDS the RR=4.0 (95% CI: 1.3-11.9) for hires before 1972 and RR=5.1 (95% CI: 
1.5-17.2) for those hired after 1972.   
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Table 23 - Relative Risk for Hematologic Neoplasms and Related Conditions, on the Basis of Selected Occupational 
Characteristics for Workers Exposed to Benzene 
 Relative Risk (no. of cases) 
Study 
Group 
Person-
Years, 
x103 
Mean 
Exposure, 
ppm*, † 
Mean 
Exposure, 
y* 
All 
Hematologic 
Neoplasms‡ 
NHL Leukemia ANLL ANLL/MDS Other 
Leukemias 
All exposed 
subjects 
698 22.5 9.3 2.6 (58) 
95% CI§ =  
1.4-4.7 
3.0 
(16) 
95% 
CI§ 
=0.9-
10.5 
2.5 (38) 
95% CI§ 
=  
1.2-5.1 
3.0 
(21) 
95% 
CI§ =  
1.0-
8.9 
4.1 (28) 
95% CI§ =  
1.4-11.6 
2.0 (17) 
95% CI§ =  
0.7-5.4 
Exposed 
subjects:  
         
      y of hire          
     <1972 404 24.9 13.2 2.9 (44) 4.1 
(15) 
2.4 (25) 2.6 
(12) 
4.0 (19) 2.2 (13) 
     ≥1972 294 19.2 4.0 2.5 (14) 0.5 
(1) 
3.4 (13) 5.1 (9) 5.1 (9) 2.0 (4) 
Exposed 
subjects: 
         
       
Occupation 
         
     
Coatings║ 
350 21.5 9.4 2.1 (23) 1.6 
(4) 
2.2 (17) 2.9 
(10) 
4.2 (14) 1.7 (7) 
     Rubber 34 53.5 11.1 1.8 (2) 4.0 
(1) 
1.3 (1) 3.0 (1) 6.1 (2) - (0) 
     
Chemical 
88 24.8 8.5 5.0 (14) 7.8 
(5) 
3.6 (7) 4.5 (4) 4.5 (4) 2.8 (3) 
     Shoe 68 21.8 7.9 1.9 (5) 1.6 
(1) 
2.5 (4) 1.5 (1) 1.3 (1) 3.2 (3) 
     
Other/mixed 
158 17.4 9.8 2.7 (14) 4.1 
(5) 
2.5 (9) 3.1 (5) 4.4 (7) 2.0 (4) 
All 
Unexposed  
Subjects 
(referent) ¶ 
405 0 0 1.0 (13) 1.0 
(3) 
1.0 (9) 1.0 (4) 1.0 (4) 1.0 (5) 
*Time-Weighted Average, Lag 1.5 y. 
†ppm = part(s) per million. 
‡Hematologic neoplasms (International Classification of Diseases [ICD]9: 200-208); NHL = non-Hodgkin’s 
lymphoma (ICD9: 200, 202); leukemia (ICD9: 204-208); ANLL = acute non-lymphocytic leukemia (ICD9: 
205.0, 206.0, 207.0); MDS = myelodysplastic syndromes (ICD-02: 9980-9989); other leukemias: includes 
leukemias other than ANLL and leukemias not otherwise specified (ICD9: 204, 205.1-205.9, 206.1-206.9, 
207.1-207.9, 208).   See (34) for ICD9 and (35) for ICD-02. 
§CI = confidence interval 
║Coatings: painters and other coating application workers. 
¶Referent: relative risk = 1.0 for unexposed workers, with all risks adjusted for age and sex.   
 
R.B. Hayes, S.-N. Yin, M. Dosemeci, G.-L. Li, S. Wacholder, L.B. Travis, C.-Y. Li, N. Rothman, R.N. Hoover, 
and M.S. Linet. 1997. Benzene and the Dose-Related Incidence of Hematologic Neoplasms in China.  Journal 
of the National Cancer Institute 89(14): 1065-1071. 
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Exposed subjects had significantly increased risks for hematologic neoplasms at 
average exposures of <10 ppm (RR=2.2; 95% CI = 1.1-4.2) and cumulative exposures of <40 
ppm-years (RR=2.2; 95% CI = 1.1-4.5).   
ANLL and ANLL/MDS both showed patterns of increasing risk with increasing 
average exposure to benzene.  These results were more consistent for the category 
ANLL/MDS versus ANLL alone.  The link of ANLL/MDS with average exposure was 
strongest when restricted to subjects with constant levels of exposure:  <10 ppm = 3.2 and 
≥25 ppm=7.1.  Risks for ANLL/MDS did not increase with duration of exposure to benzene. 
(Relative risk with <5 years = 11.7, 5.5 – 9 years = 5.2 and ≥10 years = 2.8)  Relative risk for 
ANLL/MDS increased with cumulative exposure, but the highest risk wasn’t seen in the 
highest category - RR at 40-99ppm-years = 6.0 and at ≥100 ppm = 4.4.  Clear patterns of risk 
were not seen for leukemias other than ANLL.  Risk of ANLL/MDS was strongly associated 
with increasing recent exposures (P for trend = .003) versus distant (P for trend=.51).   
The authors concluded that the results provided evidence that benzene may cause 
hematological neoplasms at average exposures of <10 ppm and cumulative exposures of <40 
ppm-years.  However, they noted the “relatively modest dose-response effect, with 
proportionally small increases in risk at increasing levels of exposure.  The dose-response 
curve can only be “estimated with caution”.   
 
Limitations: 
1. The authors noted that workers were likely exposed to a number of chemicals besides 
benzene.  However, because the subjects were employed in a number of different 
industries, and hematological disease was widespread, it suggests that the effects 
were most likely due to benzene. 
2. The underlying weakness in the exposure assessment methodology, particularly in 
workers from 1949 – 1970, severely limit the trust that can be placed in the levels 
estimated for both exposure and effect level. 
 
 
Wong, O. (1998). "Re: Benzene and the dose-related incidence of hematologic neoplasms in 
China." J Natl Cancer Inst 90(6): 469-71. (Wong 1998) 
-----AND---- 
Wong, O. (1999). "A critique of the exposure assessment in the epidemiologic study of 
benzene-exposed workers in China conducted by the Chinese Academy of Preventive 
Medicine and the US National Cancer Institute." Regul Toxicol Pharmacol 30(3): 259-67. 
(Wong 1999) 
-----AND----- 
Budinsky, R. A., R. P. DeMott, et al. (1999). "An evaluation of modeled benzene exposure 
and dose estimates published in the Chinese-National Cancer Institute collaborative 
epidemiology studies." Regul Toxicol Pharmacol 30(3): 244-58. (Budinsky, DeMott et al. 
1999)  
 
Comments: 
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1. Although the Chinese benzene study was one of the largest studies in terms of the 
number of exposed workers, many results driving the study were extremely unstable 
due to the small numbers of cases in the comparison group. This was particularly true 
for hematologic malignancies because mortality or incident rates of these diseases are 
much lower among the Chinese than among Caucasians. Study size should be judged 
not only by the number of deaths in the exposed group, but also by the number of 
deaths in the unexposed group. For example, there were only four ANLL cases 
among unexposed workers.  Misclassification of even one case would change the 
results drastically.    
2. There are a number of potential biases, including selection and cohort identification 
biases.  For instance, the prior national survey in 1987 and this could have influenced 
the choice of facilities in the current study.  Some of the records used to identify 
exposed workers could have introduced bias in the cohort selection.   
3. The vast majority of workers (95%) by one estimate were exposed to multiple 
chemicals besides benzene.  It is not appropriate to attribute any or all of the health 
outcomes in the exposed group without examining these additional exposures.    
4. The exposure estimates developed by the NCI were the most serious limitation of the 
overall study.  The exposure categories were inadequate and many of the values 
conflicted with NCI’s own prior estimates, as well as those from prior literature. See 
tables below for specific discrepancies.  
5. This was not a study of all workers exposed to benzene, it was primarily a study of 
painters (64%).  Of the 30 deaths in the original (1987) cohort, 18 were painters and 2 
were paint production workers.  In the updated expanded study, no information on 
cohort composition by industry or occupation was provided.  
6. Regarding the unexposed workers and the original cohort which stated that there was 
no known exposure to benzene or other occupational carcinogens, thus, according to 
the authors, the benzene controls were exposed to neither benzene nor any other 
occupational carcinogen. Whereas, the exposed workers were exposed to not only 
benzene but also possibly to other occupational carcinogens. Thus by design, a 
comparison between the benzene exposed workers and control workers would not be 
limited to effects of benzene, but would also reflect the effects of other occupational 
carcinogens.  Therefore, this study was not designed properly to address the affects of 
benzene only.  
7. Regarding the assumptions in the exposure estimates, it appears that Dosemeci 
consistently underestimated benzene content in solvents used, resulting in lower 
exposure estimates.  In addition, the duration of exposure per day was remarkably 
constant at 3.8 to 4.3 hours throughout the entire exposure assessment period of some 
40 years.  If assumed for all industries, this would introduce substantial 
misclassification.  They also did not take into account that until ~1995, most Chinese 
workers worked 6 days per week.  Although it was stated that significant ventilation 
improvements were made in the early 1970’s, this was not apparent from the 
estimated ventilation rate. These historical changes were not reflected in the 
assumptions used by the estimates developed in subsequent paper.  
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8. A number of average measurements calculated with the exposure methodology were 
not consistent with case reports in the literature, as well as, prior reports from 
members of the same research group.  By all indications, the estimates developed by 
the Dosemeci, et al. were not consistent with exposure levels provided by the 
investigators prior to the involvement of NCI in the study. They were substantially 
lower than previously report data.  
9. The indirect validation did not actually validate the exposure measurements.  (1) It 
simply indicated that if indeed, benzene poisoning was related to duration of 
exposure, then the duration of exposure used in the analysis was relatively valid.  (2) 
Cumulative exposure is defined as the product of duration and level of exposure. 
Cumulative exposure is not independent of duration of exposure. (3) The relationship 
between recent intensity of exposure 1.5 years prior to diagnosis was not a validation 
for exposure estimates throughout the entire exposure assessment. 
10. A variety of benzene exposure variables were extremely wide. For example, the 
benzene content in one of the categories was 60% to 100%. Since pure benzene was 
commonly used until the early 1970’s, this category of 60% to 100% would 
substantially underestimate the benzene content in solvents used prior to 1970. 
Similarly, the highest category for benzene exposure estimates was greater than 50 
parts per million. There is substantial evidence that workers were exposed to very 
high levels of benzene, up to several hundred or even a thousand parts per million. 
Grouping these workers in the same category with those exposed to 50 or 60 part per 
million, would introduce substantial misclassification.  
11. Regarding NCI’s own level of confidence in its exposure estimates, they were fully 
aware of the inadequacies of the exposure estimate. They placed little confidence in 
their own exposure estimates for the entire study period. Only 22% of the estimates 
were rated in  high confidence category. For 1949 to 1959, only 2% of the estimates 
were rated with high confidence. This was not surprising, since only 3.4%of the 
estimates were based on benzene measurements which as indicate above, were 
inadequate in themselves. This must be kept in mind when interpreting any exposure 
response analysis. Inexplicably, NCI’s lack of confidence in its own exposure 
measurements was not mentioned at all in subsequent analysis.  
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Table 24 - The Yin et al. (1987a) Painter Exposures Compared to Modeled Benzene 
Exposures for Painters 
Case No. Type of Leukemiaa Average Exposure 
Reported (ppm) 
Range of Exposures 
Reported (ppm) 
3 Acute Monocytic 15.7 0-69 
5 Lymphosarcomatous 59.7 1.6-376.2 
6 Acute Promyelocytic 8.3 0-78.4 
7 Acute Myelocytic 4.9 0.9-12.3 
8 Acute Myelocytic 4.7 3.1-6.3 
9 Chronic Myelocytic 63.7 7.8-156.7 
10 Acute Myelocytic 75.0 0-1484.6 
11 Acute Myelocytic 9.5 0-107 
14 Acute Myelocytic 346.3 1.1-1199.3 
17 Acute Myelocytic 76.4 0-193.7 
19 Chronic Myelocytic 59.8 13.2-142 
20 Acute Myelocytic 146.7 4.3-1726.5 
21 Acute Unspecified 94.4 78.4-110.3 
22 Acute Myelocytic 37.3 9.8-64.7 
23 Acute 
Erythromyelocytic 
180.3 0.7-1912.7 
25 Acute Myelocytic 30.3 Single Measurement 
26 Acute 
Monomyelocytic 
21.4 17.1-43.5 
28 Acute Lymphocytic 11.6 0.7-29.5 
aBased on the type of leukemia reported in Yin et al. (1989) and the assumption that the case 
numbers assigned to leukemia cases in the 1987a paper are identical to those reported in 
1989.   
 
R.A. Budinsky, R.P. DeMott, M.J. Wernke and J.D. Schell.  1999.  An Evaluation of 
Modeled Benzene Exposure and Dose Estimates Published in the Chinese-National Cancer 
Institute Collaborative Epidemiology Studies.  Regulatory Toxicology and Pharmacology 30: 
224-258. 
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Table 25 - Apparent Discrepancies Between Exposure Data Reported Between the Two 
Yin et al. Studies 
 Yin et al. (1987a) Yin et al. (1989) 
Case 
No. 
Leukemia Type Ave (ppm) Range 
(ppm) 
Ave (ppm) Range 
(ppm) 
3 Acute Monocytic 15.7 0-69 15 15-404 
5 Lymphosarcomatous 59.7 1.6-376.2 57 3.0-129.3 
6 Acute 
Promyelocytic 
8.3 0-78.4 17 1.2-28.7 
7 Acute Myelocytic 4.9 0.9-12.3 4.9 Single 
Measurement
8 Acute Myelocytic 4.7 3.1-6.3 4.7 Single 
Measurement
9 Chronic Myelocytic 63.7 7.8-156.7 12 11.8-108.7 
10 Acute Myelocytic 75.0 0-1484.6 36 2.9-70.5 
11 Acute Myelocytic 9.5 0-107 3 2.9-17 
14 Acute Myelocytic 346.3 1.1-1199.3 88 Single 
Measurement
17 Acute Myelocytic 76.4 0-193.7 47 46.7-120.8 
19 Chronic Myelocytic 59.8 13.2-142 54 17.9-54.3 
20 Acute Myelocytic 146.7 4.3-1726.5 14 14.1-229.6 
21 Acute Unspecified 94.4 78.4-110.3 94 Single 
Measurement
22 Acute Myelocytic 37.3 9.8-64.7 65 9.8-64.7 
23 Acute 
Erythromyelocytic 
180.3 0.7-1912.7 153 31.9-152.7 
25 Acute Myelocytic 30.3 Single 
Measurement
30.3 17.1-43.5 
26 Acute 
Monomyelocytic 
21.4 17.1-43.5 30 Single 
Measurement
28 Acute Lymphocytic 11.6 0.7-29.5 27 2.8-27.0 
 
R.A. Budinsky, R.P. DeMott, M.J. Wernke and J.D. Schell.  1999.  An Evaluation of 
Modeled Benzene Exposure and Dose Estimates Published in the Chinese-National Cancer 
Institute Collaborative Epidemiology Studies.  Regulatory Toxicology and Pharmacology 30: 
224-258. 
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Hayes, R. B., S. Yin, et al. (2000). "Benzene and lymphohematopoietic malignancies in 
China." J Toxicol Environ Health A 61(5-6): 419-32. (Hayes, Yin et al. 2000) 
 
Description of the Study and Study Methods: 
See Yin et al. (1994) for a description of basic details. 
 
Results: 
 Previously reported in 1996 – this is a restatement of the previous results. 
 
Limitations: 
1. The authors noted the samples collected were not intended for epidemiologic purpose 
and often do not represent the usual exposure condition. Thus the historical exposure 
levels estimated for workers in our study can differ from the benzene exposure 
measures recorded in a given work unit. 
 
 
Hayes, R. B., Y. Songnian, et al. (2001). "Benzene and lymphohematopoietic malignancies 
in humans." Am J Ind Med 40(2): 117-26. (Hayes, Songnian et al. 2001) 
  
Response to Wong  and Budinsky et al. (1999) 
 
1. Regarding methods of an NCI/CAPM study, it was argued that the exposure 
assessment procedures used in this study misclassified large numbers of highly 
exposed workers as having lower levels of exposure. Although the historical benzene 
exposure measurements were short-term “grab” samples and served only as one 
component of the data used for exposure assessments.  
2. The conclusion that this summary data was used to estimate factory work-unit 
calendar-specific exposures is incorrect. Consequently, the conclusion that this led to 
systematically underestimated historical exposures was also incorrect. By our 
estimates, 20% of the person-years in the NCI/CAPM study were contributed by 
workers with average exposures of 25 ppm or greater and about 40% of the person-
years were accumulated among subjects with cumulative exposures of 100 ppm or 
greater.  
3. It has been argued that the exposure assessments are in substantial disagreement with 
the truer values based on other published data from studies carried out in China.   It is 
completely without basis to conclude that the exposures in these specially chosen 
small number of workplaces would be in any sense reflective of those found in the 
672 factories in our study.  
4. Budinsky and Wong also compared exposure data reported for the NCI/CAPM study 
with benzene exposure measurements reported for workplaces in which leukemia 
occurred in the earlier CAMP study (Yin, 1987).  The CAMP study exposures were 
taken at a single point in time.  In addition, they may have been collected for any 
number of reasons.    
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5. Budinsky and Wong were concerned about the substantial shift of highly exposed 
workers in the CAMP study to assignment at lower-level categories in the 
NCI/CAMP study.  There are two more cases at the highest level of average exposure 
in the CAMP study than in the NCI/CAMP study and no greater number of subjects 
in the highest category of cumulative exposure. These differences demonstrate no 
evidence of systematic bias toward lower-exposure classification to the NCI/CAMP 
study.  
6. Budinsky and Wong also were concerned about potential confounding in the 
NCI/CAMP study. Lifestyle factors could confound an occupational association with 
disease if the confounding factor was causally associated with the disease correlated 
with the study exposure. The exposed and unexposed groups in our study derive from 
similar occupational backgrounds. There is no evidence that differential lifestyle 
factors such as tobacco use could account for benzene-associated risk differences. 
The workers in this investigation may have been exposed to chemicals other than 
benzene in principal. The observed excesses for ANLL could be due to these 
alternative chemical exposures, however risk for ANLL/MDS were systemically 
increased across the spectrum of industries studied, arguing that these associations 
were due to the common exposure to benzene and not to other industry-specific 
exposures.  
7. For the observed dose-response, it has been suggested that exposure estimates for 
benzene were incorrectly assigned; however, these assignments of incorrect levels 
would have to have been carried out with a similar degree and in each of the 12 cities.  
 
 
Wong, O. (2002). "Investigations of benzene exposure, benzene poisoning, and malignancies 
in China." Regul Toxicol Pharmacol 35(1): 126-35. (Wong 2002) 
 
Response to Hayes (2001) 
  
Previous comments and questions have been raised about several aspects of the NCI-
CAMP study on a number of occasions.  The remainder of the comments can be summarized 
as follows: 
 
1. Unstable comparison rates: The study relied on relatively small ad hoc unexposed 
groups. For example, among the four cases of ANLL and the unexposed group, the 
diagnoses of only one case was confirmed. 
2. Selection bias: Some of the secondary documents physical examination forms and 
hazardous work compensation registries were potentially related to the workers’ 
health status in using them to identify cohort members would introduce bias in the 
selection of the cohort. 
3. Bias and mortality or case ascertainment: The vital or disease status of employed or 
retired workers was determined from records maintained in the factories. Deceased 
and departed workers were followed-up with their new place of employment, 
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contacting next of kin, contacting their doctor or contacting a local police stations. 
Thus the quality of follow-up could vary markedly from location to location, industry 
to industry and factory to factory. As a result of the high awareness of the health 
hazards, particularly lymphohematopoietic disorders, associated with benzene 
exposure, workers with benzene exposure could have more complete records versus 
the unexposed workers.   
4. Low diagnostic confirmation:   Yin et al. (1994), reported that 85% to 95% or 89.5% 
of the diagnoses of HLP disorders were verified with medical records. This was 
misleading since the verification was not based on specific categories. Confirmation 
of diagnosis accuracy should be in terms of specific disease categories since the latter 
were used in the analysis. According to Travis et al. (1994), only 9 cases of ANLL 
among the exposed workers and 1 case of ANLL among the unexposed workers, were 
actually confirmed according to the criteria set forth in the chapter. According to Yin 
et al. (1996), the numbers of ANLL cases among the exposed and unexposed workers 
were 23 and 4, respectively. The corresponding diagnostic confirmation rates for 
ANLL were therefore, 39% for the exposed workers and 25% in the unexposed 
workers respectively.  
5. Confounding exposures of benzene exposed cohort: By design, a comparison between 
the benzene exposed workers and control workers would not have been limited to the 
effects of benzene, but would also reflect the effects of other occupational 
carcinogens such as insecticides. Therefore, this study was not designed properly to 
address the effects of benzene only.  
6. Confounding Factors: Hayes et al. dismissed all of the potential confounding factors 
completely.  Regarding smoking, it has been found to be a risk factor for leukemia, 
particularly ANLL.  The fact that lung cancer risk was significantly elevated among 
the exposed male workers in the Chinese benzene cohort suggested that there might 
be a disproportionately large number of smokers in the exposed cohort. Smoking 
information was collected and analyzed in the CAPM study, but not in the CAPM-
NCI study.  The possibility of confounding due to other exposures, particularly other 
chemical exposures was categorically dismissed with - only radiation and benzene 
have been linked with leukemia.   
7. Exposure Estimates Discrepancies:  He dismissed the discrepancies by making a 
blanket statement that the 1,477 actual measurements taken by Chinese scientists and 
government health agencies since 1950 were short term grab samples. In other words, 
Hayes et al. claimed that for the last 50 years, Chinese scientists and government 
health agencies, in an effort to monitor the exposures of Chinese workers, had 
virtually never taken any time weighted personnel samples. This claim is obviously 
not true. In addition, he never offered any proof that the estimates were indeed 
accurate or representative of actual exposures over time.   
 
In summary, Hayes et al. did not respond to several important mythological issues raised 
in the previous critique.  Large question still remain about potential confounding and the lack 
of any evidence validating the estimates made by Dosemeci et al. (1994). 
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3.  The Chemical Worker Studies  
 
Dow Chemical Studies – Three Successive Retrospective Mortality Studies 
 
Ott, M. G., J. C. Townsend, et al. (1978). "Mortality among individuals occupationally 
exposed to benzene." Arch Environ Health 33(1): 3-10. (Ott, Townsend et al. 1978) 
 
Cohort Description and Methods: 
 The present retrospective cohort study examines the long-term mortality experience 
of 594 workmen exposed to benzene at the Michigan Division of Dow Chemical.  Three 
production areas used benzene on a continuous basis: Chlorobenzol (1920 – present), 
alkylbenzene (1935 – present) and ethyl cellulose (1936 to present).  In the first two 
production areas, benzene is a raw material consumed in the process, whereas in the 
ethylcellulose department, benzene is employed as a solvent. Benzene concentrations in the 
work areas were estimated from industrial hygiene surveys and discussed with plant 
operating personnel. Other compounds were present in the occupational environment and 
throughout the manufacturing complex. Therefore, none of the employees in the study 
experienced exposure to benzene alone. Many long-term workers may have been exposed to 
a wide range of chemicals as a result of transfers to and from non-benzene production areas. 
A description of the environment in each benzene area is presented.  Analysis covered the 
years 1940 to 1973. 
Benzene concentrations in the work areas were estimated from industrial hygiene 
surveys and discussed with plant operating personnel.  Additional chemicals were present 
throughout the complex, and no employee was exposed to only benzene.  Many long term 
workers had exposure to a wide range of chemicals due to movement within departments of 
the facility.    
 The following categorization rules were adopted for jobs in the chlorobenzol 
production area: very low exposure - <2 ppm TWA and low exposure - 2-9 ppm TWA. Prior 
to 1960 there was limited sampling and the categorization scheme may be conservative for 
the exposures during that period.  In the ethylbenzene production area, exposures were 
categorized as follows:  very low exposure - <2 ppm TWA, low exposure –  2-9 ppm TWA, 
moderate exposure – 10-24 ppm TWA and high exposures - 25+ ppm TWA.  The 
ethylbenzene production area also had the potential for exposure to other toxicologically 
important chemicals, including ethylbenzene, divinylbenzene, toluene, xylene, 
isopropylbenzene, styrene, isopropylbenzene, and alpha-methylstyrene.  Categorization of 
exposures in the ethyl cellulose production department was similar to the two previous areas.  
Additional toxic materials in the production area were methylchloride, ethyl ether, and ethyl 
alcohol.   
 In the ethylcellulose production area, high exposures occurred in the sheeting 
operation where operators entered closed areas to make adjustments to the casting 
equipment. High levels were documented in 1953 and engineering changes were made 
including increased localized ventilation.  In 1963-1964, concentrations were once again 
found to be high due to process changes and the deteriorating condition of the equipment. At 
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that time, detailed medical examinations were given to employees. A continuous monitor was 
installed and improvements were made to lower exposure levels.  A review of the medical 
records of the 10 workmen has shown no subsequent hematopoietic abnormality.   
 Fifty-three workers had prior exposure to arsenicals, vinylchloride, or asbestos  which 
are all associated with excess malignancies.  These employees were excluded from analyses 
dealing with mortality related to benzene exposure. 
All job assignments for one or more months were categorized. The analysis of 
cumulative dose which was calculated by multiplying the time-weighted average value for 
each category of intensity by the number of months spent exposed to each level  The mean 
time-weighted value of 1 ppm was used for the very low level, 5 ppm for low level, 17 ppm 
for moderate level, and 30 ppm for high level. The mortality data were analyzed by 
production area according to cumulative dosage and interval since first exposure.  Expected 
deaths were calculated from U.S. white male mortality for the years 1942, 1947, 1952, 1957, 
1962, 1967, and 1971. Age and cause-specific standardized mortality ratios were utilized in 
the comparison.  
Five hundred ninety individuals were included in the cohort.  Through company 
record searches 255 were found to still be working for the company, 87 individuals were 
retired and 71 former employees were deceased.  Of the remaining 181 former employees, 31 
were identified as dead from social security records.  Sixty- four had worked for less than 1 
year in benzene areas and 165 had worked for less than 10 years in benzene areas.  Copies of 
death certificates were not obtained for 3 decedents traced through Social Security, all of 
whom were exposed to benzene doses estimated to be less than 1,000 ppm x months of 
exposure or ppm months. 
 
Results: 
No statistically significant increases were found in any cause of death category in the 
population, excluding employees with arsenicals, asbestos, or high monochloride exposure. 
No association with intensity of benzene exposure or cumulative dose was found with respect 
to these individuals.  Analysis by production area revealed no statistically significant 
differences in mortality: Chlorobenzol, SMR = 89; Alkyl benzene, SMR = 90 and 
ethylcellulose, SMR=72.     
A detailed review of medical and occupational records was undertaken for 5 
decedents whose medical findings were consistent with benzene toxicity.  Two died of 
anemia – one was pernicious anemia, while the other was aplastic anemia.  The third death 
was a case of myeloblastic leukemia.  Two deaths from leukemia were observed, compared 
with one expected, to the end of 1973.  One case was simply labeled leukemia, while the 
other was acute myelogenous leukemia.  After excluding cohort members with other 
hazardous exposure, they observed one death from leukemia versus 0.9 expected.  See table 
below for specific information on various causes of death.       
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Table 26 - Observed and Expected Deaths by Cause Including and Excluding 
Employees with Arsenicals, Asbestos, or High Vinyl Chloride Exposure, 1940-1973 
 Total Population Population Less Exclusions  
Cause of Death Category Obs/Exp SMR Obs/Exp SMR 
All Causes 102/128.2 80 91/114.1 80 
Total Malignancies 30/22.8 132 24/20.3 108 
  Lymphatic & 
Hematopoietic  
  Tissue (except Leukemia) 
2/1.5 * 2/1.3 * 
  Leukemia 2/1.0 * 1/.9 * 
  All Other 3/2.6 * 3/2.4 * 
Anemias 2/.2 * 1/.1 * 
 
*Less than five observed deaths. 
 
M. G. Ott, J.C. Townsend, W.A. Fishbeck and R.A. Langner.  1978. Mortality Among 
Individuals Occupationally Exposed to Benzene.  Archives of Environmental Health  3-10. 
 
 
Limitations: 
1. No personal, time-weighted industrial hygiene measurements. 
2. Exposure history was based upon estimated ranges from area sampling, not 
individualized data, including work practices, personal protective equipment use, etc. 
3. Exposed workers most likely had innumerable chemical exposures, including 
benzene. 
4. Use of general population data for the control introduces the possibility of the 
“healthy worker” effect, which tends to lower standardized mortality ratios artificially 
and may obscure any significant findings.   
5. No control for potential confounders and modifying factors, such as smoking. 
6. There was incomplete follow-up of the cohort members and data was very likely 
missing and possibly skewed due to non-differential effects.   
 
 
 
Bond, G. G., E. A. McLaren, et al. (1986). "An update of mortality among chemical workers 
exposed to benzene." Br J Ind Med 43(10): 685-91. (Bond, McLaren et al. 1986) 
 
Cohort Description and Methods: 
 This study updates the mortality experience of the Dow Michigan division previously 
studied with an additional nine years of follow-up to the end of 1982.  During the follow-up 
period, 364 additional employees were added to the cohort.  This study presents the mortality 
among 956 total employees.    
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Similar methods to the first study were followed with little deviation.  Company 
census lists were consulted for all workers with >1 month work experience in the three 
production areas between 1938 – 1970.  All job assignments involving potential exposure to 
benzene up to the end of 1978 were coded and considered for exposure classification. Each 
job entry was assigned one of four exposure intensity level: very low, low, moderate, and 
high - based on available industrial hygiene monitoring. All jobs held after 1972 were 
classified as either low or very low exposure.  Allowance was made for a possible latency 
period by lagging exposures 15 years. 
As in the first study, employees were identified with prior exposure to arsenic, 
vinylchloride and asbestos.  Analyses were performed both with and without these 
employees.   
 Death certificates were obtained for all but 1 (0.4%) of the decedents. This death of 
unknown cause was included in the totals for analysis but was not allocated to any specific 
category. The main duration of exposure was 7.0 years with a median of 2.6. The 956 
employees contributed a total of 24,571 person years with an average follow-up of 25.7 
years. The average age at entry into follow-up was 31 years. 
 Nearly a quarter (229 subjects) of the cohort were exposed to jobs categorized as 30 
ppm TWA benzene exposure, and nearly a third (311) were exposed in jobs categorized as 17 
ppm TWA. 
 
Results: 
All cause mortality had an SMR=84, or 83 if the arsenic, asbestos, and vinylchloride 
exposed subjects were excluded. This represented a significant deficit, but was consistent 
with the general pattern of a healthy worker effect.   Four deaths were observed from 
leukemia, which was a non-significant excess.  However, there was a significant excess of 
myelogenous leukemia, four observed versus 0.9 expected (p=0.011).  There was also a case 
of myeloblastic leukemia previously identified in the first cohort study, but the cause of death 
was walking pneumonia. See table below specific causes of death in the cohort.  
Estimated exposures for the five leukemia deaths were as follows:  1) 545 ppm 
months (45.4167 ppm-years), 2) 18 ppm months (1.5 ppm-years), 3) 305 ppm months 
(25.4167 ppm-years), 4) 421 ppm months (35.0833 ppm-years), and 5) 343 ppm months 
(28.5833 ppm-years).   Both new leukemias had the potential for unquantified brief, but 
potentially relatively high, exposure to benzene. In the alkylbenzene area, benzene levels 
were measured as high as 283 ppm in some samples and in ethylcellulose as high as 937 
ppm. Therefore, caution must be exercised when interpreting the cumulative dose in the 
cases.  An additional case (besides the two cases of anemia originally found by Ott) of a 
nonmalignant blood disease, specifically identified as myelofibrosis, was identified in an 80 
year old former worker with an estimated cumulative exposure of 6,027 ppm month (502.25 
ppm-years). 
 When the analysis for mortality in the total cohort was carried out with a 15-year 
minimal latency period, the mortality patterns were not significantly altered, although some 
of the cause specific SMR were increased slightly.  The 15 year lag effectively removed 
those cohort members first exposed after 1967 from the analysis.  
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Analysis by work area, duration of exposure and cumulative dose index did not show 
a pattern suggested of a causal association between exposure to benzene and any particular 
category of death. Three of the four patients with leukemia, one with multiple myeloma and 
one with myelofibrosis, worked in the alkyl benzene department.  This may indicate some 
additional co-factor that is important in the etiology of these deaths. 
  
 
Table 27 - Observed and Expected Deaths by Cause, SMRs and 95% confidence limits.* 
Mortality Among Benzene Cohort, 1940-82 
 Total Cohort Cohort Less Exclusions† 
Cause of Death 
(ICD-8th) 
Obs Exp SMR 95% 
CI 
Obs Exp SMR 95% 
CI 
All Causes 
(including 1 
unknown) 
225 286.6 84 73-95 200 242.3 83 72-95 
All Malignant 
Neoplasms (140-
209) 
59 54.7 108 82-139 49 49.2 100 74-132 
Lymphosarcoma 
and 
Reticulosarcoma 
(200) 
2 1.1 180 22-657 2 1.0 199 24-722 
Hodgkin’s 
Disease (201) 
0 0.7 - 0-527 0 0.6 - 0-615 
Leukaemia and 
Aleukaemia 
(204-207) 
4 2.1 194 52-488 3 1.9 162 33-461 
Other Lymphatic 
Tissue (208) 
1 1.3 76 2-429 1 1.2 84 2-464 
Other and 
Unspecified Sites 
(199) 
7 3.8 184 74-380 7 3.4 205 83-424 
Diseases Blood 
and Blood-
forming Organs 
(280-289) 
3 0.7 444 88-
1252 
1 0.6 164 4-929 
 
*Fisher’s exact limits when observed less than 20 approximate limits otherwise. 
†Less those exposed to arsenic, asbestos, or high levels of vinyl chloride. 
 
G.G. Bond, E.A. McLaren, C.L. Baldwin and R.R. Cook. 1986. An Update of Mortality 
Among Chemical Workers Exposed to Benzene.  British Journal of Industrial Medicine. 43: 
685-691. 
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Table 28 - Mortality Summary by Estimated Cumulative Dose of Benzene Exposure, Excluding 
Employees with Competing Exposures† 
 Exposure Lagged By 
 0 years 15 years 
Cause of Death and 
Cumulative Dose 
Level 
Obs Exp SMR Obs Exp SMR 
All Causes (001-
999) 
      
    0-499 ppm 
months 
115 151.4 76 105 117.8 89 
    500-999 ppm 
months 
43 35.2 122 33 25.7 129 
    ≥1000 ppm 
months 
42 55.6 76 27 37.4 72 
    Total 200 242.3 83* 165 180.5 91 
All Cancer (140-
209) 
      
    0-499  27 30.0 90 27 25.0 108 
    500-999 11 7.3 150 9 5.7 159 
    ≥1000  11 11.9 92 7 8.4 84 
    Total 49 49.2 100 43 39.1 110 
Lymphopoietic 
Cancer (200-209) 
      
    0-499  4 3.0 133 3 2.3 132 
    500-999 0 0.7 - 0 0.5 - 
    ≥1000  2 1.1 183 2 0.7 274 
    Total 6 4.8 125 5 3.5 142 
Leukaemia (204-
209) 
      
    0-499  2 1.2 167 2 0.9 222 
    500-999 0 0.3 - 0 0.2 - 
    ≥1000  1 0.4 250 1 0.3 333 
    Total 3 1.9 158 3 1.4 214 
 
*Significant at α = 0.05. 
†Less those exposed to arsenic, asbestos, or high levels of vinyl chloride. 
 
G.G. Bond, E.A. McLaren, C.L. Baldwin and R.R. Cook. 1986. An Update of Mortality 
Among Chemical Workers Exposed to Benzene.  British Journal of Industrial Medicine. 43: 
685-691. 
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Limitations: 
1. No personal, time-weighted industrial hygiene measurements. 
2. Exposure history was based upon estimated ranges from area sampling, not 
individualized data, including work practices, personal protective equipment use, etc. 
3. They were unable to account for peak exposures that may have added significant 
exposure to the cumulative dose of effected workers.   
4. Exposed workers most likely had innumerable chemical exposures, including 
benzene. 
5. Use of general population data for the control introduces the possibility of the 
“healthy worker” effect, which tends to lower standardized mortality ratios artificially 
and may obscure any significant findings.   
6. No control for potential confounders and modifying factors, such as smoking. 
7. There was incomplete follow-up of the cohort members and data was very likely 
missing and possibly skewed due to non-differential effects.   
 
 
Bloemen, L. J., A. Youk, et al. (2004). "Lymphohaematopoietic cancer risk among chemical 
workers exposed to benzene." Occup Environ Med 61(3): 270-274. (Bloemen, Youk et al. 
2004) 
 
Cohort Description and Methods: 
This is an update on the previous studies undertaken by Ott et al. and Bond et al.  The 
observation period is extended by 14 years and includes new data from previously 
unevaluated areas of low benzene exposure.  The expanded cohort included 2,266 who with 
more than one month of work in one of three benzene-exposed departments in the Dow 
Michigan operations.  The three departments were chlorobenzol, alkyl benzene and 
etylcellulose production.  Use of benzene in all three departments ceased completely by 
1978.   There were a total of 82,411 person years of observation encompassing the mortality 
experience from 1940-1996.  Approximately two-thirds (68%) worked for at least 30 years. 
The cohort is predominantly white (99.5%) and mostly male (94%). Nearly half (47%) were 
hired in the decade following 1950. A large portion was short-term workers: 42% worked 
less than a year and only 26% worked 5 or more years.  Fifty-nine percent (59%) of the 
cohort worked in ethyl cellulose. The average duration of exposure to benzene was 4.8 years, 
with a range of 3 months to 45 years. Average cumulative exposure was 39.7 ppm-years 
(range: 0.05 to 852 ppm-years) and average intensity of exposure was 9.6 ppm (range: 0.5 to 
35 ppm). 
 This update has the advantage of improvements made in the Dow Epidemiology 
department.  Starting with 1940, the complete work history of all United States workers was 
placed in a database.  The original inclusion criteria were continued in this update.  Persons 
employed in the chlorobenzol area with jobs in the lowest exposure category are now 
included in the cohort. For each employee, persons at risk for mortality were accumulated 
until date of death, date lost of follow-up, or the end of the study period, December 31, 1996, 
whichever occurred first. 
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A certified industrial hygienist with knowledge of the three production areas 
reevaluated all jobs for exposures.  The same categorization scheme was used; however, the 
very low category was changed to <1ppm, versus <2 ppm.  There were no noted changes in 
individual exposure estimates when compared to the previous study.   
Three exposure measures were used to evaluate risk:  duration of exposure, 
cumulative exposure and average intensity.  Each exposure measure was broken down into 
three levels in order to include 1/3 of cumulative cases in each level.  
A 15 year lag period was analyzed in order to evaluate risks associated with 
cumulative exposure.   
 
Results: 
A total of 1,054 (46%) deaths were noted in the cohort by the end of the evaluation 
period.  Out of the total cohort of 2,266 workers, only 13(0.6%) had an unknown vital status.    
Overall, mortality was significantly below (10%) the U.S. comparison values.  Comparisons 
with the local county data yielded similar results.  Non-malignant diseases of the blood and 
blood-forming organs had an SMR = 2.17 (95% CI: 0.87 – 4.48).  The number of deaths due 
to malignancies was in line with expectations (SMR = 0.97).  The category of multiple 
myeloma had 3 observed deaths with 4.2 expected.  Chronic lymphatic leukemia also had a 
deficit with 1 observed and 2.4 expected.  Estimates for Non-Hodgkin’s leukemia, leukemia, 
acute non-lymphatic leukemia were slightly increased (1.06, 1.14 and 1.11), although none 
were significant.  See table below for SMR related to specific causes of death. 
The analysis by duration of exposure, cumulative exposure and average intensity 
revealed some difficult to interpret findings.  Non-malignant diseases of the blood risk 
increase with increasing duration of exposure; however, this did not hold true for cumulative 
exposure or average intensity. Both leukemia and ANLL risk appeared to increase with 
cumulative exposure, but this pattern was not repeated when evaluating duration or average 
intensity.  With that said, ANLL had very low numbers of deaths, thus limiting any findings.  
The authors concluded that even with the limited number of ANLL cases the data suggests a 
weak trend of leukemia and possibly ANLL at lower levels of cumulative exposure which 
approach the low estimated exposures seen in the Pliofilm cohort.   
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Table 29 - Observed Deaths and SMRs for Selected Causes of Death Among Benzene 
Exposed Chemical Workers, Compared to the US Population† 
Cause of Death (9th revision) Deaths SMR 95% CI 
All Causes of Death (001-999) 972 0.90** 0.85 to 0.96 
All Lymphatic and Haematopoietic Tissue 
(200-208) 
27 1.01 0.66 to 1.46 
Non-Hodgkin’s Lymphoma (200.0-200.8, 
202.0, 202.8) 
10 1.06 0.51 to 1.95 
Hodgkin’s Disease (201) 2 1.01 0.12 to 3.63 
Multiple Myeloma (203) 3 0.72 0.15 to 2.10 
Leukaemia and Aleukaemia (204.1) 12 1.14 0.59 to 1.99 
Chronic Lymphatic Leukaemia (204.1) 1 0.42 0.01 to 2.36 
Acute Non-Lymphocytic Leukaemia (205.0, 
206.0, 207.0) 
4 1.11 0.30 to 2.83 
Diseases of Blood and Blood Forming Organs 
(280-289) 
7 2.17 0.87 to 4.48 
 
†Non-malignant causes: 1960-96, 2171 workers, 60 506 person-years at risk.  Malignant 
causes: 1940-96, 2266 workers 82 411 person years at risk. 
*p<0.05, **p<0.01. 
 
L.J. Bloemen, A. Youk, T.D. Bradley, K.M. Bodner and G. Marsh. 2004. 
Lymphohaematopoietic Cancer Risk Among Chemical Workers Exposed to Benzene.  
Occup. Environ. Med. 61: 270-274. 
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Table 30 - Observed Deaths and SMRs by Benzene Exposure Measures for Selected Causes of Death, Benzene 
Exposed Chemical Workers, US Comparisons 
  0 year lag 15 year lag 
Exposure Measure  Obs SMR 95% CI Obs SMR 95% CI 
Leukaemia and 
Aleukaemia 
       
Duration (y)     <5 5 0.70 0.23 to 
1.63 
6 0.78 0.29 to 
1.70 
     5-9 4 3.09 0.84 to 
7.90 
3 2.51 0.53 to 
7.34 
     10+ 3 1.44 0.30 to 
4.20 
3 1.84 0.38 to 
5.38 
Cumulative 
Exposure    
<340 4 0.60 0.16 to 
1.54 
5 0.69 0.23 to 
1.62 
(ppm-years)    28.3-79.1 4 2.00 0.54 to 
5.11 
3 1.71 0.35 to 
5.00 
 79.1+ 4 2.16 0.59 to 
5.53 
4 2.55 0.70 to 
6.54 
Average Intensity 
(ppm) 
<5 3 0.75 0.16 to 
2.20 
9 0.95 0.44 to 
1.81 
 5-14 5 1.57 0.51 to 
3.66 
3 2.96 0.61 to 
8.64 
 15+ 4 1.19 0.32 to 
3.05 
0 0.00 0.00 to 
60.93 
Acute Non-
Lymphocytic 
Leukaemia 
       
Duration (y)     <5 2 0.82 0.10 to 
2.97 
3 1.18 0.24 to 
3.46  
     5-9 1 2.20 0.06 to 
12.23 
0 0.00 0.00 to 
8.33 
     10+ 1 1.37 0.03 to 
7.66 
1 1.58 0.04 to 
8.79 
Cumulative 
Exposure    
<28.3 2 0.87 0.11 to 
3.13 
3 1.26 0.26 to 
3.69 
(ppm-years)    28.3-79.1 1 1.47 0.04 to 
8.17 
0 0.00 0.00 to 
5.65 
 79.1+ 1 1.61 0.04 to 
8.95 
1 1.71 0.04 to 
9.51 
Average Intensity 
(ppm) 
<5 0 0.00 0.00 to 
2.64 
3 0.93 0.19 to 
2.73 
 5-14 3 2.66 0.55 to 
7.76 
1 2.65 0.07 to 
14.74 
 15+ 1 0.92 0.02 to 
5.13 
0 0.00 0.00 to 
146.28 
 
L.J. Bloemen, A. Youk, T.D. Bradley, K.M. Bodner and G. Marsh. 2004. 
Lymphohaematopoietic Cancer Risk Among Chemical Workers Exposed to Benzene.  
Occup. Environ. Med. 61: 270-274. 
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Limitations: 
1. None of the risk estimates were significant.  All CI included the value 1. 
2. No personal, time-weighted industrial hygiene measurements. 
3. Exposure history was based upon estimated ranges from area sampling, not 
individualized data, including work practices, personal protective equipment use, etc. 
4. They were unable to account for peak exposures that may have added significant 
exposure to the cumulative dose of effected workers.   
5. Exposed workers most likely had innumerable chemical exposures, including benzene 
that they were unable to account for in the analysis.   
6. Use of general population data for the control introduces the possibility of the 
“healthy worker” effect, which tends to lower standardized mortality ratios artificially 
and may obscure any significant findings.   
7. No control for potential confounders and modifying factors, such as smoking. 
 
 
Monsanto/Salutia Chemical Plant Studies – Two Successive Retrospective Cohort 
Studies 
 
 
Ireland, B., J. J. Collins, et al. (1997). "Cancer mortality among workers with benzene 
exposure." Epidemiology 8(3): 318-20._(Ireland, Collins et al. 1997)___________________ 
  
Cohort Description and Methods: 
 This is an update of a cohort of employees from the Monsanto company plant in 
Sauget, Illinois.  The previous evaluation of the plant was part of an industry wide benzene 
study performed by Wong (1987).  The updated cohort includes all hourly workers who 
worked at the plant from 1940 -1991.  Person-time accumulation began on the date of hire 
and ended on December 31, 1991, or earlier if the employee left for any reason. A total of 
4,172 men were identified through company records and reports to the IRS.  Follow-up was 
completed for 4,091 (98%) of the eligible employees.  Eighty-one (2%) were lost to follow-
up.  Death certificates were ascertained for all but 20 (1%) members.  Workers without a 
death certificate were included in all cause mortality analyses.   
 Exposure assessment was completed for multiple departments, including:  
nitrobenzene, phenol, chlorobenzene, muriatic acid and alkylbenzene production. Data 
collection began in 1980 and at that time only the chlorobenzene and muriatic acid 
departments were still operational.  Most exposures had to be estimated.  Information 
regarding process changes and the input of an industrial hygienist were used to estimate 
historical exposures.  Continuous exposures were categorized into the following 8-hr TWAs: 
<1, 1-10 and 11-50 ppm.  This process was not completed for maintenance jobs.  In order 
quantify peak exposures, the number of days with a 15-minute exposure excursion above 100 
ppm were estimated for all jobs.  Cumulative daily exposures were categorized as follows:  
<12, 12-72 and >72 ppm-months.  The number of days with peaks >100 ppm were 
categorized as follows:  0, <7, 7-40 days and >40 days. The number of days with peak 
exposures greater than 100 ppm range from 1 to 2,590 with a median of 22 days.  
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Cohort member death rates were compared with death rates for the State of Illinois.   
  
Results: 
The total mortality rates for unexposed workers was higher than the rate for Illinois 
with an SMR = 1.1 (95% CI: 1- 1.2).   This was largely due to heart disease and lung cancer.  
The exposed workers had a mortality rate similar to the Illinois population, SMR=1.0 (95% 
CI:  0.9-1.1).  Maintenance workers had a slight deficit, SMR=0.9 (95% CI: 0.8 - 1.0).  No 
death from Hodgkin’s lymphoma or diseases of the blood or blood-forming organs occurred 
among exposed workers. For all leukemia, the SMR= 1.1 (95% CI: 0.4 - 2.6) in the non-
exposed group and an SMR=2.5 (95% CI:0.3 - 8.9) in <12 ppm-months (1 ppm-years) 
category, SMR=0.0 (95% CI: 0.0 -5.4) in the 12 -72 ppm-months (1 – 6 ppm-years) category 
and SMR=4.6 (95% CI: 0.9 to 13.4) in the ≥72 ppm-months (≥6 ppm-years) category.  For 
ANNL and CLL, the SMRs were also elevated in the lowest and highest continuously 
exposed groups; however, this is based on only one case of each type of leukemia in the 
respective cumulative benzene exposure categories.  The findings were similar when 
examined by peak exposure category.    
The SMR for leukemia by year of hire was 2.9 (95% CI: 0.8-7.4) for years 1940-
1949, 1.6 (95% CI: 0.0 – 8.7) for years 1950-1959 and 0.0 (95% CI: 0.0-21.7 for years 1960-
1977. The SMR for the interval from onset of exposure to death was 0.0 (95% CI:0.0 - 20.4) 
for <10 years, 2.9 (95% CI: 0.1-16.4) for 10-19 years, 0.0 (95% CI:0.0 – 7.0) for 20-29 years 
and  3.5 (95% CI: 0.9 - 8.9) for <30 years.  See table below for specific information. 
 The authors noted that they found elevated, but imprecise rates of leukemia and MM 
for workers ≥20 years from date of hire.   
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Table 31 - Observed Deaths (OBS), Expected Deaths (EXP), SMRs and 95% CIs for Selected 
Causes of Death by Cumulative Benzene Exposure Category 
 Production  
Workers OBS/EXP and SMR (95% CI) 
Cause of 
Death 
(ICD-9* 
Code) 
Non-Exposed <12 ppm-
month 
12-72 ppm-
month 
≥72 ppm-
month 
Maintenance 
Workers  
OBS/EXP and 
SMR  
(95% CI) 
All 
Cancers 
(140-209) 
157/135.8 1.2 
(1.0-
1.4) 
21/25.0 0.8 
(0.5-
1.3) 
15/20.5 0.7 
(0.4-
1.2) 
28/19.1 1.5 
(1.0-
2.1) 
242/226.54 1.1 
(0.9-
1.2) 
Hodgkin’s 
Disease 
(201) 
0/1.11 0.0 
(0.0-
3.3) 
0/0.22 0.0 
(0.0-
16.8)
0/0.17 0.0 
(0.0-
21.4)
0/0.13 0.0 
(0.0-
27.4) 
2/172 1.2 
(0.1-
4.3) 
Multiple 
Myeloma 
(203) 
1/1.97 0.5 
(0.0-
2.8) 
0/0.37 0.0 
(0.0-
10.1)
2/0.29 6.8 
(0.8-
2.5) 
1/0.27 3.7 
(0.1-
20.1) 
4/3.48 1.2 
(0.3-
2.9) 
Leukemia 
(204-207) 
5/4.51 1.1 
(0.4-
2.6) 
2/0.81 2.5 
(0.3-
8.9) 
0/0.69 0.0 
(0.0-
5.4) 
3/0.65 4.6 
(0.9-
13.4) 
9/7.16 1.3 
(0.6-
2.4) 
    Chronic 
Lymphatic  
    (204.1) 
1/1.01 1.0 
(0.0-
5.5) 
1/0.17 5.9 
(0.1-
32.6)
0/0.15 0.0 
(0.0-
24.7)
1/0.15 6.7 
(0.2-
37.7) 
1/1.56 0.6 
(0.0-
3.6) 
    Acute 
Non-
lymphatic  
    (205.0, 
206.0) 
2/1.46 1.4 
(0.2-
5.0) 
1/0.27 3.7 
(0.1-
20.6)
0/0.23 0.0 
(0.0-
44.1)
1/0.22 4.5 
(0.1-
25.3) 
2/2.27 0.9 
(0.1-
3.2) 
 
*ICD-8 = International Classification of Diseases, 8th revision. 
 
B. Ireland, J.J. Collins, C.F. Buckley and S.G. Riordan. 1997. Cancer Mortality Among 
Workers with Benzene Exposure.  Epidemiology  8(3): 318-320. 
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Limitations: 
1. None of the risk estimates were significant, with the exception of all cancers at ≥72 
ppm month (6 ppm-years).  All CI included the value 1.  In addition, the SMR 
approached significance for all leukemias at ≥72 ppm month (6 ppm-years). 
2. The authors noted that exposure estimates were “difficult” for the 1940’s and 1950’s 
because of the lack of information.  However, they assigned the highest exposure 
category to jobs during those periods.  Nevertheless, they admitted that exposures 
could have been much higher.  Four of the five leukemia cases occurred in workers 
who started working before 1950. The SMR for leukemia by year of hire was 2.9 
(95% CI: 0.8-7.4) for years 1940-1949, which approached significance. 
3. No personal, time-weighted industrial hygiene measurements. 
4. Exposure history was based upon estimated ranges from area sampling (in many 
cases incomplete), not individualized data, including work practices, personal 
protective equipment use, etc. 
5. Although an attempt was made to account for peak exposures, this categorization 
technique did not consider individual workers experience, they were simply the 
estimates made by the industrial hygienist.  
6. Confounding variables such as cigarette smoking were not accounted for, yet there 
was a clear excess of lung cancer deaths in the unexposed cohort of workers, 
SMR=1.3 (95% CL: 1.0-1.7) and in maintenance workers, SMR=1.4 (95% CI: 1.1-
1.7).  There was no significant excess of lung cancer in any category of cumulative 
exposure in exposed workers.   
7. All leukemia diagnoses were from death certificates, without verification of 
diagnosis, much less the particular cell type of the disorder.  Misclassification of even 
one case with the various categories of leukemia could drastically change the 
outcomes.  In addition, if a person died of another primary cause, it is possible that 
underlying leukemia would not be listed and would thus be underreported.   
8. There were 2 cases of ANLL in the unexposed category and 3 in the exposed 
category – such limited numbers in both the unexposed and exposed categories lead 
to very unstable estimates of risk and severely limit any conclusions being drawn 
from this study.    
9. Coal tar derived leukemia was used in the plant prior to 1950.  It has been suggested 
that PAHs from coal tar are linked to lymphocytic leukemia.  Both of the workers 
with lymphocytic leukemia started working before 1950. 
 
 
Collins, J. J., B. Ireland, et al. (2003). "Lymphohaematopoietic cancer mortality among 
workers with benzene exposure." Occup Environ Med 60(9): 676-9. (Collins, Ireland et al. 
2003) 
 
Cohort Description and Methods: 
 This is a follow-up study to the Ireland et al. (1997) study that examined mortality at 
the Solutia (formerly Monsanto) plant in Sauget, Illinois.  A particular interest of this study 
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was to examine the lymphohematopoietic effects of low cumulative benzene exposure from 
short term exposure peaks.  
All hourly workers employed between 1940-1970 were included in the cohort.  Vital 
status follow-up was complete for 4,352 (99%) and 2,431(56%) were deceased. Death 
certificates were obtained for all but 27 (1%) of decedents. Deceased workers with no death 
certificate were included in all cause mortality analysis.  
In order to ascertain exposures for individuals, the history of process changes, area 
sampling levels, individual exposures (1,090 personal TWA 8-hour benzene exposures and 
247 personal short-term exposure levels) were available.  Personal exposure sampling began 
in 1980.  Some area sampling was available for all departments.  In addition, the plant 
industrial hygienist’s judgment was used to estimate exposures.   Most exposures stratified 
by time, department and job had to be estimated without relevant personal exposure data. The 
exposure categories for cumulative exposure and number of days with peaks >100 ppm were 
carried over from the previous study.  Most job types had no potential for peaks over 100 
ppm.  The culminated individual daily exposure and divided the exposure categories into 
three groups used in the previous study. Cumulative exposures ranged from 0.1 ppm-years to 
632 ppm-years with a median of 3 ppm-years. Similarly when we culminated the number of 
days with peaks into categories used in the previous study, those job types in the plant had no 
potential or peak exposures over 100 ppm.  
We compared worker death rates with rates of the population of Illinois and 
calculated standardized mortality ratios in 95% confidence levels. 
 
 
Results: 
Cumulative exposures ranged from 0.1 ppm-years to 632 ppm-years with a median of 
3 ppm-years. 
The category of all leukemia had the following SMRs: 1.0 (95% CI: 0.5 - 1.8) for no 
exposure; 0.7 (95% CI: 0.1 - 2.5) for >1 ppm; 1.4 (95% CI:0.4 - 3.6) for 1-6 ppm-years and 
1.7 (95% CI:0.6 -3.8) for >6 ppm-years. The SMRs for ANLL were as follows:  0.8 (95% CI: 
0.1 – 2.8) for no exposure; 1.4 (95% CI: 0.1 – 5.1) for >1 ppm; 2.7 (95% CI:0.3 – 9.9) for 1-6 
ppm-years and 2.2 (95% CI:0.3 – 8.1) for >6 ppm-years.  The SMRs for multiple myeloma 
also increased with progressive cumulative exposure category. Both Hodgkin’s disease and 
non-Hodgkin’s lymphoma SMRs did not increase consistently with increasing exposure.   
When analyzed by frequency of peak exposures over 100 ppm, both multiple 
myeloma and ANLL showed an increased SMR at >40 days with a peak exposure.  Twelve 
of the cases had cumulative exposure, while 4 had both cumulative and peak exposure and 3 
had only peak exposure.   Ten out of 13 cases of multiple myeloma occurred in workers with 
benzene exposure and all 10 deaths occurred 20+ from first exposure.  Six of the cases had 
cumulative exposure, 2 had cumulative and peak exposure and 2 had only peak exposure.  
All 10 deaths from multiple myeloma occurred 20 or more years after first exposure. No 
deaths from anemia were found among benzene-exposed workers. In the 22 leukemia deaths, 
15 occurred in workers with benzene exposure.   
SMRs for leukemia by year of hire for all benzene exposed workers were 0.9 (95% 
CI: 0.4 – 1.7) if hired from 1940-1949, 1.6 (95% CI: 0.4 - 4.1 if hired from 1950-1959 and 
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3.2 (95% CI:0.7 – 9.4) if hired from 1960-1977. The SMRs for interval from onset of 
exposure in exposed workers were as follows: 1.3 (95% CI: 0.0 - 7.0) for <10 years; 2.2 
(95% CI: 0.5 - 6.5) for 10 - 19 years and 1.1 (95% CI: 0.6 - 1.9) for 20+ years.  
Unlike the Pliofilm workers there was little evidence for increasing leukemia or AML 
risk with increasing cumulative exposure to benzene. However, there were more leukemias 
(5 observed, 1.8 expected) and more AML (2 observed, 0.5 expected) when there were >40 
days of peak exposures over 100 ppm.   There was little to no risk with lower numbers of 
peak exposures in any category.  See table below for more details. 
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Table 32 - SMRs, 95% CI, Observed Deaths (OBS), and Expected Deaths (EXP) for Selected Causes of Death by 
Peak Benzene Exposure Category 
N b Number of Days with Peak Exposure over 100 ppm 
 None <7 7-40 >40 
Cause of Death 
(ICD8 Code) 
SMR (95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP 
All Deaths (000-999) 1.0 (1.0 to 1.0) 1951/1943.7 1.2 
(1.0 
to 
1.4) 
117/98.5 1.0 
(0.9 
to 
1.2) 
161/160.6 1.0 
(0.9 
to 
1.1) 
202/202.1 
All Cancer (140-209) 1.1 (1.0 to 1.2) 508/465.7 1.3 
(0.9 
to 
1.8) 
30/23.8 1.1 
(0.8 
to 
1.5) 
46/39.8 1.2 
(0.9 
to 
1.5) 
61/51.2 
Hodgkin’s Disease 
(201) 
0.7 (0.1 to 2.4) 2/3.0 0.0 
(0.0 
to 
22.8) 
0/0.2 0.0 
(0.0 
to 
14.5) 
0/0.3 0.0 
(0.0 
to 
13.1) 
0/0.3 
Non-Hodgkin’s 
Lymphoma (200, 
202) 
1.4 (0.9 to 2.2) 20/14.3 1.3 
(0.0 
to 
7.4) 
1/0.8 0.7 
(0.0 
to 
4.2) 
1/1.3 1.8 
(0.4 
to 
5.1) 
3/1.7 
Multiple Myeloma 
(203) 
1.2 (0.6 to 2.4) 9/7.2 0.0 
(0.0 
to 
10.2) 
0/0.4 1.7 
(0.0 
to 
9.4) 
1/0.6 4.0 
(0.8 
to 
11.7) 
3/0.8 
Leukaemia (204-207) 1.0 (0.5 to 1.6) 15/15.6 1.2 
(0.0 
to 
6.8) 
1/0.8 0.7 
(0.0 
to 
4.0) 
1/1.4 2.7 
(0.8 
to 
6.4) 
5/1.8 
    Chronic 
Lymphatic  
    (204.1) 
0.9 (0.2 to  
2.5) 
3/3.5 0.0 
(0.0 
to 
20.6) 
0/0.2 0.0 ( 
0.0 to 
12.2) 
0/0.3 2.5 
(0.0 
to 
13.8) 
1/0.3 
    Acute Non-
lymphatic  
    (205.0-206.0) 
1.3 (0.4 to 3.0) 5/3.9 0.0 
(0.0 
to 
10.2) 
0/0.2 0.0 
(0.0 
to 
10.4) 
0/0.4 4.1 
(0.5 
to 
14.9) 
2/0.5 
Persons at Risk 4417  898  690  339  
Person-years 129000  6991  11593  11448  
 
J.J. Collins, B. Ireland, C.F. Buckley and D. Shepperly. 2003. Lymphohaematopoietic 
Cancer Mortality Among Workers With Benzene Exposure.  Occup. Environ. Med.  20: 676-
679. 
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Table 33 - SMRs, 95% CI, Observed Deaths (OBS), and Expected Deaths (EXP) for Selected Causes of Death by 
Cumulative Benzene Exposure Category 
 Cumulative Exposure (ppm-years) 
 No Exposure <1 1-6 >6 
Cause of Death (ICD8 
Code) 
SMR 
(95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP SMR 
(95% 
CI) 
OBS/EXP 
All Deaths (000-999)  1.0 (1.0 
to 1.1) 
1300/1290.7 0.9 
(0.8 to 
1.1) 
342/361.7 1.1 
(1.0 to 
1.2) 
365/345.8 1.0 
(0.9 to 
1.1) 
424/406.8 
All Cancer (140-209) 1.1 (1.0 
to 1.2) 
336/305.2 0.9 
(0.8 to 
1.2) 
84/88.7 1.1 
(0.9 to 
1.4) 
97/85.5 1.3 
(1.1 to 
1.5) 
128/101.2 
Hodgkin’s Disease 
(201) 
0.5 (0.0 
to 2.8) 
1/2.0 1.7 
(0.0 to 
9.7) 
1/0.6 0.0 
(0.0 to 
6.7) 
0/0.6 0.0 
(0.0 to 
6.6) 
0/0.6 
Non-Hodgkin’s 
Lymphoma (200, 202) 
1.5 (0.8 
to 2.5) 
14/9.6 1.1 
(0.2 to 
3.4) 
3/2.6 1.5 
(0.4 to 
3.8) 
4/2.7 1.2 
(0.3 to 
3.2) 
4/3.2 
Multiple Myeloma 
(203) 
1.1 (0.3 
to 2.5) 
5/4.7 1.4 
(0.2 to 
5.1) 
2/1.4 1.5 
(0.2 to 
5.4) 
2/1.3 2.6 
(0.7 to 
6.7) 
4/1.5 
Leukaemia (204-207) 1.0 (0.5 
to 1.8) 
10/10.4 0.7 
(0.1 to 
2.5) 
2/2.9 1.4 
(0.4 to 
3.6) 
4/2.9 1.7 
(0.6 to 
3.8) 
6/3.5 
    Chronic Lymphatic  
    (204.1) 
0.9 (0.1 
to 3.1) 
2/2.3 1.6 
(0.0 to 
8.9) 
1/0.6 0.0 ( 
0.0 to 
5.9) 
0/0.6 1.3 
(0.0 to 
7.2) 
1/0.8 
    Acute Non-lymphatic  
    (205.0-206.0) 
0.8 (0.1 
to 2.8) 
2/2.6 1.4 
(0.1 to 
5.1) 
1/0.7 2.7 
(0.3 to 
9.9) 
2/0.7 2.2 
(0.3 to 
8.1) 
2/0.9 
Persons at Risk 4063  2037  1343  683  
Person-years 86268  25798  24106  22859  
 
J.J. Collins, B. Ireland, C.F. Buckley and D. Shepperly. 2003. Lymphohaematopoietic 
Cancer Mortality Among Workers With Benzene Exposure.  Occup. Environ. Med.  20: 676-
679.
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Limitations: 
1. None of the risk estimates were significant, with the exception of all cancers at ≥72 
ppm month (6 ppm-years).  All other CI were wide and included the value 1.  
2. The authors noted that exposure estimates were “difficult” for the 1940’s and 1950’s 
because of the lack of information.  However, they assigned the highest exposure 
category to jobs during those periods.  Nevertheless, they admitted that exposures 
could have been much higher.  Four of the five leukemia cases occurred in workers 
who started working before 1950.  
3. No personal, time-weighted industrial hygiene measurements. 
4. Exposure history was based upon estimated ranges from area sampling (in many 
cases incomplete), not individualized data, including work practices, personal 
protective equipment use, etc. 
5. Although an attempt was made to account for peak exposures, this categorization 
technique did not consider individual workers experience, they were simply the 
estimates made by the industrial hygienist.  
6. Confounding variables such as cigarette smoking were not accounted for, yet there 
was a clear excess of lung cancer deaths in the unexposed cohort of workers, 
SMR=1.3 (95% CL: 1.0-1.7) and in maintenance workers, SMR=1.4 (95% CI: 1.1-
1.7).  There was no significant excess of lung cancer in any category of cumulative 
exposure in exposed workers.   
7. All leukemia diagnoses were from death certificates, without verification of 
diagnosis, much less the particular cell type of the disorder.  Misclassification of even 
one case with the various categories of leukemia could drastically change the 
outcomes.  In addition, if a person died of another primary cause, it is possible that 
underlying leukemia would not be listed and would thus be underreported.   
8. There were 2 cases of ANLL in the unexposed category and 5 in the exposed 
category – such limited numbers in both the unexposed and exposed categories lead 
to very unstable estimates of risk and severely limit any conclusions being drawn 
from this study.    
9. Coal tar derived leukemia was used in the plant prior to 1950.  It has been suggested 
that PAHs from coal tar are linked to lymphocytic leukemia.  Both of the workers 
with lymphocytic leukemia started working before 1950. 
 
 
Wong, O. (1987). "An industry wide mortality study of chemical workers occupationally 
exposed to benzene. I. General results." Br J Ind Med 44(6): 365-81. (Wong 1987) 
 
Cohort Description and Methods: 
 This study examined the mortality of a cohort of 7676 male chemical workers from 
seven plants from January 1, 1946-December 31, 1977.  Women were not included due to 
small numbers.  All of the workers had been exposed to benzene in a continuous or 
intermittent fashion for at least six months.  The continuous category consisted of jobs in 
which work was assigned to a discrete area in which benzene was produced, separated, 
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recovered, processed, loaded/unloaded, and potential exposure to benzene occurred on at 
least 3 days a week.  The intermittent category included a pattern which could not be 
characterized as continuous.  There were a total of 130,967.9 person years of observation.  
For most plants, the comparison group consisted of all occupationally non-exposed workers 
at the same plant, although this was modified for two plants due to size considerations.  The 
U.S. rates (5 year periods) were applied to person years of observation to obtain the expected 
number of deaths when the groups were matched for person years, race and age by calendar 
year.  Race was not available for 604 (7.87%) of the cohort and these persons were 
considered to be white which may overestimate risk due to the higher death rate for leukemia 
among the U.S. white male population compared to the non-white population.    
   The beginning date of the cohort at each plant was set by the introduction of benzene 
and the earliest date with complete employment records. The closing date of cohort boundary 
was generally 1975, except that it was extended to 1976 and 1977 in two plants.  Originally, 
a cohort of 14,000 from nine plants and seven companies was assembled; however, one 
company with two plants withdrew from the study (-4,000 cohort members) and another 
company had incomplete records prior to 1957.  The cohort definition was restated for these 
two plants and moved from 1946 to 1957.   
Data were collected from the companies in a variety of ways, including abstracting 
from existing company studies and employment of an outside company to gather data.  
Nevertheless, each group used a uniform cohort definition and a common protocol.  
Demographic and complete work histories came from the companies and death certificates 
were requested and coded in a uniform fashion.  Of the 1,036 individuals who died during the 
study period, death certificates were obtained for 1,013 (97.8%). The unexposed group had 
4.29% of death certificates missing, while the exposed group was missing (1.12% and 
1.32%).  At the end of the study period, the vital status of 177 terminated employees (2.31%) 
remained unknown, which was comparable across the two groups.  
All data was verified by the research team, although this procedure was infeasible for 
one plant because of inadequate work histories and the fact that exposed workers had been 
identified by supervisors.  The number of individuals correctly included or excluded 
compared to the number of records examined was 99.2%.  In addition, 10% of records were 
checked for coding errors and a 2.6% rate was found.   
Exposures were categorized as unexposed, intermittently exposed and continuous 
exposure.  Three-thousand seventy four were unexposed, while 1,066 were intermittently 
exposed and 3,536 were exposed continuously.  If a person had continuous intermittent 
exposure, they were categorized in the continuous category.  The average duration of 
employment was 15.82 years for the total cohort, 13.00 years for the comparison group, 
15.63 years for the intermittent exposure group, and 18.32 years for the continuous exposure 
group. 
Because SMR may not be optimal for data based on small control comparison groups, 
relative risk (derived through Mantel-Haenszel chi-square procedures) may be computed to 
compare the exposed to unexposed population.    
 
Results: 
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The total number of observed deaths was 1,036, versus 1,253.06 expected. This 
resulted in an SMR=82.7, which was statistically significant at the 0.01 level.   In addition, 
mortality from all cancers was also less than expected; however, the SMR was not 
significant.  There were 7 deaths due to cancer of the lymphatic tissue (5.5 expected), which 
was not significant.  Hematopoietic and lymphopoietic combined mortality was less than 
expected with an SMR=90.3.   
 Standardized mortality ratios (SMRs) from all lymphatic and haematopoietic 
(lymphopoietic) cancer combined, leukemia, non-Hodgkin's lymphoma (lymphosarcoma, 
reticulosarcoma, and other lymphoma), and non-Hodgkin's lymphopoietic cancer (non-
Hodgkin's lymphoma and leukaemia) for the exposed group were slightly, but not 
significantly, raised above the national norm. However, these SMRs were considerably 
higher than those in the comparison group. When the group with no occupational exposure 
was used for direct comparison, the continuously exposed group experienced a relative risk 
from lymphopoietic cancer of 3.20 (p< 0.05). In addition, the Mantel-Haenszel chi-square 
showed that the association between continuous exposure to benzene and leukemia was 
statistically significant (p< 0.05).  See table below for specific results related to cause of 
death and benzene exposure. 
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Table 34 - Observed and Expected Deaths by Cause, SMRs and their 95% Confidence Limits for  
1) All (7676) Cohort Members (person Years =133 967.9),  
2) All (3536) Cohort Members Continuously Exposed to Benzene (person Years=64 482.5),  
3) All (1066) Cohort Members Intermittently Exposed to Benzene (person Years= 19 512.6), and  
4) All (4602)Cohort Members Intermittently or Continuously Exposed to Benzene (person Years=85 069.9). 
Cause of Death (8th ICDA) Observed 
Deaths 
Expected 
Deaths 
SMR Lower 
Limit 
Upper 
Limit 
All Cohort Members      
    All Causes  1036 1253.06 82.7† 77.7 87.9 
    All Cancers (140-209) 214 239.85 89.2 77.7 102.0 
    Lymphatic and haematopoietic cancer (200-
209) 
22 24.36 90.3 56.6 136.7 
    Lymphosarcoma and reticulosarcoma     
(200) 
5 5.52 90.6 29.2 211.4 
    Hodgkin’s disease (201) 3 3.71 80.9 16.3 236.3 
    Leukaemia and aleukaemia (204-207) 7 9.36 74.8 30.0 154.1 
    Other lymphatic tissue cancer (22, 203,     
208) 
7 5.55 126.1 50.5259.9  
Cohort Members Continuously Exposed to 
Benzene 
     
    All Causes  531 613.12 86.6† 79.4 94.3 
    All Cancers (140-209) 123 117.71 104.5 86.8 124.8 
    Lymphatic and haematopoietic cancer (200-
209) 
15 11.74 127.8 71.4 210.9 
    Lymphosarcoma and reticulosarcoma (200) 3 2.65 113.0 23.3 330.6 
    Hodgkin’s disease (201) 2 1.78 112.2 13.6 405.1 
    Leukaemia and aleukaemia (204-207) 6 4.43 135.4 49.6 294.9 
    Other lymphatic tissue cancer (22, 203, 
208) 
4 2.77 144.7 39.4 370.0 
Cohort Members Intermittently Exposed to 
Benzene 
     
    All Causes  179 200.88 89.1 76.5 103.2 
    All Cancers (140-209) 38 38.93 97.6 68.9 134.1 
    Lymphatic and haematopoietic cancer (200-
209) 
4 3.85 104.0 28.3 265.9 
    Lymphosarcoma and reticulosarcoma (200) 1 0.87 114.6 2.9 636.5 
    Hodgkin’s disease (201) 0 0.56 0 - - 
    Leukaemia and aleukaemia (204-207) 1 1.49 67.0 1.7 372.2 
    Other lymphatic tissue cancer (22, 203, 
208) 
2 0.88 226.0 27.4 816.1 
Cohort Members Intermittently or 
Continuously Exposed to Benzene 
     
    All Causes  710 819.49 86.6† 80.4 93.2 
    All Cancers (140-209) 161 157.36 102.3 87.1 119.3 
    Lymphatic and haematopoietic cancer (200-
209) 
19 15.68 121.1 73.0 189.3 
    Lymphosarcoma and reticulosarcoma (200) 4 3.55 112.8 30.7 288.4 
    Hodgkin’s disease (201) 2 2.37 84.4 10.2 304.6 
    Leukaemia and aleukaemia (204-207) 7 5.96 117.4 47.1 242.0 
    Other lymphatic tissue cancer (22, 203, 
208) 
6 3.66 163.8 60.0 356.8 
†Significant at 0.01 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally Exposed to Benzene. I General 
Results.  British Journal of Industrial Medicine. 44: 365-381. 
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Table 35 - Mantel-Haenszel Relative Risk and Chi-Squares for Leukaemia Between Chemical 
Workers Occupationally Exposed and Not Exposed to benzene, Adjusted for Age and Race 
 Observed Deaths:  
Exposure Groups 
Compared 
Race Exposed Non-
Exposed 
Relative 
Risk 
Mantel-
Haenszel 
Chi-
Square 
p Value 
Total exposed (continuous 
and intermittent) v 
comparison 
White 6 0 Undefined 3.58 0.06 
 Non-
white 
1 0 Undefined 0.18 0.67 
 Both 7 0 Undefined 3.73 0.05 
Continuously Exposed v 
comparison 
White 5 0 Undefined 4.26* 0.04 
 Non-
white 
1 0 Undefined 0.23 0.63 
 Both 6 0 Undefined 4.42* 0.04 
 
*Statistically significant at the 0.05 level.   
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene. I General Results.  British Journal of Industrial Medicine. 44: 365-381. 
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Table 36 - Mantel-Haenszel Relative Risk and Chi-Squares for non-Hodgkin’s Lymphopoietic 
Cancer (non-Hodgkin’s lymphoma and leukaemia) Between Chemical Workers Occupationally 
Exposed and Not Exposed to benzene, Adjusted for Age and Race 
 Observed Deaths:  
Exposure Groups Compared Race Exposed Non-
Exposed 
Relative 
Risk 
Mantel-
Haenszel 
Chi-
Square 
p Value 
Total exposed (continuous and 
intermittent) v comparison 
White 14 1 8.60 5.84* 0.02 
 Non-
white 
3 1 0.48 0.48 0.49 
 Both 17 2 3.71 4.14* 0.04 
Continuously Exposed v 
comparison 
White 11 1 9.60 6.33* 0.01 
 Non-
white 
2 1 0.43 0.60 0.44 
 Both 13 2 3.77 4.34* 0.04 
 
*Statistically significant at the 0.05 level.   
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene. I General Results.  British Journal of Industrial Medicine. 44: 365-381. 
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Limitations: 
1. The use of a relatively small internal comparison group can introduce statistical 
instability and lead to the appearance of significance where this is not true.  There 
were only seven cases of leukemia, 6 in the continuously exposed and 1 in the 
intermittent grouping.  There was a deficit of leukemia in the comparison group (0 
observed vs. 3.4 expected) which magnifies the relative risk of the exposed.    
2. The types of leukemia were not broken down by cell type, thus limiting the analysis.  
For instance, if most or all were of one type not associated with benzene exposure this 
would completely change the analysis.  
3. The diagnoses were ascertained from death certificates, which may have limited 
information, or even incorrect information, particularly regarding cell type of 
lymphohematopoietic cancer. This may have led to misclassification and significant 
changes in the outcomes primarily due to the very small numbers of individual types 
of lymphohematopoietic cancer cases in the exposed and unexposed groups.  There 
was no way of verifying the diagnosis stated on the certificate.  In addition, if a 
person died of an alternative cause, besides a lymphohematopoietic disorder, this may 
have been excluded from the death certificate if it was not the “cause” of death.  For 
instance, if a person was in the early stages of lymphohematopoietic disorder without 
clinical signs, this may have simply been missed without an autopsy.    
4. In addition of lymphohematopoietic cancer, the exposed versus unexposed group had 
higher SMRs for: all cancer, stomach cancer, lung cancer, kidney cancer, brain 
cancer, benign neoplasms, diabetes and emphysema.  This raises the question of 
whether there was an additional factor, besides benzene, that was particular to the 
exposed group versus the unexposed group.  This is particularly true regarding 
smoking, which was not controlled for in the analyses, yet two diseases which are 
closely associated with smoking, lung cancer and emphysema, were higher in the 
exposed group.   
5. There was a variety of missing information that resulted in the exclusion of some data 
in the analyses: (1) Two of the 7 plants did not include 1946-1957 – years which have 
historically been associated with higher exposures in other studies.  (2) The 
unexposed group was missing 14 death certificates (4.29% vs. 1.12% and 1.32%) 
versus the two groupings (Based upon different exposure groups, thus the two 
percentages) of exposed workers who combined were missing nine.  This could have 
potentially affected analysis, particularly given the small numbers in each disease 
category.    
 
 
Wong, O. (1987). "An industry wide mortality study of chemical workers occupationally 
exposed to benzene. II. Dose response analyses." Br J Ind Med 44(6): 382-95. (Wong 1987) 
 
Cohort Description and Methods: 
See above for general methods.  In the jobs categorized as “continuous” benzene 
exposure, categories were further delineated into 8 hr TWA and peak exposure (no control 
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for respirator use) as follows:  8 hr TWA low  <1 ppm, medium = 1-10 ppm, high = 11-50 
ppm and very high > 50 ppm. Peak exposure was categorized as follows:  low < 25 ppm, 
medium = 25-100 ppm and high >100 ppm. In the jobs categorized as “intermittent” benzene 
exposure categories were further delineated as follows (no control for respirator use):  low 
<25 ppm, medium 25-100 ppm and high > 100 ppm.  
Classification of each job by exposure was based on a uniform task approach and 
these were completed by a group of industrial hygienists from the participating companies 
who were familiar with the plant operations.  There were 34 uniform tasks.   In addition, they 
considered available industrial hygiene measurements, current and past changes in 
production and process modification to determine a concentration level of benzene exposure 
for each task. An 8-hour time-weighted average for each job was obtained by summing the 
products of the proportion of the time at each uniform task and a corresponding benzene 
concentration. 
 The industrial hygiene data for some plants were limited before 1970. Two plants did 
not use the uniform task approach to estimate exposure levels due to lack of specific 
employment histories.  At one plant, supervisors and co-workers from exposed departments 
with cohort members estimated the exposures.  At the other plant, exposure levels were 
estimated by a long term industrial hygienist who primarily used are measurements.    
 Cohort members were classified into three categories according to their occupational 
benzene exposure history.   See table below for specific categories of exposure and 
frequency/percent of the cohort. 
 
Table 37 - Distribution by Cumulative Exposure (ppm-months) of Cohort Members 
in the Continuous Exposure Group 
Cumulative Exposure 
(ppm-months) 
Frequency % 
<180 1809 51.16 
180-719 1047 29.61 
≥720 680 19.23 
Total 3536 100.00 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene.  II Dose Response Analyses.  British Journal of Industrial Medicine 44: 
382-395. 
 
The first level, 180 ppm months (15 ppm-years), is equivalent to a long-term exposure of 0.5 
ppm for 30 years or 1 ppm for 15 years and so on. This classification system did not 
distinguish between concentration and duration of exposure. Approximately 50% of the 
continuously exposed workers were exposed to < 180 ppm months, 30% to 180-719 ppm 
months and 20% to > 720 ppm months.  Because of the nature of the estimated historical 
industrial hygiene exposure, these exposure groups should be viewed on a relative vs. 
absolute basis.  
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Peak vs. cumulative exposure was also analyzed.  Each job and cohort member was 
categorized by maximum peak exposure throughout the person’s whole work history.  More 
than half of those exposed were exposed to a ceiling level of more than 100 ppm at some 
time during their employment. See table below for peak exposure information. 
 
 
Table 38 - Distribution by Maximum Peak Occupational Exposure to Benzene and Exposure 
Group 
 Intermittent Exposure Continuous Exposure Total 
Maximum 
Peak 
Frequency % Frequency % Frequency % 
<25 ppm 336 31.52 413 11.68 749 16.28 
25-100 ppm 114 10.69 1272 35.97 1386 30.12 
>100 ppm 616 57.79 1851 52.35 2467 53.61 
Total 1066 100.00 3536 100.00 4602 100.00 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene.  II Dose Response Analyses.  British Journal of Industrial Medicine 44: 
382-395. 
 
The average range of exposure was 10 years. Slightly more than half (56.66%) were 
exposed for the first time before 1955. Thus with regard to exposure to benzene, more than 
half the exposed cohort could have a latent period of at least 22 years.  There was a mildly 
increasing trend of latency detected for all cancers, lung cancer, brain cancer, leukemia, and 
arteriosclerotic heart disease.   See table below for observed deaths by cause and exposure 
category. 
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Table 39 - Observed Deaths by Cause and SMRs for: 
1) All Cohort Members Exposed to Benzene (Intermittent and Continuous Exposure) by Latency 
Since First Exposure and 
2) Continuously Exposed Cohort Members by Latency Since First Occupational Exposure  
 Duration of Exposure 
 <10 years 10-19 years ≥20 years 
Cause of Death (8th ICDA) Obs SMR Obs SMR Obs SMR 
All Cohort Members Exposed to 
Benzene (Intermittent and 
Continuous Exposure) by Latency 
Since First Exposure  
      
     All Causes 90 68.0† 201 87.2 419 91.8 
     All Cancers (140-209) 16 82.8 41 101.1 104 106.7 
     Lymphatic & Haematopoietic 
Cancer  
     (200-209) 
3 102.3 8 175.9 8 97.6 
     Lymphosarcoma and 
Reticulosarcoma (200) 
1 161.3 1 89.4 2 110.5 
     Hodgkin’s Disease (201) 1 130.5 1 121.1 0 0 
     Leukaemia & aleukaemia (204-
207) 
1 87.5 2 116.9 4 128.6 
     Other Lymphatic Tissue Cancer 
(202, 203, 208) 
0 0 4 455.6* 2 83.7 
     Benign Neoplasms (210-239) 0 0 2 268.7 1 91.7 
     Diseases of the Blood (280-289) 0 0 0 0 1 108.7 
Continuously Exposed Cohort 
Members by Latency Since First 
Occupational Exposure 
      
     All Causes 76 68.6 170 93.1 285 89.1 
     All Cancers (140-209) 14 86.2 41 126.5 68 98.5 
     Lymphatic & Haematopoietic 
Cancer  
     (200-209) 
2 84.8 7 198.2 6 102.7 
     Lymphosarcoma and 
Reticulosarcoma    
     (200) 
1 199.7 1 115.8 1 77.5 
     Hodgkin’s Disease (201) 1 166.6 1 159.8 0 0 
     Leukaemia & aleukaemia (204-
207) 
0 0 2 151.3 4 181.8 
     Other Lymphatic Tissue Cancer 
(202, 203, 208) 
0 0 3 423.3 1 58.5 
     Benign Neoplasms (210-239) 0 0 2 347.1 1 129.9 
     Diseases of the Blood (280-289) 0 0 0 0 1 156.3 
*Significant at 0.05. 
†Significant at 0.01. 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally Exposed to Benzene.  
II Dose Response Analyses.  British Journal of Industrial Medicine 44: 382-395. 
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There was monotonic increasing trend of lymphohematopoietic cancer SMR by 
cumulative exposure. The SMRs in increasing cumulative exposure order were 34.6, 91.3, 
146.8, and 175.2. The increase did not appear to be linear but rose more steeply in the lower 
exposure range and became flatter at the high exposure levels. The response relationship for 
leukemia was not strictly monotonic. The SMR rose from 0 to 96.8, dropped slightly to 78.2, 
and rose back to 275.8. The number of deaths from leukemia in each of the cumulative 
exposure groups was small and the associated statistical variability was large. 
For non-Hodgkin’s lymphoma, lymphosarcoma, reticulosarcoma, and other lymphatic 
tissue cancer, the SMRs rose from 50.8 in the comparison group through 116.7 in the > 180 
ppm-months group, to 186.3 in the 180-719 ppm-months group, and dropped to 74.6 in the > 
720 ppm months group.  See table below for specific information regarding observed deaths 
by diagnosis and exposure category. 
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Table 40 - Observed Deaths, Expected Deaths, SMRs and 95% Confidence Intervals for 
Lymphatic and Haematopoietic Cancer, Leukaemia, non-Hodgkin’s Lymphopoietic Cancer by 
Cumulative Occupational Exposure 
Cause of Death (8th ICD) Variable Non-
Exposed 
<180 
ppm-
months 
180-719 
ppm-
months 
≥720 
ppm-
months 
Lymphatic and Haematopoietic 
Cancer (200-209) 
Obs 3 5 5 5 
 Exp 8.68 5.48 3.41 2.85 
 SMR 34.6 91.3 146.8 175.2 
 95% CI 7.1-101.1 29.5-
213.3 
47.5-
343.0 
56.7-
409.3 
Leukaemia and Aleukaemia (204-
207) 
Obs 0 2 1 3 
 Exp 3.40 2.07 1.28 1.09 
 SMR 0 96.8 78.2 275.8 
 95% CI - 11.7-
349.4 
2.0-434.4 56.9-
806.4 
Non-Hodgkin’s Lymphoma (200, 
202, 203) 
Obs 2 3 3 1 
 Exp 3.94 2.57 1.61 1.34 
 SMR 50.8 116.7 186.3 74.6 
 95% CI 6.2-183.4 24.1-
341.2 
38.4-
544.7 
1.9-414.4 
Non-Hodgkin’s Lymphopoietic 
Cancer (200, 202-207) 
Obs 2 5 4 4 
 Exp 7.34 4.64 2.89 2.23 
 SMR 27.2* 107.8 138.4 164.6 
 95% CI 3.3-79.5 34.9-
251.9 
37.7-
354.0 
44.8-
421.0 
 
*Statistically significant at the 0.05 level. 
(Lymphatic and haematopoietic cancer includes non-Hodgkin’s lymphoma, Hodgkin’s 
disease and leukaemia.) 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene. I General Results.  British Journal of Industrial Medicine. 44: 365-381. 
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When examining the Mantel-Haenszel relative risk and corresponding extension chi-
squares for all lymphatic and hematopoietic cancer, leukemia, non-Hodgkin’s lymphoma, 
and non-Hodgkin’s lymphohematopoietic cancer by cumulative exposure to benzene 
adjusted for age and race, the following was found: For all lymphatic and hematopoietic 
cancer, the relative risk rose steadily from 1 in the comparison group to 3.93 in the > 720 
ppm month group. The corresponding Mantel-Haenszel extension chi-square which 
measured the significance of the upward trend was 5.42 (p value = 0.02). The Mantel-
Haenszel extension chi-square for leukemia was 6.46 (p value = 0.011).  
A number of other analyses were done and are graphically depicted in the tables on 
the following pages.  
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Table 41 - Mantel-Haenszel Relative Risk and Extension Chi-Squares for Lymphatic and 
Haematopoietic Cancer, Leukaemia, non-Hodgkin’s Lymphoma and non-Hodgkin’s 
Lymphopoietic Cancer by Cumulative Occupational Exposure to Benzene 
Cause of Death (8th ICD) Cumulative 
Exposure 
(ppm-
months) 
Observed 
Deaths 
Relative 
Risk 
Chi-
Square 
for 
Trend 
P Value 
Lymphatic and Haematopoietic 
Cancer (200-209) 
Non-
exposed 
3 1.00   
 <180 5 2.10   
 180-719 5 2.95 5.42* 0.02 
 ≥720 5 3.93   
Leukaemia and Aleukaemia (204-
207) 
Non-
exposed 
0    
 <180 2    
 180-719 1 Undefined 6.46* 0.01 
 ≥720 3    
Non-Hodgkin’s Lymphoma (200, 
202, 203) 
Non-
exposed 
2 1.00   
 <180 3 1.40   
 180-719 3 2.23 0.14 0.71 
 ≥720 1 1.07   
Non-Hodgkin’s Lymphopoietic 
Cancer (200, 202-207) 
Non-
exposed 
2 1.00   
 <180 5 2.71   
 180-719 4 2.96 3.64 0.06 
 ≥720 4 4.12   
 
*Statistically significant at the 0.05 level. 
(Lymphatic and haematopoietic cancer includes non-Hodgkin’s lymphoma, Hodgkin’s 
disease and leukaemia.) 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene. I General Results.  British Journal of Industrial Medicine. 44: 365-381. 
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Table 42- Observed Deaths by Cause and SMRs for All Cohort Members Continuously 
Exposed to Benzene by Cumulative Exposure 
 Cumulative Exposure (ppm-months) 
 <180 180-719 ≥720 
Cause of Death (8th ICDA) Obs SMR Obs SMR Obs SMR 
All Causes 259 90.5 181 98.6 91 63.5† 
All Cancers (140-209) 56 102.5 45 129.4 22 77.8 
Lymphatic & Haematopoietic 
Cancer (200-209) 
5 91.3 5 146.8 5 175.2 
Lymphosarcoma and 
Reticulosarcoma (200) 
1 81.2 1 131.6 1 151.0 
Hodgkin’s Disease (201) 0 0 1 191.6 1 240.5 
Leukaemia & aleukaemia 
(204-207) 
2 96.8 1 78.2 3 275.8 
Other Lymphatic Tissue 
Cancer (202, 203, 208) 
2 155.4 2 244.9 0 0 
Benign Neoplasms (210-239) 2 239.1 1 188.9 0 0 
Diseases of the Blood (280-
289) 
1 156.4 0 0 0 0 
 
*Significant at 0.05. 
†Significant at 0.01. 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene.  II Dose Response Analyses.  British Journal of Industrial Medicine 44: 
382-395. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111
Table 43 - Observed Deaths by Cause and SMRs for all Cohort Members Exposed to Benzene 
by Duration of Occupational Exposure to Benzene 
 Duration of Exposure 
 <5 years 5-14 years ≥15 years 
Cause of Death (8th ICDA) Obs SMR Obs SMR Obs SMR 
All Causes 263 88.6* 215 83.2† 232 87.8* 
All Cancers (140-209) 49 91.4 53 108.8 59 107.2 
Lymphatic & Haematopoietic 
Cancer (200-209) 
7 118.0 8 163.1 4 82.6 
Lymphosarcoma and 
Reticulosarcoma (200) 
1 76.3 1 89.2 2 179.5 
Hodgkin’s Disease (201) 1 92.6 1 130.1 0 0 
Leukaemia & aleukaemia 
(204-207) 
2 88.5 4 215.8 1 54.0 
Other Lymphatic Tissue 
Cancer (202, 203, 208) 
3 241.9 2 177.8 1 76.9 
Benign Neoplasms (210-239) 1 108.7 2 258.3 0 0 
Diseases of the Blood (280-
289) 
1 144.9 0 0 0 0 
 
*Significant at 0.05. 
†Significant at 0.01. 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene.  II Dose Response Analyses.  British Journal of Industrial Medicine 44: 
382-395. 
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Table 44 - Observed Deaths by Cause and SMRs for all Cohort Members Exposed to Benzene 
by Maximum Peak Occupational Exposure 
 Maximum Peak Exposure 
 <25 ppm 25-100 ppm >100 ppm 
Cause of Death (8th ICDA) Obs SMR Obs SMR Obs SMR 
All Causes 135 91.7 280 94.5 295 78.4† 
All Cancers (140-209) 35 125.5 63 113.3 63 85.3 
Lymphatic & Haematopoietic 
Cancer (200-209) 
4 141.5 7 140.8 8 101.5 
Lymphosarcoma and 
Reticulosarcoma (200) 
1 154.2 2 188.2 1 54.5 
Hodgkin’s Disease (201) 0 0 1 143.3 1 80.0 
Leukaemia & aleukaemia 
(204-207) 
1 89.9 2 108.5 4 132.9 
Other Lymphatic Tissue 
Cancer (202, 203, 208) 
2 322.8 2 150.7 2 116.5 
Benign Neoplasms (210-239) 0 0 1 120.6 2 178.4 
Diseases of the Blood (280-
289) 
1 299.5 0 0 0 0 
 
†Significant at 0.01. 
 
O. Wong. 1987. An Industry Wide Mortality Study of Chemical Workers Occupationally 
Exposed to Benzene.  II Dose Response Analyses.  British Journal of Industrial Medicine 44: 
382-395. 
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Table 45 - Characteristics of 22 Deaths from Lymphatic and Haematopoietic Cancer 
Case Exp COD Age Yrs 
Exp
Yrs 
Cont 
Exp 
ppm-
months
Max 
TWA 
Max 
Peak 
Yrs 
Latency
1 C 202.2- Giant follicular 
lymphoma 
55.0 7.2 7.2 43 L L 13.4 
2 C 201.X- Hodgkin’s 
disease 
36.2 1.8 1.6 192 H M 11.0 
3 C 200.0- Reticulum cell 
sarcoma 
54.2 0.9 0.2 14 M M 2.5 
4 C 204.1- Chronic lymphatic 
leukemia 
48.7 9.9 9.9 524 H H 14.3 
5 C 204.9  Unspecified 
lymphatic leukemia 
59.9 14.9 14.6 1361 H H 28.6 
6 C 205.1- Chronic myeloid 
leukemia 
64.2 5.8 1.9 120 H M 28.9 
7 C 202.2- Giant follicular 
lymphoma 
55.8 1.3 1.3 334 H M 10.6 
8 C 203.X- Multiple 
myeloma 
57.0 2.3 2.3 14 L L 11.3 
9 C 204.0- Acute lymphatic 
leukemia 
70.2 12.2 12.2 731 M M 49.4 
10 C 200.0- Reticulum cell 
sarcoma 
74.5 26.8 26.8 1512 M M 41.4 
11 C 205.1-Chronic myeloid 
leukemia 
61.8 1.2 1.2 7 L L 18.9 
12 C 207.0-Acute leukemia 49.6 29.2 29.2 851 M H 29.7 
13 C 202.2- Giant follicular 
lymphoma 
44.4 1.7 1.7 601 H H 21.9 
14 C 201.X- Hodgkin’s 
disease 
65.4 7.0 7.0 2522 H H 8.7 
15 C 200.1- Lymphosarcoma 50.1 8.9 8.9 533 M H 17.4 
16 I 204.1- Chronic lymphatic 
leukemia 
47.6 1.4    H 6.0 
17 I 200.0- Reticulum cell 
sarcoma 
67.3 35.4    L 38.2 
18 I 203.X- Multiple 
myeloma 
64.0 6.6    M 17.8 
19 I 203.X- Multiple 
myeloma 
56.4 20.4    H 21.1 
20 U 201.X- Hodgkin’s 
disease 
64.1       
21 U 200.1- Lymphosarcoma 68.7       
22 U 202.2- Giant follicular 
lymphoma 
71.4       
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Key: 
Exposure  Race  Peak Exposure   Eight hour TWA 
C=Continuous  W=White L= Low (<25 ppm)  L=Low (<1 ppm) 
I=Intermittent  N=Non-white M=Medium (25-100 ppm)  M=Medium (1-10 ppm)  
U=Unexposed      H=High (>100 ppm)  H=High (11-50 ppm) 
         VH=Very High (>50 ppm) 
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 The analyses indicated the duration of exposure was not a particularly sensitive 
parameter for quantification of either leukemia or the lymphopoietic cancer mortality risk. 
When analyzed by cumulative exposure (ppm-months) there was a statistically significant 
dose response for leukemia. When the data were analyzed by maximum benzene peak, no 
significant dose response relation was apparent.  In summary, the study suggests that 
cumulative exposure, not peak exposure, was the major determinant of mortality from 
lymphopoietic cancer. With that said, this must be viewed with great caution because of the 
inability to take frequency of exposure into account.   
Unlike previous studies, this did not reveal a preponderance of acute myeloid 
leukemia.   
 
Limitations: (From the Authors) 
1. The percentage lost to follow-up and the proportion of outstanding death certificates 
was low at 2.3 and 2.2%, thus it is possible that some deaths from lymphopoietic 
cancer might have been missed.  
2. The results of cohort verification indicate an error rate of 0.8. Although this error rate 
was extremely small, the small number of individuals inadvertently excluded could 
subsequently have died from lymphopoietic cancer.  
3. Based on a 10% random sample of the cohort, coding accuracy was estimated at 
97.4%. 
4. Historical exposure levels for the early part of the study were limited for some of the 
plants. The problem was personally dealt with by the uniform task approach. This 
required the breakdown of exposed jobs into specific uniform tasks for which 
benzene exposure levels could be estimated more readily. 
5. It is assumed that benzene exposed workers were also exposed to other chemicals.  
6. The cohort size was small for several specific analyses.  
7. There was no practical means of checking the comparability of the exposed and 
comparison groups with regard to some non-occupational risk factors. 
8. There are problems associated with ascertainment of specific causes of mortality for 
death certificates and a lack of in-depth clinical information.  
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4.  The Australian Petroleum Industry Studies 
 
 
Glass, D. C., C. N. Gray, et al. (2003). "Leukemia risk associated with low-level benzene 
exposure." Epidemiology 14(5): 569- 77._(Glass, Gray et al. 2003)_____________________ 
 
Cohort Description and Methods: 
This is a nested-case control study of all cause mortality and cancer incidence in the 
Australian petroleum industry.  There is a nationally funded program, Health Watch, that 
oversees the operation of this study.  The cohort members included all employees except 
head office staff and those employed at Australian sites with <10 employees. Approximately 
95% of eligible employees in the industry participated in Health Watch surveys. Members 
are recruited after 5 years employment in the petroleum industry, and remain in the cohort for 
life. Copies of death certificates were obtained, and cancer incidence was validated through 
state cancer registries and the treating doctor. Cancer registration in Australia is a legal 
requirement of pathology laboratories and hospitals.   
In 1998, the cohort consisted of 15,732 men and 1,178 women.  In the past 
evaluations, men have been shown to have standardized incident ratios (SIRs) = 2.0 for 
leukemia (95% CI: 1.3 - 2.9) and for multiple myeloma at1.9 (95% CI: 1 to 3.3).  
The occupational exposure to benzene for both cases and controls was based upon 
their entire work history correlated with a task based algorithm.  Diagnosis was confirmed by 
pathology report, cancer registration, letter from a medical practitioner, or death certificate.  
Seventy-nine (79) cohort members met the definition of a lymphohematopoietic 
cancer case. One case was found in the cancer registry, but was excluded due to the terms of 
the cohort.  All documentation of the cases was reviewed by the investigators, and cases were 
assigned to international classification of disease groupings.  
Nine cases had uncertain histology and the documentation was reviewed by 
hematologists using the French-American-British system. Five male control subjects were 
chosen for each case. Control subjects were selected randomly from a list of all cohort 
members who were eligible at the time of diagnosis and matched by year of birth. As a result 
of random selection, 5 workers were used as control subjects for more than one case. Four of 
them were used in two case control sets, and 1 in three. Thus, the total number of control 
subjects was 395. One worker selected as a control subject subsequently became a case. The 
subject was retained as a control subject because he was not diagnosed at the time of 
selection.   
The job histories were cross-checked with company personnel records.  When 
discrepancies were found, the most specific history was used.  Cases were not interviewed 
about their tasks because this information might have been subject to recall bias. Instead, 
contemporary co-workers were interviewed.  They provided information on the tasks 
performed, technology in use and the products worked with during the period they worked 
together.   The interviewers had no knowledge of the names and health status of the subjects.  
The benzene exposure of each case and control was calculated using a task based 
algorithm that incorporated the subject’s occupational history, previously measured 
exposures for a particular task, and the Australian petroleum industry and task site and period 
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specific data. We used the following additional exposure metrics to test the association with 
the risk of leukemia: (1) Start date: Subjects were divided into three groups by their start date 
in the industry: pre-1965, 1965 to 1975, and post-1975. (2) Duration of employment: The 
calculated quintiles of duration with cut points approximately every 7 years. (3) Whether 
most of the career was spent as an office worker or as a blue collar worker. (4) Site of longest 
job held and highest exposed job. Each site where a subject worked was allocated to a job 
type. (5) Intensity of exposure: the average exposure intensity, cumulative benzene exposure 
estimate divided by duration of employment and ppm for each job. (6) Subjects with 
exposure to benzene concentrate: We identified those subjects who had handled benzene 
concentrate, which is 100% benzene, or BTX (benzene-toluene-xylene) which is principally 
an aromatic mixture that contains ~70% benzene. All odds ratios and 95% confidence 
intervals are for matched analyses.  
 
Results: 
The risk of leukemia was not associated with smoking.  On average, cases had a 
higher lifetime cumulative exposure and a greater proportion of the cases were in higher 
exposure categories.  No increase in risk for non-Hodgkin’s lymphoma or multiple myeloma 
was found with increasing exposure to benzene. The highest exposure group (> 16 ppm-
years) contained 7 of 33 leukemia cases, but only 3 of their 165 matched control subjects. For 
the two highest exposure categories combined, 13 case sets with > 8 ppm cumulative 
exposure the odds ratio was 11.3 (95% CI:2.8 to 45.1).   
In a comparable study in the U.K. petroleum industry, a cut-point of 4.79 ppm-years 
was used in the analysis. For comparison purposes, we analyzed our data using the same cut-
point and obtained an odds ratio of 2.51 (95% CI: 1.1 to 5.7).  The odds ratio associated with 
cumulative exposure as a continuous measure was 1.65 (95% CI: 1.25 - 2.17).  This was 
consistent with an increase of 65% for each doubling of mean cumulative exposure.  
Blue collar workers had a three-fold risk of leukemia compared with office workers, 
but this risk disappeared when adjustment was made for cumulative benzene exposure. 
Subjects who had worked longest in an airport had nearly four times the risk of leukemia 
compared with terminal workers, but this result was based on small numbers. This finding 
did not change after adjustment for cumulative benzene exposure. There was a strong 
association between leukemia risk and exposure to benzene concentrate that was somewhat 
reduced when cumulative exposure was controlled.  Exposures to benzene concentrate 
resulted in a higher risk of leukemia than exposure to the same amount of benzene 
encountered in a more dilute form such as gasoline.  
Exposure intensity in the highest exposed job was strongly related to leukemia risk 
with the increase starting around 0.8 - 1.6 ppm.  Cohort members in the highest exposure 
category were ~20 times more likely to develop leukemia than those who were not exposed 
to benzene.  Adjusting for cumulative exposure removed the association between high 
intensity exposure and leukemia. Goodness of fit statistics and step-wise conditional logistic 
regression; however, did not provide unequivocal evidence that would distinguish between 
the relative contribution of the cumulative exposure and exposure to intensity of leukemia 
risk.  
  
 118
Odds ratios were also calculated for the leukemia subtypes: acute non-lymphocytic 
leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.  It was not possible 
to calculate the odd ratio for acute lymphocytic leukemia because there were only 2 cases.  
Because there were relatively few cases of leukemia, sometimes it was necessary to combine 
the three lowest exposure groups and the two highest exposure groups. The odds ratios in the 
combined higher exposure group were raised relative to the combined lower exposure group 
for both chronic lymphocytic leukemia and acute non-lymphocytic leukemia.  
In conclusion, these data provide strong evidence for an association between benzene 
exposure in the Australian petroleum industry and increased risk of leukemia. H. The 
estimated cumulative exposures were generally similar to those reported for other petroleum 
industry studies except the most highly exposed subjects in our study had cumulative 
exposures of < 60 ppm-years whereas those in other studies were as high as 220 ppm-years.  
Combining the two highest cumulative exposure groups resulted in an odds ratio of 11.3 
(95% CI: 2.8 - 45.1). These results differ greatly from the previous values found in the UK 
cohort of petroleum workers.     
 
Limitations: 
1. There were a relatively small number of hematological cancer cases and only 33 
leukemia cases.  Of the leukemia cases, only 11 were acute non-lymphocytic 
leukemia, while another 11 were chronic lymphocytic leukemia. These small numbers 
limit the power to detect excess risk, particularly in individual leukemia subtypes.  In 
addition, misclassification of just a few cases from the lowest groups to a higher 
group would markedly change the dose response curve.   
2. In formulating the base estimates for each job task, the research team calculated the 
arithmetic mean for each task.     
3. These results are inconsistent with the results of similar studies performed in the UK 
and Canada.  In both of those studies, the exposures were greater, yet the estimated 
risks are far less.   
4. The exposure estimates were derived from monitoring data that was collected after 
1975.  In addition, there was far more information available regarding lower exposed 
jobs versus the highly exposed jobs. 
5. The researchers collected the work history from co-workers versus the cases which 
controls for recall bias; however, it also limits the amount of personally relevant 
information about the case, their work habits and uncontrolled exposures.  If they 
were describing how a job/task would be optimally carried out, without consideration 
of these factors, it would have the effect of smoothing the peaks and potentially 
lowering the estimates for each case.  The work histories were collected through 
interview by Health Watch from 1980 onward (from co-workers) and were based on 
recall before that date. 
6. The base estimates which are the beginning of all exposure estimation in this study 
were questionable even by the author’s estimation.  When they were compared to 
relevant exposure data in the literature: 12 were not available, 19 were validated, 4 
were adjusted and 14 were not confirmed by the literature.  However, the 14 not 
confirmed were judged to be inadequate and were ignored. 
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7. The exposure level categories were very tight and small errors in exposure estimation 
could markedly affect the placement of cases into different exposure levels.  
8. The authors subsequently re-analyzed the data in a 2006 update (Glass, Gray et al. 
2006) and attempted to take into account high exposure events (HEEs) the resulted 
form spillage and poor work practices.  These estimates were added to the previously 
calculated cumulative exposures for cases and controls.  The odds ratios were 
recalculated and this increased the exposure for 25% of subjects.  For most 
individuals the increase was <5%.  With the added HEEs the odds ratio for leukemia 
with matched analyses went from 1.10 (95% CI: 1.04-1.16) to 1.03 (95% CI: 1.01 – 
1.05).  When treated as a categorical variable the odds ratio in the 7 cases of leukemia 
with >16 ppm-years was 98 (8.8 -1090), when compared to individuals with <0.5 
ppm-years cumulative exposure.  When the two lowest groups of exposure <1 ppm-
years were compared with the highest exposure group the odds ratio was 51.9 (5.6 – 
477) without HEEs and 7.79 (2.34 – 25.89) with HEEs.  It was thought that the odds 
ratio fell because leukemia is associated with higher exposures and thus the risk per 
ppm year is reduced.   
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5.  The United Kingdom Petroleum Industry Studies 
 
 
Rushton, L. and H. Romaniuk (1997). "A case-control study to investigate the risk of 
leukaemia associated with exposure to benzene in petroleum marketing and distribution 
workers in the United Kingdom." Occup Environ Med 54(3): 152-66. (Rushton and 
Romaniuk 1997)_____________________________________________________________ 
 
Cohort Description and Methods:   
In this study, the cases were recruited from the existing cohort database and were 
included if the following criteria were met:  
1. Died before January 1, 1993 with a mention of leukemia on the death certificate; 
or  
2. Had a cancer registration of leukemia.   
 
  A total of 91 cases were identified and 88 came from death certificates with or 
without cancer registration, and 3 came from cancer registration alone. In 11 cases there was 
a discrepancy between the diagnoses and the cancer registration.  In each case the more 
specific diagnosis was chosen.   
Four controls per case were randomly selected from all men in the same oil company 
with a year of birth within three years either side of the date of birth of the case. The controls 
were selected from people alive and under follow-up at the time of case occurrences. Two 
controls were erroneously selected who were not under follow up on the relevant date. These 
have been excluded from the study.  At a later time, it was found that eight of the controls 
from one company had been incorrectly matched for age. These controls have also been 
excluded from the analysis. This also resulted in the exclusion of one case of acute myeloid 
leukemia.    
Six variables were identified that were necessary to establish quantitative exposure 
estimates, including: 1. Work history, 2. Job descriptions, 3. Terminal histories, 4. Fuel 
compositions, 5. Occupation hygiene measurements, and 6. Possible confounding variables 
such as smoking.   
For any members who had incomplete information in their personnel record, the 
missing information was obtained from a variety of sources including pension records, 
medical records, and interviews with retired or long service staff.  When a work history was 
largely unavailable, a typical work history was used. When assumptions were made, these 
were flagged in the database. As a measure of quality of the work history, each study 
participant was assigned a job confidence code of 1, 2, or 3. A code 1 indicates a complete 
work history or one for which the last job only was known, but the duration of employment 
was less than ten years. Code 2 indicates a partially complete work history for which an 
assumption has been made. And code 3 indicates a poor work history and was assigned when 
only the last job title was known. This was a supervisor or managerial post, and the duration 
of employment was over ten years. None of the cases, and only 8 (2%) of the controls had a 
job confidence score of 3, the poor category. Twenty one percent of the work histories were 
assigned to the partially complete category.  This included 26% of the cases and 19% of the 
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controls.  
315 petroleum terminals were identified from work histories and over 95% were 
closed by the time of data collection. All remaining terminals were visited and retired/long 
service employees were interviewed about closed sites. Other sources of information 
included site plans, booklets, photographs, company magazines, and other materials available 
from company libraries and property engineering documents. Data collection for fuel 
compositions, occupational hygiene measurements and the methods of developing 
quantitative exposure estimates related to work histories of each study member was detailed. 
The method used for this study was an extension of that developed for the Canadian case 
control study. Similar to the Canadian study, six adjustment factors were added to the base 
estimates, including job activity, number of loads handled per day, loading technology, 
percent of benzene in the fuel product mix, and air temperature. For some terminals, the data 
on individual employees were sufficient to indicate whether drivers were assigned to road 
tankers carrying black oil or white oil. This is relevant since black oils do not contain 
benzene.  Workplace estimates were derived for each line of a work history. The base 
estimate was multiplied by the six modifying factors. This was then multiplied by the time 
spent for that job and these were then summed over each study members’ complete work 
history to give a cumulative exposure in ppm-years.   
Exposures were further classified into twelve categories according to whether they 
were likely to have occurred in intermittent peaks defined by a frequency of intensity: 1 to 3 
parts per million or greater than 3 part per million, and duration: 1 to 15 minutes and 15 to 60 
minutes. The potential for skin exposure was estimated as none, low, medium or high. 
Cumulative exposure was categorized as a continuous variable, mean intensity and 
cumulative exposure divided by duration of employment. Maximum intensity, highest 
intensity for any job in the work history, and years of employment were also analyzed. 
Cumulative exposure was analyzed in quintiles, primarily to check linearity and in four 
categories: <0.45 ppm-years, 0.45 – 4.49 ppm-years, 4.5 – 44.49 ppm-years and >45.0 ppm-
years. The cumulative exposure quintiles for all leukemias of less than 0.26, 0.26 to 0.59, 
0.60 to 1.64, and 1.65 to 4.78, and greater than equal to 4.79 ppm for all analysis. 
Categorizations per maximum mean intensity of exposure and duration of employment were 
chosen by examining the distribution of these variables for the whole study sample before 
separating them into cases and controls. Lag exposures of five to ten years were also 
analyzed. Potential confounding or effect modifying variables including smoking, 
employment status at end date, socioeconomic status based on job title, longest duration, age, 
date started working, ever had a previous job, never had a previous job as a driver were all 
considered. The highest potential skin contact in the work history was used to characterize 
dermal exposure. Two variables which categorized peak exposure were derived - the number 
of years exposed to the peak, and ever experiencing the peak for more than one year. 
Although these derived variables attempt to characterize the nature of peak exposures, the 
results of these variables proved difficult to interpret and should be treated with caution.  
Separate analyses were carried out for all leukemias and for four leukemia groups, 
acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid and acute 
monocytic leukemia and chronic myeloid leukemia. See table below for a description of the 
cohort characteristics. 
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Table 46 - Characteristics of the Study Sample 
Variable Cases n (%) Controls n (%) Total n (%) 
Cumulative Exposure 
(ppm-y) 
   
<1 44 (49) 183 (52) 227 (51) 
1-4 27 (30) 105 (30) 132 (29) 
5-9 11 (12) 40 (11) 51 (12) 
≥10 8 (9) 26 (7) 34 (8) 
Mean Cumulative 
Exposure 
5.6 4.4 4.6 
Mean Intensity (ppm)    
<0.02 32 (36) 114 (32) 146 (33) 
0.02-0.19 33 (37) 163 (46) 196 (44) 
0.2-0.39 19 (21) 45 (13) 64 (14) 
≥0.4 6 (7) 32 (9) 38 (9) 
Mean of Mean Intensity 
(ppm) 
0.20 0.22 0.21 
Maximum Intensity 
(ppm) 
31 (35) 104 (29) 135 (30) 
<0.02 30 (33) 131 (37) 161 (36) 
0.02-0.19 9 (10) 43 (12) 52 (12) 
0.2-0.39 20 (22) 76 (22) 96 (22) 
≥0.4 0.39 0.41 0.40 
 
L. Rushton and H. Romaniuk. 1997. A Case-Control Study to Investigate the Risk of 
Leukaemia Associated with Exposure to Benzene in Petroleum Marketing and Distribution 
Workers in the United Kingdom.  Occupational and Environmental Medicine 54: 152-166. 
 
Emphasis has been placed on exploration of patterns and magnitude of risk with sensitivity 
analysis were appropriate.   
  
Results: 
Cumulative exposures range from close to 0 to greater than 200 parts per million 
years, although 81% of exposures were less than 5 parts per million years. The upper tail of 
the distribution was distorted by 15 subjects who were known to have worked previously for 
a company which had marketed benzene enriched products. Only one of these was a case. 
There was a larger proportion of cases and controls with a mean intensity of exposure 
between 0.2 and 0.4 part per million. The distribution of smokers and nonsmokers was the 
same in case and controls but information on smoking was unobtainable for nearly 90% of 
the study members.  For all leukemias, cumulative exposure tended to be highly correlated 
with both mean intensity of exposure (R=.084) and maximum intensity of exposure 
(R=0.82), but not with duration of employment (R=0.15).  See table below for a listing of 
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leukemia by subtype.  
  
Table 47 - Number of Leukaemias by Subtype 
Lymphoid  
     Acute 7 
     Chronic  31 
     Other 1 
     Total 39 
Myeloid  
      Acute 31 
     Chronic 11 
     Other 2 
     Total 44 
Monocytic  
      Acute 1 
     Chronic 1 
     Other 1 
     Total 3 
Other  
      Acute 3 
     Other 2 
     Total 5 
Total Leukaemia 91 
 
L. Rushton and H. Romaniuk. 1997. A Case-Control Study to Investigate the Risk of 
Leukaemia Associated with Exposure to Benzene in Petroleum Marketing and Distribution 
Workers in the United Kingdom.  Occupational and Environmental Medicine 54: 152-166. 
 
There was little evidence of an increasing risk of all leukemias with increased 
cumulative exposure.  There were seven cases of acute lymphoblastic leukemia, including the 
only case who was previously employed by a company marketing benzene enriched 
products. The mean cumulative exposure for all seven cases was 29.6 ppm-years, compared 
with 2.06 ppm-years for controls.  There were 31 cases of chronic lymphocytic leukemia. 
The cases had a lower mean cumulative exposure of 2.6 ppm-years versus the controls at 3.6 
ppm-years. Nearly a third of the cases were white collar men compared with only 14% of the 
controls.   
There were 31 cases of acute myeloid and monocytic leukemia included in the 
analysis, all but one being myeloid. One further case was excluded, as all four controls were 
erroneously matched.  Most of the cases, 94%, were blue collar workers, compared with 89% 
of the controls. The cases and controls had similar mean cumulative exposures with cases at 
3.7 ppm-years and controls with 3.8 ppm-years,  The range for the controls was much greater 
(up to 103.8 ppm-years) than for the cases (up to 22.3 ppm-years).  Cases had slightly more 
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exposure to peaks than controls with 75% of cases versus 66% of controls, and slightly more 
medium or high skin contact (cases 71% vs. controls 65%).  
  Acute myeloid leukemia has been most frequently associated with exposure to 
benzene and in contrast with chronic lymphocytic leukemia, 94% of cases occurred in blue 
collar workers. Risk was highest in men with cumulative exposures of 4.5 to 45 ppm-years.  
There was no association with cumulative exposure when analyzed as a continuous variable. 
The excess of cases with cumulative exposures of 4.5 to 45 ppm-years occurred particularly 
in men with daily or weekly peak exposure. Risks also increased to greater than 2 for a mean 
intensity of 0.2 to 0.4 part per million compared with less than 0.02 part per million.  See 
table below for risk of acute myeloid and monocytic leukemia in the cohort members. 
It was not possible to assess the risk of smoking and the risk of acute myeloid and 
monocytic leukemia in the study due to the lack of data.   
The authors concluded “in view of the limitations, doubt remains to whether the risk 
for acute myeloid and monocytic leukemia is increased by cumulative exposures of less than 
45 part per million years”. 
  
Table 48 - Odds Ratios (95% CIs) for Acute Myeloid and Monocytic Leukaemia 
     OR 
Variable Cases n Controls n OR ((95% CI) Goodness of Fit 
(p value) 
White Oil* Black Oil† 
Cumulative 
Exposure 
(continuous) 
- - 1.00 (0.96 to 
1.04) 
0.95 1.00 1.00 
Cumulative 
Exposure Quintiles 
(ppm) 
      
     <0.26 6 35 (1) 0.75 (1) (1) 
     0.26-0.59 5 17 1.88 (0.49 to 
7.16) 
- 2.57 1.67 
     0.60-1.64 6 23 1.68 (0.46 to 
6.11) 
- 1.60 1.47 
     1.65-4.78 6 24 1.60 (0.44 to 
5.79) 
- 2.16 1.78 
     ≥4.79 8 22 2.38 (0.65 to 
8.73) 
- 3.21 2.16 
Cumulative 
Exposure Working 
Lifetime (ppm-y) 
      
     <0.45 7 46 (1) 0.18 (1) (1) 
     0.45-4.49 15 51 2.17 (0.77 to 
6.09) 
- 1.95 1.61 
     4.5-44.9 9 23 2.82 (0.82 to 
9.38) 
- 2.78 2.28 
     ≥45 0 1 0 - 0 0 
Duration of 
Employment 
(continuous)  
- - 1.03 (0.99 to 
1.07) 
0.19 - - 
Years of 
Employment 
      
     <10 7 48 (1) 0.38 - - 
     10-19 10 29 2.65 (0.88 to 
7.93) 
- - - 
     20-29 8 23 2.76 (0.79 to 
9.58) 
- - - 
     30-39 5 16 2.86 (0.66 to 
12.29) 
- - - 
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     ≥40 1 5 1.86 (0.12 to 
29.52) 
- - - 
Maximum Intensity 
(continuous) 
- - 0.66 (0.28 to 
1.52) 
0.22 0.68 0.69 
Maximum Intensity 
(ppm) 
      
     <0.02 6 32 (1) 0.86 (1) (1) 
     0.02-0.19 13 47 1.45 (0.51 to 
4.10) 
- 1.35 1.62 
     0.2-0.39 5 14 1.69 (0.46 to 
6.17) 
- 1.70 2.27 
     ≥0.4 7 28 1.34 (0.37 to 
4.86) 
- 1.53 1.56 
Mean Intensity 
(continuous) 
- - 0.68 (0.17 to 
2.82) 
0.57 0.77 0.72 
Mean Intensity 
(ppm) 
      
     <0.02 6 34 (1) 0.13 (1) (1) 
     0.02-0.19 14 56 1.34 (0.48 to 
3.74) 
- 1.20 1.31 
     0.2-0.39 10 18 2.76 (0.90 to 
8.48) 
- 2.89 2.84 
     ≥0.4 1 13 0.43 (0.05 to 
4.05) 
- 0.43 0.46 
Highest Potential 
Skin Exposure 
      
     None 6 30 (1) 0.84 Does not 
converge 
(1) 
     Low 3 12 1.19 (0.26 to 
5.42) 
-  1.70 
     Medium 16 51 1.54 (0.54 to 
4.39) 
-  1.56 
      High 6 28 1.11 (0.32 to 
3.87) 
-  1.35 
Date of Hire        
     Before 1950 15 63 (1) (0.46 to 
3.17) 
0.69 - - 
     After 1950 16 58 1.21 - - - - 
Ever Employed as 
Previous Driver 
4 4 1.71 (0.49 to 
6.03) 
0.41 - - 
Employment Status 
at Study End Date 
11 26 2.97 (0.95 to 
9.27) 
0.06 - - 
Socioeconomic 
Status 
      
     Blue Collar 29 108 (1) (0.12 to 
2.53) 
0.42 - - 
     White Collar 2 13 0.56 - - - 
Age Started Work 
(continuous) 
- - 1.01 (0.96 to 
1.05) 
0.75 - - 
Age Started Work:       
     <25 14 49 (1) 0.90 - - 
     25-34 12 50 0.84 (0.36 to 
1.93) 
- - - 
     ≥35 5 22 0.81 (0.25 to 
2.62) 
- - - 
 
*Assumes exposure to white oil products which contain benzene. 
†Assumes exposure to black oil products which do not contain benzene.   
 
L. Rushton and H. Romaniuk. 1997. A Case-Control Study to Investigate the Risk of Leukaemia Associated with Exposure to Benzene in 
Petroleum Marketing and Distribution Workers in the United Kingdom.  Occupational and Environmental Medicine 54: 152-166. 
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Limitations: 
1. The work history was incomplete in many cases and controls.  This information was 
extrapolated in most instances from existing records. 
2. According to the authors, some bias may have been possible because information was 
more readily available for surviving controls.   
3. In the data sets which included only work histories taken mainly from personnel 
records which still exist, the patterns were similar for three of the leukemia subtypes, 
but different for acute myeloid and monocytic leukemia.  
4. Workers who were employed prior to 1950, yet left before that date were excluded 
from the cohort.  This precludes any estimation of risk for that period. 
 
 
Wong, O. and G. K. Raabe (1998). "Acute myeloid and monocytic leukaemia and benzene 
exposure in petroleum distribution workers in the United Kingdom." Occup Environ Med 
55(5): 360-1. (Wong and Raabe 1998)___________________________________________ 
   
Comments on the Study: 
Employment histories of only 48 cases (53%) based on personnel records.  The 
employment histories of the remaining 47% of the cases were reconstructed or synthesized 
from sources such as recall interviews, entries in medical records, etc. Similarly, the work 
histories of only 55%, or 193 of 354 controls were based on complete personnel records. 
Furthermore, although these percentages for the cases and controls in the entire study seem 
comparable, this was not true for some important subcohort analyses. Based on the analysis 
of all subjects regardless of quality of employment histories, the authors assigned an 
increased odds ratio of 2.82, which was not significant at 0.05 level, for cumulative 
exposures of 4.5 to 44.9 part per million. However, of the 9 cases assumed to have 4.5 - 44.9 
ppm-years exposure, the employment histories of only 2, or 22%, were based on personnel 
records. Furthermore, there was a strong possibility of differential bias between the cases and 
controls in this exposure category, as the employment histories of 65%, or 15 of 23 controls, 
were based on personnel records. If the analysis were restricted to workers with complete 
employment histories from personnel records, the odds ratio for the greater than equal to 4.5 
ppm year group was 0.33.  Clearly, the excess based on all subjects came from those workers 
with employment histories of poorer quality.  
The authors seem to downplay the sensitivity analysis for AMML.   The finding of 
AMML of an increased odds ratio of 2.82 for the 4.5 to 44.9 part per million year cumulative 
exposure group was further weakened by the lack of internal consistency.  For example, the 
model treating cumulative exposures as a continuous variable did not find any increased risk, 
odds ratio of 1.0 with a 95% competence interval of 0.96 to 1.04. In general, a model based 
on continuous variables is more informative and less vulnerable to artifacts created by 
categorization. Analysis based on group data can be influenced heavily by the grouping 
itself.  Furthermore, in many of the 50 models on AMML presented in an earlier report dated 
April, 1995, no increased risk was found for cumulative exposure of greater than 4.5 ppm-
years.  
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Unfortunately, all the uncertainty in employment histories and exposure assessment 
seemed to have been lost in the statistical manipulation of the data. We doubt very much that 
the quality of the employment and exposure data in the study warranted such a fine 
distinction as when the authors attempted several analysis to discriminate the potential 
difference in risk resulting from exposure to 0.2, 0.3, or 0.4 part per million. In fact, we 
question whether measurements in early present study period, even if such data were 
available or that precise. The level of analysis was inappropriate given the uncertainties of 
the original data.  
Another problem with the paper is the multiple comparison issue. An extremely large 
number of risk estimates were calculated.  With this many odds ratios calculated several 
would be significant due to chance alone. The authors themselves recognize the multiple 
comparison problem and labeled the entire investigation as hypothesis generating in the early 
reports.  
In summary, an interpretation by the authors that exposure to low concentrations of 
benzene in the range of 4.5 to 45 part per million could increase the risk of developing 
AMML was not justified.   
 
In response, the authors replied.  
 
As well as the deficiencies noted by Wong and Raabe, there were other limitation 
including quality of information on distribution terminals and inconsistencies in some of the 
analyses. However, hey seem to be confusing the quality of information compared with the 
source of information. As we point out in our discussion, use of work histories from only 
existing personnel records excluded much good quality and reliable information from other 
sources. 
In response to there comments on Dr. Peto’s observations, Dr. Peto also commented, 
“The study seemed to be very well conducted and analyzed. There is no evidence in this 
study of an association between exposure to benzene and lymphoid leukemia, either acute or 
chronic… however, in view of the limitations of this study, doubt remains as to whether the 
risk of acute myeloid and monocytic leukemias increase with an exposure of less than 45 
ppm-years.” 
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6.  The Canadian Petroleum Industry Studies 
 
 
Schnatter, A. R., T. W. Armstrong, et al. (1996). "The relationship between low-level 
benzene exposure and leukemia in Canadian petroleum distribution workers." Environ Health 
Perspect 104 Suppl 6: 1375-9. (Schnatter, Armstrong et al. 1996) 
-----AND----- 
Schnatter, A. R., T. W. Armstrong, et al. (1996). "Lymphohaematopoietic malignancies and 
quantitative estimates of exposure to benzene in Canadian petroleum distribution workers." 
Occup Environ Med 53(11): 773-81. (Schnatter, Armstrong et al. 1996) 
 
Description of the Underlying Cohort, the Case Control Study and Methods: 
 Petroleum distribution workers are potentially exposed to benzene in white (gasoline) 
and black (heating oil) petroleum products while transferring the product into and out of 
containers/trucks.  Generally, the exposure is <1 ppm 8 hr TWA.  This case control study 
examines mortality in a group of workers previously examined in a retrospective cohort 
study (Schnatter, 1993).  Cases for this study were identified using the following criteria:   
1. Died with an underlying cause of death of leukemia (ICD-8 204-207), multiple 
myeloma (ICD-8 203) or non-Hodgkin’s lymphoma (ICD-8 200, 202.0, 202.1, 202.2, 
and 202.9). 
1. Ever worked in either the marking/distribution marine or pipeline segments. 
2. Died between 1964 and 1983 
 
From the above criteria 16 leukemia cases, 7 multiple myeloma and 8 non-Hodgkin’s 
lymphoma cases were identified.  Leukemia cell types were not available.  Four controls 
were selected from the same cohort of male workers and were matched by decade of birth.  
In addition, the controls were required to be alive at the time of the case’s death.  After 
examining information on work histories, two leukemia cases were eliminated from further 
analysis due to inadequate job information.  This left 14 cases of leukemia matched with 115 
controls.   
Of the 155 workers, 30 (19%) had some missing work history and 10 (6%) were 
missing more than half of their work history.  Missing job histories were interpolated from 
the other jobs held.  The exposure assessment process was a lengthy process which involved 
exposure estimation by industrial hygienists for benzene and total hydrocarbons for every 
job, location and era combination.  The process began with site characterization for the 89 
study locations.  This included the following information:  loading/unloading frequency, 
technology in use at the sites, types of materials handled, typical tasks performed by workers 
and typical environmental conditions such as average temperature. Surveys were not 
available for all locations; however, the information was drawn from data on similar 
operations from outside the company.  This information was used to derive “base exposure 
estimates” for job/location/area scenarios in each work history. Adjustment factor(s) were 
then added to the base estimate by the industrial hygienists in order to take into account 
 129
differences in environmental, operational, task and worksite conditions.  The values for the 
adjustment factors were always estimated through physical/chemical or empirical data 
preferably.   
 In order to test the validity of the estimated exposures, exposure estimates were 
compared with actual industrial hygiene surveys taken during the relevant time period.  On 
average, estimates were within 22% of the measured data. This was considered reasonable 
agreement.  
8 hr TWA exposure intensity estimates were assigned to each worker’s job/location 
history. Absentee information was taken into account.  Intensity estimates were then 
estimated by the length of time in every particular job category.  We subtracted absentee 
information from time at work and then multiplied the intensity estimates by length of time at 
a job. Dermal absorption was estimated by the industrial hygienists based upon presumed 
exposures ranked as low, medium and high for potential exposure.   
Potential confounders were extracted from company medical records, including 
smoking status, hobby, previous exposures previous occupations, diagnostic radiation 
exposure and family history of cancer.  Additional exposure metrics, such as dermal 
exposure and average intensity during the entire working career were also analyzed.   
Cumulative exposure was categorized in a number of ways to minimize cut point 
effect.  Schemes using the distribution of exposure in the controls were also examined, 
including:   
• quartile distribution 
•  tertile distribution 
• four categories split at the median, 75th and 90th percentile,  
• ppm-years split at 0.45, 4.5 and 45 part per million years. The category 
boundaries corresponding to 0.01, 0.1 and 1 ppm for 45 years.  
• ppm-years split at 0.9, at 9.9 and 99 part per million years. The category 
midpoints corresponding to 0.01, 0.1, and 1.0 ppm for 45 years.  
 
Results: 
Average daily benzene ranged for 0.01 to 6.2 ppm for all jobs.   
The two strongest risk factors for the leukemia cases were family history of cancer 
(OR-=2.51) and smoking (OR=∞).  Both had wide and/or non calculable confidence 
intervals. The highest risk of leukemia was found in managerial and professional job 
designations.  For the category managerial/professional the OR=0.0, for clerk/technician the 
OR=.34 (95% CI: 0.03-3.10) and for operator/driver the OR=.41 (95% CI: 0.07-2.33).   
With an alternative categorization by cumulative exposure, there was a monotonic 
trend for leukemia; however, there were a small number of cases and controls in each 
category.  The highest risk with cumulative exposure was found in the second quartile 
(OR=5.06) and middle tertile (OR=4.37).  The odds ratio decreased in the higher quartiles 
and tertile.  All five of the categorizations suggest risk consistent with a unity.   See table 
below for an estimation of risk by cumulative exposure to benzene.  
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Table 49 - Leukemia Risk by Cumulative Exposure to Benzene 
Benzene Exposure, 
ppm-years 
No. Exposed Cases Odds Ratio 95% CI 
0-0.17a 2 1.00 - 
0.18-0.49 8 5.06 0.34-295 
0.50-7.9 1 0.88 0.01-18.2 
8.0-219.8 3 2.11 0.10-138 
0-0.22b 3 1.00 - 
0.23-5.49 8 4.37 0.72-48.6 
5.50-219.8 3 0.92 0.10-11.2 
0-0.49c 10 1.00 - 
0.50-7.99 1 0.22 0-1.82 
8.0-19.99 1 0.42 0.01-3.95 
20.0-219.8 2 0.96 0.09-6.81 
0-0.45d 10 1.00 - 
>0.45-4.5 1 0.43 0.01-4.05 
>4.5-45 1 0.16 0-1.32 
>45 2 1.47 0.16-13.1 
0-0.90d 10 1.00 - 
>0.90-9.9 2 0.43 0.04-2.36 
>9.9-99.9 1 0.48 0.01-4.55 
>99.9 1 1.03 0.02-20.3 
a
Categorized according to quartiles. 
bCategorized according to tertiles. 
cCategorized according to median, 75th and 90th percentiles. 
dCategorized according to regulatory considerations. 
 
A.R. Schnatter, T.W. Armstrong, L.S. Thompson, M.J. Nicolich, A.M. Katz, W.W. Huebner and E.D. Pearlman. 1996. The Relationship 
Between Low-Level Benzene Exposure and Leukemia in Canadian Petroleum Distribution Workers.  Environmental Health Perspectives. 
104: 1375-1379.
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Cumulative benzene exposure did not show a strong relationship with leukemia when 
regressed separately.  This model did not fit the data well.   For these data, measurement of 
exposure duration was most closely associated with leukemia.  Alternatively, benzene 
exposure and mean intensity did not explain leukemia risk.  
The authors also examined whether exposure above a certain level was related to 
leukemia risk by using the number of years worked above either 0.5 or 1 ppm as independent 
variables. Neither of these variables explained leukemia risk, or fit the data well.  See table 
below for an examination of risk by alternative exposure metrics. 
For leukaemia, the logistic regression model predicted an OR of 1.002 (P < 0.77) for 
each ppm-year of exposure to benzene. 
 
 
Table 50 - Leukemia Risk by Alternate Benzene Exposure Metrics 
 No. Exposed 
Cases 
Odds Ratio 95% CI 
Benzene Intensity, mean ppm    
     0-0.01 9 1.00 - 
     >0.01-0.19 2 0.88 0.08-6.47 
     0.20-0.49 1 0.19 0-1.55 
     0.50-6.16 2 0.96 0.09-6.81 
Maximum Benzene Intensity, 
ppm 
   
     <0.5 10 1.00 - 
     0.5-0.99 0 0 0-7.57 
    1.0+ 4 1.02 0.21-4.26 
Maximum Probability of 
Dermal Exposure 
   
     Low 8 1.00 - 
     Medium 4 0.61 0.12-2.51 
     High 2 0.47 0.04-2.86 
 
A.R. Schnatter, T.W. Armstrong, L.S. Thompson, M.J. Nicolich, A.M. Katz, W.W. Huebner 
and E.D. Pearlman. 1996. The Relationship Between Low-Level Benzene Exposure and 
Leukemia in Canadian Petroleum Distribution Workers.  Environmental Health Perspectives. 
104: 1375-1379. 
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The Mantel-Haenszl analysis showed that leukemia risk did not increase with 
increasing categories of cumulative exposure, therefore, they constructed models with square 
terms for duration and intensity of exposure. This allows for non exponential increases in risk 
per unit exposure. For all combinations of duration and intensity of exposure in the squares 
of these variables a model with only duration of exposure squared fit the data best with a p 
value = 0.05. The odds ratio for this model was not quite statistically significant. 
The authors concluded that they did not find evidence that low level exposure 
increased the risk of leukemia, multiple myeloma or non-Hodgkin’s lymphoma.  The fact 
that duration of exposure was most strongly related to leukemia occurrence versus exposure 
intensity or cumulative exposure might have indicated that long term exposure regardless of 
the concentration can result in leukemia.  However, this interpretation would suggest that 
there was severe misclassification even between the highest and lowest intensity 
designations.  This was judged to be unlikely given the validation exercise.   
 
Limitations: 
1. The size of the study was small and this limited any findings.  For instance, if 
benzene exposure caused a two fold increase in risk for >45 ppm year category, the 
study would have only a 16% chance of discovering the relationship at a 20% 
exposure rate and a 5% significance level.  In order to attain 80% power, 90 cases 
would have been needed. 
2. None of the OR for cumulative exposure were significant at the p=0.05 level.  For 
cumulative exposure, the risks were not monotonically increased, and in fact, the 
highest (non-significant) OR were found near the lowest levels - 0.18-0.49 ppm-
years, 0.23-5.49 ppm-years, 0-0.49 ppm-years, 0-0.45 ppm-years and 0-0.90 ppm-
years, depending upon the cut points chosen.  
3. The authors concluded that the results were consistent with insufficient power to 
detect a small effect, or a lack of effect for low benzene exposure, particularly 
between 0.1 - 1.0 part per million. 
4. The highest risk of leukemia was found in the managerial/professional category 
which should have had limited, or no potential for benzene exposure beyond the 
background levels.   
5. There was limited amount of smoking information available and therefore this 
potentially confounding variable was not controlled for in the analysis.  However, 
smoking was one of two strongest predictors for leukemia risk.  Seven of the 14 cases 
were ever smokers and the remaining persons had an unknown smoking status.      
6. There was no breakdown of leukemia by cell type.   
7. By their own validation exercise, exposure estimates were within 22%.  In addition, 
some of the exposure data was extrapolated from other facilities.  In addition, the 
exposure assessment did not include personal monitoring, so the actual exposure level 
of each case and control is unknown.    
8. There was missing work information for 25% of the 115 workers included in this 
analysis.  Of that number, 19% were missing some information and 6% were missing 
more than halve.  This could have introduced error due to mistakes made in the 
interpolation of jobs from other information.   
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9. The authors eliminated 2/16 cases of leukemia due to missing job information, thus 
further limiting the power of the study.    
 
 
Armstrong, T. W., E. D. Pearlman, et al. (1996). "Retrospective benzene and total 
hydrocarbon exposure assessment for a petroleum marketing and distribution worker 
epidemiology study." Am Ind Hyg Assoc J 57(4): 333-43. (Armstrong, Pearlman et al. 1996) 
 
High quality industrial hygiene monitoring data were only available from the early 
1970s forward. As has been done in other similar industrial studies, the authors evaluated 
current jobs and then applied modifying factors to take into account historical process 
information and estimate “tenable” quantitative estimates of past exposure to benzene and 
hydrocarbons.  The modifying factors were categorized into four types:  workplace (control 
technology, product throughput), task (loading frequency, work practices), environment 
(wind speed, ambient temperature) and material (benzene content, volatility).  The total 
values derived from the modifying factors was added to a base estimate for a task, tasks were 
tabulated by day for each worker and this was then culminated in a total worker exposure.   
Where sufficient measurements were available log normality was verified. All data 
sets evaluated were statistically consistent with log normality.  The Maximum Likelihood 
Estimator (MLE) was used to estimate the population arithmetic mean from the sample data 
for base estimates. MLE has been generally used when arithmetic means were reported with 
data and it was believed that consistency was needed in the study.  The modified Cox 
calculation was used to derive 95% confidence intervals.  The confidence intervals were used 
to evaluate precision of estimates, evaluate uncertainty as well as sensitivity and to assist 
with the validation exercise.   
Base estimates were derived from some internal industrial hygiene measurements 
(170) as well as select literature sources.  However, average shift measurements were only 
available after the 1970s.  Company records supplied base estimates for the following job 
titles: agent, gauger, loader, checker, delivery driver, barrel washer, barrel filler, marine deck 
attendant, and marine pump man. The number of measurements used to ascertain the base 
estimates ranged from 3 for marine pumpman to 1335 for general population background 
data.  A significant portion of the exposures in areas involved either general population 
exposure or facility background exposure with low or no direct occupational exposure to the 
products distributed at the facilities.  
A limited validation of the exposure estimating algorithm was performed using available 
monitoring data. Criteria for selection included documentation of the survey methods and 
results, as well as measurements of exposure and adequate descriptive information on the 
operations and job titles of central interest to the study.  When estimating exposure validation 
the results were generally within the estimated confidence intervals for the exposure 
estimates. Excluding one estimate, the average difference between the estimate and the 
sampling data was < 15% for the benzene exposures.  With that said, the authors noted that 
validation was limited by the availability of measured exposure data, especially for jobs or 
conditions that diverged from the base estimate conditions. The only measured exposure data 
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available for validation was for modern operations with relatively consistent technology 
work practices and materials.  The confidence intervals for the measured data in this test 
exercise were not shown because the intervals are very wide and only based on a few 
measurements, as was the case with the measured data available here.  Earlier operations had 
different exposure potential, but measured data from those earlier, more varied, operations 
are not available.  
 
 
The sensitivity analysis of principal exposure modifiers indicated that percent 
benzene in the fuel and loading technology could increase the exposure estimates greatly as 
seen in Table 51 below. 
 
Table 51 - Sensitivity Analysis of Principal Exposure Modifiers 
Principal Exposure 
Modifier 
Estimated Range of Values Impact on Benzene 
Exposure Estimates 
Percent Benzene in Fuel 0.7 to 3.7A -30% to +370% 
Loading Technology 1 or 3 0% or +300% 
Task 0.1B to 2 -90% to +200% 
Temperature 0.63 to 1 -37% to 0% 
Fuel Volatility 0.75 to 1 -25% to 0% 
Product Mix 0.77 to 1.3 -23% to 30% 
AWithout benzole addition. 
BFor foreman. 
 
T.W. Armstrong, E.D. Pearlman, A.R. Schnattter, S.M. Bowes, N. Murray and M.J. Nicolich. 
1996. Retrospective Benzene and Total Hydrocarbon Exposure Assessment for a Petroleum 
Marketing and Distribution Worker Epidemiology Study.  American Industrial Hygiene 
Association Journal. 57: 333-343. 
 
 
Limitations: 
1. Close scrutiny of the base estimates revealed that several of the most highly exposed 
workers (barrel washer and loader) were derived from limited numbers of 
measurements, derivations from total hydrocarbon content and short term 
measurements.  For instance, the loader base estimate (historic) was derived from the 
total hydrocarbons and (14) short term measurements.  The calculated benzene 
concentration used for this category was 2.6 ppm.  The highest base estimate was for 
the barrel washer, yet the benzene concentration was derived from the total 
hydrocarbon level and (4) short term measurements.     
2. The limited validation exercise did not include measurements of benzene exposure in 
highly exposed workers.  Only the total hydrocarbons were estimated in those 
workers and they varied as follows: -21%, -9%, -11%, -49%, +220% and +85%.  
Alternatively, the benzene measurements varied as follows:  33%, 10%, 130%, 4.5%, 
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0, 0, 0, 14.3% and -14%.  Obviously, with a more highly exposed worker a 
hypothetical percent difference is of far greater importance than in a worker with only 
background exposure.  In addition, all of the confidence intervals used in the 
validation exercise were very wide.  The only jobs evaluated were route sales, loader 
and plantman.   
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7.  The Caprolactam, Italian Shoe Worker and Gas/Electric Utility Worker Studies  
 
Swaen, G. M., T. Scheffers, et al. (2005). "Leukemia risk in caprolactam workers exposed to 
benzene." Ann Epidemiol 15(1): 21-8. (Swaen, Scheffers et al. 2005)___________________ 
 
Cohort Description and Methods:  
This study was composed of Dutch chemical industry association members. Pure 
benzene is used to extract the caprolactam from the neutralized caprolactam ammonium 
sulphate solution.   Benzene extraction was performed indoors and rather primitive in the 
early years of production.  According to former employees this resulted in high background 
exposures with peak and skin exposure due to technical problems and limitations.   
There were 311 caprolactam workers who had been employed in the caprolactam 
plant at some time between January 1, 1951 and December 31, 1968. These workers were 
followed for mortality and the end date of the follow-up was January 1, 2001, covering a 
maximum risk period of follow-up of 40 years and a minimum risk period of 32 years in case 
a person survived until the end of the study. 
Individual exposure estimates were constructed for 275 of the 311 workers. Workers 
with no exposure assessment were treated as a separate group in the analysis with a supposed 
equal exposure distribution. Cumulative individual exposure was assessed as a summation of 
exposures per cohort year.  Modifying factors were derived from the expert judgment 
process. The factors 1 (low) to 6 (high) are assigned to the percentiles of the benzene 
exposure distribution of available exposure data in the 1970s and 1990s. The factors 2 to 6 
are assumed to be within the 25-75 percentile range of the exposure distribution.  Three 
additional factors were assigned to take into account major changes in the production process 
between 1951 and 1968.  
Regarding the expert judgment process, a group interview was held with 7 former 
employees to reconstruct past exposure to benzene of workers at the caprolactam factory. 
The panel consisted of the following employees: two heads of shift, instructor, chemical 
analyst, chief of production, and two production workers.  The following four issues were 
discussed: the job location and timeframe at the caprolactam factory from 1951 to 1968, the 
influences of process and work practices changes on benzene exposure, workplace air 
exposure to benzene during regular production incidence and stops, ranking of jobs related to 
the workplace air concentrations.  
  The cohort time period of 1951 to 1968 was split in three periods on the basis of 
major changes in the production process. Period 1 was from 1951 to 1957; Period 2 was from 
1957 to 1962; and Period 3 was 1962 to 1968. In total 30 changes that had an affect on 
benzene concentrations in the caprolactam factory were identified.  
A factor was used as a modifier in the assessment of the background concentration of 
benzene in the caprolactam factory. Intensity of the benzene exposure was divided into three 
classes: low, middle, and high. To achieve consensus in the interpretation of the exposure 
classes, the following definitions were employed: none to low exposure – no smell of 
benzene; middle – a weak benzene smell; and high – strong benzene odor. However, it 
should also be noted that the odor threshold for benzene varies between persons.  
To derive individual exposure estimates, the main task name and the description of 
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the job as it appears in the planning work were used. The job time concentrations were 
established and checked using the exposure assessment expert system (EAES). The first 
period (1951-1957) the exposure factors were determined at the panel meeting, the history 
recommended workplace levels, and the exposure measurements conducted in the factory 
from 1978 to 1988.  
Benzene measurements from 1978 to 1980 and later were used to establish the base 
estimate distribution of benzene exposure ppm.  
 
Results: 
The total cumulative exposure of the 275 cohort members was 43,725 ppm-years, and 
49,500 ppm-years when extrapolated to the total cohort. The daily mean workplace exposure 
was 20.9 ppm per person. The average number of exposure years was 9.6 with a standard 
deviation of 6.0 and a range from 1 to 18 years.  
It was clear that exposure fell over time.  For example, average daily mean exposures 
in the early period (1951-1957) were estimated to be over 26 ppm, compared with 0.6 in the 
1963-1968 period.  For 47% of the workers, the cumulative exposure was < 50 ppm-years 
and for 28% higher than 200 ppm-years with a maximum of 1,080 ppm-years. The highest 
contribution in ppm was found for the operator extraction. The highest contribution in term 
of number of years of contribution was observed for the job descriptions reserve (219 years) 
and chemical analyst (168 years).  
According to former employees, it is likely that there was extensive and frequent 
dermal exposure to benzene.  Former workers helped us to identify jobs and time periods 
with daily and weekly skin contact. Relevant skin exposure occurred primarily in the early 
years. An arbitrary 2% to 10% ppm-years of the air exposure was added if the job was 
identified with a weekly or daily skin contact. This approach led to the addition of 1,654 
ppm-years to the cohort.   
Next all exposed workers were classified into three cumulative dose groups: low, 
medium, and high. The cut-off points of the three dose groups were chosen in such a way 
that all three dose groups contained one-third of the cohort. Of the 311 workers included in 
the study, 121 had died before the end date of the follow-up. One hundred eighty (180) or 
57.9% were still alive, and 8 or 2.6% had emigrated. For workers who emigrated, the person 
years at risk accumulated was stopped at emigration date. Two (1.1%) of employees were 
lost to follow-up. The workers who had emigrated or were lost to follow-up had no particular 
exposure pattern. Of the 121 deceased workers, 5 or 4.1% could not be linked to the 
particular cause of death.  
Regarding total mortality, the SMR was 85.9 with a 95% confidence interval of 71.3 
to 102.6.  Only one death from leukemia was observed compared with an expected number 
of 1.17. The leukemia found was a non-ANLL type.  The one leukemia death was not found 
in the highest exposure group.   
We applied three quantitative risk estimates to the data of the caprolactam cohort to 
see which of these earlier risk assessments are compatible with the findings in the 
caprolactam cohort. Of the risk models applied to the caprolactam cohort, two overestimate 
the leukemia risk from benzene exposure in such a way that they predict benzene-induced 
excesses from leukemia that are statistically significant, but different from our findings.   
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The authors stated that their study added some support for a threshold dose. 
  
Limitations: 
1. This is a very small study with only one leukemia case, so the conclusions drawn 
from it are necessarily limited.   
2. The exposure assessment was based upon very limited industrial hygiene 
measurements with a great deal dependant upon “expert” judgment.   
3. Eight of the workers emigrated, two were lost to follow-up and five did not have a 
particular cause of death.  This is 5.4% unaccounted for from the original cohort.  The 
addition of even one case would drastically alter the conclusions from this study.   
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B. Studies with Only Qualitative Exposure Measurements 
  
1. Petroleum Industry Studies 
(Please see the following pages for the charts containing the petroleum studies)
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Table 52 - Gulf Oil and Chevron Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(Tsai, Wen 
et al. 
1983) 
Refinery 
Retrospec
tive 
Cohort, 
Mortality, 
09/15/52-
01/01/78 
US 
General 
Populatio
n 
454 workers 
(all male 
workers ever 
employed 
during the 
period who 
worked 
directly on 
benzene, 
ethylene, 
aromatic 
distillate 
hydrogenatio
n or cumene 
units. 
All 
Lymphop
oietic 
Cancer 
0 0.42 SMR=0.00 
(0.00-8.73) 
 
    Leukemia 
and 
Aleukemi
a 
15 27.8
9 
SMR=0.54 
(0.30-0.89) 
 
(Wen, Tsai 
et al. 
1983) 
Refinery 
Longitudi
nal,  
Mortality, 
01/01/37-
01/01/78 
US 
General 
Populatio
n 
16,880 
hourly and 
salaried 
workers 
Lymphati
c and 
Hematopo
ietic 
Cancer 
80 78.7
1 
SMR=1.02 
(0.80-1.26) 
Adjusted 
SMR= 1.08 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
4 16.3
6 
SMR=0.24 
(0.07-0.63) 
Adjusted 
SMR=0.26 
 
    Hodgkin’
s Disease 
16 11.0
2 
SMR=1.45 
(0.83-2.36) 
Adjusted 
SMR=1.55 
 
    Leukemia 
and 
Aleukemi
a 
38 33.2
8 
SMR=1.14 
(0.81-1.57) 
Adjusted 
SMR=1.22 
 
    Cancer of 
Other 
Lymphati
c Tissue 
20 17.4
4 
SMR=1.15 
(0.70-1.77) 
Adjusted 
SMR=1.22 
 
(Dagg, 
Satin et al. 
1992) 
2 
Petroleum 
Refineries 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/50-
12/31/86 
US 
Populatio
n 
14,074 
workers 
(operating 
and 
maintenance, 
clerical, 
technical 
Lymphati
c and 
Haematop
oietic 
System 
Total=88 
Richmon
d=61 
El 
Segundo=
27 
 Total 
SMR=106 
(86-132) 
Richmond 
SMR=117 
(90-151) 
El Segundo 
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supervisory 
or 
administrativ
e) 
SMR=92 
(60-133) 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
Total=18 
Richmon
d=14 
El 
Segundo=
4 
 Total 
SMR=106 
(63-167) 
Richmond 
SMR=129 
(71-217) 
El Segundo 
SMR=66 
(18-168) 
 
    Hodgkin’
s Disease 
Total=8 
Richmon
d=5 
El 
Segundo=
3 
 Total 
SMR=88 
(38-173) 
Richmond 
SMR=86 
(28-200) 
El Segundo 
SMR=94 
(19-274) 
 
    Leukemia 
and 
Aleukemi
a 
Total=33 
Richmon
d=21 
El 
Segundo=
12 
 Total 
SMR=98 
(67-137) 
Richmond 
SMR=98 
(61-150) 
El Segundo 
SMR=99 
(51-172) 
 
    Other 
Lymphati
c tissue 
Total=28 
Richmon
d=20 
El 
Segundo=
8 
 Total 
SMR=136 
(90-197) 
Richmond 
SMR=154 
(94-238) 
El Segundo 
SMR=108 
(46-212) 
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Table 53 – Chevron Oil Company Studies 
(Satin, 
Wong et 
al. 1996) 
Oil 
Refinery 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/37-
12/31/83 
General 
populatio
n in 
Texas and 
US 
Populatio
n 
17,844 
workers 
Cancer of 
All 
Lymphati
c, 
Haemotop
oietic 
Tissue  
138 TX=
131.
7 
US=
135.
6 
TX 
SMR=104.
8 
(88.0-
123.8) 
US 
SMR=135.
6 
(85.5-
120.3) 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
13 TX=
23.0 
US=
25.4 
TX 
SMR=56.5 
(30.1-96.5) 
US 
SMR=51.2 
(27.3-87.6) 
 
    Hodgkin’
s Disease 
18 TX=
12.7 
US=
14.2 
TX 
SMR=141.
3 
(83.7-
223.3) 
US 
SMR=127.
1 
(75.0-
200.9) 
 
    Leukemia 
and 
Aleukemi
a 
57 TX=
55.9 
US=
55.0 
TX 
SMR=102.
0 
(77.3-
132.2) 
US 
SMR=103.
7 
(78.6-
134.4) 
 
    Cancer of 
All Other 
Lymphop
oietic 
Tissue 
50 TX=
40.1 
US=
41.1 
TX 
SMR=124.
7 
(92.6-
164.5) 
US 
SMR=121.
7 
(90.3-
160.4) 
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Table 54 – Exxon Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
Baton Rouge 
(Hanis, 
Holmes et 
al. 1982) 
Refinery 
and 
Chemical 
Plant 
Retrospec
tive 
Cohort, 
Mortality 
01/01/70-
12/31/77 
US Death 
rates 
8,666 regular 
employees 
who worked 
at least one 
month, plus 
retirees who 
were alive as 
of 01/01/70. 
All 
Lymphop
oietic  
25 23.0 SMR=109 
(70-161) 
 
    Lymphore
ticular 
Sarcoma 
5 4.2 SMR=119 
(39-278) 
 
    Leukemia 9 9.3 SMR=97 
(44-184) 
 
    Other 
Lymphati
c Tissue 
7 7.2 SMR=97 
(39-200) 
 
(Hanis, 
Shallenber
ger et al. 
1985) 3 
Refinery 
and 
Chemical 
Plants 
Retrospec
tive 
Cohort,  
Mortality, 
01/01/70-
12/31/77 
 
US 
Populatio
n 
21,698 
workers 
All 
Lymphop
oietic 
55 61.8 SMR=89 
(67-116) 
 
    Lymphos
arcoma/R
eticulosar
coma 
13 11.4 SMR=114 
(61-196) 
 
    Leukemia 20 25.9 SMR=77 
(47-119) 
 
    Other 
Lymphati
c Tissue 
15 18.6 SMR=81 
(45-133) 
 
(Hanis, 
Shallenber
ger et al. 
1985)3 
Refinery 
and 
Chemical 
Plants 
Retrospec
tive 
Cohort,  
Mortality, 
01/01/70-
12/31/77 
 
 21,698 
workers 
All 
Lymphop
oietic 
Potentiall
y 
Exposed=
45 
Non-
Exposed=
9 
Pote
ntiall
y 
Expo
sed=
4.4 
Non-
Expo
sed=
3.8 
  
    Lymphos
arcoma/R
eticulosar
coma 
Potentiall
y 
Exposed=
10 
Pote
ntiall
y 
Expo
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Non-
Exposed=
3 
sed=
0.9 
Non-
Expo
sed=
… 
    Leukemia Potentiall
y 
Exposed=
15 
Non-
Exposed=
4 
Pote
ntiall
y 
Expo
sed=
1.7 
Non-
Expo
sed=
… 
  
(Shallenbe
rger, 
Acquavell
a et al. 
1992) 3 
Refinery 
and 
Chemical 
Plants 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/70-
12/31/82 
General 
populatio
ns in 
Louisiana
, Texas 
and New 
Jersey  
25,321 
workers 
(including 
retirees and 
terminated 
employees) 
 Baton 
Rouge=5
0 
Baytown
=32 
Bayway/
Bayonne=
30 
Total 
Populatio
n=111 
 Baton 
Rouge 
SMR=125 
Baytown 
SMR=103 
Bayway/Ba
yonne 
SMR=99 
Total 
Population
=110 
The 
compariso
n 
population 
state was 
matched to 
the same 
state where 
the plant 
was 
located. 
     Baton 
Rouge=2
3 
Baytown
=15 
Bayway/
Bayonne=
9 
Total 
Populatio
n=46 
 Baton 
Rouge 
SMR=129 
Baytown 
SMR=114 
Bayway/Ba
yonne 
SMR=68 
Total 
Population
=104 
 
     Baton 
Rouge=9 
Baytown
=6 
Bayway/
Bayonne=
6 
Total 
Populatio
n=21 
 Baton 
Rouge 
SMR=156 
Baytown 
SMR=117 
Bayway/Ba
yonne 
SMR=111 
Total 
Population
=21 
 
     Baton 
Rouge=1
7 
Baytown
=9 
Bayway/
 Baton 
Rouge 
SMR=122 
Baytown 
SMR=84 
Bayway/Ba
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Bayonne=
14 
Total 
Populatio
n=40 
yonne 
SMR=141 
Total 
Population
=116 
(Huebner, 
Schnatter 
et al. 
1997) 
Petrochem
ical 
Retrospec
tive 
Cohort,  
Mortality, 
01/01/79-
12/31/92 
US 
Populatio
n adjusted 
for 
gender, 
race and 
calendar 
time.  
81,746 
former and 
current 
petrochemica
l company 
employees. 
All 
Lymphati
c/Hemato
poietic 
Males=12
3 
Females=
15 
Male
s=12
8.5 
Fem
ales=
17.4 
Males 
SMR=0.96 
(0.80-1.14) 
Females 
SMR=0.86 
(0.48-1.42) 
 
    Lymphos
arcoma/R
eticulosar
coma 
Males=5 
Females=
2 
Male
s=12
.3 
Fem
ales=
1.5 
Males 
SMR=0.41 
(0.13-0.95) 
Females 
SMR=none 
listed 
(none 
listed) 
 
    Hodgkin’
s Disease 
Males=7 
Females=
3 
Male
s=8.
4 
Fem
ales=
1.4 
Males 
SMR=0.83 
(0.33-1.71) 
Females 
SMR=none 
listed 
(none 
listed) 
 
    Leukemia
/Aleukem
ia 
Males=60 
Females=
2 
Male
s=58
.7 
Fem
ales=
7.1 
Males 
SMR=1.02 
(0.78-1.32) 
Females 
SMR=0.28 
(0.03-1.02) 
 
    All Other 
Lymphop
oietic 
Males=23 
Females=
8 
Male
s=20
.2 
Fem
ales=
7.3 
Males 
SMR=1.14 
(0.72-1.71) 
Females 
SMR=1.09 
(0.47-2.15) 
 
    Multiple 
Myeloma 
Males=18 
Females=
4 
Male
s=15
.0 
Fem
ales=
2.4 
Males 
SMR=1.20 
(0.71-1.90) 
Females 
SMR=none 
listed 
(none 
listed) 
 
(Lewis, 
Gamble et 
al. 2000) 
3 
Refinery/P
etrochemic
Retrospec
tive 
Cohort, 
Mortality, 
01/01/70-
12/31/82 
National 
and State 
Populatio
n for the 
respective 
states of 
19,075 
Active/Termi
nated 
workers.  
Lymphati
c and 
Hemopoie
tic Tissue 
116 95.2 SMR=122 
(101-146) 
Data was 
only 
provided 
for males. 
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al Plants each 
plant.   
    Lymphos
arcoma 
and 
Reticulos
arcoma 
13 11.4 SMR=114 
(61-196) 
 
    Leukemia 56 37.3 SMR=150 
(113-195) 
 
    Other 
Lymphop
oietic 
Tissue 
45 41.0 SMR=110 
(80-147) 
 
(Gamble, 
Lewis et 
al. 2000) 
3 
Refinery/P
etrochemic
al Plants 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/70-
12/31/82 
US and 
State 
Populatio
n  
6,238 male 
retirees from 
the three 
plants 
(almost all 
deceased) 
Lymphati
c and 
Hemopoie
tic Tissue 
98 86.8 SMR=113 
(92-138) 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
13 11.0 SMR=118 
(63-202) 
 
    Leukemia 35 39.1 SMR=90 
(62-124) 
 
    Other 
Lymphop
oietic 
Tissue 
46 33.6 SMR=137 
(100-182) 
 
(Huebner, 
Wojcik et 
al. 2004) 
2 
Refinery/P
etrochemic
al Plants 
Retrospec
tive 
Cohort, 
Mortality 
01/01/70-
12/31/97 
General 
Populatio
ns for 
Louisiana 
(for Baton 
Rouge 
Plant) or 
Texas 
(Baytown 
Plant).  
US rates 
were also 
used for 
comparis
on 
purposes 
7,637 Baton 
Rouge 
Employees 
and 7,007 
Baytown 
Employees.  
Predominantl
y white 
males. 
Malignant 
Neoplasm
s of 
Lymphati
c and 
Hematopo
ietic 
Tissue 
BR=81 
B=54 
BR=
55.1
7 
B=4
9.32 
BR 
SMR=1.47 
(1.17-1.82) 
B SMR= 
1.10 
(0.82-1.43) 
BR=Baton 
Rouge 
B=Baytow
n 
    Hodgkin’
s Disease 
BR=0 
B=1 
BR=
2.70 
B=2.
25 
BR SMR= 
- 
( - ) 
B SMR=  -  
( - ) 
 
    Non-
Hodgkin’
s 
BR=29 
B=15 
BR=
19.7
7 
BR 
SMR=1.47 
(0.98-2.11) 
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Lymphom
a 
B=1
7.85 
B SMR= 
0.84 
(0.47-1.39) 
    Multiple 
Myeloma 
BR=13 
B=11 
BR=
10.0
01 
B=9.
03 
BR 
SMR=1.30 
(0.69-2.22) 
B SMR= 
1.22 
(0.61-2.18) 
 
    Leukemia BR=37 
B=27 
BR=
21.9
2 
B=1
9.56 
BR 
SMR=1.69 
(1.19-2.33) 
B SMR= 
1.38 
(0.91-2.01) 
 
    Acute 
Non-
lymphocy
tic  
BR=11 
B=12 
BR=
7.23 
B=5.
62 
BR 
SMR=1.52 
(0.76-2.72) 
B 
SMR=2.13  
(1.10-3.73) 
 
    Chronic 
Myelocyti
c 
BR=5 
B=4 
BR=
2.75 
B=2.
61 
BR 
SMR=1.82 
(0.59-4.25) 
B SMR= 
1.54 
(0.42-3.93) 
 
    Acute 
Lymphoc
ytic 
BR=2 
B=2 
BR=
0.89 
B=1 
BR SMR= 
-  
( - ) 
B SMR=  -  
(  - ) 
 
    Chronic 
Lymphoc
ytic 
BR=10 
B=5 
BR=
4.13 
B=4.
07 
BR 
SMR=2.42 
(1.16-4.45) 
B SMR= 
1.23 
(0.40-2.87) 
 
    Other and 
Unspecifi
ed 
Leukemia 
BR=9 
B=4 
BR=
6.90 
B=6.
22 
BR 
SMR=1.30 
(0.60-2.48) 
B SMR= 
0.64 
(0.18-1.65) 
 
(Wong, 
Harris et 
al. 2001) 
Petroleum 
Refinery 
Retrospec
tive 
Cohort, 
Mortality 
01/01/59-
12/31/97 
US 
Populatio
n 
3,328 
workers 
Cancer of 
all 
Lymphati
c, 
Hemopoie
tic Tissue 
19 18.6
5 
SMR=101.
9 
(61.3-
159.1) 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
1 2.11 SMR=47.4 
(1.2-264.3) 
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    Hodgkin’
s Disease 
1 1.13 SMR=88.4 
(2.2-492.8) 
 
    Leukemia 
and 
Aleukemi
a 
5 7.37 SMR=67.8 
(22.0-
158.3) 
 
    Cancer of 
all other 
Lymphop
oietic 
Tissue 
12 8.04 SMR=149.
2 
(77.1-
260.6) 
 
(Lewis, 
Yarboroug
h et al. 
1999) 
Petrochem
ical 
researchers 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/64-
12/31/92 
US and 
New 
Jersey 
Populatio
ns 
13,188 New 
Jersey USA 
based 
employees 
All 
Lymphop
oietic 
Cancer 
Males=33 
Females=
2 
Male
s=36
.2 
Fem
ales=
4.8 
Males 
SMR=91 
(63-128) 
Females 
SMR= -  
( - ) 
 
    Lymphos
arcoma, 
Reticulos
arcoma 
Males=2 
Females=
0 
Male
s=4.
6 
Fem
ales=
0.5 
Males 
SMR= -  
( - ) 
Females 
SMR= -  
( - ) 
 
    Hodgkin’
s Disease 
Males=1 
Females=
0 
Male
s=3.
5 
Fem
ales= 
0.7 
Males 
SMR= -  
( - ) 
Females 
SMR= -  
( - ) 
 
    Leukaemi
a, 
Aleukaem
ia 
Males=14 
Females=
0 
Male
s=13
.5 
Fem
ales=
1.8 
Males 
SMR=103 
(57-174) 
Females= -  
( - ) 
 
    All Other 
Lymphop
oietic 
Males=16 
Females=
2 
Male
s=14
.6 
Fem
ales=
1.7 
Males 
SMR=110 
(63-178) 
Females 
SMR= -  
( - ) 
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Table 55 – Mobil Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(Collingw
ood, 
Milcarek 
et al. 
1991) 
2 Refinery 
Plants 
Retrospec
tive 
Cohort, 
Mortality 
01/01/45-
12/31/78 
US Males 2,467 
workers in 
lubrication 
products and 
blending 
(97% male) 
Lymphos
arcoma 
and 
Reticulos
arcoma 
0  SMR=0 
(0-121) 
 
    Hodgkin’
s Disease 
1  SMR=58 
(2-324) 
 
    Leukemia 
and 
Aleukemi
a 
6  SMR=106 
(39-230) 
 
    Other 
Lymphati
c Tissue 
5  SMR=149 
(49-349) 
 
(Raabe, 
Collingwo
od et al. 
1998) 
Petroleum 
Refinery 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/45-
12/31/87 
US Age 
specific 
mortality 
rates 
7,119 
workers 
Lymphati
c and 
Hematopo
ietic 
Cancer 
TP=65 
WM=54 
TP=
48.7 
WM
=40.
2 
TP 
SMR=133 
(103-170) 
WM 
SMR=134 
(101-175) 
TP= Total 
population 
WM = 
White 
Males 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
TP=9 
WM=7 
TP=
8.6 
WM
=7.4 
TP 
SMR=105 
(48-199) 
WM 
SMR=95 
(38-196) 
 
    Hodgkin’
s Disease 
TP=3 
WM=3 
TP=
4.5 
WM
=3.8 
TP 
SMR=66 
(14-194) 
WM 
SMR=79 
(16-230) 
 
    Leukemia 
and 
Aleukemi
a 
TP=28 
WM=24 
TP=
20.1 
WM
=16.
9 
TP 
SMR=139 
(92-201) 
WM 
SMR=142 
(91-211) 
 
    Other 
Lymphati
c Tissue 
TP=24 
WM=19 
TP=
15.2 
WM
=11.
9 
TP 
SMR=158 
(101-235) 
WM 
SMR=160 
(96-249) 
 
(Wong, 
Harris et 
Retrospec
tive 
US 
Populatio
7543 workers All 
Lymphati
83 69.4
9 
SMR=119.
4 (95.1-
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al. 2001) 
Petroleum 
Refinery 
Cohort, 
Mortality, 
01/01/45-
12/31/96 
n c, 
Hemopoie
tic Tissue 
148.1) 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
9 9.74 SMR=92.4 
(42.3-
175.5) 
 
    Hodgkin’
s Disease 
3 5.14 SMR=58.4 
(12.0-
170.6) 
 
    Leukemia 
and 
Aleukemi
a 
39 28.0
7 
SMR=138.
9 
(98.8-
189.9) 
 
    Cancer of 
All Other 
Lymphop
oietic 
Tissue 
32 26.5
6 
SMR=120.
5 
(82.4-
170.1) 
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Table 56 - Shell Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(McCraw, 
Joyner et 
al. 1985)  
Petroleum 
Refinery 
Retrospec
tive 
Cohort 
Mortality 
01/01/73- 
12/31/82 
US 3,976 men 
Hourly & 
Salaried 
Leukemia 14 6.6 SMR=213 
(117-358) 
Subjects 
not in area 
with 
highest 
benzene 
levels 
    Acute 
Myeloid 
8 2.0 SMR=394  
(172-788) 
No 
exposure 
data 
    Acute 
Monocyti
c 
1 0.2 SMR=661 
(6-2,782) 
 
    Chronic 
Myeloid 
1 0.8 SMR=121 
(2-696) 
 
    Acute 
Lymphati
c 
1 0.3 SMR=340 
(4-1,854) 
 
    Chronic 
Lymphati
c 
1 1.3 SMR=73 
(1-428) 
 
    Other and 
Non-
Specified 
2 2.0 SMR=100 
(11-361) 
 
(Austin, 
Cole et al. 
1986) 
Oil 
Refinery 
Case 
Control 
Mortality 
01/01/73-
12/31/82 
 
50 
matched 
controls 
14 cases with 
leukemia (8 
cases with 
AML) All 
white males 
with 
leukemia 
who worked 
or had 
worked at the 
refinery for 
at least 6 
months.  
Leukemia 14 8  4 controls 
matched to 
each case 
on year of 
birth (plus 
or minus 2 
years).  
Controls 
had to 
have 
worked for 
at the 
refinery 
for at least 
6 months 
and could 
not have 
died from 
lymphoma 
or diseases 
of the 
blood-
forming 
organs.  
Controls 
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had to 
have 
survived at 
least as 
long as 
their 
matched 
case.    
    Acute 
Myeloid 
Leukemia 
8 2  These 8 
were 
included in 
the 
original 
count of 14 
cases of 
leukemia. 
(Tsai, 
Dowd et 
al. 1991) 
Petroleum/
petrochemi
cal 
Refinery 
Prospecti
ve 
Cohort,  
Morbidity
, 
01/01/81-
12/31/88 
 2132 full-
time male  
(1380 
production 
and 752 staff 
employees of 
the Shell Oil 
Company) 
All 
Neoplasm
s 
Productio
n-46, 
Staff-17 
Prod
uctio
n-
44.2, 
Staff
-15.2 
SMR= 
Production-
104, Staff-
112 
No CI was 
given. 
(Wongsric
hanalai, 
Delzell et 
al. 1989) 
Petroleum 
Refinery 
Retrospec
tive and 
Case 
Control, 
Mortality, 
01/01/42-
01/01/84  
US White 
Men 
9,484 white 
men who 
worked at the 
petroleum 
refinery. 
All 
Lymphati
c and 
Hematopo
ietic 
Tissue 
90  SMR=126  
(101-155) 
Three 
deaths 
attributed 
to 
myelofibro
sis are 
included in 
the 
category of 
“all 
lymphatic 
and 
hematopoi
etic 
tissue”, but 
not in any 
of the 
other 
subcategor
ies. 
    Lymphos
arcoma 
14  SMR=99 
(54-166) 
 
    Hodgkin’
s Disease 
9  SMR=114  
(52-216) 
 
    Leukemia 44  SMR=149 
(108-200) 
 
    Other 
Lymphati
c and 
Hematopo
ietic 
20  SMR=105 
(64-162) 
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tissue  
(Honda, 
Delzell et 
al. 1995) 
Petroleum 
Manufactu
ring Plant  
Retrospec
tive 
Cohort, 
Mortality, 
01/01/42-
1989 
US White 
Men 
9,796 white 
male hourly 
and salaried 
workers 
All 
Lymphop
oietic 
Cancer 
104  SMR=114 
(93-138) 
Individuals 
had to 
have 
worked at 
the plant at 
least 6 
months 
before 
1990 
    Lymphos
arcoma 
14  SMR=89 
(49-149) 
 
    Hodgkin’
s 
Lymphom
a 
9  SMR=106  
(48-200) 
 
    Leukemia 46  SMR=123 
(90-164) 
 
    Other 
Lymphop
oietic 
Tissue 
29  SMR=99 
(66-142) 
 
(Tsai, 
Gilstrap et 
al. 1993)      
Two 
Refinery 
and 
Petrochem
ical Plants  
Retrospec
tive 
Cohort 
Mortality 
01/01/73-
12/31/89 
California 
Mortality 
Rates  
4,585  MMC 
and WMC 
full-time 
male 
employees 
who worked 
at least 6 
months prior 
to 12/31/89, 
were actively 
employed as 
of 01/01/73 
and were 
pensioners 
who were 
alive as of 
01/01/73.   
Lymphati
c and 
Hematopo
ietic 
Tissue 
MMC=14 
WMC=12 
Combine
d=26 
 MMC 
SMR=1.04 
(0.57-1.74) 
WMC 
SMR=1.04 
(0.54-1.82) 
Combined 
SMR=1.04 
(0.68-1.52) 
The two 
plants 
were 
Martinez 
Manufactu
ring 
Complex 
(MMC) 
and 
Wilmingto
n 
Manufactu
ring 
Complex 
(WMC) 
    Lymphos
arcoma 
and 
reticulosa
rcoma 
MMC=2 
WMC=0 
Combine
d=2 
 MMC 
SMR=1.21 
(0.15-4.37) 
WMC 
SMR=none 
listed. 
Combined 
SMR=0.65 
(0.08-2.36) 
 
    Hodgkin’
s Disease 
MMC=2 
WMC=0 
Combine
d=2 
 MMC 
SMR=3.66 
(0.44- ) 
WMC 
SMR=none 
listed. 
Combined 
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SMR=1.99 
(0.24-7.18) 
    Leukemia MMC=2 
WMC=7 
Combine
d=9 
 MMC 
SMR=0.36 
(0.04-1.29) 
WMC 
SMR=1.47 
(0.59-3.02) 
Combined 
SMR=0.87 
(0.40-1.65) 
 
    Other 
Lymphati
c Tissue 
MMC=8 
WMC=5 
Combine
d=13 
 MMC 
SMR=1.39 
(0.60-2.75) 
WMC 
SMR=1.02 
(0.33-2.39) 
Combined 
SMR=1.22 
(0.65-2.09) 
 
Shell in Louisiana 
(Tsai, 
Gilstrap et 
al. 1997) 
Petrochem
ical 
Company 
Prospecti
ve 
Cohort, 
Mortality 
01/01/73-
01/01/94 
United 
States, 
Louisiana 
and/or 
Surroundi
ng Tri-
Parish 
area. 
3,803 
Refinery and 
Petrochemica
l Workers 
(active and 
retired) 
All 
Lymphati
c and 
Hematopo
ietic 
tissue 
9 12.2 SMR=0.74  
(0.34-1.41) 
Must have 
worked at 
least 6 
months 
prior to 
01/01/94. 
    Leukemia 
and 
Aleukemi
a 
4 5.0 SMR=0.81  
(0.22-2.07) 
 
    All 
Lymphati
c and 
Hematopo
ietic 
tissue 
8 US=
11.3 
LA=
11.5 
Tri-
Paris
hes=
11.2 
US 
SMR=0.71 
LA 
SMR=0.70 
Tri-
Parishes 
SMR=0.71 
With at 
least 10 
years time 
since first 
employme
nt 
    Leukemia 
and 
Aleukemi
a 
3 US=
4.6 
LA=
4.7 
Tri-
Paris
hes=
4.3 
US 
SMR=0.66 
LA 
SMR=0.63 
Tri-
Parishes 
SMR=0.70 
With at 
least 10 
years time 
since first 
employme
nt 
(Tsai, 
Wendt et 
al. 2003) 
Refinery 
and 
Chemical 
Prospecti
ve 
Mortality 
Surveillan
ce  
(01/01/73
US, 
Louisiana 
and the 
seven 
parish 
region 
Morbidity 
Study = 
4,221 
employees 
and retirees 
Mortality 
All 
Lymphati
c and 
Haematop
oietic 
Tissue 
15 18.0 SMR=0.83 
(0.47-1.38) 
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Facility -
12/31/99) 
and 
Morbidity
: (1990-
1999) 
Study= 2,203 
individuals 
who ever 
worked at the 
plant during 
this period.   
    Lymphos
arcoma 
and 
Reticulos
arcoma 
3 1.3 SMR=2.32 
(0.48-6.79) 
 
    Hodgkin’
s Disease 
0 0.9 SMR= -  
(0.00-4.24) 
 
    Leukaemi
a and 
Aleukami
a 
4 7.0 SMR=0.57 
(0.16-1.46) 
 
    All other 
Lymphop
oietic 
Tissue 
8 8.8 SMR=0.91 
(0.39-1.79) 
 
    All 
Lymphati
c and 
Hematopo
ietic 
tissue 
14 US=
16.2 
LA=
17.1 
Indu
strial 
Corri
dor=
17.6 
US 
SMR=0.87 
LA 
SMR=0.82 
Tri-
Parishes 
SMR=0.79 
With at 
least 10 
years of 
employme
nt 
    Leukemia 
and 
Aleukemi
a 
3 US=
6.3 
LA=
6.8 
Indu
strial 
Corri
dor=
7.0 
US 
SMR=0.48 
LA 
SMR=0.44 
Tri-
Parishes 
SMR=0.43 
With at 
least 10 
years of 
employme
nt 
Shell Deer Park 
(Marsh, 
Enterline 
et al. 
1991) 
Petroleum 
Refinery 
and 
Chemical 
Plant 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/48-
12/31/72 
US,  
Texas and 
Harris 
County 
populatio
ns 
6,831 male 
and female 
hourly and 
salaried 
workers who 
were 
employed for 
at least 3 
months 
during the 
period 
studied.  
All 
Lymphop
oietic  
Tissue 
36  US 
SMR=110 
TX 
SMR=115 
Harris 
County 
SMR=110 
 
    Lymphop
oietic 
Tissue 
26=Refin
ery Only 
9=Chemi
 127=Refine
ry Only 
111=Chemi
Harris 
County 
Compariso
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cal Plant 
Only 
1=Both 
Plants 
Combine
d 
cal Plant 
Only 
25=Both 
Plants 
Combined 
n Only 
    Lympho-
Reticulos
arcoma 
9=Refiner
y Only 
1=Chemi
cal Plant 
Only 
0=Both 
Plants 
Combine
d 
 189=Refine
ry Only 
59=Chemic
al Plant 
Only 
- =Both 
Plants 
Combined 
Harris 
County 
Compariso
n Only 
    Hodgkin’
s Disease 
3=Refiner
y Only 
0=Chemi
cal Plant 
Only 
0=Both 
Plants 
Combine
d 
 135=Refine
ry Only 
- 
=Chemical 
Plant Only 
- =Both 
Plants 
Combined 
Harris 
County 
Compariso
n Only 
    Leukemia 8=Refiner
y Only 
3=Chemi
cal Plant 
Only 
0=Both 
Plants 
Combine
d 
 97=Refiner
y Only 
93=Chemic
al Plant 
Only 
- =Both 
Plants 
Combined 
Harris 
County 
Compariso
n Only 
    Other 
Lymphop
oietic 
(residual) 
7=Refiner
y Only 
5=Chemi
cal Plant 
Only 
1=Both 
Plants 
Combine
d 
 120=Refine
ry Only 
237=Chemi
cal Plant 
Only 
1=Both 
Plants 
Combined 
Harris 
County 
Compariso
n Only 
(Tsai, 
Dowd et 
al. 1992) 
Petroleum 
and 
Chemical 
Plant 
Prospecti
ve 
Cohort,  
Morbidity 
01/01/81-
12/31/88 
All 
manufact
uring 
employee
s of the 
Shell Oil 
Company 
3,422 male 
employees 
Lymphati
c and 
haematop
oietic 
Tissue  
Productio
n=4 
Staff=2 
 Production 
SMR=124 
(33-340) 
Staff=91 
(10-379) 
 
(Tsai, 
Gilstrap et 
al. 1996) 
Petroleum 
Refinery 
and 
Retrospec
tive 
Cohort,  
Mortality, 
01/01/48-
12/31/89 
Death 
rates for 
Harris 
County, 
Texas 
9,720 hourly 
and salaried 
employees 
with routine 
field or 
laboratory 
All 
Lymphati
c and 
Hematopo
ietic 
Tissue 
Refinery=
39 
Chemical
=17 
Total=56 
 Refinery 
SMR=122.
0 
(87-167) 
Chemical 
SMR=92.3 
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Chemical 
Plant 
assignments  (54-148) 
Total 
SMR=111.
2 
(84-144) 
    Lymphos
arcoma 
and 
Lympho-
Reticulos
arcoma 
Refinery=
9 
Chemical
=1 
Total=10 
 Refinery 
SMR=169.
5 
(77-322) 
Chemical 
SMR=34.7 
(1-194) 
Total 
SMR=122.
1 
(59-225) 
 
    Hodgkin’
s Disease 
Refinery=
4 
Chemical
=0 
Total=4 
 Refinery 
SMR=137.
0 
(37-351) 
Chemical 
SMR= - 
(-) 
Total 
SMR=84.2 
(23-215) 
 
    Leukemia 
and 
Aleukemi
a 
Refinery=
14 
Chemical
=7 
Total=21 
 Refinery 
SMR=109.
4 
(60-84) 
Chemical 
SMR=98.3 
(39-202) 
Total 
SMR=105.
4 
(65-161) 
 
    All Other 
Lymphop
oietic 
(residual) 
Refinery=
12 
Chemical
=9 
Total=21 
 Refinery 
SMR=109.
8 
(57-192) 
Chemical 
SMR=136.
9 
(63-260) 
Total 
SMR=120.
0 
(74-183) 
 
(Tsai, 
Ahmed et 
al. 2007) 
Petroleum 
Refinery  
Retrospec
tive 
Cohort, 
Mortality,  
01/01/48-
12/31/03 
Harris 
County, 
Texas 
Populatio
n 
10,621 
employees 
who worked 
for at least 3 
months 
during the 
All 
Lymphati
c, 
Hematopo
ietic 
Tissue 
Refinery=
62 
Chemical
=41 
Total=10
3 
 Refinery 
SMR=0.98 
(0.75-1.25) 
Chemical 
SMR=0.94 
(0.67-1.27) 
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period 
studied. 
Total 
SMR=0.96 
(0.79-1.17) 
    Hodgkin 
Diseases 
Refinery=
4 
Chemical
=0 
Total=4 
 Refinery 
SMR=1.16 
(0.32-2.97) 
Chemical 
SMR= - 
(0.0-1.63) 
Total 
SMR=0.70 
(0.19-1.79) 
 
    Non-
Hodgkin 
Lymphom
a 
Refinery=
27 
Chemical
=13 
Total=40 
 Refinery 
SMR=1.13 
(0.74-1.64) 
Chemical 
SMR=0.75 
(0.40-1.28) 
Total 
SMR=0.97 
(0.69-1.32) 
 
    Leukemia
, 
Aleukemi
a 
Refinery=
23 
Chemical
=18 
Total=41 
 Refinery 
SMR=0.95 
(0.60-1.42) 
Chemical 
SMR=1.10 
(0.65-1.73) 
Total 
SMR=1.01 
(0.72-1.36) 
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Table 57 - Texaco Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(Divine, 
Barron et 
al. 1985) 
Refining, 
Petrochem
ical or 
Research 
Facility 
Retrospec
tive 
Follow-
up, 
Mortality, 
01/01/47-
12/31/77 
US White 
male 
populatio
n 
19,077 white 
men - All 
employees of 
Texaco Inc., 
who worked 
at the 
refinery, 
petrochemica
l or research 
facilities. 
Lymphos
arcoma 
20 22.2 SMR=90 
(55-139) 
To be 
included, 
employees 
had to 
have 
worked at 
least 5 
years prior 
to 
12/31/77. 
    Hodgkin’
s Disease 
13 12.0 SMR=108 
(58-185) 
 
    Leukemia 48 40.7 SMR=118 
(87-156) 
 
    Cancer of 
the 
Lymphati
c Tissue 
25 21.8 SMR=115 
(74-170) 
 
(Divine 
and Barron 
1986) 
Refining, 
Petrochem
ical or 
Research 
Facility 
Cohort, 
Mortality, 
(01/01/47
-
12/31/77) 
US white 
male 
populatio
n of 
similar 
age and 
calendar 
time. 
18,798 
persons 
employed 5 
years or 
more at a 
Texaco 
refinery, 
petrochemica
l plant or 
research 
laboratory.  
Lymphos
arcoma 
OM >1 
year=6 
OM >5 
years=4 
O >1 
year=13 
O >5 
years=8 
M >1 
year=6 
M >5 
years=2 
L >1 
year=1 
L >5 
years=1 
PB >1 
year=5 
PB >5 
years=3 
 OM >1 
year 
SMR=78 
CI=(28-
169) 
OM >5 
years 
SMR=64 
CI=(17-
163) 
O >1 year 
SMR=106 
CI=(56-
181) 
O >5 years 
SMR=82 
CI=(22-
210) 
M >1 year 
SMR=46 
CI=(17-
101) 
M >5 years 
SMR=24 
CI=(3-88) 
L >1 year 
SMR=42 
CI=(1-236) 
L >5 years 
SMR=53 
Office/Ma
nager=OM 
Operators=
O 
Maintenan
ce=M 
Laboratory
=L 
Pipefitters/
Boilermak
ers=PB 
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CI=(1-293) 
PB >1 year 
SMR=117 
CI=(38-
274) 
PB >5 
years 
SMR=133 
CI=(27-
387) 
    Hodgkin’
s Disease 
OM >1 
year=1 
OM >5 
years=1 
O >1 
year=7 
O >5 
years=4 
M >1 
year=6 
M >5 
years=6 
L >1 
year=1 
L >5 
years=1 
PB >1 
year=1 
PB >5 
years=1 
 OM >1 
year 
SMR=27 
CI=(0-150) 
OM >5 
years 
SMR=34 
CI=(0-188) 
O >1 year 
SMR=106 
CI=(43-
219) 
O >5 years 
SMR=82 
CI=(22-
210) 
M >1 year 
SMR=86 
CI=(31-
186) 
M >5 years 
SMR=138 
CI=(50-
299) 
L >1 year 
SMR=72 
CI=(1-403) 
L >5 years 
SMR=90 
CI=(1-498) 
PB >1 year 
SMR=46 
CI=(1-256) 
PB >5 
years 
SMR=88 
CI=(1-488) 
 
    Leukemia OM >1 
year=18 
OM >5 
years=11 
O >1 
year=31 
O >5 
years=21 
 OM >1 
year 
SMR=124 
CI=(74-
197) 
OM >5 
years 
SMR=93 
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M >1 
year=27 
M >5 
years=14 
L >1 
year=3 
L >5 
years=3 
PB >1 
year=17 
PB >5 
years=12 
CI=(46-
167) 
O >1 year 
SMR=137 
CI=(93-
194) 
O >5 years 
SMR=120 
CI=(74-
184) 
M >1 year 
SMR=115 
CI=(76-
167) 
M >5 years 
SMR=93 
CI=(51-
156) 
L >1 year 
SMR=74 
CI=(15-
218) 
L >5 years 
SMR=94 
CI=(19-
274) 
PB >1 year 
SMR=212 
CI=(123-
339) 
PB >5 
years 
SMR=285 
CI=(147-
498) 
    Cancer of 
the 
Lymphati
c Tissue 
OM >1 
year=8 
OM >5 
years=6 
O >1 
year=16 
O >5 
years=12 
M >1 
year=18 
M >5 
years=13 
L >1 
year=1 
L >5 
years=0 
PB >1 
year=7 
PB >5 
years=1 
 OM >1 
year 
SMR=97 
CI=(67-
136) 
OM >5 
years 
SMR=92 
CI=(34-
201) 
O >1 year 
SMR=132 
CI=(75-
214) 
O >5 years 
SMR=127 
CI=(66-
223) 
M >1 year 
SMR=142 
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CI=(84-
225) 
M >5 years 
SMR=161 
CI=(86-
275) 
L >1 year 
SMR=43 
CI=(1-242) 
L >5 years 
SMR=0 
CI=(0-199) 
PB >1 year 
SMR=164 
CI=(66-
338) 
PB >5 
years 
SMR=44 
CI=(1-246) 
(Divine 
and Barron 
1987) 
Producing 
or Pipeline 
Location 
Retrospec
tive 
follow-up, 
Mortality, 
01/01/46-
12/31/80 
US white 
male  
populatio
n 
11,098 white 
men who 
were 
employed for 
at least 6 
months. 
Lymphos
arcoma 
7 11.8 SMR=59 
(24-122) 
 
    Hodgkin’
s Disease 
4 6.6 SMR=60 
(16-154) 
 
    Leukemia 25 22.7 SMR=110 
(71-163) 
 
    Cancer of 
Other 
Lymphati
c Tissue 
12 13.5 SMR=89 
(46-155) 
 
(Divine, 
Hartman et 
al. 1999) 
Refining, 
Research 
and 
Petrochem
ical 
Facilities 
Retrospec
tive 
follow-up, 
Mortality, 
01/01/47-
12/31/93 
US 
Populatio
n 
28,480 
employees  
Lymphati
c and 
Haematop
oietic 
Cancer 
White 
Men=226 
Non-
White 
Men=3 
All 
Women=
11 
 White 
Men= 
99SMR= 
(87-113) 
Non-White 
Men= 
SMR=36 
(7-106) 
All 
Women= 
SMR=131 
(65-234) 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
White 
Men=26 
Non-
White 
Men=0 
All 
Women=
0 
 White 
Men= 
SMR=75 
(49-110) 
Non-White 
Men= 
SMR=0 
(0-417) 
All 
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Women= 
SMR=0 
(0-309) 
    Hodgkin’
s Disease 
White 
Men=17 
Non-
White 
Men=0 
All 
Women=
0 
 White 
Men= 
SMR=98 
(57-156) 
Non-White 
Men= 
SMR=0 
(0-615) 
All 
Women= 
SMR=0 
(0-618) 
 
    Leukemia White 
Men=93 
Non-
White 
Men=0 
All 
Women=
4 
 White 
Men= 
SMR=101 
(81-123) 
Non-White 
Men= 
SMR=0 
(0-122) 
All 
Women= 
SMR=129 
(35-331) 
 
    Other 
Lymphati
c Tissue 
White 
Men=85 
Non-
White 
Men=3 
All 
Women=
7 
 White 
Men= 
SMR=109 
(87-135) 
Non-White 
Men= 
SMR=81 
(16-237) 
All 
Women= 
SMR=209 
(84-431) 
 
(Divine, 
Hartman et 
al. 1999) 
Refining, 
Research 
and 
Petrochem
ical sites 
Retrospec
tive 
follow-up, 
Mortality, 
01/01/47-
12/31/93 
US 
Populatio
n 
28,840 
workers 
(employed 
for ≥5 years) 
Non-
Hodgkin’
s 
Lymphom
a 
74   SMR=88 
(69-111) 
Data was 
provided 
only on 
white men 
for all of 
the 
leukemias. 
    Multiple 
Myeloma 
Leukemia 
36   SMR=101 
(70-140) 
 
    Acute 
Lymphoc
ytic 
Leukemia 
5 4.9 SMR=101 
(32-235) 
 
    Chronic 15 18.6 SMR=80  
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Lymphoc
ytic 
Leukemia 
(45-133) 
    Acute 
Myelogen
ous 
Leukemia 
20 15.5 SMR=129 
(78-199) 
 
    Chronic 
Myelogen
ous 
Leukemia 
12 11.4 SMR=105 
(54-183) 
 
    Acute 
Unspecifi
ed 
Leukemia 
15 5.4 SMR=276 
(154-455) 
 
    Cell-Type 
Unspecifi
ed 
Leukemia 
15 6.5 SMR=231 
(129-381) 
 
(Divine 
and 
Hartman 
2000) 
Crude Oil 
Production 
site 
Retrospec
tive 
follow-up, 
Mortality, 
01/01/46-
12/31/94 
US 
populatio
n 
24,124 
workers 
broken up 
into two 
groups: white 
men, on-
white men 
and all 
women 
Lymphati
c and 
Haematop
oietic 
Employed 
<5 yrs=8 
Employed 
5-9 
yrs=10 
Employed 
10-19 
yrs=19 
Employed 
≥20 
yrs=79 
 <5 yr 
SMR=54 
(23-107) 
5-9 yrs 
SMR=86 
(41-159) 
10-19 yrs 
SMR=89 
(53-139) 
≥20 yrs 
SMR=102 
(81-128) 
Data was 
provided 
only on 
white men 
for all of 
the 
leukemias. 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
Employed 
<5 yrs=2 
Employed 
5-9 yrs=0 
Employed 
10-19 
yrs=3 
Employed 
≥20 yrs=5 
 <5 yr 
SMR=111 
(12-401) 
5-9 yrs 
SMR=0 
(0-235) 
10-19 yrs 
SMR=83 
(16-243) 
≥20 yrs 
SMR=46 
(15-107) 
 
    Hodgkin’
s Disease 
Employed 
<5 yrs=1 
Employed 
5-9 yrs=0 
Employed 
10-19 
yrs=0 
Employed 
≥20 yrs=4 
 <5 yr 
SMR=50 
(0-278) 
5-9 yrs 
SMR=0 
(0-249) 
10-19 yrs 
SMR=0 
(0-159) 
≥20 yrs 
SMR=97 
(26-248) 
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    Leukaemi
a 
Employed 
<5 yrs=3 
Employed 
5-9 yrs=3 
Employed 
10-19 
yrs=8 
Employed 
≥20 
yrs=35 
 <5 yr 
SMR=52 
(10-153) 
5-9 yrs 
SMR=66 
(13-194) 
10-19 yrs 
SMR=94 
(40-185) 
≥20 yrs 
SMR=111 
(77-154) 
 
    Other 
Lymphati
c Tissue 
Employed 
<5 yrs=2 
Employed 
5-9 yrs=7 
Employed 
10-19 
yrs=5 
Employed 
≥20 
yrs=31 
 <5 yr 
SMR=40 
(4-147) 
5-9 yrs 
SMR=184 
(73-379) 
10-19 yrs 
SMR=75 
(24-176) 
≥20 yrs 
SMR=109 
(74-155) 
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Table 58 - Union Oil Company Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(Sathiaku
mar, 
Delzell et 
al. 
1995)Petr
oleum 
Company 
Case-
Control, 
Mortality
, 
(1976-
1990) 
284 
matched 
by year 
of birth  
(±2 
years) 
and 
(active 
employee
s who 
had 
worked 
for at 
least 1 
year or 
retired 
employee
s) 
69 cases of 
leukemia 
(any cohort 
member 
who had 
leukemia 
listed on 
death 
certificate. 
    For those 
individuals 
who died 
while 
actively 
working, 
they were 
matched 
with an 
actively 
working 
employee 
with the 
same birth 
year (±2 
years) and 
race.  For 
those 
individual
s who died 
after 
retirement
, they 
were 
matched 
by a birth 
year (±2 
years) and 
retiree 
status. 
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2.  Studies Conducted in Various Industries with Benzene Exposure 
 
(Please see the following pages for the charts containing various industrial studies)
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Table 59 - Various Industry Studies 
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
Highway Maintenance Workers 
(Bender, 
Parker et 
al. 1989) 
Highway 
Maintenan
ce Worker 
(HMW) 
Occupatio
nal 
Cohort, 
Mortality, 
01/01/45-
12/31/84 
White 
Male 
Minnesot
a 
Mortality 
Experienc
e 
4,849 men 
with 1 or 
more years 
of experience 
as a HMW 
for the 
Minnesota 
DOT 
Lymphore
ticular 
34 35.7 SMR=95 
(66-133) 
 
    Lymphos
arcoma 
7 6.2 SMR=113 
(45-233) 
 
    Hodgkin’
s Disease 
2 3.4 SMR=58 
(7-209) 
 
    Leukemia 17 15.9 SMR=107 
(62-171) 
 
    Multiple 
Myeloma 
3 5.7 SMR=53 
(11-155) 
 
    Other 
Lymphore
ticular 
5 4.5 SMR=110 
(36-257) 
 
Shoe Manufacturing Plants 
(Paci, 
Buiatti et 
al. 1989) 
Shoe 
manufactu
ring  plant 
Historical 
Cohort, 
Mortality, 
01/01/39-
12/31/84 
National 
Italian 
Mortality 
rates 
specific 
for cause, 
age, sex 
and 
calendar 
period, 
plus the 
mortality 
data bank 
of the  
World 
Health 
Organizat
ion. 
2,014 
individuals 
who worked 
or had ever 
worked at the 
plant during 
the period, 
but that were 
still 
employed in 
or after 
January 
1950. 
Leukemia Men=6 
Women= 
-  
Men
= 
1.5 
Wo
men
=0.9 
Men 
SMR=400 
(146-870) 
Women 
SMR=0 
(..) 
 
    Other 
Lymphati
c and 
Hematopo
ietic 
Neoplasm
s 
Men=1 
Women=
1 
Men
= 
1.8 
Wo
men
=0.9 
Men 
SMR=55 
(..) 
Women 
SMR=111 
(..) 
 
(Walrath, 
Decoufle 
Case-
Control, 
US 
Populatio
4,374 
deceased 
Lymphos
arcoma 
Male=13 
Female=9 
Male
= 
Male 
PMR=110 
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et al. 
1987) 
Shoe 
manufactu
ring 
company 
Mortality 
01/0160-
12/31/79 
n former 
employees 
who died 
during the 
period of 
time 
identified. 
and 
Reticulos
arcoma 
11.9 
Fem
ale=
5.3 
Female 
PMR=171 
    Hodgkin’
s Disease 
Male=3 
Female=2 
Male
= 
4.2 
Fem
ale=
1.7 
Male 
PMR= -  
Female 
PMR= -  
 
    Multiple 
Myeloma 
Male=10 
Female=8 
Male
= 
5.2 
Fem
ale=
2.3 
Male 
PMR=193 
Female 
PMR=346 
 
    Other 
Lymphati
c Tumors 
Male=10 
Female=6 
Male
= 
9.2 
Fem
ale=
4.1 
Male 
PMR=109 
Female 
PMR=148 
 
    Leukemia Male=22 
Female=7 
Male
= 
25.6 
Fem
ale= 
8.8 
Male 
PMR=86 
Female 
PMR=79 
 
(Lehman 
and Hein 
2006)  
2 Shoe 
manufactu
ring plants 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/40-
12/31/79 
US 
Populatio
n 
7,828 men 
and women 
who had 
worked at 
one of the 2 
plants for 
one  month 
or more 
during the 
period. 
Neoplasm
s of  
Lymphati
c and 
Hematopo
ietic 
Tissue 
Male=20 
Female=4
6 
Combine
d=66 
 Male 
SMR=0.74 
(0.45-1.15) 
Female 
SMR=1.10 
(0.81-1.47) 
Combined 
SMR=0.96 
(0.74-1.22) 
 
    Leukemia 
and 
Aleukemi
a 
Male=8 
Female=1
9 
Combine
d=27 
 Male 
SMR=0.72 
(0.31-1.42) 
Female 
SMR=1.22 
(0.74-1.91) 
Combined 
SMR=1.01 
(0.67-1.48) 
 
(Fu, 
Demers et 
al. 1996) 2 
Shoe 
manufactu
Retrospec
tive 
Cohort, 
Mortality, 
 
 Total: 6,223:  
4,215 male 
shoemakers 
from 
England and 
Non-
Hodgkin’
s 
Lymphom
a 
English=6 
Italian=2 
 English 
SMR=55 
(20-120) 
Italian 
SMR=106 
English 
cohort 
time 
period: 
1939-1991 
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ring plants 2,008 male 
and female 
shoemakers 
from Italy 
(13-382) – but only 
those alive  
in 1950 
could 
participate. 
Italian 
cohort: 
1939-
1984, but 
only those 
who had 
worked 
between 
1950-
1984. 
    Leukemia
s 
English=1
6 
Italian=8 
 English 
SMR=89 
(51-145) 
Italian 
SMR=214 
(92-421) 
 
    Multiple 
Myeloma 
English=8 
Italian=3 
 English 
SMR=104 
(45-206) 
Italian 
SMR=288 
(60-843) 
 
Filling or Service Stations 
(Lagorio, 
Forastiere 
et al. 
1994)   
Filling 
Station 
Attendants 
Cohort, 
Mortality, 
01/01/81-
07/31/91 
Regional 
Populatio
n 
2,665 service 
station 
managers in 
Italy – both 
men and 
women. 
Lymphoh
ematopoie
tic 
Men=5 
Women= 
-  
Total=5 
Men
= 
6.7 
Wo
men
=0.7 
Total
=7.3 
Men 
SMR=75 
(29-157) 
Women 
SMR= -  
( - ) 
Total 
SMR=68 
(27-143) 
 
    Non-
Hodgkin’
s 
Lymphom
a 
Men=3 
Women= 
-  
Total= - 3 
Men
= 
1.7 
Wo
men
=0.2 
Total
=1.9 
Men 
SMR=173 
(47-448) 
Women 
SMR= -  
( - ) 
Total 
SMR=158 
(43-408) 
 
    Leukemia Men=2 
Women= 
-  
Total=2 
Men
= 
3.3 
Wo
men
=0.3 
Total
=3.6 
Men 
SMR=61 
(11-192) 
Women 
SMR= -  
( - ) 
Total 
SMR=56 
(10-175) 
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(Lynge, 
Andersen 
et al. 
1997)  
Service 
Stations 
Cohort, 
Mortality, 
~15 years 
with start 
and end 
dates 
dependent 
upon 
country. 
National 
Incidence 
Rates 
19,000 
service 
station 
workers from 
Denmark, 
Norway, 
Sweden and 
Finland 
Non-
Hodgkin’
s 
Lymphom
a 
Male: 
D=8 
N=9 
S=18 
F=2 
T=37 
  
Female: 
D=1 
N=1 
S=0 
F=0 
T=2 
Male
: 
D=5.
98 
N=9.
25 
S=16
.90 
F=2.
47 
T=34
.60 
 
Fem
ale: 
D=1.
31 
N=1.
02 
S=1.
11 
F=0.
18 
T=3.
62 
Male: 
D SIR=1.3 
N SIR=1.0 
S SIR=1.0 
F SIR=0.8 
T SIR=1.1 
(0.8-1.5) 
Female: 
D SIR=0.8 
N SIR=1.0 
S SIR= -  
F SIR= -  
T SIR=0.6 
(0.0-2.0) 
Start and 
End Dates: 
Demark: 
11/09/70-
11/08/87 
Norway: 
01/01/71-
12/31/91 
Sweden: 
11/01/70-
12/31/89 
Finland: 
12/31/70-
12/31/85 
    Hodgkin’
s disease 
Male: 
D=3 
N=2 
S=5 
F=0 
T=10 
 
Female: 
D=0 
N=0 
S=0 
F=0 
T=0 
Male
: 
D=2.
86 
N=2.
00 
S=4.
85 
F=1.
03 
T=10
.24 
 
Fem
ale: 
D=0.
41 
N=0.
15 
S=0.
23 
F=0.
05 
T=0.
85 
Male: 
D SIR=1.3 
N SIR=1.0 
S SIR=1.0 
F SIR= -  
T SIR=1.0 
(0.5-1.8) 
Female: 
D SIR= -  
N SIR= -  
S SIR= -  
F SIR= -  
T SIR= -  
( - ) 
D=Denmar
k 
N=Norway 
S=Sweden 
F=Finland 
T=Total 
    Multiple 
Myeloma 
Male: 
D=2 
N=3 
S=3 
F=1 
Male
: 
D=2.
60 
N=5.
Male: 
D SIR=0.8 
N SIR=0.6 
S SIR=0.4 
F SIR=1.1 
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T=9 
 
Female: 
D=0 
N=0 
S=2 
F=0 
T=0 
 
35 
S=7.
13 
F=0.
91 
T=15
.99 
 
Fem
ale: 
D=0.
52 
N=0.
56 
S=0.
50 
F=0.
07 
T=1.
65 
T SIR=0.6 
(0.3-1.1) 
Female: 
D SIR= -  
N SIR= -  
S SIR=4.0 
F SIR= -  
T SIR= -  
( - ) 
    Leukemia Male: 
D=5 
N=9 
S=12 
F=0 
T=26 
 
Female: 
D=2 
N=0 
S=0 
F=0 
T=2 
Male
: 
D=6.
74 
N=6.
58 
S=13
.69 
F=2.
15 
T=29
.16 
 
Fem
ale: 
D=1.
32 
N=0.
63 
S=0.
88 
F=0.
16 
T=2.
99 
Male: 
D SIR=0.7 
N SIR=1.4 
S SIR=0.9 
F SIR= -  
T SIR=0.9 
(0.6-1.3) 
Female: 
D SIR=1.5 
N SIR= -  
S SIR= -  
F SIR= -  
T SIR=0.7 
( - 0.1-2.4) 
 
    Acute 
Myeloid 
Leukemia 
Male: 
D=1 
N=4 
S=8 
F=0 
T=13 
 
Female: 
D=0 
N=0 
Male
: 
D=2.
18 
N=2.
33 
S=3.
86 
F=0.
8 
Male: 
D SIR=0.5 
N SIR=1.7 
S SIR=2.1 
F SIR= -  
T SIR= 1.4 
(0.8-2.4) 
Female: 
D SIR= -  
N SIR= -  
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S=0 
F=0 
T=0 
T=9.
14 
 
Fem
ale: 
D=0.
57 
N=0.
26 
S=0.
33 
F=0.
1 
T=1.
23 
S SIR= -  
F SIR= -  
T SIR= -  
( - ) 
    Chronic 
Lymphati
c 
Leukemia 
Male: 
D=2 
N=2 
S=4 
F=0 
T=8 
 
Female: 
D=2 
N=0 
S=0 
F=0 
T=2 
Male
: 
D=2.
63 
N=1.
83 
S=5.
06 
F=0.
6 
T=10
.16 
 
Fem
ale: 
D=0.
34 
N=0.
14 
S=0.
24 
F=0.
0 
T=0.
75 
Male: 
D SIR=0.8 
N SIR=1.1 
S SIR=5.06 
F SIR= -  
T SIR=0.8 
(0.3-1.6) 
Female: 
D SIR=5.9 
N SIR= -  
S SIR= -  
F SIR= -  
T SIR=2.7 
(0.3-9.6) 
 
    All Other 
Leukemia 
Male: 
D=2 
N=3 
S=0 
F=0 
T=5 
 
Female: 
D=0 
N=0 
S=0 
F=0 
T=0 
Male
: 
D=1.
93 
N=2.
42 
S=4.
77 
F=0.
8 
T=9.
87 
 
Fem
ale: 
Male: 
D SIR=1.0 
N SIR=1.2 
S SIR= -  
F SIR= -  
T SIR=0.5 
(0.2-1.2) 
Female: 
D SIR= -  
N SIR= - 
S SIR= -  
F SIR= -  
T SIR= -  
( - ) 
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D=0.
41 
N=0.
23 
S=0.
33 
F=0.
1 
T=1.
04 
Printing 
(Zoloth, 
Michaels 
et al. 
1986) 
Printing 
Retrospec
tive 
Cohort, 
Mortality, 
01/01/58-
12/31/81 
US 
Populatio
n 
1,401 white 
male 
deceased 
commercial 
pressmen 
All 
Lymphati
c and 
Hematopo
ietic 
27 22.2 SMR=122 
(83-178) 
 
    Other 
Lymphati
c Cancer 
11 5.2 SMR=209 
(117-375) 
 
    Leukemia 
and 
Aleukemi
a 
9 10.0 SMR=89 
(47-173) 
 
Chemical Workers 
(Decoufle, 
Blattner et 
al. 1983) 
Chemical 
Plant 
Retrospec
tive 
Cohort,  
Mortality, 
01/01/47-
12/31/77 
US 
Populatio
n 
259 male 
employees 
who worked 
between 
01/01/47-
12/31/60 
Lymphati
c and 
Hematopo
ietic 
Tissue 
4 1.06 (1.09-
10.24) 
No SMR 
was given. 
(Arnetz, 
Raymond 
et al. 
1991) 
Petrochem
ical 
Commerci
al 
Research 
and 
Developm
ent 
Personnel  
Dynamic 
Cohort, 
Mortality 
Surveillan
ce Study, 
01/01/64-
12/31/86 
 
New 
Jersey 
Populatio
n 
13,250 
present and 
former New 
Jersey based 
employees in 
the Exxon 
Research and 
Engineering 
Company 
and the 
Chemical 
Technology 
Dept. of 
Exxon 
Chemical 
Co. 
Leukemia 
and 
Lymphati
c Cancer 
26 29.7 SMR=87 
(57-128) 
 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
2 5.3 SMR=37 
(4-135) 
 
    Hodgkin’
s Disease 
2 3.6 SMR=55 
(6-201) 
 
    Leukemia 8 12.1 SMR=66  
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and 
Aleukemi
a 
(28-130) 
    Cancer of 
all other 
Lymph. 
Tissue 
14 8.7 SMR=161 
(87-270) 
 
Sweden and Finland 
(Gustavsso
n, 
Hogstedt 
et al. 
1986) 
Rubber 
Industry 
Retrospec
tive 
Cohort, 
Mortality 
and 
Incidence, 
Morality: 
1952-
1981 
Cancer 
Incidence: 
1959-
1980 
National 
Populatio
n 
12,212  
workers from 
2 Swedish 
rubber 
manufacturin
g companies. 
Cause of 
death: 
Lymphom
a and 
Myeloma 
8 8.92 SMR=90 
(38-176) 
 
    Cause of 
Death: 
Leukemia 
6 6.58 SMR=91 
(33-198) 
 
    Incidence 
of 
Cancer: 
Multiple 
Myeloma 
5 3.90 SMR=128 
(41-299) 
 
    Incidence 
of 
Cancer: 
Leukemia 
7 7.46 SMR=94 
(37-193) 
 
(Jarvholm, 
Mellblom 
et al. 
1997)  
Transport 
and 
Refinery 
Industry 
Retrospec
tive 
Cohort, 
Morbidity
, 
1958-
1987 
General 
populatio
n 
4,128 Men 
and 191 
women who 
had worked 
at least one 
year in the 
petroleum 
industry 
Lymphom
a 
≥1 y; ≥1 
y=9 
≥1 y; ≥20 
y=3 
≥10 y; 
≥20 y=2 
 ≥1 y; ≥1 y 
SIR=0.93 
(0.48-1.6) 
≥1 y; ≥20 y 
SIR=0.65 
(0.18-1.7) 
≥10 y; ≥20 
y SIR=0.48 
(0.08-1.5) 
Explanatio
n of  
categories: 
Duration 
of 
exposure; 
time since 
onset of 
exposure 
≥1 y; ≥1 y 
≥1 y; ≥20 
y 
≥10 y; ≥20 
y 
    Leukemia ≥1 y; ≥1 
y=6 
≥1 y; ≥20 
y=3 
≥10 y; 
≥20 y=3 
 ≥1 y; ≥1 y 
SIR=1.4 
(0.59-2.7) 
≥1 y; ≥20 y 
SIR=1.4 
(0.39-3.7) 
≥10 y; ≥20 
y SIR=1.5 
Data 
presented 
is on males 
only.  No 
data was 
available 
for 
females. 
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(0.41-3.9) 
(Pukkala 
1998) 
Oil 
refinery 
Retrospec
tive 
Cohort, 
Morbidity
, 
01/01/71-
12/31/94 
Finish 
populatio
n. 
7,512 men 
and 1,942 
women 
Hodgkin’
s Disease 
7 5 SMR=1.35 
(0.54-2.79) 
 
    Non-
Hodgkin’
s 
Lymphom
a 
12 10 SMR=1.24 
(0.64-2.17) 
 
    Leukemia 9 9 SMR=1.02 
(0.47-1.93) 
 
Italian 
(Dario 
Consonni 
1999)Petro
leum 
Refinery 
Industry 
Retrospec
tive 
Follow-up 
Cohort,  
Mortality, 
01/01/49-
12/31/82 
 
Lombard
y Region 
Populatio
n 
1,583 male 
workers  
Lymphati
c and 
Hematopo
ietic 
15 8.4 SMR=179 
(100-295) 
 
    Lymphom
a 
7 3.7 SMR=190 
(76-391) 
 
    Hodgkin’
s Disease 
2 1.3 SMR=151 
(17-544) 
 
    Non-
Hodgkin’
s 
Lymphom
a 
5 2.4 SMR=212 
(68-495) 
 
    Leukemia 8 3.6 SMR=225 
(97-443) 
 
UK 
(Sorahan, 
Kinlen et 
al. 2005) 
Plant 
workers 
Retrospec
tive 
Historical  
Cohort, 
Mortality, 
01/01/68-
12/31/02 
Serial 
mortality 
rates for 
England 
and 
Wales 
5,514 (5,130 
men and 384 
women) 
individuals 
who had 
been exposed 
at work to 
benzene  
Hodgkin’
s Disease 
3 2.8 SMR=108 
(22-317) 
Workers 
came from 
factories in 
Wales and 
in 
England. 
    Non-
Hodgkin’
s 
Lymphom
a 
15 15.9 SMR=94 
(53-156) 
 
    Multiple 
Myeloma 
6 9.5 SMR=63 
(23-137) 
 
    Leukaemi
a 
22 16.1 SMR=137 
(86-207) 
 
    Lymphoid 5 5.05 SMR=99  
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Leukaemi
a 
(32-231) 
    Acute 
Lymphoid 
Leukaemi
a 
0 0.83 SMR=0 
(0-444)) 
 
    Chronic 
Lymphoid 
Leukaemi
a 
5 4.04 SMR=124 
(40-289) 
 
    Other/Uns
pecified 
Lymphoid 
Leukaemi
a 
0 0.18 SMR=0 
( - ) 
 
    Myeloid 
Leukaemi
a 
14 9.41 SMR=149 
(81-250) 
 
    Acute 
Myeloid 
Leukaemi
a 
12 6.60 SMR=182 
(94-318) 
 
    Chronic 
Myeloid 
Leukaemi
a 
2 2.57 SMR=78 
(9-281) 
 
    Other/Uns
pecified 
Myeloid 
Leukaemi
a 
0 0.24 SMR=0 
( - ) 
 
    Monocyti
c 
Leukaemi
a 
0 0.34 SMR=0 
( - ) 
 
    Acute 
Monocyti
c 
Leukaemi
a 
0 0.25 SMR=0 
( - ) 
 
    Chronic  
Monocyti
c 
Leukaemi
a 
0 0.05 SMR=0 
( - ) 
 
    Other/Uns
pecified 
Monocyti
c 
Leukaemi
a 
0 0.04 SMR=0 
( - ) 
 
    Other and 
Unspecifi
ed Cell 
Types 
3 1.28 SMR=234 
(48-685) 
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    Acute 
Other and 
Unspecifi
ed Cell 
Types 
2 0.80 SMR=250 
(30-904) 
 
    Chronic 
Other and 
Unspecifi
ed Cell 
Types 
1 0.05 SMR=1843 
(47-10271) 
 
    Other and 
Unspecifi
ed Cell 
Types 
0 0.43 SMR=0 
( - ) 
 
    Acute 
Non-
Lymphoc
ytic 
Leukaemi
a (ANLL) 
14 7.65 SMR=183 
(100-307) 
 
    All 
Leukaemi
as 
excluding 
ANLL 
8 8.43 SMR=95 
(41-187) 
 
Oil, Chemical and Atomic Workers International Union (OCAW Union) 
(Thomas, 
Decoufle 
et al. 
1980) 
Petroleum 
Refining 
and 
Petrochem
ical Plants 
Cause-
Specific 
Mortality, 
1947-
1977 
US 
General 
Populatio
n and 
Texas 
Male 
Populatio
n 
3,105 active 
deceased 
members of 
the OCAW 
Union 
Lymphati
c and 
Hematopo
ietic 
Tissue 
White 
Males=63 
Non-
White 
Males=7 
Whit
e 
Male
s=54
.4 
Non-
Whit
e 
Male
s=6.
3 
White 
Males 
PMR=1.16 
Non-White 
Males 
PMR=1.11 
 
(Thomas, 
Waxweiler 
et al. 
1984) Oil 
Refineries 
Proportio
nate 
Mortality 
Study, 
 
Active 
and 
Retired 
union 
members 
who 
worked at 
the same 
refinery, 
were of 
the same 
race and 
sex and 
died of 
other 
causes.   
2,132 
deceased 
members of 
the OCAW 
Union 
employed in 
three Texas 
Oil 
Refineries. 
Leukemia 34 
(employe
d at least 
1 day, 
with a 
median 
duration 
employed 
28.2 
years) 
96 
(emp
loye
d at 
least 
1 
day, 
with 
a 
medi
an 
durat
ion 
empl
oyed 
31.8 
years
) 
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DOW Chemical  
(Bond, 
McLaren 
et al. 
1987) 
Chemical 
Company 
Cause-
Specific 
Mortality, 
01/01/40-
12/31/82 
US, 
Michigan 
or Seven 
Local 
Counties 
37,682 male 
employees 
with 3 or 
more days of 
service at 
Midland or 
Bay City, 
Michigan 
locations of 
Dow 
Chemical.  
(Majority 
were hourly 
workers) 
Lymphati
c and 
Hematopo
ietic 
Cancer 
114 US= 
100.
7 
MI= 
107.
6 
7C= 
111.
1 
US 
SMR=113 
MI 
SMR=106 
7C 
SMR=103 
US=United 
States 
MI=Michi
gan 
7C=7 
Counties 
    Lymphos
arcoma 
and 
Reticulos
arcoma 
21 US=
18.4 
MI=
18.8 
7C=
20.4 
US 
SMR=114 
MI 
SMR=112 
7C 
SMR=103 
 
    Hodgkin’ 
Disease 
5 US=
8.7 
MI=
9.3 
7C=
10.8 
US 
SMR=57 
MI 
SMR=54 
7C 
SMR=46 
 
    Leukemia 
and 
Aleukemi
a 
49 US=
37.6 
MI=
42.2 
7C=
42.1 
US 
SMR=130 
MI 
SMR=116 
7C 
SMR=116 
 
    Cancer of 
Other 
Lymphati
c Tissue 
37 US=
32.5 
MI=
35.7 
7C=
37.1 
US 
SMR=114 
MI 
SMR=104 
7C 
SMR=100 
 
Rubber Industry 
(Monson 
and 
Nakano 
1976) 
Rubber 
Industry 
Mortality 
Experienc
e, 
01/01/40-
06/30/74 
US White 
Males 
13571 white 
male rubber 
workers in an 
Akron, OH 
rubber plant. 
Lymphati
c and 
Hematopo
ietic 
4 3.8   
(Monson 
and 
Nakano 
1976) 
Rubber 
Industry 
Mortality 
Experienc
e, 
01/01/40-
06/30/74 
US 
Populatio
n 
5816 
Females, 986 
black males 
and 3727 
white 
salaried 
males in an 
Akron, OH 
rubber Plant.  
Lymphati
c and 
Hematopo
ietic 
14 11.8   
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(Delzell 
and 
Monson 
1981) 
Rubber 
plant 
Cause-
Specific 
Mortality, 
01/01/40-
07/01/78 
US 
Populatio
n 
29,087 men 
and women 
who worked 
at least 2 
years at a 
large rubber 
manufacturin
g facility.   
Lymphati
c and 
Multiple 
Myeloma 
WM=76 
NW=6 
F=11 
SM=15 
SF=10 
 WM 
SMR=109 
(86-137) 
NW 
SMR=171 
(62-372) 
F SMR=74 
(37-133) 
SM 
SMR=101 
(57-167) 
SF 
SMR=88 
(42-162) 
WM=Whit
e Male 
F=All 
Females 
NW=Non-
White 
Male 
SM=Salari
ed Males 
SF=Salarie
d Females 
    Leukemia WM=68 
NW=no 
data 
provided 
F=8 
SM=7 
SF=1 
 WM 
SMR=121 
(94-153) 
NW 
SMR=no 
data 
provided 
F SMR=79 
(34-156) 
SM SMR= 
139 
(56-287) 
SF 
SMR=29 
(1-162) 
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Table 60 - Meta Analysis  
Author/Y
ear 
Industry 
& 
Workers 
Study 
Type 
Endpoint 
& 
Years 
Comp 
pop 
Total 
Pop 
(#) 
Disorder Cases 
(#) 
Cont
rol 
(#) 
Statistical 
Measure  
CI or p-
value 
Comment
s 
(Wong and 
Raabe 
1989) 
Petroleum 
Industry 
Over 100 
studies 
were 
examined 
Different 
for each 
study 
Different for 
each study 
    Multiple 
studies 
compared, 
with a  
quantitativ
e meta-
analysis by 
cancer site. 
    Lymphop
oietic 
460 448.
71 
SMR=1.03 
(0.94-1.13) 
p-
value=0.85 
MIN 
SMR=1.12 
    Lymphos
arcoma 
97 111.
75 
SMR=0.87 
(0.71-1.06) 
p-
value=0.16 
MIN 
SMR=1.25 
    Leukemia 279 253.
54 
SMR=1.10 
(0.97-1.23) 
p-
value=0.10 
MIN 
SMR=1.16 
    Other 
Lymphati
c Tissue 
122 106.
39 
SMR=1.15 
(1.15-0.95) 
p-
value=0.13 
MIN 
SMR=1.25 
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C. Evaluation of Animal Studies with Quantitative Exposure 
 
1.  Sub-chronic Toxicity in Animals  
 
Animal studies have revealed that mice are more sensitive to hematopoietic insult by 
benzene than rats. (Zhu, Li et al. 1995; Henderson 1996)   While all species appear to have 
similar mechanisms of detoxification, mice have greater capacity, relative to their size, for 
metabolism versus either monkeys or rats.  Mice preferentially metabolize more benzene to 
hydroquinone metabolites, particularly at low doses.  However, in all non-human species a 
greater portion of benzene is converted to hydroquinone and other ring-breaking metabolites 
at lower doses.  This potentially presents problems when attempting to extrapolate studies 
utilizing a “high” dose of benzene to the predicted toxicity at a “low” dose.  In addition, it 
has been noted that mice bone marrow stromal cells are more susceptible to cytotoxicity 
induced by hydroquinone and benzoquinone.  This may be the result of decreased (50%) 
glutathione levels and quinine reductase (28 times less) activity in mice stromal cells versus 
rat stromal cells. (Zhu, Li et al. 1995) There are significant intra-species and strain 
differences in rodents, which makes comparison of results challenging, and in many cases, 
impossible.    
The simplest parameters to evaluate in human and animal studies of hematopoiesis 
are measures in peripheral blood, including erythroctytes and lymphocytes.  A number of 
studies have measured these values in benzene exposed animals.  Baarson and colleagues 
exposed C57Bi mice to 10 ppm for 6 hours a day, 5 days a week (Baarson, Snyder et al. 
1984).  They saw a gradual decrease in a erythroid progenitor cell, the colony-forming unit-
erythroid (CFU-E) after 178 days of exposure.  Prior to that point, they saw a 45% depression 
of burst forming cell growth at 66 days that returned to control level at 178 days.  In addition, 
the animals had a depression of splenic nucleated red cells, circulating red blood cells, as 
well as circulating lymphocytes.       
In 1978, researchers at New York University began reporting on various 
hematological abnormalities following benzene exposure.  In the first study, Sprague-Dawley 
rats and AKR/J mice were exposed to 300ppm benzene for 6 hours a day, 5 days a week for 
life (Snyder, Goldstein et al. 1978b).  The rats developed lymphocytopenia, mild anemia, and 
moderately decreased survival. The mice also had severe lymphocytopenia, as well as anemia 
accompanied by granulocytosis and reticulocytosis. There was no indication of leukemia or 
preleukemia in any animals.  In a follow-up study reported in 1980, AKR/J and C57BL/6J 
mice were given duplicate lifetime exposures for 100ppm and 300ppm, respectively (Snyder, 
Goldstein et al. 1980).  All of the AKR mice had anemia and lymphocytopenia, and 20% 
developed bone marrow hypoplasia (2% in controls).  However, these abnormalities were not 
as severe as those seen at 300ppm.  The C57BL/6J mice had anemia, lymphocytopenia and 
neutrophilia with a left shift.  Thirty-three percent of animals   developed bone marrow 
hypoplasia.  Snyder et al. also reported significant hematological abnormalities in a study of 
Sprague-Dawley rats and three species of mice (CD-1, AKR, C57BL) exposed to either 
100ppm or 300 ppm for 6 hours a day, 5 days a week for life (Snyder, Erlichman et al. 1981).  
All of the mice exposed at 300ppm had decreased survival, blood lymphocytopenia and 
neutrophilia with intermittent immature granulocytes.  At 100ppm, the AKR mice had blood 
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lymphocytopenia and anemia.  The rats exposed to 300ppm had slightly decreased survival 
and peripheral lymphocytopenia.  This same group of researchers reported myeloblast and 
promyelocyte proliferation in the bone marrow of male CD-1 mice exposed to 300ppm 
benzene for 6 hours a day, 5 days a week for 26 weeks (Snyder, Green et al. 1981).  Utilizing 
this same exposure protocol (300 ppm), they also found significantly (± 2 S.E.) depressed 
levels of peripheral red blood cells and lymphocytes (Snyder, Goldstein et al. 1982).   This 
was in addition to Howell-Jolly bodies at 7 days, anisocytosis after 22 days, poikilocytosis at 
92 days and a shift to immature myeloid cells at 217 days.  (Howell-Jolly bodies are 
basophilic DNA remnants found in circulating red blood cells. Typically, they are removed 
by the spleen.  Anisocytosis is different size red blood cells, typically found in anemia.  
Poikilocytosis is evidence of abnormally shaped red blood cells.)  Neoplasia free animals 
also had a higher incidence of bone marrow hypoplasia and bone marrow hyperplasia 
compared to control animals.      
Another research group, Cronkite and colleagues, exposed C57B1/6 mice to 10, 25 
and 100 ppm for 6 hours a day, five days per week for 2 weeks (Cronkite, Drew et al. 1985).  
The animals in the 10 and 25 ppm groups did not have any decrease of nucleated cells in 
bone marrow, decrease in stem cells (CFU) or decrease in stem cells synthesizing DNA.  At 
100ppm there was significant (p<0.001) depression of bone marrow cellularity and number 
of stem cells.  However, there was a slight (non-significant) increase in the fraction of stem 
cells in DNA synthesis. At 400ppm there was also a significant (p<0.0004) decrease in stem 
cells and a non-significant increase in stem cells in DNA synthesis.  In a previous study of 
400ppm for up to 9.5 weeks, bone marrow cellularity  and stem cell count were also 
depressed (Cronkite, Inoue et al. 1982).  However, stem cells in DNA synthesis were 
significantly increased.  There was also significant depression of red and white blood cells 
throughout the exposure, which persisted for at least 14 days after the cessation of exposure.  
In the 1984 study, following inhalation of 10, 25, 100 or 400ppm for 6 hours a day, 5 days a 
week for 2 weeks, there was no significant effect on hematocrit at 10 or 25ppm.  At 100 and 
400ppm, there was a significant effect with a dose-effect relationship.  There was no effect 
on lymphocytes at 10ppm; however, there was a dose-effect relationship with higher doses.  
No effect on granulocytes was noted at any dose.  In another arm of the same study, stem cell 
numbers were evaluated after exposure to 300ppm benzene for 2, 4, 8 or 16 weeks.  There 
was no effect after 2 or 4 weeks.  At 8 weeks of exposure, the stem cell numbers were ~50% 
of age matched controls.  Three days after 16 weeks of exposure the stem cell numbers were 
27% of controls, but this increased to 60% at 16 weeks post exposure and 92% at 25 weeks 
post exposure.  Blood lymphocytes did not show any effects after 2 weeks of exposure to 
300ppm benzene.  Following 4 weeks of exposure, there was a significant deficit of blood 
lymphocytes at 2 and 4 weeks post exposure which resolved by 8 and 16 weeks post 
exposure.  The same was true after 8 weeks of exposure (p<0.0002).  After 16 weeks of 
exposure, this was also the case (p<0.008).  In a 1989 study, Cronkite et al. exposed CBA/Ca 
mice to 10, 25, 100, 300, 400, and 3000 ppm for 6 hours a day, 5 days a week for 2-16 weeks 
(Cronkite, Drew et al. 1989). Two weeks of inhaling 10 ppm produced no hematologic 
effects, while 25 ppm induced a significant lymphopenia. Inhalation of 100, 300, and 400 
ppm produced dose-dependent decreases in blood lymphocytes, bone marrow cellularity, 
marrow content of spleen colony-forming units (CFU-S) and an increased fraction of CFU-S 
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in DNA synthesis. Exposure to 300 ppm for 2, 4, 8, and 16 weeks produced severe 
lymphopenia and decrease in bone marrow CFU-S. Recovery was rapid and complete after 2 
and 4 weeks of exposure. However, after 8 and 16 weeks of exposure, recovery of 
lymphocytes took 8 weeks. It took 16 weeks for the CFU-S to recover to that of the age-
matched controls after 8 weeks of exposure and 25 weeks to recover to age-matched after 16 
weeks of exposure. Interestingly, the authors also examined damage Inhalation of 3000 ppm 
for 8 days created less hematological damage than inhalation of 300 ppm for 80 days.  It was 
suggested that saturation of metabolizing enzymes with 3000 ppm resulted in reduced 
metabolites and resultant hematotoxicity.     
In a study involving CD-1 mice and Sprague Dawley rats, inhalation exposure to 1, 
10, 30 and 300 ppm benzene for 6 hours a day, five days per week for 13 weeks produced 
significant hematological changes at 300 ppm (Ward, Kuna et al. 1985). The findings in mice 
included decreased hematocrit, total hemoglobin, erythrocyte count, leukocyte count, platelet 
count and myeloid/erythrocyte ratio, while the rats only showed a decrease in lymphocyte 
count and a slight increase in neutrophil count.  Histopathological changes noted in the mice 
included myeloid hypoplasia of the femoral bone marrow and slightly decreased marrow 
cellularity in rats.  It was noted that in male mice the incidence, severity and timing (earlier) 
was greater.  This is in direct contrast to earlier research which indicated a greater 
susceptibility to hematological abnormalities in female rats and mice, following benzene 
exposure (Leong 1977).  
In 1996, Farris and colleagues evaluated benzene-induced hematotoxicity following 
exposure to a low concentration of benzene (Farris, Robinson et al. 1996). Male B6C3F1 
mice were exposed to 0, 1, 10, 100, or 200 ppm benzene by inhalation for 6 hours a day, five 
days per week for 1, 2, 4, or 8 weeks. At each milestone, they evaluated primitive and 
committed progenitor cells, differentiating and maturing lineage-specific cells, and stromal 
cells in the bone marrow; T and B lymphocytes of the spleen and thymus; micronucleated 
reticulocytes and erythrocytes; and standard blood parameters.  At the regulatory limit of 
1ppm, there was no significant effect on any parameter.   At 10 ppm, the only parameter 
affected was a transient reduction in the number of splenic B lymphocytes.  This value 
reverted to the control value by 4 weeks.  At 100 and 200 ppm benzene, there were rapid (5 
day) and significant reductions in number of reticulocytes in the blood, B lymphocytes in the 
bone marrow and spleen, and an increased frequency of micronucleated reticulocytes in the 
bone marrow. At 100 ppm, there was a return towards control values at week 8 versus those 
values noted at 2 and 4 weeks.  This indicated compensation of the bone marrow to 
continued exposure.  At two weeks of exposure to 100 ppm benzene, the B lymphocytes 
were 26% of control and at 8 weeks 38%.  Once again, this was viewed as evidence of 
compensation by increased progenitor cell replication and replenishment.  This same research 
group re-examined a similar question in a paper the following year.  Once again B6C3F1 
mice were exposed to benzene; however, a 5ppm dose was added.  There were no significant 
effects on hematopoietic measures at ≤ 10 ppm.  At 100 and 200 ppm, benzene reduced the 
total number of bone marrow cells, progenitor cells, differentiating hematopoietic cells, and 
most blood parameters. Replication of primitive progenitor cells in the bone marrow was 
increased during the exposure period as a compensation for the cytotoxicity induced by 100 
and 200 ppm benzene. In mice exposed to 200 ppm benzene, the primitive progenitor cells 
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maintained an increased percentage of cells in S-phase through 25 days of recovery 
compared with controls. The authors suggested that these processes were a plausible mode of 
action for benzene-induced leukemia in humans exposed to high concentrations.    In a 
related study, they found that B6C3F1 mice exposed to 100–200 ppm benzene for eight 
weeks showed persistent reductions in femoral bone marrow B-lymphocytes, splenic T- and 
B-lymphocytes, as well as, Thymic T-lymphocytes (Farris, Robinson et al. 1997).  The 
percentage of apoptotic femoral B-lymphocytes and thymic T-lymphocytes was increased 6 
and15-fold by 200 ppm benzene.  At both 100 and 200 ppm exposure femoral B-
lymphocytes were increased in a compensatory fashion.   At ≤10 ppm benzene there was no 
significant effect on the numbers or replication of the lymphocyte populations.  The authors 
concluded that a reduced number of splenic B-lymphocytes after 2 weeks of exposure to 
benzene appeared to be the most sensitive end point and time point for evaluating benzene 
cytotoxicity in this study. 
A number of additional research groups have examined the effects of benzene 
exposure on the immune system.  At 50 ppm of inhaled benzene for 6 hours a day and 7 
consecutive days, Aoyama found that BALB/c mice T and B lymphocyte levels in both the 
blood and spleen were depressed.  The level of B lymphocytes was dose dependent and more 
intense than that of T lymphocytes. The ability to form antibodies was suppressed by 
benzene at all exposure levels, but the cell mediated immune response was resistant to 
benzene inhalation and actually enhanced at 200 ppm exposure for 14 days.  Rozen et al. 
reported a significant decrease in bone marrow B-lymphocytes, splenic B-lymphocytes, as 
well as thymic and splenic T-lymphocytes in male C57BL/6J mice exposed to 300 ppm for 6 
hours a day, five days a week after 6, 30, and 115 days of exposure (Rozen and Snyder 
1985).  In addition, mitogen-induced proliferation of B-lymphocytes in the thymus and 
spleen were progressively depression to zero at the 115th exposure.  Bone marrow cellularity 
increased 3-fold and the numbers of thymic T-cells increased 15-fold in benzene-exposed 
mice between the 6th and 30th exposure.  Prior to that study, they had found depressed 
mitogen-induced blastogenesis of B-lymphocytes in male B57BL mice exposed to 6 days for 
6 hours a day of 10ppm benzene, although the overall number of B-lymphocytes was not 
decreased (Rozen, Snyder et al. 1984).  At 31ppm for the same time period, splenic T-
lymphocyte mitogen-induced blastogenesis was significantly reduced.   
 
 
2. Carcinogenicity in Animals 
 
Although data from animal models are frequently used in risk assessments, including 
benzene, it must be understood that extrapolation from animal studies to humans is fraught 
with potential error and misunderstandings.  For instance, some of the earliest animal studies 
by Maltoni and colleagues indicated significant elevation of Zymbal gland carcinomas in 
Sprague-Dawley rats (Maltoni, Cotti et al. 1982).  With that said, humans do not have a 
Zymbal gland and therefore this finding is of questionable relevance to human 
carcinogenesis.  In further work, Maltoni and colleagues reported additional cancers in 
Sprague Dawley rats, (carcinomas of the oral cavity, carcinomas of the nasal cavities, 
carcinomas of the skin, hepatocarcinomas and increased incidence of total malignant tumors) 
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as well as, cancers in Swiss mice (Zymbal gland carcinoma, mammary carcinomas in 
females, lung tumors and increased total malignant tumors (Maltoni and Scarnato 1979; 
Maltoni, Conti et al. 1982; Maltoni, Cotti et al. 1982; Maltoni, Conti et al. 1983; Maltoni, 
Conti et al. 1985; Maltoni, Conti et al. 1988; Maltoni, Ciliberti et al. 1989).  Through this 
data, and that of additional research groups in the United States (Huff, Haseman et al. 1989), 
it was concluded that benzene is a multipotential rodent carcinogen that can produce 
cancerous lesions in multiple species and organs by different routes, including ingestion, 
injection and inhalation.  Early studies looking for evidence of benzene-induced 
myelogenous leukemia in laboratory animals, did not find any evidence of leukemogenesis at 
a variety of doses and routes in mice, guinea pigs, rats and rabbits (Ward, Weisburger et al. 
1975; Leong 1977)  
In 1982, Goldstein and Snyder reported four cases of myelogenous leukemia in rats 
and mice (Goldstein, Snyder et al. 1982).  Sprague-Dawley rats, AKR mice, C57B1 mice and 
CD-1 mice were exposed to either 100ppm or 300ppm of inhaled benzene for 6 hours a day, 
five days a week for life.  Semimonthly hematological surveys were drawn in 10 animals in 
each group, including the control group.  As noted in previous studies, mice were more 
susceptible to the aplastic effects of exposure, particularly the AKR strain (Snyder, Goldstein 
et al. 1980).  Although not statistically significant, one Sprague-Dawley rat developed 
chronic myelogenous leukemia at 100 ppm during the 35th week of exposure.  In addition, 
three CD-1 mice developed myeloproliferative disorders, including 1 case of acute (exposure 
week 29) and 1 case of chronic myelogenous (exposure week 26) leukemia, as well as, 1 case 
of granulocytic hyperplasia (exposure week 38).  All cases occurred in the 300ppm group.  
Sprague-Dawley rats and CD-1 mice are not known to have a background rate of 
myelogenous leukemia, and it was assumed by the authors that their findings were related to 
benzene exposure.         
Further research by another group, Cronkite et al. reported an increase of leukemia in 
female C57B1/6 mice following a 16 week exposure to 300ppm for 6 hours a day and 5 days 
per week (Cronkite, Bullis et al. 1984).  Unlike earlier studies which utilized lifetime 
exposures, this study allowed for hematopoietic recovery.  At 64 weeks, 8% of exposed 
animals had thymic lymphoma.  Although the authors described lymphoma-leukemia, both 
entities were collated in one group “leukemia”.  There was no evidence that animals had 
myelogenous “leukemia” in the exposed groups; however, the sham exposure groups had 
three cases.  C57B1/6 mice carry a radiation leukemia virus which makes them susceptible to 
thymic lymphomas.  Cronkite and colleagues also found an increase in myelogenous 
(resembles acute myeloblastic and chronic granulocytic) leukemia following the inhalation of 
300ppm benzene 6 hours a day for 16 weeks in male CBA/Ca mice (Cronkite, Drew et al. 
1989).  This increased incidence appeared shortly after exposures started.  Eventually, 19.3% 
of animals developed a myelogenous neoplasm.  Inhalation of 100 ppm benzene for the same 
exposure period did not significantly increase (2.4 exposed, 0.0 control, p=0.19) the 
incidence of myelogenous leukemia.  The authors concluded, 
 
Our data suggest that there may be an effective time-dose relation (or 
concentration) of benzene that may not increase the incidence of myelogenous 
neoplasms, but will induce other neoplasms.  Our data suggest that exposure 
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to 100ppm benzene 6hr/day, 5 days/week for 16 weeks may be close to such a 
time-dose threshold for myelogenous leukemias. 
 
Farris et al. exposed CBA/Ca mice to 300 ppm benzene via inhalation for 6 hours a 
day, 5 days per week for 16 weeks and then maintained the exposed and control groups for 
18 months (Farris, Everitt et al. 1993).  Fourteen exposed animals developed lymphoma 
(lymphoblastic, lymphocytic, or mixed) as compared to only 2 sham-exposed mice. Moderate 
to marked granulocytic hyperplasia was present in exposed animals (36% in bone 
marrow/6% in spleen), compared to control levels of 8% and 0% respectively.  There were 
no cases of granulocytic leukemia sham-exposed with 8 and 0%, respectively. Interpretation 
of the granulocytic response as a direct effect of benzene was complicated by the presence of 
inflammation in the mice. Although inhaled benzene was clearly carcinogenic in CBA mice, 
it did not induce granulocytic leukemia. 
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Chapter Four: Discussion 
 
1.  General Comments from this Investigation 
 
In the course of conducting this research, over 450 scientific articles and studies on 
benzene exposure, health effects, biomarkers and physiology were critically evaluated.  Of 
these 450, approximately 50 articles were critical to understanding the issue of a possible 
threshold dose associated with benzene exposure.  Most important are the seven groups of 
human studies that have compared the measured or estimated dose of average and cumulative 
benzene dose to the risk of hematologic neoplasm formation.  These seven groups included:  
1) The Pliofilm Cohort, 2) The Chinese (NCI-CAPM) Study Series, 3) The Chemical 
Industry Studies, 4) The Australian Petroleum Industry Studies, 5) The United Kingdom 
Petroleum Industry Studies, 6) The Canadian Petroleum Industry Studies and 7) Various 
Small Studies (The Caprolactam, Shoe Workers and Gas/Electric Utility Studies).  In 
addition, a large number of qualitative studies that did not measure or estimate exposure were 
analyzed to understand the prevailing evidence which suggests that only acute myelogenous 
leukemia (and closely related acute non-lymphocytic leukemia) is associated with benzene 
exposure.  This close association with only myelogenous leukemia is further substantiated by 
the fact that myelogenous leukemia has been found to “drive” the risk of leukemia.  From a 
mechanistic standpoint this also makes sense, as hydroquinone, a benzene metabolite 
increases the recruitment and propagation of myeloid progenitor cells (Irons, Stillman et al. 
1992).  Following evaluation of the human studies, relevant animal research was examined.  
It was clear from this extensive analysis that not all studies are created equally, and close 
scrutiny is required to elucidate proven facts from suggestive anomalies or artifacts of 
statistical evaluation, i.e. – significance is the guidepost to eliminating chance as long as 
study power is adequate to support the conclusions.  
Prior to any discussion regarding a possible threshold dose of benzene, I believe it is 
in imperative to restate some of the obvious limitations in the data set.  The most glaring item 
that is present in every single human study is the difficulty in retrospectively assigning 
exposure assessments.  This is particularly true for the Pliofilm cohort.  At this point, there 
are several “interested” parties that trade upon the continuing refinement of the exposure 
assessment process.  There does not appear to be any more information that will be 
discovered, so continuing efforts will focus on the interpretation of what is known and 
unknown.   
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2.  Results from the Seven Quantitative Groups and the Animal Studies 
 
In summary, the authors of the human studies with a quantitative exposure 
assessment came to the following conclusions: 
1. The Pliofilm Cohort – There are three generally accepted exposure matrices that each 
generate different levels of risk; however, all consistently reveal a statistically 
significant relationship with leukemia mortality.  Up through 1996, there were 22 (10 
acute myeloid line, 1 myeloid–unspecified, 3 chronic myeloid line, 1 acute lymphoid 
and 2 unspecified) leukemia cases and 8 multiple myeloma cases.  Regardless of the 
exposure matrix utilized, none of the three exposure matrices (Rinsky, Crump & 
Allen and Paustenbach) shows a significant elevation of leukemia risk at <50 ppm 
year (Paxton, Chinchilli et al. 1994).  When further refined to only acute 
myelogenous leukemia, significance is only achieved at >200 ppm-years (Wong 
1995). 
2. The Chinese (NCI-CAPM) Study Series – The authors of the 1997 case-control study 
found a non-significant elevation of acute non-lymphocytic leukemia (2.0 95% CI: 
0.6 – 7.0) in (7) cases with <10 ppm average exposure and a non significant elevation 
of risk in cases (5) exposed for <40 ppm-years (1.9 95% CI: 0.5 – 7.0).  Significance 
was only achieved with cumulative exposure to 40-99 ppm-years (4.2 95% CI: 1.1-
11.6) (Hayes, Yin et al. 1997).   
3. The Chemical Industry Studies - (Dow Chemical) In the initial study published in 
1978, there was a non-significant rise in leukemia (3 cases of myelocytic) at 
estimated cumulative doses of 45.4, 1.5 (The individual only worked for 18 months at 
<2 ppm TWA.) and 25.4 ppm-years (Ott, Townsend et al. 1978). A follow-up study 
found a non-significant rise in all leukemia; however, four of the cases were 
myelogenous and this was a significant finding (p=0.011) (Bond, McLaren et al. 
1987).  The forth case was in addition to the three previously found in the first study 
and the individual had an estimated cumulative exposure of 351 ppm-years.  A final 
follow-up in 2004 found no new cases of ANLL and the SMR was non-significant 
(1.11 95% CI: 0.30 – 2.83) (Bloemen, Youk et al. 2004).  At all levels of cumulative 
exposure (<28.3, 28.3-79.1 and >79.1 ppm-years) there was a non-significant 
elevation of risk.  (Monsanto/Salutia) The initial study in 1997 reported a non-
significant elevation in leukemia (SMR=2.3 95% CI: 0.7 – 5.3) and multiple 
myeloma (SMR=2.3 95% CI: 0.7-9.4).  Three workers with leukemia were exposed 
to benzene at ≥6 ppm-years (SMR=4.6 95% CI:0.9 – 13.4), as was one worker ANLL 
(SMR=4.5, 95% CI: 0.1 – 25.3) (Ireland, Collins et al. 1997).  In a 2003 follow-up 
study, the authors suggested that peak exposure frequency was a better predictor of 
risk than cumulative exposure (Collins, Ireland et al. 2003).  At >40 days of >100 
ppm peak exposure there was a non-significant elevation of ANLL (SMR=4.1 95% 
CI: 0.5 – 14.9) with two workers vs. 0.5 expected, and leukemia (SMR=2.7, 95% 
CI:0.8 – 6.4) with five workers vs. 1.8 expected.  (Chemical Manufacturers 
Association) In 1987, Wong found that SMRs were non-significant for all leukemia; 
however, with internal analysis the association between continuous exposure to 
benzene and leukemia was significant.  In addition, the trend for increasing exposure 
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was significant (Wong 1987).  There were 3 cases of myeloid leukemia out of 22 total 
lymphohematopoietic cancer cases and this subtype was not analyzed specifically.   
4. The Australian Petroleum Industry Studies – A case-control study with age matched 
controls found that risk of leukemia was increased at >2 ppm-years.  For the 13 cases 
with >8 ppm-years the odds ratio=11.3 (95% CI: 2.85 – 45.1) (Glass, Gray et al. 
2003).  There were 11 cases of ANLL (9 AML and 2 acute undifferentiated leukemia) 
and when ≤4 ppm-years was the reference category, >4-8 ppm-years (OR=0.52, 95% 
CI: 0.05-5.0) and >8 ppm-years (OR=7.17, 95% CI: 1.27-40.4).  They did not find an 
association with multiple myeloma or non-Hodgkin’s lymphoma.   There was also a 
strong association between leukemia risk and benzene concentrate.  In 2006, the 
authors re-analyzed the data in a 2006 update (Glass, Gray et al. 2006) and attempted 
to take into account high exposure events (HEEs) that resulted from spillage and poor 
work practices.  These estimates were added to the previously calculated cumulative 
exposures for cases and controls.  The odds ratios were recalculated and this 
increased the exposure for 25% of subjects.  For most individuals the increase was 
<5%.  With the added HEEs the odds ratio for leukemia with matched analyses went 
from 1.10 (95% CI: 1.04-1.16) to 1.03 (95% CI: 1.01 – 1.05).  When treated as a 
categorical variable the odds ratio in the 7 cases of leukemia with >16 ppm-years was 
98 (8.8 -1090), when compared to individuals with <0.5 ppm-years cumulative 
exposure.  When the two lowest groups of exposure <1 ppm-years were compared 
with the highest exposure group the odds ratio was 51.9 (5.6 – 477) without HEEs 
and 7.79 (2.34 – 25.89) with HEEs.  It was thought that the odds ratio fell because 
leukemia is associated with higher exposures and thus the risk per ppm year is 
reduced.  They did not report recalculated results for ANLL with HEEs. 
5. The United Kingdom Petroleum Industry Studies – There was no significant 
increase in leukemia risk with cumulative exposure or intensity of exposure; however, 
risk doubled with employment >10 years (Rushton and Romaniuk 1997).  There was 
a non-significant increase (OR=2.82 95% CI: 0.8-9.4) for acute myeloid/monocytic 
leukemia (31 total cases) with a cumulative exposure 4.5 – 45 ppm-years (9 cases) 
when compared to the <.0.45 group (7).  For the exposure category 0.45 – 4.5 ppm-
years (15 cases) the OR=2.17 (95% CI: 0.77-6.09).  The average exposure for all 31 
cases was 3.7 ppm-years, while the controls had 3.8 ppm-years.  There were no cases 
with a cumulative exposure >45 ppm-years.  They found weak evidence of an 
association between acute myeloid/monocytic leukemia and peaked exposure.         
6. The Canadian Petroleum Industry Studies – Leukemia risk was not increased in this 
case-control study for increasing cumulative exposure (Schnatter, Armstrong et al. 
1996).  Average benzene concentrations ranged from 0.01 to 6.2 ppm.  There were a 
total of 14 leukemia cases, after excluding 2 because of inadequate work histories.   
7. Various Small Studies - (The Caprolactam Workers Study) – There was one death 
due to leukemia in this retrospective cohort mortality study of 311 men, versus the 
expected rate of 1.17 (Swaen, Scheffers et al. 2005).  The estimated exposure for the 
group was 159 ppm-years.  The daily mean exposure was 20.9 ppm.  (Italian Shoe 
Workers Study) - This was a study of 1687 shoe workers with cumulative benzene 
exposure ranging from 0 - >500 ppm-years (Seniori Costantini, Quinn et al. 2003). 
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The SMR for leukemia in men was significantly elevated for with >200 ppm-years 
cumulative exposure to benzene (7.0, 95% CI: 1.9 – 18.0).  There were non-
significant elevations at <40 (1.4, 95% CI: 0.2-5.0), 40-99 (3.7, 0.1 – 20.6) and 100-
199 (3.0, 95% CI: 0.4-10.9).  The mean cumulative exposure for men and women was 
71.8 ppm-years and 43.4 ppm-years, respectively.  The following cases were detailed: 
1 reticulum cell sarcoma, 1 other primary malignant neoplasm of lymphoid tissue, 3 
multiple myeloma, 3 chronic lymphatic leukemia, 1 acute myeloid leukemia (22.8 
ppm-years), 1 chronic myeloid leukemia, 4 unspecified acute leukemia (41.2, 251.9, 
285.4 and 98.8 ppm-years), 1 acute erythemia (108.2 ppm-years) and 2 unspecified 
leukemia (380.4, 140.4 ppm-years).  In addition, the authors found an elevated risk of 
leukemia with peak exposures ≥30 ppm (6 cases vs. 1.7, SMR=3.5, 95% CI: 1.3 – 7.6 
for men and women - 6 cases vs. 1.3, SMR=4.5, 95% CI: 1.1 – 9.9 for men only).  
(Gas/Electric Utility Workers) – This was a nested-case control study of 72 leukemia 
cases within a cohort of 170,000 workers (Guenel, Imbernon et al. 2002).  They use a 
relative value exposure matrix.  The risk of leukemia increased in workers with an 
estimated cumulative exposure ≥16.8 ppm-years (OR=3.6, 95% CI: 1.1-11.7).  There 
was an indication of a dose response relationship with every 10 ppm-years increase in 
exposure (OR=1.2, 95% CI: 1.0-1.5).  The link with benzene was more pronounced 
for acute leukemia versus chronic leukemia.  There were 20 cases of AML with no 
exposure, 1 with 0-<5.5 ppm and 5 with ≥5.5 ppm.  In addition, there were 3 cases of 
acute leukemia of unknown cytology.      
 
Unfortunately, animal studies have little to offer when evaluating the potential for a 
threshold dose of leukemogenesis.  In order to induce leukemia in rodents, a relatively high 
dose must be used simply because the lifespan is too short to allow normal induction 
intervals as seen in human beings.  However, animal studies are extremely valuable for 
studying the mechanisms and metabolism of benzene.  As noted in the animal study section 
above, doses of 100-300 ppm were necessary in order to induce leukemia in mice and rats.    
 
3.  Limitations of the Seven Quantitative Study Groups 
 
 The section above lists the interpretation of the various studies as reported by the 
authors.  In some cases, limitations of the studies were frankly stated in the Discussion 
section of the respective studies; alternatively, some authors minimized or did not even 
address potential limitation(s) of their study.  The following text is critical in order to put the 
findings of the studies into context. 
 
The Pliofilm Cohort: 
The overwhelming limitation with the Pliofilm cohort is the lack of quality industrial 
hygiene data, particularly from the earliest periods of operation.  Although it is still 
contended by Rinsky, most evidence points to significantly higher levels of exposure in the 
various Pliofilm plants during the 1940s and 1950s.  Quality, periodic industrial hygiene data 
collection only became available during the mid-1970s.  However, there were some very 
limited grab samples taken at several points up to that time.  In many ways, these limited 
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samples have only complicated matters by providing reference points that may or may not be 
valuable.  That has led to very contentious debate about the purpose, quality, methodology, 
placement and relevance of these measurements.  For example, in one report it was 
mentioned secondhand that exposures were thought to have followed the appropriate 
regulatory level of the time.  That is, the plant was operating within the accepted limits, such 
as 100 ppm.  With each successive reduction in the PEL, the company complied.  
Alternatively, there is some documentation to suggest that there was the opportunity for 
limited time, very high exposures that were far greater than the acceptable limit.  This in fact 
happened to one of the early cases of leukemia.  It is impossible to come to a concrete answer 
for all of these variables – literally the “facts” are unverifiable.  In addition, the samples that 
are available came from one plant, while most of the cases came from a plant with little 
industrial hygiene information.  Once again, this creates a point of contention – Is one plant 
the same as the other plant?  In addition to the poor industrial hygiene data, there are also 
questions about what, if any, ventilation was available during the 1940s.  There are some 
cryptic comments and records about the ventilation function; however, they are very limited 
and not particularly enlightening.  Although it was mentioned that the ventilation kept local 
levels to 0 or 10-15 ppm, this was only apparently measured once.  In addition to the 
limitations of the industrial hygiene data, some assumptions were initially made about areas 
of exposure (wet-side) versus (dry-side) operations.  Although the dry-side workers very 
likely had lower exposures, their levels were not zero, as originally assumed by the National 
Institute of Occupational Safety and Health (NIOSH) research team.        
There is some limited information, once again incomplete, that consisted of 
peripheral blood samples collected from the late 1940s onward.  These blood samples were at 
the center of several studies (Kipen, Cody et al. 1988; Hornung, Ward et al. 1989; Cody, 
Strawderman et al. 1993; Ward, Hornung et al. 1996) that examined the change in white 
blood cell counts over time with benzene exposure.  The interpretation by Kipen and Cody is 
most consistent with relatively high level benzene exposure and this has been co-opted to 
support the higher estimates by Crump and Allen, as well as Paustenbach.  Unanswerable 
questions still remain as to the exact methodology used to measure the various blood counts.   
Some additional factors that have been brought up in the analyses have been the 
effect of shutdowns during World War II due to lack of rubber, the effect of dermal 
absorption on cumulative benzene exposure, as well as, personal protection use and function.  
 
The Chinese (NCI-CAPM) Study Series: 
The Chinese NCI-CAPM study has a number of problems that in many ways 
potentially invalidate the findings, or at least significantly diminish the usefulness of the data.  
Although this is a very large study that could potentially offer much good data, these workers 
are not exposed to only benzene, unlike the Pliofilm Cohort.  The factories being studied are 
a mixture (64% paint manufacture/use) of industrial types, including rubber production, 
printing, paint, etc. that have the potential for a very wide range of chemical exposures.  The 
major weakness of this study is the lack of confidence that the research team had in the 
existing industrial hygiene measurements.  Similar to the Pliofilm Cohort, in many cases 
when measurements were collected during the early years of the study the purpose, 
technology, sample time and other factors were not documented.  Short term grab samples 
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were often the only source of industrial hygiene data.  The research team developed a 
confidence rating system for the measurements and a high level of confidence was ascribed 
to only 2% of measurements in the 1940s. During the periods when most of the workers who 
eventually developed cancer were working, the confidence in the measurements was very 
low. The level of confidence rose slowly in the succeeding years and reached 42% after 
1985.  In addition, there was no central team of industrial hygienists to evaluate all of the 
~700 factories involved in the study, and estimates of exposure depended upon local 
industrial hygienists at each factory, although there was “uniform” training of all study 
members.   
In a related matter, there are persistent allegations that the levels of exposure 
estimated by the research team are not consistent with the Chinese occupational literature, or 
the results of their own co-investigators.  Although the lead researchers have explained many 
of the incidentally elevated levels as isolated inconsistencies, there is good documentation of 
elevated benzene levels in many industries in China (Wong 2002; Vermeulen, Li et al. 2004).  
In addition, related questions have been raised about the level of ventilation, personal 
protection, length of the workday, number of days worked per week and benzene content of 
produces used in manufacturing.  All of these factors have significant bearing on the dose 
estimation and thus the study outcomes.     
There are inconsistencies in data collection and documentation of disease status in a 
significant proportion of leukemia cases; particularly ANLL, the type of leukemia most 
closely associated with benzene exposure.  In addition, there are questions about acquisition 
of cases and possible bias.  There are also problems with unexposed rates of disease in the 
control population and the effect they have on statistical stability.  The highest level of 
benzene exposure categorization is 50 ppm, yet there is significant documentation that levels 
far higher are frequently encountered in Chinese industrial settings.  This will introduce 
substantial misclassification and an overestimation of risk.   
In summary, potentially major problems in the Chinese (NCI-CAPM) studies include: 
scientifically unsound industrial hygiene practices, unreliable data sources and collection 
techniques, flawed epidemiologic practices, misclassification and a narrow/incomplete scope 
when considering exposures and resulting diseases.  
 
The Chemical Industry Studies - (Dow Chemical, Monsanto/Salutia, and Chemical 
Manufacturers Association)  
A common weakness of these studies was a lack of personal, time-weighted industrial 
hygiene measurements.  Concurrently the exposure history was based upon estimated ranges 
from area sampling, not individualized data which would include work practices, personal 
protective equipment use and operator specific factors.  In each of the study groups, the 
populations had the opportunity for innumerable chemical exposures, in addition to benzene.  
In addition to the underlying problems with a lack of personal monitoring data, most were 
unable to take important factors such as peak exposure levels and frequency into account.  
Peak exposures can add significant amounts of benzene to cumulative exposure; in addition, 
they have been consistently linked to an increased risk of leukemia.  Another problem 
frequently found in these studies was inadequate exposure estimates from the early years of 
production, particularly before the 1950s.   
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Another common problem among the chemical cohort studies was the use of the U.S. 
population as the control group.  This practice introduces the possibility of the “healthy 
worker” effect, which tends to lower standardized mortality ratios artificially and may 
obscure any significant findings.  In addition, many of the studies did not control for 
potential confounders and modifying factors, such as smoking.  In one study, where 
confounding variables such as cigarette smoking were not accounted for, there was a clear 
excess of lung cancer deaths in the unexposed cohort of workers. Also problematic was 
incomplete follow-up of the cohort members, resulting in missing data and possibly skewed 
data due to non-differential effects.   
There were also limitations that resulted from the ascertainment of leukemia 
diagnoses.  For several of the studies, the leukemia diagnoses were obtained from death 
certificates, without verification of diagnosis, much less the particular cell type of the 
disorder.  If the types of leukemia are not broken down by cell type, the analysis is limited.  
Misclassification of even one case within the various subtypes of leukemia can drastically 
change the outcome of a study with few cases.  In addition, if a person died of an alternative 
cause, besides a lymphohematopoietic disorder, this may have been excluded from the death 
certificate if it was not the “cause” of death.  For instance, if a person was in the early stages 
of lymphohematopoietic disorder without clinical signs, this may have simply been missed 
without an autopsy.    
In one study, there were two cases of ANLL in the unexposed category and three in 
the exposed category – such limited numbers in both the unexposed and exposed categories 
lead to very unstable estimates of risk and severely limit any conclusions being drawn from 
this study.   Likewise, in another study the use of a relatively small internal comparison 
group introduced statistical instability and lead to the appearance of significance where it was 
not true.  There were only seven cases of leukemia, six in the continuously exposed and one 
in the intermittent grouping.  There was a deficit of leukemia in the comparison group (0 
observed vs. 3.4 expected) which magnified the relative risk of the exposed.    
In the Chemical Manufacturers Association Study, two of the seven plants did not 
include 1946-1957 – years which have historically been associated with higher exposures in 
other studies.  The unexposed group was missing 14 death certificates (4.29% vs. 1.12% and 
1.32%) versus the two groupings (based upon different exposure groups, thus the two 
percentages) of exposed workers that were missing 9 death certificates.  This could have 
potentially affected analysis, particularly given the small numbers in each disease category.    
 
The Australian Petroleum Industry Studies  
The Australian Petroleum Industry Studies had numerous problems.  As in other 
studies, there were problems related to collecting the work history/data collection, small 
numbers of cancers that led to potentially unstable estimates of risk and possible problems 
with the exposure assessment.   
There were a relatively small number of hematological cancer cases and only 33 
leukemia cases.  Of the leukemia cases, only 11 were acute non-lymphocytic leukemia, while 
another 11 were chronic lymphocytic leukemia. These small numbers limit the power to 
detect excess risk, particularly in individual leukemia subtypes.  In addition, misclassification 
of just a few cases from the lowest groups to a higher group would markedly change the dose 
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response curve.   
Information about lower exposed jobs was far greater than information available for 
the highly exposed jobs.  Exposure estimates were derived from monitoring data that was 
collected after 1975.  While work history information was collected from contemporary co-
workers versus the cases in order to limit recall bias, this likely led to significant under-
ascertainment of exposure related to personal work habits and accidents, spills and other 
short-term high level exposures.   If the co-worker only described a job/task as it would have 
been optimally carried out, without consideration of these factors, it would have the effect of 
smoothing the peaks and potentially lowering the estimates for each case.   
The base estimates which are the beginning of all exposure estimation in this study 
were questionable even by the author’s estimation.  When they were compared to relevant 
exposure data in the literature 12 were not available, 19 were validated, four were adjusted 
and 14 were not confirmed by the literature.  However, the 14 not confirmed were judged to 
be inadequate and were ignored.  The exposure level categories were very small and 
seemingly insignificant errors in exposure estimation could markedly affect the placement of 
cases into different exposure levels.  This was noted by the research team in a later 
publication and several of the lower exposure values were combined.    
 
The United Kingdom Petroleum Industry Studies  
The United Kingdom Petroleum studies had limited value for several reasons.  For 
many of the cases and controls, the work history was incomplete.  Data was extrapolated 
from the existing records.  As noted in other studies, there were different patterns used for 
taking work histories.  Work histories were taken mainly from personnel records, if they still 
existed.  Alternatively, a significant number of records were incomplete and they had to be 
reconstructed through additional information gathering that would not be specific to the 
individual, and through extrapolation from existing data.  In addition, ~95% of the terminals 
where work had historically taken place were closed by the time of the study.  This required 
the extrapolation of data from similar terminals still in operation and reliance upon tertiary 
literature and materials that were also used to fill in information gaps. 
 
The Canadian Petroleum Industry Studies  
Although no significant leukemic effect was found in this study, significant 
limitations were still present.  The study was small and thus had limited power to predict 
disease outcomes.  If benzene exposure caused a two fold increase in risk for >45 ppm year 
category, the study would have only a 16% chance of discovering the relationship at a 20% 
exposure rate and a 5% significance level.  In order to attain 80% power, 90 cases would 
have been needed.  None of the odds ratios for cumulative exposure were significant at the 
p=0.05 level.  For cumulative exposure, the risks were not monotonically increased, and in 
fact, the highest (non-significant) odds ratios were found near the lowest levels - 0.18-0.49 
ppm-years, 0.23-5.49 ppm-years, 0-0.49 ppm-years, 0-0.45 ppm-years and 0-0.90 ppm-years, 
depending upon the cut points chosen.   The authors concluded that the results were 
consistent with insufficient power to detect a small effect, or a lack of effect for low benzene 
exposure, particularly between 0.1 - 1.0 part per million. 
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The case-control study eliminated 2 of the 16 identified leukemia cases due to 
incomplete work histories.  In addition, smoking status was largely unknown and 
unaccounted for in the analysis.   However, smoking was one of two strongest predictors for 
leukemia risk. Of the 14 cases of leukemia, seven were ever smokers and the smoking status 
of the remaining seven was unknown.   
The highest risk of leukemia was found in the managerial/professional category 
which should have had limited, or no potential for benzene exposure beyond the background 
levels.     
As in other studies, there was limited or no industrial hygiene measurement data 
available and they had to be estimated with an exposure matrix.  By the authors’ own 
validation exercise, exposure estimates were within 22%.  In addition, some of the exposure 
data was extrapolated from other facilities.     
 Data collection was also problematic.  Work information for 25% of the 115 workers 
who were included in the analysis was missing.  Of that number, 19% were missing some 
information and 6% were missing more than half.   
The third study had critical problems related to measurement data.  Close scrutiny of 
the base estimates revealed that several of the most highly exposed workers (barrel washer 
and loader) were derived from limited numbers of measurements, derivations from total 
hydrocarbon content and short term measurements.  For instance, the loader base estimate 
(historic) was derived from the total hydrocarbons and (14) short term measurements.  The 
calculated benzene concentration used for this category was 2.6 ppm.  The highest base 
estimate was for the barrel washer, yet the benzene concentration was derived from the total 
hydrocarbon level and (4) short term measurements.    Further, the limited validation exercise 
did not include measurements of benzene exposure in highly exposed workers.  Only the 
total hydrocarbons were estimated in those workers and they varied as follows: -21%, -9%, -
11%, -49%, +220% and +85%.  Alternatively, the benzene measurements varied as follows:  
33%, 10%, 130%, 4.5%, 0, 0, 0, 14.3% and -14%.  Obviously, with a more highly exposed 
worker a hypothetical percent difference is of far greater importance than in a worker with 
only background exposure.  In addition, all of the confidence intervals used in the validation 
exercise were very wide.  The only jobs evaluated were route sales, loader and plantman.   
 
Various Small Studies - (The Caprolactam Workers Study) – (Italian Shoe Workers Study) 
- (Gas/Electric Utility Workers)  
 These were all very small studies, particularly the Caprolactam study which had only 
one case of leukemia.  In addition, both the Caprolactam and Shoe Worker studies had 
estimated exposure assessments based primarily on expert judgment.  In the Caprolactam 
study the researchers utilized a panel of employees.  The modifying factor was determined 
based upon the strength of several subjective measures following process changes and the 
base estimate was derived from industrial hygiene measurements collected in 1978-1988.  A 
similar method was used to estimate the exposures in the Shoe Worker Study because there 
were very limited industrial hygiene measurements.  The Gas/Electric Utility Workers Study 
utilized a relative value system to estimate benzene exposure.  It is not clear how they 
established there baseline value, which they modified as the concentration of benzene in the 
glue changed with time. 
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 The Caprolactam Study also had a significant number of workers unaccounted for in 
the analysis.  Of the workers, eight emigrated, two were lost to follow-up and five did not 
have a particular cause of death.  This reduced the original cohort by 5.4%, which had the 
potential of dramatically affecting the conclusions if just one more case were added. 
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4.  Evidence for a Threshold Dose – Use of the Hill Criteria 
 
Strength 
 Although there will always be questions regarding the Pliofilm Cohort, it is apparent 
that the Crump and Allen model, as well as, the Paustenbach 1992 model explain the 
mortality in the cohort better than the Rinsky 1987 model.  Interestingly, Williams and 
Paustenbach revised the estimations of the Paustenbach (1992) model in a recent article 
(Williams and Paustenbach 2003).  Using Monte Carlo techniques, they found that many of 
the very highest levels were most likely not realistic.  However, they concluded that their 
revised analysis did not markedly change the earlier findings, although the article failed to 
calculate new individualized dose estimates for the 22 cases of lymphohematopoietic cancer.  
Perhaps the strongest evidence for a threshold dose in this cohort is the observation by 
Paxton (1994) that regardless of the estimating model, there have been no cases found in 
persons with <50 ppm-years of cumulative exposure.  Wong (1995) took this even farther 
when he re-analyzed the data specifically for acute myeloid leukemia and determined that no 
cases occurred with <200 ppm-years cumulative exposure using the Rinsky (1987) 
estimations.  Although this appears to fully answer the question unconditionally, it is 
important to realize that the Pliofilm has a small number of cases and it is underpowered to 
detect an excess of cancer at lower cumulative doses. 
 The Chinese (NCI-CAPM) clearly has multiple methodological limitations which 
make the conclusions drawn at very low doses questionable.  Nevertheless, the authors 
reported a non-significant risk for ANLL, which includes acute myelogenous leukemia, 
below 40 ppm-years cumulative exposure.  Given the very real weaknesses in the exposure 
methodology and the reported findings of the study, it is not unreasonable to conclude that 
the study is within the range of the Paxton (1994) estimation of 50 ppm-years cumulative 
dose of benzene.   
The Dow Chemical Studies revealed a significant elevation of myelogenous 
leukemia; however, the numbers were so small that this study has the potential for significant 
statistical instability.  Three of the cases had significant cumulative exposures (45.4167, 25. 
4167 and 350.9167 ppm-years) based upon estimates that were primarily based upon expert 
judgment and some limited industrial hygiene measurements which were most likely 
conservative according to the original report.  One other case had a cumulative exposure of 
1.5 ppm-years and he worked only 18 months in a low exposure (> 2 ppm) job.  It is probable 
that this case was not related to benzene exposure.  By the second update, the SMRs were 
non-significant and near baseline rates.  The Monsanto/Salutia studies reported relatively low 
levels of cumulative exposure; however, the leukemia risks were all non-significant.  The 
data did suggest that peak exposure frequency may be associated with leukemia risk.  The 
Chemical Manufacturers Association study did not find an elevated SMR for leukemia and 
there were only 3 myeloid cases in the cohort. 
The Australian Petroleum Industry Studies are the strongest evidence contradicting 
the findings of the Pliofilm Cohort.  They found a highly elevated and significant risk of 
leukemia at >8 ppm-years cumulative exposure, as well as a significant risk for ANLL at that 
same level.  Interestingly, although this is the third study to use the base estimate X 
modifying factor exposure estimating methodology, estimates of peak exposures were not 
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taken into account in the initial (2003) case-control study.  In a subsequent re-analysis with 
added high level exposures (HHEs) the risk for leukemia was only highly significant at >16 
ppm-years.  The revised risk for ANLL was not reported.  Besides the limited number of 
cases in the referent group, which creates potential instability in the statistical measures, the 
missing peak exposures cast some doubt on the exact level of risk, if any, associated with the 
original measurements.  It is possible with further study that this will still be the case; 
however, it is not a foregone conclusion of irrefutable evidence for risk at these low levels. 
The United Kingdom Petroleum Industry Studies did not reveal any elevated risk of 
leukemia.  However, there was a non-significant increase in risk for acute myeloid/monocytic 
leukemia with a cumulative exposure range of 4.5 – 45 ppm-years.  The upper limit of the 
interval is within the same range suggested by Paxton (1994). The author noted, “The present 
study, along with these other studies, suggests that risks under about 50 ppm-years are either 
small or nonexistent.” 
The Canadian Petroleum Industry Studies did not find an elevated risk for leukemia; 
however, the exposures were on the low side (0.01 – 6.2 ppm).   
The Various Other Studies including the Caprolactam workers, Italian Shoe Workers 
and Gas/Electric Utility Workers were all small studies.  The Caprolactam and Shoe Worker 
studies both suggested little or no risk at low levels of exposure.  However, there was only 
one case of leukemia in the Caprolactam study, thus it was not too informative.  The Italian 
Shoe Workers only had an elevated risk at > 200 ppm-years cumulative exposure.  There 
were non-significant elevations at doses >40 ppm-years exposure, which is consistent with 
the suggested level proposed by Paxton (1994).  The Gas/Electric Utility Workers study 
showed an elevated risk at or above their extrapolated value of 16 ppm-years cumulative 
exposure.  However the number of cases was very small and it is not clear if the ppm-years 
calculation was a relative versus absolute value.  They did not measure any benzene levels. 
As you can see from the above discussion, the argument for little to no risk for 
leukemia and acute myelogenous leukemia in the range of 40-50 ppm-years cumulative dose 
is strong.  Although the Australian study suggests that there is significant risk at a lower 
level, this estimate has already been revised.  Nevertheless, I believe that there is strong 
support for a threshold that most likely fall around 40-50 ppm-years.  It will be potentially 
enlightening if the UK, Canada and Australian cohorts are even combined, as was suggested 
by the Institute of Medicine in 2005.   
 
Consistency  
  There is no epidemiologic evidence that suggests an individual with only a 
background level of benzene exposure is at any risk of developing leukemia of any type.  By 
default, this answers the part of the question that was originally posed in this investigation – 
Is there evidence for a threshold dose of benzene?  However, I believe that the studies noted 
above clearly show a high level of consistency, except for the Australian outlier.   
 
Specificity 
Throughout the collection of case reports, case series and epidemiologic studies, the 
acute myelogenous leukemias (ANLL) have been consistently and specifically associated 
with benzene exposure, unlike the remaining types of leukemia.  The Pliofilm Cohort is one 
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of the strongest pieces of evidence for the specificity of benzene related cancer.  Pliofilm 
workers were exposed to little else besides benzene and the overwhelming type of leukemia 
was acute myelogenous leukemia. There is no other group, regardless of whether exposure 
was quantified that had this singular solvent exposure.  
 
Temporality  
 There is a background rate of all subtypes of leukemia, including acute myelogenous 
leukemia.  It was interesting that the Gas/Utility Electric Study had 20 cases of AML in non-
exposed workers.  Many of the cases with very low exposure to benzene probably do not 
have a benzene related neoplasm.   
 
Biological Gradient  
 Once the threshold dose is reached, acute myelogenous leukemia incidence and 
mortality rises rapidly.  However, below that dose there is no expectation of risk. 
 
Plausibility 
 Although sub-chronic effects such as chromosomal aberrations and hematological 
changes have been widely reported at a variety of doses, their presence is not necessarily a 
direct link to leukemogenesis.  For instance, the vast majority of persons who develop the 
aforementioned sub-chronic effects return to their baseline values very quickly.  For those 
persons with persistent abnormalities, there is scientific proof that they will inevitably 
proceed to leukemogenesis.  Even individuals who develop aplastic anemia from very high 
level exposures do not necessarily develop leukemia, although their risk is certainly elevated.  
 
Coherence  
 As mentioned earlier, animal data cannot be directly extrapolated to human beings; 
however in lifetime inhalation studies there does appear to be a threshold dose at a dose 
dependant on the species and breed.   
 
Experiment  
Many of the quantitative and qualitative epidemiologic studies have been updated and 
invariably any elevated risk found in the previous investigation has fallen with decreasing 
exposure.  In most studies, the risk falls to insignificance and in many it return to background 
rates.   
 
Analogy 
 Unfortunately, benzene is the only known leukemogen that has been studied so 
thoroughly.  In addition, although leukemogenesis is most likely related to the quinone 
metabolites of benzene, the exact mechanism of action has not been fully elucidated.  
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Chapter Five: Conclusions, Limitations and Recommendations 
 
 The purpose of this investigation was to determine whether there is a threshold where 
no theoretical risk for benzene-related leukemogenesis exists.  From the evidence examined 
and with an understanding that there are limitations in any data set, this investigation 
revealed that there is a threshold dose for benzene-induced carcinogenicity.  The threshold 
dose where a theoretical risk for benzene-induced leukemogenesis is around 50 ppm-years, 
although it may be higher based upon information presented in other studies.   
 This investigation utilized secondhand data from the publically available medical and 
scientific literature; as such, it is dependent upon and subject to the inherent limitations of the 
underlying data sets.   
 Future research on this important topic is certainly encouraged.  A meta-analysis of 
the UK, Canadian and Australian (Health Watch) data would be worthwhile and potentially 
offer further clarity to the potential for adverse health outcomes in petroleum industry 
workers.   
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